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Abstract 
The autotransporters are a family of extracellular proteins, found in various Gram-negative 
bacteria, that have many different functions but appear to have a similar mechanism of 
export. In B. pertussis, the virulence-regulated proteins Pertactin, BrkA, Tcf, and Vag8 
have structural homology at their C-termini (30-kDa) and the N-terminal of the mature 
proteins share structural characteristics such as RGD and SGXG motifs. Recently, another 
member of the B. pertussis autotransporter family, Bap-5 (Blackburn, 2000) (GenBank 
accession number AF081494) or BapC (GenBank accession number AJ277634.1) was 
identified. Subsequent work by Bokhari (2002) suggested that BapC, like BrkA (Fernandez 
and Weiss, 1994), could function as a serum-resistance factor and was important in 
colonization of the mouse respiratory tract. However, the relative contributions of these 
two components to serum resistance and mouse virulence were difficult to estimate 
because the studies had been done with brkA and bapC mutants of different B. pertussis 
strains. 
The first part of the current project involved the creation of bapC and brkA, bapC mutants 
in the same genetic background as the brkA mutant, namely B. pertussis strain BP338, an 
antibiotic-resistant derivative of strain Tohama. When these strains were compared to the 
wild-type strains available, B. pertussis Tohama (wild-type, W/T), Taberman (W/T) and 
BP338, they were shown to be less resistant to killing by normal human serum. The brkA, 
bapC double mutant of BP338 was more serum sensitive than the bapC or brkA single 
mutants but not as sensitive as a bvg mutant BP347, also a derivative of strain BP338, 
which lacks expression of almost all known virulence factors. These findings supported the 
suggestion that BapC, like BrkA, is a serum-resistance factor but also indicated that other 
bvg-regulated factor(s) may be able to confer some serum resistance on B. pertussis. In 
addition, an E. coli strain previously constructed by Blackburn (2000) expressing a large 
part of the BapC protein was shown to be more serum-resistant than control strains.          
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It had been reported previously that the brkA mutant of B. pertussis BP338 was not only 
more sensitive to serum, but also had altered sensitivity to certain antimicrobial peptides 
(Fernandez and Weiss, 1996). In the present study, the bapC and brkA mutants were found 
to be more sensitive to cecropin P1 than the parent strain, and the double mutant and the 
bvg mutant were even more sensitive. In contrast, the bapC and brkA mutants were more 
resistant to protamine whereas the double mutant and bvg mutant were even more resistant.  
Competition assays, by intranasal infection of mice, were done to compare the virulence of 
the mutant strains with that of the parent strain BP338. The order of virulence determined 
by these assays was: BP338 (W/T) > BP338 (BrkA-) > BP338 (BapC-) > BP338 (BrkA-, 
BapC-) > BP347 (Bvg-), which is approximately the same as the order of resistance to 
serum killing: BP338 (W/T) > BP338 (BapC-) ≥ BP338 (BrkA-) > BP338 (BrkA-, BapC-) > 
BP347 (Bvg-) and resistance to antimicrobial peptide (cecropin P1): BP338 > BP338 
(BapC-) = BP338 (BrkA-) > BP338 (BrkA-, BapC-) > BP347 (Bvg-). These findings 
suggest that BapC, like BrkA, is an important virulence determinant of B. pertussis and 
also that resistance to serum killing and possibly to certain antimicrobial peptides may 
have important roles in virulence. 
During the course of the current study, the genome sequences of B. pertussis, B. 
parapertussis and B. bronchiseptica were published (Parkhill et al., 2003) and it became 
evident that the bap5/bapC sequences identified previously were not, in fact, the whole 
gene. It also became evident that bapC in the Tohama strain of B. pertussis used to obtain 
the genome sequence was actually a pseudogene, due to a frameshift in homopolymeric 
tract of C residues at the 3’ end of the gene. This information clearly conflicted with the 
evidence from the current and previous studies from our laboratory that BapC was 
expressed and conferred serum resistance and virulence properties on the producing 
strains. Nucleotide and amino acid analyses of the bapC region spanning the poly(C) and 
poly(G) tracts of a number of B. pertussis strains in this study showed some minor 
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nucleotide and amino acid polymorphisms in some strains but it appeared that all had an 
ORF that would be able to produce some form of BapC.  
DNA hybridisation of a bapC probe to the genomes of other Bordetella species showed the 
presence of the bapC gene in B. pertussis, B. parapertussis and B. bronchiseptica but there 
was no evidence of the bapC locus or orthologous gene in B. avium, B. hinzii, B. holmesii 
or B. trematum.  
Prediction of the signal sequence of BapC in B. pertussis, B. parapertussis and B. 
bronchiseptica was performed according to the amino acid sequences available in the 
database (GenBank) and showed a maximum cleavage site probability between amino 
acids 38 and 39. Other comparative analysis of proteins and genes between BapC, BrkA 
and pertactin clearly revealed the homology in their C-termini (β-domains), as would be 
expected for autotransporter proteins. However, apart from some common motifs (RGD, 
SGXG), no clear homology could be seen in their passenger domains (α-domains) to 
suggest common functions.  
The entire bapC gene was cloned from BP338 and expressed in E. coli and a band of ∼90 
kDa was obtained by SDS-PAGE. The predicted size of BapC is 104 kDa, comprising a 74 
kDa α-domain and 30 kDa β-domain. Peptide fingerprinting and mass spectrometry 
analysis showed that this band corresponded, with a high peptide coverage, to the BapC 
protein published in the database (GenBank), without the frameshift, and confirmed that 
BapC would be expressed in B. pertussis strain BP338. This recombinant BapC, free from 
other B. pertussis components, will be very useful for further studies, for example in 
determining the mechanism of serum resistance and its potential as a protective antigen for 
inclusion in any new generation of acellular pertussis vaccines.    
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1. Introduction  
Bordetella pertussis, the causative agent of pertussis or whooping cough, was first isolated 
and implicated as the cause of the disease in 1906 (Bordet and Gengou, 1906). Whooping 
cough is presently one of the ten most common causes of death from infectious disease. It 
was reported by the World Health Organization (WHO) to cause 50 million cases and 
294,000 deaths worldwide in 2002, mainly among unvaccinated individuals in Third World 
countries. In the USA, where there is a high vaccine uptake, the Centers for Disease Control 
and Prevention recorded 18,957 reported cases in 2004. In the UK, 1054 cases were 
reported in 2002, despite a vaccine uptake of 95% (WHO, Statistics, 2006). The 
introduction of a pre-school booster vaccination is predicted to reduce the number of 
hospitalizations by approximately 1400 and pertussis cases in the UK by up to 28000 over a 
5-year period (Stevenson et al., 2002).  
1.1 The genus Bordetella 
    The genus Bordetella is comprised of minute (0.2-0.5µm x 0.5-2.0 µm), Gram- negative, 
catalase-positive, non-acid fast, non-sporing, aerobic (with the exception of B. petrii) 
coccobacilli. They do not ferment carbohydrates. Members of the genus Bordetella (except 
for B. petrii) appear to be obligatory parasites, mostly inhabiting the surface of the 
respiratory tract of man and other warm-blooded animals, including birds. According to 
Lapin (1943), the small Gram-negative coccobacillus, now known as B. pertussis, was first 
clearly described in 1906, by Bordet and Gengou, in the sputum of an infant with whooping 
cough, although other investigators had noted similar organisms previously. By 1906, 
Bordet and Gengou had developed a suitable medium for cultivation of the organism and 
were then able to establish its morphology, cultural characteristics, virulence and 
antigenicity. The G+C content of the genus is in the range of 61-68% and the optimum 
growth temperature is 35-37ºC (Parton, 1998).  
By comparative 16S rRNA sequence analysis, amplified ribosomal DNA restriction 
analysis and DNA-RNA hybridization studies and the high G+C content in their DNA, it 
has been suggested that the Bordetella species are closely related to Achromobacter species. 
Achromobacter is a genus of Gram-negative, aerobic, motile bacteria that occurs in water 
and soil. Some are common inhabitants of the intestinal tract of vertebrates and they 
occasionally cause opportunistic infections in humans. Evidence from 16S rRNA sequence 
  Introduction  
 
2 
analysis has also confirmed a common phylogeny with Alcaligenes and it may be difficult 
to differentiate these genera on the basis of phenotypic criteria (Parton, 1998). 
1.2 Species of Bordetella 
    DNA-DNA hybridization analyses, Tm values of rRNA-DNA hybrids, mean G + C 
contents of genomic DNA, similarity in 23S rRNA gene sequences, and whole genomic 
sequencing have suggested a very close relationship between B. pertussis, B. parapertussis, 
and B. bronchiseptica (van der Zee et al., 1997). B. pertussis strains, which are restricted to 
humans and the human respiratory tract, show little genetic variation, indicating that the 
species derived from a common ancestor in the recent past, perhaps only a few thousand 
years ago. B. parapertussis infects both humans and sheep; in human infants it may cause 
whooping cough. Phylogenetic analysis has shown that B. parapertussis strains isolated 
from humans are distinct from those isolated from sheep. It has been suggested that the two 
types evolved independently from a common ancestor (B. bronchiseptica), and there is little 
or no transmission between the two reservoirs (sheep and human). Furthermore, isolates 
from sheep are genetically diverse, whereas those isolated from humans are more uniform. 
In contrast, B. bronchiseptica has a broad host range, causing chronic and often 
asymptomatic respiratory tract infections in a wide range of animals, and only occasionally 
causes infection in humans (Goodnow, 1980),  or opportunistic infection in the 
immunocompromised (Kerr and Matthews, 2000).  
B. pertussis, B. parapertussis and B. bronchiseptica were the first species assigned to the 
genus Bordetella. In recent years, six new species have been added to the genus. B. avium 
was first proposed as a species by Kersters et al. (1984) to include agents of respiratory 
disease of turkey poults and other birds. B. hinzii is the name given to a B. avium-like group 
of organisms found mainly in the respiratory tracts of chickens and turkeys but human 
isolates have been reported (Vandamme et al., 1995). It was reported that B. hinzii might 
cause disease in humans under certain conditions e.g. in HIV and cystic fibrosis patients 
(Funke et al., 1996; Kattar et al., 2000). B. holmesii was originally isolated from human 
blood cultures (Weyant et al., 1995) but also from sputum (Tang et al., 1998) and 
nasopharyngeal specimens from patients with pertussis-like symptoms (Mazengia et al., 
2000).  
A recently named species, B. trematum, contains isolates from human wound and ear 
infections which were described originally as atypical bordetella or unidentified 
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(Vandamme et al., 1996). The pathogenic potential of B. hinzii, B. holmesii and B. 
trematum is unclear, although B. hinzii has been identified as the cause of a fatal septicemia 
(Kattar et al., 2000). Like B. bronchiseptica, they appear to be opportunistic in humans 
although it has been reported that there are no hosts other than humans for B. holmesii and 
B. trematum.  
More recently, B. petrii has been described (von Wintzingerode et al., 2001). This is the 
first member of this genus to be isolated from the environment and may therefore be very 
closely related to a common ancestor of the pathogenic Bordetella. Only one strain has been 
isolated, from an anaerobic, dechlorinating bioreactor culture enriched from river sediment. 
This strain, Se-1111R (T), is able to anaerobically reduce selenate to elemental selenium. B. 
petrii is also the first member of this genus capable of anaerobic growth (von 
Wintzingerode et al., 2001).  
It has been confirmed by using multilocus enzyme electrophoresis (MLEE) and microarray-
based comparative genome hybridization (CGH) that there is a close genetic relationship 
between all known bordetellae, with the B. petrii facultative anaerobe as the proposed 
environmental progenitor of pathogenic bordetellae (Cummings et al., 2004; Mattoo and 
Cherry, 2005) (Fig. 1.1). Moreover, B. bronchiseptica seems to be the evolutionary 
progenitor of B. pertussis, B. parapertussishu, and B. parapertussisov; as such, these species 
have been reclassified as subspecies of the “B. bronchiseptica cluster” (Mattoo and Cherry, 
2005). 
Very recently, a new Bordetella species, B. ansorpii, was isolated from the purulent exudate 
of an epidermic cyst (Ko et al., 2005), and the first UK clinical isolate was found in an 
immunocompromised patient (Fry et al., 2007). It is a Gram-negative bacillus and grows on 
both blood agar and MacConkey agar. The organism is motile on LB swarming agar (0.8% 
NaCL, 0.4% agar [wt/vol]), which distinguishes it from B. holmesii. Sequence analysis of 
the 16S rRNA gene, and comparative analysis of two protein coding genes (risA and ompA) 
have revealed that this bacterium belongs to the genus Bordetella but is distinct from 
previously described Bordetella species (Ko et al., 2005). Cellular fatty acid analysis and 
biochemical tests have also confirmed that this bacterium is separate from other Bordetella 
species. The G+C content of B. ansorpii is 63.8 mol%, and compares with that of other 
Bordetella species which range from 60 to 69 mol%.  
 
  Introduction  
 
4 
        
Figure 1.1 Phylogenetic relationships among nine Bordetella species based 
on multilocus enzyme electrophoresis (MLEE), IS element, and sequence analysis. These species 
appear to have derived from a common B. petrii ancestor (Mattoo and Cherry, 2005).  
 
Various studies on the relatedness of the above strains have suggested that B. pertussis, B. 
parapertussis, B. bronchiseptica are in fact subtypes of a single genomic species. B. avium, 
B. holmesii, B. hinzii, B. trematum and perhaps B. petrii and B. ansorpii each in contrast 
form true genomic species (Vandamme et al., 1995, 1996; Weyant et al., 1995; Ko et al., 
2005). Evolutionary history of B. pertussis, B. parapertussis, B. bronchiseptica and their 
close phylogenetic relationship with Alcaligenes and other bacteria widespread in the 
environment suggests that the ancestral bordetellae were free-living and evolved to infect 
warm-blooded animals (Roberts and Parton, 2001). These suggestions have been supported 
by the more recent isolation and characterization of B. petrii (Matto and Cherry, 2005). 
Genotyping studies, by multi-locus enzyme electrophoresis and the distribution of IS 
elements, have suggested that B. pertussis and B. parapertussis evolved at different times 
from distinct clones of B. bronchiseptica (van der Zee et al., 1996). In addition, the 
sequence comparison and genome sizes of B. pertussis, B. parapertussis and B. 
bronchiseptica also support the hypothesis that B. pertussis and B. parapertussis recently 
and independently evolved from B. bronchiseptica-like ancestors (Parkhill et. al., 2003). 
Moreover, other evidence from DNA fingerprinting by PFGE (Pulsed-Field Gel 
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Electrophoresis) and arbitrarily-primed PCR (Yuk et al., 1998) shows that B. pertussis 
strains and human strains of B. parapertussis are both still very homogeneous clonal 
populations, supporting the suggestion of their relatively recent adaptation to humans 
(Parkhill et al., 2003). 
1.3 Pertussis: The disease 
1.3.1 Epidemiology of pertussis 
    Bordetella pertussis is the causative agent of pertussis or whooping cough, a serious and 
highly contagious disease of the respiratory tract, presently responsible for one of the ten 
most common causes of death from infectious diseases worldwide (Preston and Kerr, 2001). 
It has historically been reported that the attack rate in females was higher than in males 
(Cherry, 1984). Despite a high vaccine uptake, resurgences of this disease have been 
observed in several developed countries in the last two decades (Kerr and Matthews, 2000). 
Throughout the previous century infants and young children have remained most 
susceptible to pertussis-related morbidity and mortality. Infants younger than 6 months who 
have not received three doses of the diphtheria-tetanus-pertussis vaccine and under-
vaccinated preschool children are at highest risk for pertussis-associated complications. In 
the United States, in spite of a stable or increasing vaccination rate since 1962, pertussis 
infection rates have been rising since the early 1980s. In 1993, the pertussis infection rate 
increased by 82% over reported cases during the previous year and it was the highest 
incidence rate of pertussis since 1967 (Black, 1997).  
In the United States, pertussis was reported as the most common vaccine-preventable 
disease among children younger than 5 years old in 1993. Although, widespread 
immunization has reduced the potential for individuals to acquire exposure-induced 
immunity, the primary factor contributing to the resurgence of pertussis in the US was the 
growth of a susceptible adult population (Black, 1997). In the UK, following an increased 
incidence in the late 1970s and early 1980s due to a reduction in vaccine uptake, infection 
rates fell again once vaccination uptake had resumed and remained low in the 1990s [2390 
cases were reported in 1996, despite a vaccine uptake of 95% (Miller, 1999)]. In most 
countries the disease is endemic, with regular epidemic cycles occurring every 3-5 years, 
both at a low level in immunized populations and at a high level in populations without 
vaccination (Kerr and Matthews, 2000). This traditional cycle pattern happens because it 
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takes a few years to develop a significant number of susceptibles in the population so that 
widespread transmission can occur.  
The average yearly incidence of reported or observed pertussis in the United States in the 
prevaccine period was 157 cases per 100,000 populations (Cherry, 1984). The average 
yearly incidence of reported pertussis in the prevaccine era in England and Wales was 230 
per 100,000 populations. However, it has been estimated that only 18% of cases were 
reported in the United States, giving an actual rate in the range of 872 cases per 100,000 
populations. Pertussis was an ever-present disease in the prevaccine period, and the 
epidemic cycles were every 2 to 5 years (on average about every 3 years) (Fine and 
Clarkson, 1982). The average interval between epidemic peaks in the prevaccine era in the 
USA (1922 to 1942) was similar to that in the early vaccine era (1962 to 1982) and the 
present vaccine era (1983 to 2004) (Cherry, 2003).  
It has been suggested that adults are now the majority of individuals that become infected 
with pertussis. Adults are often found to be the first case in a household with multiple 
pertussis cases. The importance of pertussis has been confirmed as the cause of persistent 
cough among teenagers and adults (Mattoo and Cherry, 2005). Adolescents and adults have 
thus become an important source of transmission of pertussis to other household members 
particularly infants and young children who are not adequately immunized since the 
diagnosis of pertussis often goes unrecognized in these older-age groups and treatment is 
delayed or administered only partially (Black, 1997).       
Pertussis is highly contagious and secondary attack rates may exceed 80% among 
susceptible household contacts. Transmission occurs by direct contact with respiratory 
secretions or via aerosol droplets from the respiratory tract of infected people. The organism 
is not thought to survive in the environment for a prolonged period and so transmission 
must occur from one individual to another (Black, 1997; Cherry, 1999). It is generally 
accepted that prolonged human carriage does not occur.  
1.3.2 Clinical features 
    The clinical features of pertussis tend to vary with age, general health and immune status. 
For example adults and older children often show mild or atypical symptoms (Roberts and 
Parton, 2001). The incubation period of pertussis is commonly 7 to 10 days, with a range of 
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4 to 21 days, and rarely may be as long as 42 days. The clinical course of the illness is 
divided into three stages.  
The first stage, the catarrhal stage, is characterized by the onset of coryza (runny nose), 
sneezing, low-grade fever, and a mild, occasional cough, and is similar to the common cold. 
The patient is most infectious during the initial stage of the disease before it is clearly 
distinguishable from a common cold. The cough gradually becomes more severe and, after 
1-2 weeks, the second or paroxysmal stage begins. 
It is during the paroxysmal stage that the diagnosis of pertussis is usually suspected. 
Characteristically, the patient has bursts, or paroxysms of numerous, rapid coughs, 
apparently due to difficulty in expelling thick mucus from the tracheobronchial tree. At the 
end of the paroxysm, a long inspiratory effort is usually accompanied by a characteristic 
high-pitched whoop. During such an attack, the patient may become cyanotic (turn blue). 
Children and young infants, especially, appear very ill and distressed. Vomiting and 
exhaustion commonly follow the episode. The patient usually appears normal between 
attacks. 
Paroxysmal attacks occur more frequently at night, with an average of 15 attacks per 24 
hours. During the first 1 or 2 weeks of this stage the attacks increase in frequency, then 
remain at the same level for 2 to 3 weeks, and then gradually decrease. The paroxysmal 
stage usually lasts 1 to 6 weeks, but may persist for up to 10 weeks. Infants under 6 months 
of age may not have the strength to have a whoop, but they do have paroxysms of coughing.  
In the convalescent stage, recovery is gradual. The cough becomes less paroxysmal and 
disappears over 2 to 3 weeks. However, paroxysms often persist with subsequent respiratory 
infections, many months after the commencement of pertussis.  
During the course of pertussis, fever is generally minimal. Older persons (i.e., adolescents 
and adults), and those incompletely protected by the vaccine, typically have milder disease. 
Pertussis in these persons may present as a continual (>7 days) cough, and may be difficult 
to differentiate from other upper respiratory infections. Up to 7% of cough illnesses per year 
in adults is estimated to be because of pertussis infection. Although the disease may be 
milder in older persons, these infected persons may transmit the disease to other vulnerable 
persons, including unimmunized or under-immunized infants. Secondary infections, such as 
otitis media and pneumonia, are relatively frequent, especially in infants, and may result 
from impairment of clearance mechanisms by the bacterium. Systemic manifestations of 
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disease may develop, associated with complications such as pulmonary atelectasis, 
bronchopneumonia, cyanotic paroxysms, and convulsions and, in rare instances, death 
(Halperin, 2004). Hypoxia from coughing may cause neurological complications, such as 
seizures and encephalopathy (a diffuse disorder of the brain), which are more common in 
infants.  
A high percentage of all reported cases of pertussis require hospitalization, especially those 
in infants less than 6 months of age. A recent estimate of the case-fatality rate in the US was 
0.2 % and the majority of these deaths (84%) were in infants < 6 months (Centers for 
Disease Control and Prevention: http://www.cdc.gov/health/diseases.htm).  
1.3.3 Pathogenesis 
    It is believed that B. pertussis enters the respiratory tract in aerosol droplets produced by 
the coughing of an infected person. The organism is able to change from virulent to 
avirulent states by switching on and off the expression of groups of genes in response to 
specific environmental stimuli (Roberts and Parton, 2001). Pertussis is thought to be 
primarily a toxin-mediated disease. The bacteria attach to the respiratory cilia; using various 
factors such as FHA (Filamentous haemagglutinin), FIM (Fimbriae), PT (Pertussis toxin), 
TcfA (Tracheal colonization factor), BrkA (Bordetella resistance to killing), Vag8 
(Virulence-activated gene-8 protein) and pertactin. They then produce toxins such as TCT 
(Tracheal cytotoxin), DNT (Dermonecrotic toxin) and CyaA (Adenylate cyclase) that 
paralyse the cilia, and cause inflammation of the respiratory tract, thus interfering with the 
clearing of pulmonary secretions and potentially causing pneumonia. Pertactin may act as 
an important adhesin but, in its absence, other proteins can perform this function (Mattoo 
and Cherry, 2005). 
B. pertussis can evade host defences using its various virulence factors. With increased 
numbers of bacteria, local damage employing TCT, DNT, and perhaps CyaA develops 
consisting of ciliostasis, extrusion of dead ciliated cells, and infiltration of inflammatory 
cells. It is suggested that B. pertussis has the ability not only to protect itself, but also to 
inhibit the normal host reaction to other potential pathogens. Hewlett et al. (1985) 
demonstrated that children with culture-proven pertussis have a reversible impairment in 
delayed hypersensitivity responses to a battery of antigens, which is not seen in children 
with other bacterial infections. 
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1.3.4 Diagnosis 
    Early diagnosis is important for effective therapy and prevention of transmission. 
Although diagnosis of pertussis on clinical grounds is easily accomplished when a patient 
presents with a whoop and other characteristic features, diagnosis without classical signs 
and symptoms is problematic (Halperin, 2004).  
In the past, laboratory diagnosis of these cases relied on conventional methods, including 
isolation in culture, direct detection of B. pertussis and/or B. parapertussis by direct 
fluorescent antibody (DFA) staining or by serological testing of paired acute and 
convalescent sera specimens. Isolation from respiratory specimens has a sensitivity and 
specificity of 73% and 85%-100% respectively, and often requires three to seven days for 
identification (Muller et al., 1997). Gram staining, urease, oxidase, and nitrate reduction 
reactions usually can confirm identity. The direct fluorescent antibody test uses fluorescein-
labelled antibodies to B. pertussis and B. parapertussis to detect the bacteria. The test is 
technically demanding, of low sensitivity and may give false negative results if the number 
of organisms in the specimen is low, or false positive results, due to lack of technical 
expertise, poor quality slides or antigenic cross-reactions with other organisms. Sensitivity 
and specificity of DFA are quite low (33% and 66%, respectively) with broad cross 
reactivity with normal microbial flora of the oropharynx and nasopharynx (Halperin et al., 
1989). Various serological tests such as agglutination, complement fixation and ELISA 
have been used to confirm the diagnosis of pertussis and parapertussis and are valuable in 
epidemiological and vaccine efficacy studies (Parton, 2003). Serological testing of sera of 
acute and convalescent specimens is a sensitive and specific epidemiological tool, but only 
yields retrospective information on infection.  
Polymerase chain reaction (PCR) is the most rapid and sensitive detection method for B. 
pertussis and other fastidious, slow-growing pathogens. Several polymerase chain reaction 
(PCR) assays for detection of Bordetella DNA have been developed that demonstrate 
significantly greater sensitivity and specificity than either isolation or DFA testing provides. 
Primers have been designed to target four regions in the chromosome: (i) the promoter 
region of the genes encoding PT, (ii) a DNA segment upstream of the porin gene, (iii) 
repeated insertion sequences, and (iv) the adenylate cyclase toxin gene, cyaA. All except 
cyaA primers are specific for B. pertussis (Dragsted et al., 2004). PCR for Bordetella 
pertussis has a sensitivity of 95.8%-98.9% and a specificity of 99.0%, which is dependent 
on the primers used and the gene targeted for amplification (Muller et al., 1997). With the 
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advent of real-time PCR technology, identification can be completed within 1h after 
extraction of the DNA from a swab sample (Sloan et al. 2002). PCR methods provide the 
clinician with more timely and accurate information than that provided by isolation, DFA, 
or serological testing methods. The potential problem associated with PCR in the diagnosis 
of pertussis and other respiratory illnesses is false-positive results (Meade and Bollen, 
1994). While the presence of B. pertussis and/or B. parapertussis DNA in a nasopharyngeal 
specimen strongly suggests active infection, the results should be used in conjunction with 
clinical presentation, patient history, and other diagnostic tests. When culture is associated 
with PCR and serologic testing, the greatest sensitivity occurs (Mattoo and Cherry, 2005).  
1.3.5 Antimicrobial therapy 
    Decreasing the infectivity of the patient by protecting close contacts of that patient can 
limit spread of pertussis. Antibiotics given in the catarrhal stage may ameliorate the disease. 
However after the onset of paroxysms, antimicrobials have no apparent effect on the course 
of illness and are given mainly to limit the spread of the organisms to others. The drug of 
choice is erythromycin for 14 days, during the catarrhal stage of illness, which shortens the 
duration of symptoms and eliminates the organism from the upper respiratory tract within 5 
days of initiation of therapy in most cases. Trimethoprim-sulfamethoxazole is a possible 
alternative for patients or contacts that do not tolerate erythromycin, and is effective in 
eradicating B. pertussis from the nasopharynx (CDC guidelines, 2005). 
1.3.6 Vaccination and prevention (whole-cell and acellular 
pertussis vaccines) 
    Pertussis vaccination is considered to be more effective at preventing disease rather than 
infection due to the fact that the interepidemic period has not increased since the 
introduction of vaccination (Crowcroft and Britto, 2002). Pertussis vaccines used world-
wide are generally whole-cell vaccines (WCVs). Vaccine potency, reactogenicity and the 
immune response that they produce, as well as the vaccination schedules, vary from country 
to country. Currently, worldwide pertussis vaccination coverage of children is about 80% 
(http://www.who.int/vaccines/en/pertussis.shtml).  
Whole-cell vaccines (WCVs) and the more recently developed acellular vaccines (ACVs) 
are the two types of vaccines used. Whole-cell pertussis vaccines composed of killed whole 
B. pertussis organisms were developed in the 1940s, when the role of B. pertussis antigens 
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in immunity was still unclear, and have been used worldwide for many years. It was 
recognized early on that the production of serum antibodies, clinical protection and clinical 
toxicity were directly correlated with the number of organisms in the vaccine. In the mid-
1940s, routine immunization of children with pertussis vaccines was started in the United 
States’ and, during the 1950s, other countries also started performing routine pertussis 
immunization (Cherry, 1984). These proved to be highly efficacious but concerns about 
safety and reactogenicity led to the development of acellular pertussis vaccines in the 1970s 
(Mooi et al., 2001).  
Sato et al. (1984) in Japan first described the production of acellular pertussis component 
vaccines, which contained known antigenic components in measurable quantities. The first 
DTaP vaccines were developed at the Japanese National Institutes of Health in the late 
1970s, where such vaccines were licensed for immunization of children aged two years or 
more in 1981, and for infants from the age of three months in 1989. All current acellular 
pertussis (aP) vaccines contain inactivated pertussis toxin which, in most cases, is combined 
with filamentous haemagglutinin and sometimes additional B. pertussis components such as 
fimbrial antigens and pertactin. The Ap vaccines are now available, either as individual 
vaccines or DTaP combinations, with or without the addition of hepatitis B, Hib, or 
poliovirus vaccine (IPV).  
One monocomponent aP vaccine consists of PT alone, which has been toxoided by 
hydrogen peroxide treatment. PT and FHA are used for the two component aP and the 
addition of Prn is used for the three component aP. The five component vaccines contain the 
same antigens that are used for the three component aP with the addition of fimbriae 2 and 
3. Most vaccines contain chemically toxoided PT (Hewlett, 1997). However, a third 
generation aP containing recombinant pertussis toxoid has been developed. This was 
considered to be an improvement over the chemically-toxoided PT as this treatment can 
change the structure and epitopes of molecules and reduce immunogenicity, thus requiring 
larger amounts of the antigen (Roberts and Parton, 2001). Field trials have shown the lower 
reactogenicity of ACVs (Jefferson et al., 2003), but only one of them, containing PT, 
pertactin, Fim and FHA has revealed an efficacy level as good as WCV (Miller, 1999). The 
WCVs have therefore been replaced in some countries by ACVs because of their lower 
reactogenicity. ACVs provide some level of protection against pertussis and it seems that 
the more components an ACV contains, the greater the protection it provides (Hewlett, 
1997).  
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DTaP causes moderate complications in less than 1% of injections, which include high 
fever greater than 105 degrees F (1 in 16,000 children), non-stop crying for more than 3 
hours (1 in 1,000 children) and seizure (1 in 14,000 children) (WHO, 2003). Side effects 
and the probability of reactions seem to be highest in recipients of boosters in whom 
acellular vaccines were used for priming (Miller et al., 2001). However, the aP vaccines are 
associated with immunological interference with other vaccines simultaneously 
administered at different sites. For example, the reduced immunogenicity of Hib vaccine 
when combined with some aP vaccines is of concern and needs further investigation 
(Mawas et al., 2005; Mawas et al., 2006). 
The complete genome sequence data is now available for B. pertussis (Parkhil et al., 2003) 
and it will give information on all the surface exposed and secreted proteins of an organism. 
This can lead to the identification of potential novel antigens from the genome sequence for 
possible addition to the next generation of acellular vaccines, a strategy known as reverse 
vaccinology (Preston and Maskell, 2002).   
1.3.7 Re-emergence of pertussis 
    Pertussis is an endemic disease even with the widespread use of vaccination, with 
frequent epidemic outbreaks. Mass vaccination has greatly reduced the incidence of 
pertussis; however, the disease is re-emerging even in some countries with high vaccination 
coverage. The resurgence of pertussis in countries such as the Netherlands, the United 
States, Canada and Australia has been studied to find an explanation for this re-emergence.   
In spite of mass vaccination against B. pertussis in the Netherlands since 1953, outbreaks of 
pertussis occurred in 1996, 1999 and 2001, when the vaccine coverage rate was 96% for at 
least three vaccinations in the first year of life. During the inter-epidemic years, the 
incidence of the disease did not return to levels observed before 1996. It has been suggested 
that B. pertussis variants in genes such as PT or pertactin may be responsible for a reduced 
efficacy of currently-used vaccines and an associated re-emergence of pertussis among 
vaccinated populations. Another postulate for re-emergence is that the role of herd 
immunity due to high levels of pertussis vaccination may influence endemic B. pertussis 
populations via selective pressure for strains which contain variants of genes (Byrne and 
Slack, 2006). The antigenic divergence between vaccine strains and clinical isolates has also 
been detected in other countries such as the US and Finland with high vaccine coverage 
(Mooi et al., 1999; Cassiday et al., 2000). Other possibilities for re-emergence might be 
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changes in surveillance (accuracy of notifications) and diagnostic criteria, changes in 
vaccine quality, decrease in vaccine coverage or waning vaccine-induced immunity.  
1.4 Bordetella pertussis 
1.4.1 Virulence factors 
    A pathogen is able to enter the host and interacts with a specific target tissue, evades host 
defences to survive, develops localized damage at the site of infection and may disseminate 
either itself or its products to cause systemic disease by its virulence factors. Many of the 
virulence factors characterized in the bordetellae are common to B. pertussis, B. 
parapertussis, and B. bronchiseptica. These consist of adhesins, such as filamentous 
hemagglutinin (FHA), pertactin, tracheal colonization factor and fimbriae, and toxins, such 
as adenylate cyclase haemolysin, dermonecrotic toxin and tracheal cytotoxin (Fig. 1.2). 
However, there are other virulence factors, which are expressed by just one of the species; 
such as pertussis toxin and serum resistance to killing protein (BrkA) expressed by B. 
pertussis or a type III secretion system expressed by B. bronchiseptica (Parkhill et al, 
2003).  
One of the strategies used in the recognition of virulence factors of pertussis include 
application of a modified form of Koch’s postulates (for example, the factor is produced 
only by virulent organisms and the purified factor produces effects analogous to the 
disease), by the characterization of mutant strains developed using transposon-mediated 
mutagenesis, and the use of bacterial challenge in immunized animals. However, this last 
approach is restricted, since a protective antigen is not necessarily a virulence factor. There 
are various possible virulence factors of B. pertussis (Kerr and Matthews, 2000). 
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Figure 1.2 Virulence factors of Bordetella pertussis (adapted from                   
www.molgen.uc.edu/_mediaPDF/faculty/alison.weiss.pdf.) 
  
1.4.1.1 Adhesins           
    Adhesion to host cells is critical to the initiation of infection by most bacterial pathogens. 
B. pertussis, B. parapertussis and B. bronchiseptica exhibit tropism for ciliated epithelia in 
the respiratory tract (Weiss and Hewlett, 1986; Soane et al., 2000). Bacterial replication 
leads to a great increase in the number of B. pertussis attached to the cilia and is coupled 
with the loss of ciliated and non-ciliated cells. B. pertussis produces, under the control of 
the BvgA/S system (see section 1.4.3), a number of surface adhesin molecules including 
fimbriae, also called agglutinogens, filamentous haemagglutinin, pertactin, the serum-
resistance protein BrkA and the attachment factor Tcf. 
1.4.1.1.1 Fimbriae  
    B. pertussis has two related but genetically-distinct serotypes, serotype 2 and serotype 3, 
due to expression of the major fimbrial subunits Fim2 (22.5 kDa) and Fim3 (22kDa) 
respectively. The bvg locus positively regulates their expression (Zhang et al., 1985; Mooi, 
1994).  In addition to the major subunits, the fimbriae also have the minor 40-kDa subunit 
FimD, at the tip of both types of fimbriae that acts as the adhesin (Willems et al., 1993; 
Geuijen et al., 1997). A periplasmic chaperone, FimB and an outer-membrane usher protein, 
FimC are required for the assembly of B. pertussis fimbriae.  
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In addition to bvg regulation, expression of the fim2 and fim3 genes is also regulated by 
mutations in their promoter regions, which leads to serotype switching (Willems et al., 
1990). In particular, a C-rich region may experience relatively frequent deletions or 
insertions, which strongly alters the transcription of the fimbrial genes. Therefore, some 
strains produce both types of fimbriae (serotype 2, 3), some only one (either serotype 2 or 
3), or some none at all (Locht, 1999). The genes fim2, fim3, fimX (a homologous gene, 
whose product has not been identified); and a recently identified fourth fimbrial locus, fimN 
(in B. bronchiseptica) (Kania et al., 2000) are single genes on the chromosome (Stibitz and 
Garletts, 1992), but the fimBCD genes are clustered together with the fha and bvg genes and 
compose a polycistronic operon with fhaC (Willems et al., 1994). It has been proposed that 
FimB and FimC function as a chaperone and usher, respectively, similar to the E. coli PapD 
and PapC (Willems et al., 1992). The arrangement of those genes, which are necessary for 
the production of Fim2 and Fim3 and the structural gene for the adhesive tip protein 
(FimD), is fimABCD. The first gene, fimA, is not expressed in B. pertussis because of a 
deletion at its 5`end. In contrast, intact fimA genes are present in B. bronchiseptica and B. 
parapertussis, and fimA is expressed in B. bronchiseptica, although its function has not 
been discerned (Locht et al., 1992; Willems et al., 1992; Boschwitz et al., 1997). 
The major fimbrial subunit, like FHA (see below), can bind sulphated glycoconjugates 
similar to heparan sulphate on the surface of epithelial cells (Geuijen et al., 1998). The 
minor subunit FimD attaches to the VLA-5 integrin of monocytes and macrophages. The 
binding of B. pertussis to VLA-5 upregulates CR3 (Complement Receptor type III) 
(Menozzi et al., 1991) integrin expression, and consequently increases the attachment of the 
organism via FHA to macrophages (Hazenbos et al., 1995) (section 1.4.1.1.2). Thus, the 
fimbriae and FHA may both assist in B. pertussis adhesion to, and perhaps invasion of, 
alveolar macrophages. Some studies in animal models using B. pertussis mutants have also 
suggested that FHA and fimbriae collaborate in the colonization of the trachea, which offers 
some biological insight to the tightly coordinated expression of these two adhesins.  The 
binding affinity of fimbriae is determined by both the degree and arrangement of sulphate 
groups on the cell surface receptors (Yanagishita et al., 1992). It has also been suggested 
that fimbriae play a minor role in biofilm formation (Irie et al., 2004).  
Fimbriae are highly immunogenic and stimulate the production of agglutinating antibodies 
(Robinson et al., 1986). The fimbriae were initially termed agglutinogens in view of the fact 
that anti-fimbrial antibodies in the sera of infected or vaccinated children agglutinated the 
bacteria. Furthermore, a correlation between the presence of agglutinating antibodies and 
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protection (Preston, 1976), supported the inclusion of Fim2 and Fim3 as antigens in some of 
the new acellular pertussis vaccines. The interactions of FIM with epithelial cells and 
monocytes/macrophages play an important role not only in adherence but also in the degree 
and nature of the immune response to pertussis (Mattoo and Cherry, 2005).     
1.4.1.1.2 Filamentous haemagglutinin 
    The best-studied B. pertussis adhesin is filamentous haemagglutinin (FHA). It appears to 
be the major adhesin of B. pertussis and one of the two haemagglutinins (the other being 
PT) and its primary role appears to be in colonization of the ciliated epithelium (Parton, 
2003). It is produced as a 367-kDa precursor encoded by the fhaB gene, which is positioned 
directly upstream of the bvg genes (Locht et al., 1993). The N-terminal and C-terminal 
proteolytic processing of the FhaB precursor leads to the 220-kDa mature FHA (Renauld-
Mongénie et al., 1996). Transport across the inner membrane is directed by a 71 amino acid 
signal sequence, which is then removed. Transport across the outer membrane requires an 
accessory outer membrane protein FhaC (Jacob-Dubuisson et al., 2000), whose gene is 
placed directly downstream of the structural fhaB gene. Eventually, the C-terminal portion 
is cleaved by the surface bound serine protease SphB1 (Coutte et al., 2001) (see below) and 
the N-terminal 220-kDa mature FHA is released.  
FHA is a filamentous structure about 2 nm wide and 50 nm long, folded into a monomeric 
inflexible rod based on a 19-residue repeat motif, which is rich in beta strands and turns 
(Makhov et al., 1994). The critical step in colonization and infection of the upper 
respiratory tract in pertussis is the adherence of B. pertussis to ciliated cells and 
macrophages, which requires the recognition of eukaryotic carbohydrates or integrins by 
FHA. Hence, three different domains of the mature FHA are involved in the differential 
recognition of receptors on host cells: (1) the first part, consisting of residues from 1 to 400 
are responsible for binding to sulphated sugars on mucus-secreting epithelial cells (Hannah 
et al., 1994), (2) a fragment including residues 1097 to 1099, the RGD sequence, binds to 
CR3 integrins on macrophages and ciliated cells (Locht et al., 1993), (3) A region from 
1141 to 1279, the carbohydrate recognition domain (CRD), is responsible for binding to 
lactosylceramides on macrophages and ciliated cells (Prasad et al., 1993), although it is not 
important for uptake of B. pertussis into macrophages. It has also been reported that the 
RGD motif of FHA binds to very late antigen 5 (VLA-5; an α5β1-integrin) of bronchial 
epithelial cells (Ishibashi et al., 2001), which consequently induces activation of NF-κB, 
followed by an up-regulation of the epithelial intercellular adhesion molecule 1 (ICAM-1) 
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(Ishibashi and Nishikawa, 2002). This up-regulation leads to the accumulation and 
activation of leukocytes at the site of bacterial infection. 
In the absence of opsonizing antibodies, FHA-mediated binding of B. pertussis to 
macrophages via CR3 leads to phagocytosis that does not result in subsequent killing and 
may be critical in the intracellular survival of this organism by enabling the bacteria to 
avoid triggering an oxidative burst and to survive and multiply intracellularly (Relman et 
al., 1990). FHA also binds the integrin sites that are important for recognition of C3bi, 
coagulation factor X, and endothelial cells. It can also inhibit the production of IL-12 by 
macrophages in response to LPS and γ-IFN, by stimulating the production of IL-10 
(McGuirk and Mills, 2000). Interaction of FHA with monocytes/macrophages has also been 
shown to induce apoptosis and to inhibit antigen-dependent CD4+ T cell proliferation 
(Abramson et al., 2001). FHA in B. bronchiseptica has been shown to play a critical role in 
immunomodulation and a role in host specificity (Inatsuka et al., 2005).     
FHA provokes a strong antibody response, in both humans and animal models, both 
systemically and mucosally (Thomas et al., 1989), and vaccination with purified FHA 
protects against respiratory challenge in mice. Therefore, FHA was incorporated in second-
generation acellular vaccines against whooping cough (Sato et al., 1984). It has been 
reported that acellular vaccines that contain FHA as well as PT toxoid have slightly greater 
efficacy than monocomponent PT toxoids (Cherry and Heininger, 2004). FHA also has 
adjuvant activity for antigens delivered with it by the nasal route (Poulain-Godefroy et al., 
1998). These properties have been considered for developing systems for presenting 
heterologous antigens to the epithelium of the respiratory tract (Renauld-Mongénie et al., 
1996).  
1.4.1.1.3 Pertactin   
    The autotransporter pertactin is a Bvg-regulated surface-located and secreted protein. 
This was initially referred to as P69 or 69-kDa protein, which reflected its apparent 
molecular weight and processed from a 93-kDa large precursor (Charles et al., 1994), as 
determined by SDS-PAGE. The actual size of the processed form is estimated to be 61 kDa, 
and the β-domain is 32 kDa. The protein is a virulence factor, and a member of the pertussis 
autotransporter proteins family (see section 1.5), and mediates adhesion to mammalian 
cells, a reaction mediated partly by an RGD sequence.  
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The X-ray crystal structure of P.69 pertactin has been solved to 2.5Å (the only 
autotransporter protein for which the crystal structure has been determined). The protein 
structure demonstrates a 16-strand parallel β-helix (the largest β-helix known to date) with a 
V-shaped cross-section. A number of weakly conserved amino acid repeats form internal 
and external ladders. Several loops project from the helix and contain sequence motifs that 
are responsible for the biological activity of the protein. A (GGXXP)5 sequence motif is 
positioned directly down from the RGD motif and may mediate interaction with epithelial 
cells, while the C-terminus region of P.69 pertactin contains a (PQP)5 motif loop with a 
major immunoprotective epitope (Emsley et al., 1996).  
It has been noted that pertactin is polymorphic between the various Bordetella species, and 
even between different strains within the same species (Mooi et al., 1998). Pertactin in B. 
pertussis (Charles et al., 1989), B. parapertussis (Li et al., 1991), and B. bronchiseptica (Li 
et al., 1992) corresponds to proteins of 69 kDa (P.69), 70 kDa (P.70), and 68-kDa (P.68), 
respectively. The different number of internal proline-rich tracts and leucine-rich repeats 
within the proteins explain the difference in size between mature P.68, P.69, and P.70, 
where the P.68 has the fewest and P.70 the most (Henderson and Nataro, 2001). These 
motifs are frequently present in molecules that are responsible for protein-protein 
interactions in eukaryotic cells (Emsley et al., 1994).   
Pertactin is produced at an intermediate phase, in vitro, during B. pertussis growth, after 
FHA and before pertussis toxin production (Kinnear et al., 1999). It supports the idea that, 
in vivo, FHA performs as an early adhesin molecule and pertactin encourages more intimate 
adhesion to mammalian cells at a following step and earlier to toxin release.  
During the development of a veterinary vaccine against B. bronchiseptica, pertactin was 
discovered (Novotny et al., 1985) and it was found that it provided protection in animal 
models. However, mutant strains lacking the pertactin protein appeared to colonize the 
mouse respiratory tract as efficiently as the wild type parent strains, although mutant strains 
deficient in both pertactin and FHA were shown to be cleared much more quickly than the 
wild-type parent strains (Locht, 1999). This supports the idea that pertactin is involved in 
bacterial adhesion. The protective effect of pertactin in animal models and its involvement 
in adhesion has targeted it as one of the antigens included in some of the new acellular 
pertussis vaccines (Gustafsson et al., 1996). 
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1.4.1.1.4 Bordetella resistance to killing protein (BrkA) 
    The autotransporter BrkA protein is a B. pertussis virulence factor that confers serum 
resistance and also operates as an adhesin (Fernandez and Weiss, 1994). Fernandez and 
Weiss identified an insertional mutant of B. pertussis, from a panel of strains with mutations 
in bvg-regulated genes caused by insertion of the transposon Tn5 lac (a transposon which 
possesses a promoterless β-galactosidase (β-Gal) gene, which is expressed only if the 
transposon inserts downstream of a functional promoter) which was at least 10-fold more 
susceptible to serum killing than the wild type (Fernandez and Weiss, 1994) and was less 
virulent in an infant mouse model where approximately 107 bacteria (CFU) were 
administered intranasally (Weiss and Goodwin, 1987). Serum sensitivity was assessed in 
vitro by exposing strains to 20% normal human serum for 60 min at 37°C, using 107 
organisms, followed by diluting the organisms 10-fold in phosphate-buffered saline (PBS) 
containing 10 mM EDTA to halt the complement activity (Fernandez and Weiss, 1994). 
The locus encoding this serum resistance function encodes two divergently-transcribed open 
reading frames, named BrkA and BrkB. Although both ORFs were originally thought to be 
essential for serum resistance (Fernandez and Weiss, 1994), the results observed for a BrkB 
mutant in its serum resistance were not statistically significant (Fernandez and Weiss, 
1998). Putative sites for BvgA binding are located within the 300 bases that separate the 
two ORFs. A third ORF is about 100 bases downstream of brkA, encoded on the 
complementary strand, is not necessary for serum resistance, and is homologous at the 
amino acid level to the heat shock protein-chaperonin Cpn60. BrkA shows an overall 29% 
sequence identity to pertactin and has two RGD motifs, a conserved proteolytic processing 
site and an outer membrane-targeting signal (Fig. 1.3). Like pertactin, BrkA has been shown 
to be involved in adherence to mammalian cells (see below). Despite the similarities, a 
pertactin mutant was not as sensitive to serum killing as the BrkA mutants. BrkB is 
comparable to ORFs of unknown function in E. coli and Mycobacterium leprae and is 
considered to be a cytoplasmic membrane protein (Fernandez and Weiss, 1994).  
BrkA is expressed as a 103-kDa precursor and like pertactin, contains outer-membrane 
localization signals and an approximately 300-residue C-terminal autotranslocator domain, 
which has 54.5% identity to that of pertactin (Fig. 1.3), suggesting that BrkA, like pertactin, 
may use a similar secretion mechanism (Locht, 1999). Recent analysis of BrkA with 
SignalP V2.0 (Nielsen et al., 1998) has predicted a 42-amino-acid signal peptide. The 103-
kDa precursor is processed during secretion to yield a 73-kDa N-terminal (passenger) α-
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domain and a 30-kDa C-terminal β-domain (Shannon and Fernandez, 1999). The cleaved 
73-kDa BrkA passenger remains firmly associated with the bacterial surface (Oliver and 
Fernandez, 2001; Oliver et al., 2003a) and cannot be detected in culture supernatants of B. 
pertussis (Oliver and Fernandez, 2001). The BrkA C-terminal domain is able to form a pore 
that supports the proposed model of autotransporter export (Shannon and Fernandez, 1999). 
The processing site, using the outer membrane fractions isolated from B. pertussis, lies 
between residues Asn 731  and Ala732  (Passerini et al., 1999). 
 
 
Figure 1.3 Structural comparison of BrkA and pertactin (Prn). The overall 
sequence identity of 29% rises to 54.5% at the C terminus. X and Xaa refer to any amino acid 
(Adapted from Fernandez and Weiss, 1994). 
 
It was shown recently that a region in the C-terminus of the BrkA passenger domain is 
necessary for its folding simultaneously with or subsequent to the translocation via the β-
domain channel (Oliver et al., 2003b) (see TypeV secretion system, section 1.6.5). This 31- 
to 39-amino-acid region, termed the linker region, is located immediately upstream of the β-
domain and, using deletion analysis, was found to be essential for surface expression of 
BrkA. This linker region, together with the β-domain, is characterized as the minimal BrkA 
translocation unit. Moreover, the linker region may also anchor the BrkA α-domain to the 
bacterial surface (Oliver et al., 2003b). This conserved region can be observed in a large 
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group of autotransporters with various functions, which indicates that it provides an 
important function for secretion of autotransporters.  
Several features in BrkA suggest that it is involved in adhesion to host cells. It contains two 
Arg-Gly-Asp motifs (RGD), which bind to integrin receptors on host cells, and two putative 
binding sites for sulphated glycoconjugates (SGXG), which could possibly imitate the 
FHA-heparin interaction (Fig. 1.3). It has been shown in vitro that the binding of a BrkA 
mutant strain to eukaryotic cells (human lung fibroblast cell line MRC-5) is about half of 
the level of the wild-type in a 3-h assay and, in mice challenged intranasally. The mutant is 
also less virulent than the wild-type parent strain in terms of lung colonization at 7 days 
(Fernandez and Weiss, 1994). 
Possible mechanisms of serum resistance have been suggested on the basis of the predicted 
amino acid sequences of BrkA. The outer membrane localization signal (Struyvé et al., 
1991) on BrkA suggests that it is targeted to the surface of B. pertussis, and it may act to 
prevent or block the binding of lytic antibody to a bactericidal target, or it could draw 
blocking antibody, which would present a similar function. Alternatively, the putative 
glycosaminoglycan attachment site (SGXG) (Fig. 1.3) on BrkA may control serum 
resistance. A heparin- (glycosaminoglycan) binding site on the serum protein vitronectin 
acts to inhibit the polymerization of the complement component C9 (Milis et al., 1993). It is 
supposed that BrkA could possibly utilize its putative heparin-binding site to prevent C9 
polymerization. The Rck protein mediates serum resistance in Salmonella typhimurium by a 
mechanism that inhibits the polymerization of the C9 protein of complement (Heffernan et 
al., 1992).  
It has also been suggested that BrkA inhibits activation or promotes degradation of C4 after 
deposition (Barnes and Weiss, 2001). This could occur either by preventing complement 
function or by recruiting a complement-inhibitory protein. BrkA could prevent complement 
function by acting as a protease against C1r, C1s, or C4, which would inactivate the C1r or 
C1s and inhibit deposition of C4. On the other hand, proteolysis of activated C4 would also 
result in decreased C4 deposition (Barnes and Weiss, 2001). Another possibility is that 
BrkA may bind to and activate a complement inhibitor. There are lots of inhibitors of the 
complement cascade but only four operate at the C1/C4 step, which are soluble C4 binding 
protein, C1 inhibitor, membrane-bound CD46 (membrane cofactor protein) and CR1. The 
likeliest binding partners for BrkA are the soluble complement regulators (Barnes and 
Weiss, 2001). It has been shown that purified C4 binding protein binds to filamentous 
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haemagglutinin (FHA) (Berggard et al., 1997). However, FHA is not an essential molecule 
for resistance to complement (Fernandez and Weiss, 1998), suggesting that C4 binding 
protein bound to FHA is not protective. It has been shown that deposition of C4 binding 
protein was greatly reduced on a FHA mutant, and less deposition was detected on a bvg 
mutant, which could not express all virulence factors, such as BrkA. Therefore, this 
additional decrease in binding may possibly indicate that BrkA can also bind C4 binding 
protein and this binding of C4 to BrkA may cause serum resistance (Barnes and Weiss, 
2001). 
Another possible mechanism of action could be the presence of two SGXG proteoglycan 
binding motifs on BrkA (Fernandez and Weiss, 1994), which permit efficient binding of the 
highly glycosylated C1 inhibitor (Bock et al., 986). Thus, the accumulation of C4 on the 
surface of the bacteria would be decreased via recruitment of either C4 binding protein or 
C1 inhibitor by BrkA. 
BrkA can therefore protect the bacterium, by inhibiting the activation of the complement 
cascade and this would have obvious benefits in the human respiratory tract where 
complement can be found. Inhibition of immune responses has obvious benefits for the 
bacterium (Barnes and Weiss, 2001). However, it has been shown that antibody alone is 
usually effective at opsonizing bacteria and promoting phagocytosis; adenylate cyclase 
toxin of B. pertussis (section 1.4.1.2.2) interferes with the process of opsonization with 
antibodies, as it inhibits phagocytosis by human neutrophils (Towbin et al., 1979). 
Southern blot analysis showed the presence of brkAB sequences in B. bronchiseptica and B. 
parapertussis but not in B. avium. Clinical isolates of B. bronchiseptica and B. 
parapertussis were also shown to be serum resistant, and wild-type strains with extra copies 
of the brk locus were two- to fivefold more resistant to serum killing (Fernandez and Weiss, 
1998). BrkA conferred resistance to killing by complement in a BrkA-deficient mutant 
strain of B. pertussis, but sensitivity to complement-mediated killing was not observed in a 
B. bronchiseptica BrkA mutant strain. This may possibly be due to the fact that B. 
bronchiseptica is naturally more resistant to complement than B. pertussis due to its LPS 
composition or because B. pertussis has an abbreviated O-antigen structure (Rambow et al., 
1998) (see section 1.4.1.2.5). 
BrkA is not a current component of any acellular pertussis vaccines although its role as a 
possible adhesin molecule and in mediating protection from complement suggests that it 
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might be considered for inclusion in any future generations of acellular pertussis vaccines. It 
has been shown recently that both the purified 73 kDa N-terminal α-domain of BrkA 
combined with Cpn60 chaperonin from B. pertussis soluble fractions stimulated antibodies 
in mice and induced a 42% protection rate against intracerebral challenge with live B. 
pertussis strain 18323 (Cainelli Gebara et al., 2007). Since acellular vaccines, unlike the 
generally more protective whole-cell vaccines, do not protect against intracerebral challenge 
in mice, these findings suggest that BrkA/Cpn60 might be useful additional components of 
acellular vaccines.                            
1.4.1.1.5 Tracheal colonization factor 
    Tracheal colonization factor A (TcfA) is produced by B. pertussis but not by B. 
bronchiseptica or B. parapertussis strains. The protein structure of TcfA is similar to 
pertactin, and seems to be particularly involved in the colonization of the trachea. When 
mice were challenged in a competition assay, with wild-type and a TcfA mutant strain of B. 
pertussis, the number of mutant bacteria isolated from the trachea was decreased 10-fold 
compared with the number of the wild-type strain (Finn and Stevens, 1995). The 
mechanism involved in the observed difference has yet to be clarified. 
The predicted amino acid sequence of TcfA shows a 68-kDa RGD-containing, proline-rich 
protein (Finn and Stevens, 1995). The C-terminal end of unprocessed TcfA is an 
autotransporter domain with a high degree of sequence similarity to those of pertactin and 
BrkA, suggesting a similar secretion mechanism. The C-terminus has a 50% amino acid 
identity to the pertactin β-domain (Finn and Stevens, 1995). The 34-kDa N-terminal α-
domain of TcfA contains an RGD motif presumed to be involved in integrin binding, like 
those of FHA, pertactin and BrkA. Immunoblots of B. pertussis whole-cell lysates with 
polyclonal antiserum raised against a part of the N-terminal portion of TcfA identified 90- 
and 60-kDa bands. Nevertheless, culture supernates of B. pertussis contained only the 60-
kDa form, suggesting the presence of outer-membrane-associated and secreted forms of the 
α-domain (Henderson and Nataro, 2001).  
1.4.1.2 Toxins 
    Apart from lipopolysaccharide, also called endotoxin, and the tracheal cytotoxin, which is 
a fragment of the Bordetella peptidoglycan, the other known B. pertussis toxins are 
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proteins. The three major protein toxins are pertussis toxin, adenylate cyclase toxin and 
dermonecrotic toxin (Locht, 1999). 
1.4.1.2.1 Pertussis toxin (PT) 
    Pertussis toxin (PT) is an exotoxin and a main colonization factor. It is released into the 
extracellular milieu and also remains cell-bound. PT is a 105 kDa hexamer, consisting of an 
A subunit, the S1 polypeptide (MW 26,026) and a complex pentamer B subunit comprising 
S2 (MW 21,925), S3 (MW 21,873), S4 (MW 12,059) and S5 (MW 11,013) polypeptides in 
a molar ratio of 1: 1: 2: 1 (Tamura et al., 1982; Saukkonen et al., 1992). The S1 subunit of 
PT, also called the A protomer, is responsible for most of the biological activities of the 
toxin and has enzymatic activity. The S2 to S5 subunits are responsible for the interaction of 
the toxin with the receptors of target cells by forming the B moiety of the toxin. There is a 
significant structural homology between the A and B subunits of PT and other bacterial 
toxins like cholera toxin of Vibrio cholerae, shiga toxin of Shigella dysenteriae and the 
heat-labile toxin of E. coli (Madan Babu et al., 2001). 
PT is expressed by B. pertussis and is actively secreted. The full set of structural genes for 
the toxin subunits, ptx, and for toxin translocation, ptl, are also present in the B. 
parapertussis and B. bronchiseptica genomes (Marchitto et al., 1987). However, it has been 
shown to be transcriptionally silent due to the existence of defective promoters or activator 
(BvgA) binding sites (Arico and Rappuoli, 1987). All the toxin subunits are individually 
translocated through the inner membrane, via classical signal peptides. The subunits 
assemble into the holotoxin structure inside the periplasm, after the removal of signal 
peptides, and then the assembled toxin is secreted into the extracellular milieu of B. 
pertussis. Nine accessory proteins encoded by the ptl genes, which are positioned 
immediately downstream from the five structural ptx genes, are required for this last step in 
toxin secretion (Weiss et al., 1993). They are cotranscribed with the ptx genes, in a single 
polycistronic operon. As with many other virulence genes of B. pertussis, the activation of 
the ptx operon is Bvg-dependent (Boucher et al., 1997). 
The molecular action of the toxin can be separated into three main steps, (i) the toxin 
becomes attached to target cell receptors by the B oligomer, (ii) the S1 subunit is 
translocated into the cytosol, and (iii) the enzyme activity of the translocated S1 subunit is 
activated (Locht and Antoine, 1995). ADP-ribosyltransferase activity in the S1 subunit 
employs NAD for signal transduction, and G proteins in target cells as ADP-ribosyl 
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acceptors. The toxin has a diversity of pathophysiological effects, depending on the affected 
cell type, such as histamine sensitization, activation of insulin secretion, or lymphocytosis, 
hallmarks of the whooping cough syndrome (Munoz, 1985). However, it has been 
suggested that this toxin is probably not directly responsible for the typical paroxysmal 
cough and vomiting which are characteristic of pertussis (Locht, 1999). Recently, in the rat, 
it was shown that the PT caused relaxation of small arteries without causing vascular lesions 
or inducing morphological or numerical changes in cell organelles such as contractile 
elements of vascular smooth muscle cells (van Meijeren et al., 2004).  
After human infection with B. pertussis or vaccination with classical whole-cell vaccine, 
high levels of antibody to PT can be detected (Thomas et al., 1989). Moreover, the toxin 
alone, in toxoid form, provides protection against challenge in mouse models (Locht, 1999). 
Today, inactivated PT is therefore the major protective antigen in all the available acellular 
vaccines. More recently, plasmid DNA expressing the S1 subunit of PT was evaluated for 
immunogenicity and for the ability to induce protection against PT challenge or B. pertussis 
infection in mice. This DNA vaccination induced anti-PT IgG antibody production, 
inhibited leukocytosis-promoting activity and induced protection against intracerebral 
challenge with B. pertussis (Kamachi et al., 2003). 
1.4.1.2.2 Adenylate cyclase toxin (CyaA) 
    Adenylate cyclase toxin (CyaA), an important invasive toxin secreted by B. pertussis, is a 
bifunctional calmodulin-sensitive adenylate cyclase/haemolysin. The cya operon of B. 
pertussis encodes the adenylate cyclase toxin and contains five genes: cyaA, B, C, D and E 
(Figure 1.4). The cya operon is under the regulation of the bvg locus and expressed 
maximally in the Bvg+ phase. Adenylate cyclase is secreted without proteolytic processing 
which is different from other Bordetella virulence factors. Three accessory proteins, CyaB, 
CyaD and CyaE, the genes for which are positioned directly downstream of the adenylate 
cyclase structural gene (cyaA), are responsible for toxin secretion (Glaser et al., 1988). A 
single promoter controls the expression of cyaA, which encodes the toxin. This region binds 
BvgA phosphate to a widespread sequence covering positions from –137 to –51 on the 
promoter upstream to the transcriptional start site. This part includes several heptameric 
variants of the BvgA-binding consensus 5’-TTTCCTA-3’. A second promoter, located 
between cyaA and cyaB genes, controls the expression of cyaB, D and E. The gene cyaC is 
transcribed in the opposite direction to the other genes in the cya operon and the cyaC 
product is essential for the palmitoylation of CyaA at Lys 983 in terms of converting it into 
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the active form (Glaser et al., 1988). Secretion of a functional CyaA requires the products of 
all these genes (Glaser et al., 1988). 
CyaA has two activities, adenylate cyclase enzymatic activity and pore-forming/haemolytic 
activity, which are on different domains of the protein (Fig. 1.5). The pore 
forming/haemolytic domain enables the enzymatic domain to enter into the target cell. The 
entry of the CyaA toxin into eukaryotic cells is performed in the following order: (i) the 
toxin binds to the target cell surface by interacting with integrin receptor CD11b/CD18 
(Guermonprez et al., 2001) but in the absence of this receptor can also penetrate lipid 
bilayers (Martin et al., 2004). Binding is dependent on the palmitoylation of Lys 983. (ii) 
The haemolytic domain of the toxin makes a pore or channel (Iwaki et al., 2000). 
Subsequent to its entry into the cell, the toxin demonstrates adenylate cyclase activity which 
is activated in eukaryotic cells by calmodulin (Ladant, 1988). It generates almost a 
thousand-fold increase in intracellular cAMP levels in phagocytic cells which are thought to 
be the primary target, and inhibits their various chemotactic, phagocytic and bactericidal 
activities (Mooi, 1988).  
 
Figure 1.4 The cya operon. The cyaC gene is controlled by promoter PCyaC and transcribed 
in the opposite direction to that of the other genes in the cya operon (Adopted from Madan Babu et 
al., 2001).   
   
The N-terminal portion of the toxin contains the catalytic domain. Multiple GGXGXDXLX 
repeats (Fig. 1.5) in the C-terminal portion makes adenylate cyclase toxin a member of the 
RTX (repeats-in-toxin) family, a group of calcium-dependent, pore-forming cytotoxins. 
Calcium ion may bind to these repeats as an essential ion for toxin activity (Glaser et al., 
1988). 
It has been shown that adenylate cyclase mutant strains of B. pertussis colonized the 
respiratory tract of infected mice much less than the wild-type strains (Weiss et al., 1984). 
Moreover, CyaA-deficient mutants were not able to produce lethal infection in infant mice, 
unlike wild-type strains (Weiss and Goodwin, 1989). Also, the adenylate cyclase toxin is 
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responsible for cell death, via apoptosis, of alveolar macrophages that come into contact 
with B. pertussis. This phenomenon may possibly be a main way for the organism to escape 
the innate immune system of the infected host, and enable it to efficiently colonize the host. 
For the initiation of apoptosis, both enzymic and pore-forming activities are required 
(Khelef et al., 1992). It has been suggested therefore that CyaA acts primarily as an 
antiphagocytic and anti-inflammatory factor during infection. It has also been shown that 
the B. bronchiseptica adenylate cyclase toxin (ACT) and a type III secretion system (T3SS) 
modulate multiple signal transduction pathways resulting in bacterial persistance (Skinner et 
al., 2005). ACT and TTSS disrupt cell-signalling pathways resulting in production of 
immunosuppressive cytokines and the systemic suppression of IFN-γ production 
(Reissinger et al., 2005).      
It has been shown that adenylate cyclase toxin from B. pertussis protected infant mice 
against lethal challenge and also shortened the duration of lung colonisation challenged 14 
days after vaccination (Guiso et al., 1989; Guiso et al., 1991). The purified active CyaA, 
either the native form from B. pertussis or the recombinant form, also showed protective 
activity in mice against intranasal challenge with B. pertussis (Hormozi et al., 1999).  
 
 
  
Figure 1.5 Structural organization of the CyaA toxin. The catalytic domain extends 
from 1 to 400 amino acid residues, and contains the T25 and T18 subdomains. The T18 domain 
includes the calmodulin-binding site. The pore-forming haemolytic domain extends from amino 
acids 401 to 1706 and contains Lys 983 (required for activation by palmitoylation mediated by 
CyaC) and calcium binding sites with tandem repeats of the sequence GGXGXDXLX (Adapted 
from Ladant and Ullmann, 1999). 
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More recently, it has been shown that the adenylate cyclase of B. pertussis can act as an 
adjuvant for other antigens, particularly a form of CyaA lacking enzymatic activity 
(CyaA*). The CyaA* form enhanced protection when co-administered intraperitonealy with 
an acellular pertussis vaccine and this enhancement was associated with an augmentation of 
both Th1 and Th2 immune responses to B. pertussis antigens (Cheung et al., 2006). CyaA* 
was also shown to act as a mucosal adjuvant when co-administered with other antigens by 
the intranasal route (Orr et al., 2007). Moreover, since CyaA can deliver its N-terminal 
catalytic domain into antigen-presenting cells, and has several permissive sites that allows 
peptides to be inserted without altering the ability of the toxin to enter cells, recombinant 
CyaA toxoids have been designed to deliver epitopes into antigen-presenting cells to induce 
cell-mediated immune responses in vivo (Fayolle et al., 2001).  
1.4.1.2.3 Dermonecrotic toxin (DNT)       
    Dermonecrotic toxin (DNT), originally called heat-labile toxin, is a 102 kDa protein 
(Nakase and Endoh, 1985), whose activity is destroyed by heating at 60˚C for 10 min. It 
induces lethality when injected intravenously or intraperitoneally into animals and 
inflammation, vasoconstriction and local dermonecrotic lesions when injected intradermally 
into mice (Endoh et al., 1990). DNT is not secreted like the other Bordetella toxins and was 
therefore initially misidentified as an endotoxin (Bordet and Gengou, 1909).  
The toxin is an A-B toxin composed of an N-terminal receptor-binding (B) domain and a C-
terminal enzymatically active (A) domain (Matsuzawa et al., 2002). Nearly identical 
proteins are produced by all three major Bordetella species (Locht, 1999) and by B. avium. 
DNT is another virulence factor that is controlled by the regulatory locus bvg. Avirulent 
phase B. bronchiseptica strains express some DNT but in much reduced amounts compared 
to wild-type strains (Pullinger et al., 1996). It has also been shown that transposon mutants 
of B. pertussis lacking dermonecrotic toxin are not noticeably less virulent than wild type 
strains in mice (Weiss and Goodwin, 1989) and, therefore, its role as a virulence factor in 
pertussis remains obscure.  
DNT is known to induce nuclear division in mammalian cells without subsequent cell 
division, resulting in bi- or multi-nucleation and stimulation of stress fibre formation. DNT 
binds to cells through its N-terminal region consisting of 54 amino acids (Matsuzawa et al., 
2002). This region appears to recognize and bind to a cell surface receptor specific to toxin-
sensitive cells and not to resistant cells.  
  Introduction  
 
29 
It has been reported that DNT inhibits the elevation of alkaline phosphatase activity and 
reduces the expression of type-I collagen in an osteoblast-like cell line (Horiguchi et al., 
1991). It also induces the assembly of actin stress fibres and tyrosine phosphorylation of 
focal adhesion kinase (Horiguchi et al., 1994). Deamidation of glutamine 63, which is 
essential for GTP hydrolysis by Rho (the small GTP-binding protein), involving residues 
1136 to 1451 of DNT is believed to be the reason for the effects of DNT (Schmidt et al., 
1999). Deamidation of glutamine by DNT inhibits the GTPase activity of Rho and causes 
the Rho protein to be constitutively active. Rho GTPases are regulators of the actin 
cytoskeleton and act as molecular switches to trigger several intracellular signalling 
pathways (Madan Babu et al., 2001). 
1.4.1.2.4 Tracheal cytotoxin (TCT) 
    The characteristic paroxysmal cough (pertussis) caused by B. pertussis is likely to be 
attributed, in part at least, to the elaboration of the tracheal cytotoxin (TCT). TCT 
production is not controlled via the two components BvgA/S regulatory system (Locht, 
1999). Purified and biologically-active TCT contains amino acids and amino sugar residues 
consistent with its proposed peptidoglycan origin and it was found to be a released fragment 
of B. pertussis peptidoglycan (Cookson et al., 1989). Tracheal cytotoxin (TCT) was 
discovered by its ability to cause ciliostasis (restriction of the free movement of cilia) and 
effects the killing and extrusion of ciliated epithelial cells in hamster tracheal organ cultures 
and inhibition of DNA synthesis in hamster tracheal epithelial cell cultures (Goldman et al., 
1982).  
TCT stimulates release of intracellular interleukin-1 (IL-1) and of nitric oxide (NO), the 
most likely triggers of TCT-mediated cytopathy (Heiss et al., 1994). The TCT-dependent 
increase in NO is proposed to be the cause of respiratory cytopathology in the ciliated 
epithelial cells of the bronchial tract associated with the infection. The production of NO in 
the airway epithelium is induced synergistically by the action of TCT and Bordetella LPS 
(Flak and Goldman, 1999). TCT, even at very low concentrations, also impairs neutrophil 
functions and may thereby contribute to survival of bordetellae in vivo (Cundell et al., 
1994). TCT is also produced by at least some other Bordetella species, B. pertussis, B. 
parapertussis, B. bronchiseptica and B. avium, suggesting that it may be of general 
importance in bordetellosis. A promising new attenuated live B. pertussis vaccine strain was 
developed by the inactivation or removal of genes for PT, DNT and prevention of release of 
TCT. The latter was accomplished by replacement of the B. pertussis ampG gene by E. coli 
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ampG, more efficient at recycling the petidoglycan fragments, resulting in expression of 
<1% of the original TCT activity. This strain was able to colonize the respiratory tract of 
mice and induce strong protective immunity after a single nasal administration (Mielcarek 
et al., 2006).    
1.4.1.2.5 Lipopolysaccharide 
    The outer membranes of gram-negative bacteria (Fig. 1.6) (such as B. pertussis) are 
composed of lipopolysaccharides (LPS), proteins and phospholipids that are organised in a 
complex manner. The outer membrane acts as a barrier to exclude harmful substances and 
explains the fact that Gram-negative bacteria are less affected than Gram-positive bacteria 
by lysozyme and penicillin, as well as by other antibiotics (Voet & Voet, 1995). 
           
 
Figure 1.6  Schematic representation of the inner and outer membranes of E. 
coli K-12. Coloured ovals and rectangles represent sugar residues, whereas circles represent polar 
headgroups of various lipids (Raetz and Whitfield, 2002). Abbreviations: MDO, membrane-derived 
oligosaccharide; PPEtn, phosphoethanolamine; Kdo, 3-deoxy-d-manno-oct-2-ulosonic acid; LPS, 
lipopolysaccharide 
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LPS of Gram-negative bacteria, also called endotoxin, are amphipathic molecules and 
located in bacterial outer membranes (Figure 1.6).  All LPS contain a non-polar lipid A, 
which anchors LPS in the outer membrane and is covalently attached to a 
heteropolysaccharide chain. This chain is composed of a core oligosaccharide and in some 
cases, an O-antigen. The heteropolysaccharide can contribute to the serological identity of 
the bacterium since it is exposed to the extracellular medium. The O-antigen is composed of 
repeating oligosaccharide units, which are specifically exhibited on each bacterial strain. 
The O-antigen confers smoothness to the organism, which decreases the likelihood that a 
bacterial cell will be phagocytised. The surface hydrophobicity of the organism is reduced 
by O-antigen to allow better interaction with other protein-coated membranes.  
The LPS molecules from the three bordetellae (B. pertussis, B. parapertussis and B. 
bronchiseptica) share basic structural features such as the lipid A domain and a branched-
chain core oligosaccharide (Lebbar et al., 1994), but there are also considerable differences. 
One of the most important of these is that B. bronchiseptica and B. parapertussis synthesize 
a long chain polysaccharide structure including a homopolymer of 2,3-dideoxy-2,3-diN-
acetylgalactosaminuronic acid (2,3-di-NAcGalA), whereas B. pertussis does not (DiFabio et 
al., 1992). The endotoxin of B. pertussis is referred to as lipo-oligosaccharide (LOS) 
(Brodeur et al., 1993). This structural difference between the LPS molecules of the three 
main pathogenic bordetellae leads to quite different surface properties of the different 
species.  
The full structure of the LPS (LOS) of B. pertussis (Fig. 1.7) has been identified (Caroff, 
2000). It is resolved as two separate bands (A and B) on silver-stained SDS-PAGE.  
Monosaccharides of the B. pertussis core oligosaccharide (band B) (faster-migrating band) 
are composed of charged galactosaminuronic acid (GalNAc), glucuronic acid (GlcA) and 
glucosamine (GlcN), which are not commonly found as components of other LPS core 
molecules. The lipid A of LPS is covalently linked to a single ketodeoxyoctulosonic acid 
(Kdo) residue and then to a branched-chain oligosaccharide (Allen et al., 1998b).  
The wlb gene locus (formerly bpl) (Reeves et al., 1996) in B. pertussis is well conserved 
among the Bordetella subspecies using sequence homology studies. This gene locus is 
required for LPS trisaccharide biosynthesis (Allen et al., 1998a) and is composed of 12 
genes, wlbA to wlbL. The first two open reading frames in the wlb locus point leftwards and 
encode WaaA (for the addition of Kdo) and WaaC (for the addition of the first heptose). 
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The stop codon of the waaC gene overlaps with the start codon of waaA, which suggests 
that the two enzymes are translated together.  
 
 
Figure 1.7 Chemical structure of B. pertussis LPS (LOS) and its abbreviated 
formula (From Caroff, 2000) 
 
It has been suggested that wlbA encodes a dehydrogenase, wlbB encodes an acetylation 
enzyme, the product of wlbC transfers amino groups to sugars (and is homologous to 
WlbF), that of wlbD is a UDP-GlcNAc-2’-empimerase, which catalyses the formation of 
UDP-ManNAc, and wlbE encodes a sugar transferase. wlbF, wlbG, wlbH, encode a putative 
enzyme, a transferase, and a transferase, all of which are involved in adding sugars to the 
trisaccharide unit, respectively. wlbI encodes an integral membrane protein which is 
probably responsible for the export of band A and/or assembly of the final full-length LPS 
molecule. However, wlbJ and wlbK are two distinct genes in B. pertussis, but are in a single 
open reading frame in B. bronchiseptica and B. parapertussis. It has been shown that LPS 
biosynthesis is not affected by mutations in wlbJK. The wbm locus is located adjacent 
(immediately downstream) to the wlb locus in B. bronchiseptica and B. parapertussis, and 
is for the assembly of O antigen.The locus is replaced by an insertion sequence (IS) in B. 
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pertussis (Preston et al., 1999). A deletion of wbm in these species led to loss of O antigen 
expression (Burns et al., 2003). The Maskell group has constructed some B. pertussis 
mutants lacking the LPS band A trisaccharide, which have been shown to be severely 
compromised in their ability to infect mice (Maskell and Allen, 1996). 
It has been suggested that changes of LPS structure in B. bronchiseptica is controlled by the 
BvgAS virulence regulatory system. A BvgAS-regulated lipid A palmitoyl transferase gene, 
pagP, is responsible for the palmitoylation of lipid A in B. bronchiseptica (Pilione et al., 
2004). However, identical open reading frames for pagP have been identified in B. pertussis 
and B. parapertussis, but the pagP gene is not expressed in B. pertussis due to a disruption 
of the putative promoter by an IS element (Pilione et al., 2004).  
LPS modification is a mechanism employed by Gram-negative bacteria during infection to 
resist host antimicrobial factors, avoidance of immune system recognition and maintaining a 
virulence phenotype (Gunn, 2001). These modifications include fatty acid additions, 
phosphoethanolamine (PEtN) addition to the core and lipid A regions, 4-amino-4-deoxy-L-
arabinose (Ara4N) addition to the core and lipid A regions, acetylation of the O-antigen, 
and probably hydroxylation of fatty acids. Antimicrobial peptides (APs) are considered to 
kill micro-organisms by disturbing membrane integrity. These positively-charged peptides 
interact with negative charges in the LPS of Gram-negative bacteria (Gunn, 2001). It has 
been reported that LPS (LOS) protects B. pertussis from surfactant protein A (SP-A)-
mediated clearance, by limiting access of SP-A to the lipid A region, the target for SP-A 
binding (Schaeffer et al., 2004). LPS may also have a role in the resistance of B. pertussis to 
antibiotics (Turcotte, 1997). The lipid A pathway could therefore be an excellent target for 
the design of new antibiotics against Gram-negative bacteria, such as Bordetella pertussis 
(Onishi et al., 1996).   
It has been shown that the B. bronchiseptica is more resistant to complement than B. 
pertussis (Byrd et al., 1991), and that BrkA does not mediate serum resistance in B. 
bronchiseptica (Rambow et al., 1998). This difference could be explained by the 
compositions of their LPS. As explained above, in contrast to B. bronchiseptica, which 
produces long LPS molecules with many O-chain repeats similar to the LPS of Escherichia 
coli, B. pertussis has an abbreviated LPS structure and its O chain is composed of a single 
trisaccharide that is not repeated (Allen and Maskell, 1996). These long LPS molecules of 
the enterics are thought to confer resistance to complement by blocking the membrane 
attack complex from binding to the bacterial membrane (Moffitt and Frank, 1994). An O-
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chain repeats deficient mutant of B. bronchiseptica was shown to be extremely sensitive to 
complement (Byrd et al., 1991). However, the resistance of the avirulent-phase bvg mutant 
RB54 remains to be determined (Rambow et al., 1998) 
B. pertussis LOS has the properties of toxicity, pyrogenicity and adjuvanticity characteristic 
of endotoxin (Parton, 2004). It also has the ability to induce antiviral activity, B-cell 
mitogenicity and polyclonal B-cell activation (Chaby and Caroff, 1988). LOS in the whole-
cell pertussis vaccine is considered to be non-protective and can contribute to the vaccine’s 
toxicity and reactogenicity, therefore it was suggested that LOS should be excluded from 
acellular pertussis vaccines (Robinson et al., 1985). However, B. pertussis LOS may 
contribute to induction of immunity. LOS signalling through toll-like receptor 4 (TLR4) in 
innate immune cells has been shown to play a critical role in the production of 
inflammatory cytokines such as IL-12, IL-23 and IL-1, which induce Th1 and Th-17 cells, 
after immunisation of mice with whole-pertussis vaccine, to finally promote bacterial killing 
by macrophages (Higgins et al., 2006).   
1.4.2 Other potential virulence factors 
1.4.2.1 Outer-membrane protein P 
    B. pertussis produces a 40 kDa porin protein which complexes in the outer membrane to 
form a channel for anionic molecules and this porin resembles porin protein P of 
Pseudomonas aeruginosa (Armstrong et al., 1986). The structural gene for this major porin, 
ompP was identified and sequenced by Li et al. (1991b). OmpP is expressed by Bvg+ and 
Bvg- B. pertussis strains and Southern blot analysis also revealed the presence of the gene in 
B. parapertussis and B. bronchiseptica. In Bvg+ strains of B. pertussis this porin has the 
property of existing in a native crystalline pattern whereas Bvg- strains did not display this 
property (Kessel et al., 1988).  
1.4.2.2 Outer-membrane protein Q  
    The gene ompQ encodes a porin-like protein OmpQ, which has a molecular mass of 
39,133 Da (Finn et al., 1995). A mutant of B. pertussis strain 18323 lacking OmpQ was not 
adversely affected in its ability in to survive in the mouse aerosol challenge model and was 
not affected in its ability to survive in vitro (Finn et al., 1995). The lack of effect was 
unexpected as Finn et al. (1995) had suggested that OmpQ may have an important role in 
  Introduction  
 
35 
allowing the bacterium to have access to essential nutrients. In the mouse model system, it 
may be that other outer membrane proteins are able to substitute for OmpQ or the protein 
may not be involved in the infectious process. OmpQ is expressed along with other Bvg+ 
proteins and for this reason it was suggested that the protein plays a role during the 
infectious process in the human host or in the establishment of a carrier state. ompQ was 
present in B. parapertussis and B. bronchiseptica but was not found to be present in B. 
avium (Finn et al., 1995).  
1.4.2.3 Bordetella intermediate phase protein 
    Bordetella intermediate phase protein (BipA), a surface-expressed protein, is encoded by 
the gene bipA. BipA is expressed by B. pertussis, ovine B. parapertussis and B. 
bronchiseptica strains but not by human B. parapertussis strains (Fuchslocher et al., 2003). 
RT-PCR analysis indicated that bipA was expressed maximally under semi-modulating 
(Bvgi phase) conditions and that expression was controlled at the level of transcription 
(Stockbauer et al., 2001). The C-terminus of BipA is exposed on the surface of B. 
bronchiseptica and, consistent with this topology, the predicted amino acid sequence of the 
N-terminal 500 amino acids shares significant similarity with the membrane localisation 
domains of EHEC and EPEC intimin and Yersinia invasin. The fact that bipA is absent from 
some strains and is not expressed or expressed at very low levels in others suggests that the 
role that BipA plays in the infectious cycle is either not essential or can be compensated for 
by other genes (Fuchslocher et al., 2003). However, BipA could play some important role 
that is unique to the strains that express it.  
1.4.2.4 Vir90 
    A potential virulence factor of B. pertussis, Vir90, has been described recently (Passerini 
de Rossi et al., 2003). The protein sequence displayed closest homology with a number of 
ferrisiderophore receptors from Gram-negative bacteria. vir90 open reading frames were 
also found in B. parapertussis and B. bronchiseptica genomes. This protein is encoded by a 
gene of 2322 bp, which is highly conserved between B. pertussis and B. bronchiseptica 
(99% homology) and between B. pertussis and B. parapertussis (98% homology). Its 
expression is under control of a vegetative promoter whose transcription could be 
environmentally-modulated, during infection, by the concerted action of BvgA and the 
repressor Fur (Passerini de Rossi et al., 2003). It was suggested that Vir90 may play a role 
in the uptake of iron. 
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1.4.2.5 Subtilisin-like Ser protease/lipoprotein (SphB1)    
    Maturation of many secreted proteins in eukaryotes is performed by pro-protein 
convertases that belong to the superfamily of subtilisin-like proteases (Bergeron et al., 
2000). SphB1 is the first reported autotransporter whose α-domain provides a maturation 
factor for another protein secreted by the same organism. It has been identified as a 
subtilisin-like serine protease/lipoprotein, which is essential for the cleavage and maturation 
of FHA. As mentioned earlier (see section 1.4.1.1.2), the maturation and secretion of the 
230 kDa FHA of B. pertussis requires the proteolytic removal of a ∼130 kDa C-terminal 
intramolecular chaperone domain from the 367 kDa precursor (FhaB), which SphB1, a 
specific protease, is responsible for. SphB1 is probably not a general-purpose protease, and 
the maturation of FHA might be the major, if not only, function of it (Coutte et al., 2001). 
1.4.2.6 Virulence-activated gene-8 (vag-8) 
    B. pertussis expresses a bvg-regulated 95-kDa protein called Vag8, the fourth member of 
the bordetella autotransporter family to be identified (Finn and Amsbaugh, 1998). The N-
terminal sequence of a 92-kDa protein described by Hamstra et al. (1995) identified this 
protein as Vag8 and a 91-kDa virulence-associated protein described by Armstrong and 
Parker (1986) can also now be identified as Vag8. The N-terminus of this polypeptide 
possesses a predicted 37 amino acid signal sequence and the cleavage of this would 
generate a mature protein of 91 kDa (Finn and Amsbaugh, 1998). Moreover, it is not 
cleaved away from its β-domain like some other Bordetella autotransporters. Southern blot 
analysis indicated that strains of B. bronchiseptica and B. parapertussis carry vag8-
homologous DNA, yet expression of the protein has not been detected in B. parapertussis 
(Finn and Amsbaugh, 1998). 
This protein showed greatest homology with the C-terminal ends of Prn, BrkA, and Tcf, 
with amino acid identity of their transport domains ranging from 33-44%.  Vag-8 like other 
well-known B. pertussis autotransporters i.e. Prn, Tcf and BrkA, also contains an RGD site 
and two SGXG motifs (Fig 1.11). It has been shown that a Vag8-knock out derivative of B. 
pertussis colonized mice as efficiently as the parent B. pertussis strain in a mouse aerosol 
model of pertussis (Finn and Amsbaugh, 1998) so its role in virulence was unclear.   
More recent data have indicated that Vag8 is involved in type III secretion in B. 
bronchiseptica. Genes encoding components of type III secretion system and its potential 
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translocated proteins have been identified in B. bronchiseptica, ovine B. parapertussis, 
human B. parapertussis and B. pertussis. Previously this secretion system appeared to only 
be expressed in B. bronchiseptica and ovine B. parapertussis strains (Yuk et al., 1998; 
2000) but it is now thought to be also expressed by B. pertussis and human B. parapertussis 
isolates (Hennuy et al., 2002).  B. bronchiseptica contains a bvg-regulated extracytoplasmic 
sigma factor (ECF), TrS, which controls the expression of virulence factors including the 
type III secretion system. Vag8 also seems to be regulated by TrS as analysis of the vag8 
promoter region revealed the presence of three putative sites where ECFs bind (Mattoo et 
al., 2004). 
1.4.2.7 Pertactin homologous gene (phg) 
    Phg is highly conserved in B. pertussis, B. parapertussis and B. bronchiseptica but it is 
not present in B. avium and B. petrii (Middendorf et al., 2005) and its role as a virulence 
factor is unclear. The ORF of this gene was named phg due to its relatedness to pertactin 
and it codes for a putative protein with 418 amino acids. The protein is integrated in the 
outer membrane, to form a β-barrel structure, where the N-terminal β-strand spans the outer 
membrane from the priplasmic space to the exterior (Middendorf et al., 2005). It has been 
shown that the phg gene is continously and slightly expressed in B. pertussis and B. 
bronchiseptica, those species that have been analysed so far. In Phg, the presumptive 
processing site is not conserved as compared to Prn, TcfA, BrkA and BapC (Middendorf et 
al., 2005) and, the RGD adhesin motif is absent.  In a virulence test of a kanamycin 
insertion mutant of Phg of B. pertussis in a mouse model of respiratory infection, it showed 
the same colonisation as the wild type strain, possibly because related proteins may 
compensate for the loss of its function. 
1.4.3 Regulation of virulence genes  
    B. pertussis virulence factors are typically divided into two main categories: adhesins and 
toxins. Most are proteins, and the expression of their structural genes is coordinately 
regulated at the transcriptional level in response to environmental signals. B. pertussis can 
alternate between virulent and avirulent forms either by genotypic changes (serotype 
variation and phase variation) or by phenotypic changes (antigenic modulation) in response 
to growth conditions in vitro (Roberts and Parton, 2001).  
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It has been shown that most of the virulence factors are not expressed at low temperature 
(except tracheal cytotoxin) or in the presence of MgSO4 or nicotinic acid. This reversible 
phenomenon of adaptation in B. pertussis was named antigenic (phenotypic) modulation 
(Lacey, 1960). Among the population of Bordetella cells, irreversible loss of virulence 
factor production also occasionally occurs even at 37°C and in the absence of MgSO4 and 
nicotinic acid, and has been termed phase variation, which indicates an irreversible 
alteration in the genotype caused by mutations. The genetic locus responsible for these 
phenomena is the bvg (Bordetella virulence gene) locus, composed of two closely linked 
genes, bvgA and bvgS which were identified as an example of the two-component family of 
transcriptional regulators. The bvg genes share homology with a family of prokaryotic 
regulatory proteins that react to environmental stimuli, and the bvg locus occupies ~ 5 kb on 
the total genome. BvgA, a transcriptional regulator, is a 23-kDa DNA-binding response 
regulator, and contains an N-terminal receiver domain and a C-terminal output domain with 
a helix-turn-helix (HTH) motif which is able to bind its DNA target sequences. BvgS is a 
135-kDa transmembrane sensor kinase containing a periplasmic domain, a linker region (L), 
a transmitter (T), a receiver (R), and a histidine phosphotransfer domain (HPD) (Fig. 1.8). 
BvgS is located in the inner membrane of the organism and contains a large periplasmic 
domain, which is coupled to a cytoplasmic domain by a membrane spanning and a linker 
region. The BvgS is an unusual sensor among the two-component sensor proteins family 
since it has a particularly large cytoplasmic region with several subdomains (Locht, 1999). 
A proposed model suggests that signal inputs detected by the periplasmic domain are 
transmitted via the membrane to the transmitter (T) which autophosphorylates at His-729 
(H) by a reaction that is reversible in vitro. His-729 then gives the phosphoryl group to Asp-
1023 (D) of the receiver domain (R). Asp-1023 can provide the phosphoryl group to His-
1172 of the HPD which can then relocate the phosphate to BvgA and thereby activate it. 
BvgR, a 32-kDa cytoplasmic repressor and intermediate regulatory protein, is the product of 
the bvgR gene which is located directly downstream to the bvgA and bvgS genes (Merkel et 
al., 1998). Its expression represses some of the genes controlled by the bvgAS operon. BvgA 
transcriptionally controls the expression of bvgR. While the BvgA/S system is activated, in 
the virulent phase, both virulence-activated genes (vags) (see below) and bvgR are 
expressed so as to in turn repress the virulence-repressed genes (vrgs). If BvgA/S system is 
inactivated, vags and bvgR are not expressed and vrgs are derepressed in modulating 
conditions such as at 25°C or in the presence of sulphate anion or nicotinic acid. This gives 
rise to an absence of vag-encoded factors and is termed the Bvg- phase or phenotype. 
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Figure 1.8 Model for the two-component signal transduction system by the 
BvgAS proteins (Uhl and Miller, 1994). Signal transduction by the BvgA/S system occurs 
via a succession of phosphotransfer reaction through the transmitter (T), receiver (R), and C-
terminal domain (C) of BvgS to the N-terminal receiver domain (D) of BvgA. Abbreviations: HTH, 
helix-turn-helix; HPD, histidine phosphotransfer domain; L, linker region; H, histidine   
Transcription of the bvgAS locus is controlled by a 350 bp DNA fragment with four 
promoters. The transcription of the bvg locus is controlled by three of them, P1, P2 and P3, 
whereas the fourth, P4, is involved in the synthesis of an antisense RNA complementary to 
the RNAs synthesized by the P1, P2 and P3 promoters (Fig. 1.9).  
A low expression level of BvgA (the regulatory protein), which is inactive, is maintained 
under non-inducing conditions by the basally-active promoter P2. BvgA is activated by 
phosphorylation, under inducing conditions, and it subsequently transactivates the 
promoters P1, P2, P3, P4, PFHA and all other promoters of the bvg regulon or virulence-
activated genes (vags). The vags form a group of loci including genes encoding the adhesins 
and toxins, activated through BvgA binding to cis-acting sequences in their promoter 
regions. This signifies the Bvg+ phase or phenotype. Hybridization of the antisense RNA 
coded from P4 to the 5’-untranslated regions (20 bp upstream from the AUG start codon of 
the bvgA gene) of P1, P2 and P3 positively regulates these promoters, since the activation of 
the P4 promoter coincides with an increased production of BvgA (Scarlato et al., 1990). 
The bvg locus is also involved in the expression of a second class of bvg-regulated genes 
HPD 
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during the Bvg- phase, the virulence-repressed genes (vrgs) (Beattie, 1993). The products of 
these genes, such as vrg6, vrg18, vrg24, vrg53 and vrg73, are much less well characterised 
than those of the vags.   
 
Figure 1.9 The bvg locus with bvgAS genes and the promoters P1, P2, P3 and 
P4 (Diagram from Madan Babu et al., 2001). The role in signalling by the BvgA and BvgS proteins 
is indicated beneath the ORFs.   
 
It is also important to note that BvgA can directly activate transcription of the fha and bvg 
promoters, while the bvg locus alone is not sufficient for the activation of the ptx and cya 
promoters. Apart from the BvgA, recent work has also confirmed the necessity of additional 
accessory factors such as the newly identified Baf protein or the effects of different DNA 
topology on the selection and activation of some promoters (Madan Babu et al., 2001). 
The BvgAS system controls expression of at least three distinct phenotypic phases (Bvg-, 
Bvgi and Bvg+) by regulating the expression of at least four classes of genes (Williams and 
Cotter, 2006). Those that are expressed maximally only under Bvg+ phase (such as cyaA) 
are referred to as “late” Bvg-activated genes and require high concentration of Bvg∼P which 
interact with primary binding sites with a relatively low affinity for Bvg∼P (black curve in 
Fig. 1.10) (Beier and Gross, 2006). Those that are expressed maximally under both the Bvg+ 
and Bvgi (intermediate) phases (such as fhaB) are characterised by high-affinity binding 
sites for Bvg∼P and are referred to as “early” Bvg-activated genes (green curve in Fig. 
1.10). Those that are expressed maximally only under Bvgi phase conditions such as bipA 
are shown by the gold curve in Fig. 1.10. High-affinity binding sites for Bvg∼P upstream of 
the RNA polymerase binding site are involved in bipA expression and low-affinity binding 
sites within the transcribed region counteract the activation of high-affinity binding sites 
and decrease the transcription at high Bvg∼P concentrations (Williams et al., 2005). Finally, 
  Introduction  
 
41 
those that are repressed by BvgAS and expressed maximally only under Bvg- phase 
conditions (such as genes involved in motility in B. bronchiseptica) are shown by the red 
curve in Fig. 1.10. Therefore, only Bvg-repressed genes are transcribed in the absence of 
Bvg∼P (Beier and Gross, 2006). 
 
Figure 1.10 BvgAS controls expression of at least four classes of genes 
(Adopted from Mattoo and Cherry, 2005). Systematic analysis of gene expression in the Bvg+, Bvgi, 
and Bvg- phases of Bordetella shows the existence of at least four classes of Bvg-regulated genes 
(see the text). Abbreviation: nic, nicotinic acid. 
 
1.5 Other members of B. pertussis autotransporter family 
    The autotransporters are a growing family of extracellular proteins, found in many Gram-
negative bacteria that have many different functions but appear to have the same mechanism 
of export (Henderson et al., 1998). As the name implies, secretion through the 
autotransporter pathway does not require any accessory factors (See Type V secretion). 
Recent work has shown that the vag-encoded virulence proteins in B. pertussis, namely: Tcf 
(Finn and Amsbaugh, 1998), BrkA (Fernandez and Weiss, 1994), pertactin (Charles et al., 
1989), Vag8 (Finn and Amsbaugh, 1998), and most recently Bap-5 or BapC belong to this 
family of proteins because of structural homology at their C termini (30-kDa). The N-
termini also share structural characteristics: each contains one or more RGD and SGXG 
motifs (except pertactin), although the function of these proteins appears to differ. PRN 
(pertactin), BrkA, Tcf and Vag8 have already been described in previous sections and the  
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Figure 1.11 Structural features of some autotransporter proteins in B. pertussis  
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Table 1.1 Bordetella autotransporter proteins 
ORF designation and no. of 
residuesa 
Known or 
predicted 
Bordetella 
auto-
transporter 
 
Bp 
 
Bpa 
 
Bb 
 
Accession 
no.b 
Reference(s) 
or best 
BLAST hit 
of passenger 
Bvg- 
regul
ationc 
Known 
(predicted) 
signal 
peptided 
 
Notable 
motifse 
   Pertactin BP1054, 
910 
BPP1150, 
922 
BB1366, 
916 
P14283 47, 61 + 34 RGD (2) 
BrkA BP3494, 
1010 
BPP0867, 
(173) BB0961, (127) 
AAA51646 132 + 42 RGD (2) 
SphB1f BP0216, 
1039 
BPP0417, 
1043 
BB0419, 
1039 
CAC44081 82, 83 + No Serine 
protease 
lipoprotein 
Tcf BP1201, 
647 
 BB3291, 
(145) 
CAA08832 141 + (39) RGD 
Vag8 BP2315, 
915 
BPP2415, 
915 
BB1864, 
915 
AAC31247 140 + 37 RGD 
Phg BP1767, 
418 
BPP1998, 
415 
BB2246, 
415 
CAB38010 None 0 (35) None 
SphB2 BP1660, 
1024 
BPP2745, 
(193) BB2741, 
1025 
 
12 0 (37) None 
SphB3 BP1110, 
1076 
BPP2053, 
1076 
BB2301, 
1076 
 
12 0 (29) Thiol 
protease 
BapA 
(AidB)g 
BP2224, 
903 
BPP2251, 
(295)[I] BB1649, 
903 
CAC14165 AIDA-1 0 (30)h None 
BapB BP1200, (119)[I] 
BPP1815, 
605 
BB3292, 
613 
CAC14166 None ND (41) None 
BapC (BatE)g BP2738, 
(102) 
BPP2591, 
(100) 
BB2033, 
998 
CAC14167 Pertactin ND (45) RGD (2) 
BatA BP1793, 
(53)[I] 
BPP2022, 
538 
BB2270, 
536 
 
None ND (33) None 
BatB BP0529, 
2300 
BPP0452, 
1769 
BB0452, 
2300 
 
ShdA ND (38) RGD (2), P-1 
aspartyl 
protease 
Novel BP0775, 
340 
BPP0337, 
340 
BB0340, 
340 
 
None ND ? None 
Novel BP1344, 
866 
BPP2678, 
(717) 
BB2830, 
866 
 
Ag43, AIDA-1, 
BapA 
ND (36) RGD (2) 
Novel BP1610, 
(124) 
BPP2975, 
937 
BB2941, 
937 
 
Pertactin ND 32h None 
Novel 
 
BPP1617, 
491 
BB3111, 
497 
 
None ND (33) None 
Novel 
 
BPP0449, 
1616 
BB0450, 
2152 
 
ShdA ND (40)h P-loop, 
lipase 
Novel 
 
BPP0735, 
996 
BB0821, 
999 
 
YapE ND (30) RGD 
Novel 
 
BPP0822, 
1196 
BB0916, 
1196 
 
SSP-h1 ND (23)h RGD 
Novel 
 
BPP1618, 
519 
BB3110, 
705 
 
Tcf ND BP1618 (33), 
BB3110 (54) 
None 
Novel BP2627, 
(178) 
BPP1256, 
718 
BB2324, 
718 
  
 (34) Lipoprotein 
 
Adapted from Henderson et al. 2004. 
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others are described below. Figure 1.11 shows the major structural similarities among some 
of these autotransporter proteins of B. pertussis.  
During the course of this current project, analysis of the genome in B. pertussis, B. 
parapertussis and B. bronchiseptica has uncovered an inventory of 22 known or putative 
autotransporter proteins (Table 1.1) (Henderson et al., 2004). In addition to those mentioned 
above, a-number of other autotransporters have been characterised to some extent. While 
most of the autotransporter ORFs are intact, not all appear to be expressed in all these 
species, due to frameshifts or insertion of a stop codon or insertion elements and these 
proteins are indicated in red. It is assumed that B. pertussis, B. parapertussis and B. 
bronchiseptica have the capacity to express 12, 16, and 20 putative functional 
autotransporters, respectively (Henderson et al., 2004). These proteins are indicated in blue. 
The nine putative autotransporters described in Table 1.1 as ‘novel’ include a putative 
adhesin and a putative lipase. SphB1 (subtilisin-like protease) (Coutte et al., 2001) and Phg 
(Pertactin homologous gene) (Henderson et al., 2004) have been described in earlier 
sections (1.4.2.5 and 1.4.2.7). However, SphB2, SphB3, BapA, BapB, BatA and BatB have 
been named and have homology with proteins/virulence factors in other organisms, are not 
yet fully-characterized. Some of these Bordetella autotransporter proteins are Bvg-
regulated, some are not and some have not been yet determined. Table 1.1 also shows 
known or predicted signal peptides. Some of the autotransporters contain one or more RGD 
motifs (shown in green) (9 ATs) and several are predicted to have protease activity. The 
autotransporter that is the focus of interest in this thesis is described below.   
1.5.1 B. pertussis autotransporter protein-5 (Bap-5) (BapC) 
    A PCR amplicon MR30 produced by Prof. M. Roberts (Department of Veterinary 
Pathology, University of Glasgow) using primers directed to the region encoding the C-
terminal domain of pertactin on B. pertussis genomic DNA, was later identified as a gene 
for what was then the fifth member of B. pertussis autotransporter family (Blackburn, 
1998). The gene sequence was deposited in GenBank under accession no. AF081494. In 
view of its sequence similarity to prn and genes encoding the three other proteins 
recognized as belonging to the autotransporter protein family (BrkA, Tcf and Vag8), the 
sequence was designated bap-5 (Bordetella autotransporter protein 5). More recently, 
Henderson et al. (2000) reported the same sequence as bapC/BapC and this latter 
designation was used in the published Bordetella genome sequence (Parkhill et al., 2003). 
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The presence of bapC in the genomes of B. pertussis, B. bronchiseptica and B. 
parapertussis has been identified via Southern blotting with a part of the MR30 amplicon in 
the EcoRI-digested genomes of these species (Blackburn, 2000). By using amino acid 
homology with Prn and BrkA, the ORF for BapC was predicted to begin at the serine 
residue encoded at nucleotide position 300, according to the sequence data of Blackburn 
(2000). This finding had suggested that a methionine upstream from this sequence 
(nucleotide position 261 according to the sequence data of Blackburn, 2000) might be the 
possible translational start. The presence of an upstream stop codon in this particular 
reading frame indicated that the open reading frame began at this point. Blackburn (2000), 
however, noted that there were alternative potential start sites and that it would require 
further study to ascertain the true ATG/GTG translational start codon. There were no 
translational stop codons within this open reading frame until position 2538 according to the 
sequence data of Blackburn (2000), which was consistent with previously characterized B. 
pertussis autotransporters as it is immediately preceded by a consensus outer-membrane 
localization motif.  
Sequence analysis of the bap-5 region by Blackburn (2000) did not reveal a typical Shine-
Dalgarno sequence (Shine and Dalgarno, 1975) in the 5` region of its proposed open 
reading frame, as has been shown for other known autotransporter genes. It was also 
suggested that BapC, unlike other B. pertussis autotransporter proteins such as PRN, does 
not possess a typical amino-terminal signal sequence upstream from its putative 
translational start site (Blackburn, 2000). 
Further study on the genome sequence has showed the existence of two potential BvgA 
dimer binding sites TTTC (A/G) TA upstream from the predicted translational start site of 
bapC (ATG1) according to the sequence data of Blackburn (2000). Upstream of the Bvg-
regulated prn, fha, ptx, cya and bvg genes of B. pertussis, similar repeats are located. The 
BvgA dimer is required for regulating the transcription of these genes through its interaction 
with the RNA polymerase. No upstream regulatory elements (e.g. Ribosome binding site or 
promoter sequences) were identified in the bapC gene (Bokhari, 2002).   
There appears to be a rho-independent terminator sequence downstream of the bapC gene 
as with prn, with the exception that it is further from the translational stop codon and 
smaller than that of prn. This potential transcriptional terminator was identified in the form 
of mRNA secondary hairpin structure, which is located downstream of the predicted ORF. 
This potential hairpin structure at the 3`end of the mRNA could be responsible for causing 
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the RNA polymerase to pause and therefore preventing further mRNA synthesis beyond the 
point of palindrome formation (Blackburn, 2000).   
Sequence analysis of BapC, according to the sequence data of Blackburn (2000), showed 
the presence of an integrin-binding motif (RGD, position 945-953), a glycosaminoglycan-
binding site (SGSG, position 1347-1358), a proteolytic processing site (ALSKRLGEL, 
position 1700-1727) and an outer-membrane localization signal (FHLGYRYRW, position 
2510-2537) (Appendix II.3). The presence of an integrin-binding motif (RGD) within the 
N-terminus of BapC suggested that this protein may play a role in adhesion and invasion of 
the bacterium. Such motifs are present in the N-terminal domains of Prn, BrkA and Tcf. In 
Prn, the role of the RGD in adhesion and invasion has been studied using synthetic RGD-
containing sequences in competitive binding experiments with HeLa cells. The result 
suggested that RGD in pertactin might play a role in adhesion and invasion (Leininger et 
al., 1992). However, a RGD→RGE mutant of recombinant pertactin expressed by E. coli 
had no significant effect on adhesion to CHO or HepC cells (Everest et al., 1996). The 
presence of a glycosaminoglycan-binding motif (serine-glycine-serine-glycine) (SGSG) 
provided further evidence that BapC may function as an adhesin and promote binding to 
glycosaminoglycans such as heparin. Such motifs are also present in BrkA and Tcf (Fig 
1.11). However, as explained below, these conclusions were drawn from an incomplete 
knowledge of the structure of BapC.  
The predicted molecular weight of BapC was 79.5 kDa using the first ATG translational 
start codon, according to the sequence data of Blackburn (2000). The processing of BapC at 
the putative cleavage site (ALSKRLGEL) would lead to a mature N-terminus product of 
49.5 kDa and a 30-kDa ß-barrel C-terminus domain in the outer membrane (Bokhari, 2002). 
However, during the course of the present investigation, with the publication of the genome 
sequences of three Bordetella species (Parkhill et al., 2003), it became apparent that the 
bap5/bapC sequence identified by Blackburn et al. (1998) and Henderson et al. (2000) was 
not the whole bapC gene. As shown in Table 1.1, the ORF in B. bronchiseptica (strain 
RB50) encodes a protein of 998 amino acids. In B. pertussis Tohama and B. parapertussis 
(strain 12822), however, these ORFs were truncated at 102 and 100 amino acids, 
respectively, due to frameshifts. The bap5/bapC sequence in B. pertussis Taberman 
identified by Blackburn et al. (1998) and in strain Tohama by Henderson et al. (2000) 
showed 100% nucleotide identity with that of B. pertussis Tohama sequenced by the Sanger 
centre, although it was only the 3’ end of the gene, downstream from the frameshifts. The 
non-mutated gene in B. pertussis was predicted to encode of protein of 993 amino acids 
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(reported by Sebaihia in 2006, GenBank Accession No. NP_888576), which would give a 
molecular weight of 104 kDa and would be processed, into a 74 kDa α-domain (including 
the signal sequence) and a 30 kDa β-domain.      
Despite the above anomalies, the works of Blackburn (2000) and Bokhari (2002) had 
suggested that BapC was in fact expressed in the B. pertussis Taberman and Tohama strains 
that they used. Preliminary work on characterising the role of the BapC protein was 
undertaken by Bokhari (2002). The bapC gene amplified from B. pertussis strain Taberman 
was mutated by a kanamycin resistance cassette and incorporated into the suicide vector 
pSS1129 (Stibitz, 1989) for gene replacement into the chromosomes of B. pertussis strains 
Taberman and Tohama (Bokhari, 2002). Preliminary work, using an ELISA-based adhesion 
study, suggested that, with some cells such as HeLa 229, Hep-2 and murine macrophages 
RAW 264.7, the Taberman and Tohama bapC mutants adhered less well than the wild-type 
strain, and a rabbit anti-BapC serum had significant effect in reducing adherence of the 
wild-type strain. However, anti-BapC serum did not have an effect on adherence of the 
wild-type strain to other cells i.e. A549 (human lung epithelial cells), Caco-2 (human 
carcinoma intestinal cell line) and to P338D-1 macrophages, suggesting that the interaction 
between the bacterium and mammalian cells is complex and possibly depends on many 
different adhesins and receptors. Therefore, in those cases where the bapC mutant adhered 
less well than the wild-type strain or the anti-BapC serum reduced adherence, the 
interaction of BapC and its unspecified receptors may play a significant role in the adhesion 
process (Bokhari, 2002).  
It was also suggested that BapC may have a role in B. pertussis Taberman and Tohama in 
resisting complement-mediated killing (Bokhari, 2002). BapC was shown to confer a 
considerable resistance on the B. pertussis Taberman and Tohama strains to killing by 
normal human serum compared to its BapC-deficient mutant. Moreover, it was shown that 
BapC protected B. pertussis apparently from the classical (antibody-dependent) pathway of 
complement activation. The sensitivity of the wild-type and mutant strains to normal human 
serum and to guinea pig complement alone was inhibited by the addition of EGTA.MgCl2, 
suggesting that complement killing is Ca++ dependent and therefore due to the classical 
pathway or MBL (Mannan Binding Lectin) pathway.  However, the exact mechanism by 
which BapC mediates this protection was not investigated.  
A mouse virulence test showed that BapC, like Prn, appeared to participate in establishing 
B. pertussis infection in the respiratory tract of the mouse. A bapC mutant of B. pertussis 
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strain Taberman had greatly reduced ability to persist and colonize the mouse lungs/trachea, 
when assessed at 7 days after intranasal administration. Mouse protection studies using the 
purified C-terminal domain of BapC suggested that it was not immunodominant or a 
protective region of the autotransporter protein (Blackburn, 2000), but no protection studies 
have been done with the whole BapC protein or the N-terminal moiety as the complete 
structure of BapC was not appreciated at the time.  
The altered properties of the BapC mutants of B. pertussis strains Taberman and Tohama, 
compared with their wild types, provided evidence for BapC expression in these strains 
despite the fact that in the genome sequence of B. pertussis Tohama, bapC is a pseudogene 
(Table 1.1). Other evidence for expression of BapC in B. pertussis Taberman and Tohama 
was provided by RT-PCR and Western blotting. The RT-PCR and Western blotting results 
suggested that the expression of BapC is under bvg-regulation, like some other B. pertussis 
autotransporter proteins such as Prn and BrkA (Bokhari, 2002).  
1.6 General mechanisms for secretion in Gram-negative 
bacteria 
    Pathogenic and non-pathogenic bacteria decorate their cell surfaces with, or secrete into 
the extracellular environment, many different proteins. The expression of virulence factors 
directly or indirectly affects the host and so increases the pathogen’s ability to continue to 
exist and reproduce. In the case of Gram-positive organisms, which produce a single plasma 
membrane followed by a thick cell wall layer, surface proteins generally follow the sec-
dependent pathway to cross the cell membrane. They are either released into the 
extracellular milieu or remain attached by one of several peptide-anchoring signals (Novick, 
2000). Secretion in Gram-negative bacteria, however, is limited by the presence of the outer 
membrane, which requires more complex and specialized protein secretion pathways. At 
least five major protein secretion pathways (numbered from I to V), which are highly 
conserved, have been characterized for Gram-negative bacteria. They differ with respect to 
the mechanisms of outer membrane translocation but some have common inner membrane 
transport mechanisms.  
1.6.1 Signal sequence-independent pathway (Type I):  
    The Type I sec-independent secretion system (T1SS) is exemplified by the secretion 
pathway defined for Escherichia coli haemolysin (HlyA) and other RTX toxins including B. 
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pertussis CyaA (see section 1.4.1.2.2). Secretion requires three accessory proteins, which 
form a channel spanning both the inner and outer membranes (Stanley et al., 1998), which 
allows substrate to secrete directly from the cytoplasm to the extracellular milieu (Fig 1.12). 
Three protein subunits consist of two cytoplasmic membrane proteins; the ABC transporter 
and membrane fusion protein (MFP), and an outer membrane protein (OMP) (Koronakis et 
al., 2001). Type I secretion system transports various molecules, from inorganic ions, amino 
acids, sugars, peptides, to protein of various sizes (20 - 100 kDa). The membrane 
components required for secretion of HlyA from E. coli are shown in fig. 1.13. 
 
Figure 1.12 Model of the type I protein secretion system. A channel domain in the 
outer membrane anchors the channel-tunnel (blue). The membrane fusion protein (red) and the ABC 
(ATP-binding cassette) transporter (yellow) form a complex in the inner membrane. The preprotein 
(black line) binds to the transporter and the cytoplasmic part of the accessory membrane fusion 
protein (MFP) and induces a conformational change in the periplasmic domain of the accessory 
protein, allowing the recruitment of the channel-tunnel. A tight complex is formed, the tunnel 
entrance of the channel-tunnel is opened and the protein is secreted. After the process is finished the 
proteins return into their resting states (http://archive.bmn.com/supp/ceb/ain1.html). 
 
 
Secretion of HlyA, and similar effector molecules, thus occurs in a Sec-independent manner 
and in a continuous process across both the inner and outer membranes. Moreover, proteins 
secreted by T1SSs are not processed during secretion and do not form separate periplasmic 
intermediates. HlyA is translocated simultaneously across the inner and outer membrane 
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(Fig. 1.13) in a reaction that requires ATP hydrolysis in the bacterial cytoplasm and 
interaction of trimeric HlyD with the trimeric outer membrane transporter TolC (pore-
forming outer membrane protein). 
                                       
Figure 1.13 Type I secretion of RTX toxins. E. coli HlyA interacts with its associated 
ABC transporter (B = HlyB, ATP-binding cassette) and the trimeric membrane fusion protein 
(MFP) (D = HlyD), in a proton motive force (PMF) dependent manner. [Drawing adapted from 
Stanley et al., 1998] 
 
1.6.2 General secretory pathway (GSP, Type II):  
    This protein secretion system is exemplified by the pullulanase (PulA) system of 
Klebsiella oxytoca. This type of secretion pathway is often referred to as the main terminal 
branch (MTB) of the Sec-dependent GSP. This system is able to secrete a large variety of 
proteins, which are synthesized as pre (pro) polypeptides. PulA secretion requires the action 
of approximately 14 additional accessory proteins, which are encoded in an operon 
(Pugsley, 1997). The type II system also features a macromolecular, multicomponent 
structure that most probably spans both inner and outer membranes (Nunn, 1999). Unlike 
the type I and type III secretion systems and some members of the type IV secretion system, 
secretion of pullulanase across the inner membrane is sec-dependent. This pathway is the 
transporter for many of the B. pertussis proteins like the autotransporter proteins pertactin, 
tracheal colonisation factor, as well as the major B. pertussis adhesion FHA and fimbriae 
across the inner membrane and into the periplasmic space. Type II secretion pathway is also 
presumed to be involved in transporting the pertussis toxin subunits into the periplasmic 
space. 
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Secretion of proteins through the MTB pathway is performed in a two-step Sec-dependent 
fashion. Proteins secreted via the type II pathway are translocated with an N-terminal signal 
sequence that targets proteins to the Sec inner membrane secretion pathway. The Sec 
machinery consists of an ATPase, SecA, several integral inner membrane proteins and a 
signal peptidase. The energy for transport through the translocon is provided by SecA 
through binding and hydrolyzing ATP, which leads to major conformational changes in this 
protein. During translocation signal peptidase cleaves the signal sequence and the remainder 
of the protein is released into the periplasm. It has been suggested that the protein acquires a 
native state in the periplasm, which is necessary for translocation across the outer 
membrane and performed by certain chaperones such as these involved in disulphide bond 
formation and isomerization (e.g. DsbA) or specific molecular chaperones. The 
translocation across the outer membrane, which is highly specific for the type II system, 
requires several additional accessory proteins (Sandkvist, 2001).  
                
Figure 1.14 Type II secretion system of the pullulanase (PulA) in Klebsiella 
oxytoca. The secretion machinery can be depicted as comprising three building blocks: proteins 
GspE–GspF–GspL–GspM, which form a large platform in the inner membrane; the pseudopilus 
composed of GspG–GspH–GspI–GspJ–GspK proteins; and the gated outer membrane proteins 
GspC–GspD–GspS, which are able to form a pore in the outer membrane. 
(www.genome.ad.jp/kegg/pathway/map/map03090.html).  
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1.6.3 Type III secretion pathway (the injectisome): 
    The type III secretion system (T3SS) is a highly regulated process, first identified in 
pathogenic Yersinia spp, which allows Gram-negative pathogens to carry bacterial effector 
molecules into eukaryotic cells and change host cell signalling functions (Francis et al., 
2002). Although among type III secretion systems most of the secretion apparatus elements 
are conserved, the set of delivered effector proteins is often unique for each bacterial 
species. The ability to target effector molecules directly into eukaryotic cells is the most 
prominent feature of T3SS. 
The type III secretion pathway has a primary role in the virulence of some pathogens such 
as Salmonella enterica, Shigella flexneri, E. coli and Chlamydia trachomatis. A complex 
machinery of proteins, which bring together into a strongly regulated oligomeric structure 
spanning the inner and outer membranes, is required for the secretion of type III effector 
molecules. Like the T1SS, the sec system is not required for secretion of the effector 
molecules; however the sec machinery is required for translocation of some of the structural 
component proteins of the secretion apparatus across the inner membrane (Galan and 
Collmer, 1999). Secretion of effector molecules may occur without the formation of 
periplasmic intermediates, and is through a needle-like structure which consists of 20 
different proteins. This needle-like structure crosses both the inner and outer membrane, 
like a hypodermic needle. This phenomenon has been termed “contact dependent” (Zierler 
and Galan, 1995), since in some cases it is started when the bacterium contacts with a target 
cell, and the analogy of the T3SS with a hypodermic syringe to inject proteins directly into 
the host cytoplasm, has lead to the term “injectisome” to describe this secretion system.  
The Bordetella type III secretion system has been studied in B. bronchiseptica (Stockbauer 
et al., 2003), which appears to be the evolutionary progenitor for some Bordetella 
subspecies. A highly conserved type III secretion locus is shared by members of the 
Bordetella genus that cause respiratory infections in mammals (Yuk et al., 1998). Type III 
secretion is positively-regulated in B. bronchiseptica at the transcriptional level by the 
products of the bvgAS locus (Cotter and Jones, 2003). A highly regulated region encoding 
the first 20 amino acids of the effector proteins is necessary for secretion and processing of 
these proteins via the type III pathway (Hueck, 1998).  
The chromosomal bsc locus includes 22 genes that encode components of the Bordetella 
type III secretion apparatus, secreted proteins and putative chaperones and is similar to that 
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of Yersinia as shown in Fig. 1.15. In general, genes encoding components required for T3SS 
are located on a single plasmid or chromosomal locus, and are conserved among different 
species. In B. bronchiseptica, type III secreted polypeptides, which are easily detected in 
culture supernatants, are encoded by bopB, bopD, bopN and bsp22 (Yuk et al., 2000). BopB 
and BopD are orthologues of the Yersinia YopB and YopD translocation proteins (Cornelis, 
2002). BopN is orthologous to YopN, which acts as a plug to avoid Yop secretion in 
Yersinia lacking host cell contact (Cheng et al., 2001). DNA sequence analysis of the 
Bordetella genome in regions adjacent to the bsc locus has shown five well-conserved open 
reading frames (ORFs), btrS, btrU, btrX, btrW and btrV, which are activated by BvgAS and 
encode regulatory factors that control type III secretion at the levels of transcription, protein 
expression and secretion (Mattoo et al., 2004).  
                          
Figure 1.15 Type III secretion system in Yersinia. Yersinia spp exploits type III 
secretion for the delivery of effectors (YopE, YopH, YopM, YopN, YopO, YopP, and YopT) into 
host cells, begins with needle-forming machine components, providing for bacterial escape from 
phagocytic killing (www.genome.ad.jp/kegg/pathway/map/map03070.html).  
 
1.6.4 Type IV secretion system (T4SS):  
    Type IV secretion systems are employed not only to carry macromolecules such as 
multimeric toxic molecules (such as pertussis toxin of B. pertussis, see section 1.4.1.2.1) or 
monomeric proteins to host cells, but also are utilized to transfer DNA or protein-DNA 
complexes from one bacterium to another (bacterial conjugation) or from a bacterium to a 
  Introduction  
 
54 
eukaryotic cell (Vincent and Schneewind, 2001). Horizontal gene transfer, via conjugation 
systems, contributes to the evolution of infectious pathogens (Hacker et al., 2003). Type IV 
secretion machineries play central roles in the spread of antibiotic resistance genes amongst 
bacteria by facilitating conjugative transfer. The IncF, IncP and IncW plasmid transfer 
systems (Tra) are some of the conjugal transfer systems (Lawely et al., 2003). Type IV 
secretion systems are also involved in pathogenicity of bacteria, such as Helicobacter pylori 
responsible for peptic ulcers, or Legionella pneumophila responsible for Legionnaire’s 
disease. Type IV secretion systems require a subclass of ATPases termed VirB11 ATPases 
(Fig. 1.16), which are crucial for conjugative transfer of DNA in most systems studied to 
date, and toxin transfer. 
The role of VirB11 ATPase may differ from one organism to another relating to the type of 
transport they mediate such as in the conjugative system encoded by the RP4 plasmid, 
where the VirB11 ATPase, TrbB is identified to be involved in pilus biogenesis. Type IV 
secretion systems, particularly those involved in conjugative transfer; operate in conjunction 
with a fibrous cell surface organelle called a "pilus" which is considered to be essential for 
adhesion between bacteria or between bacteria and host eukaryotic cells. Nevertheless, there 
has not been an identified pilus associated with the type IV secretion system in Helicobacter 
pylori (the causative agent of peptic ulcers). Therefore, the VirB11 ATPase of H. pylori 
may be directly involved in transport of toxins through the inner membrane. It has been 
suggested that the potential roles of VirB11 proteins are at least in part associated with the 
inner membrane (IM) and localized to the cytoplasmic side of the IM.  
The protein-DNA complex of A. tumefaciens is exported in a single continuous step from 
cytoplasm to the outside of the cell; however in the case of pertussis toxin, in a process 
resembling the type II secretion pathway, this occurs in two steps. The toxin subunits, PtxA 
and PtxB, are initially translocated across the cytoplasmic membrane via the Sec machinery 
and then targeted for export to the outer membrane. T4SS has been generally divided into 
two subclasses: type IVa correspond to protein machinery containing VirB homologues of 
A. tumefaciens, and type IVb corresponds to functional secretion systems assembled from 
Tra homologues of the Incl Collb-P9 plasmid of Shigella flexneri (Christie and Vogel, 
2000).  
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Figure 1.16 Type IV secretion system in H. pylori. Type IV secretion systems require a 
subclass of ATPases, VirB11 ATPases, which are essential for conjugative transfer of DNA in most 
systems, and toxin transfer (http://people.cryst.bbk.ac.uk/~ubcg54.type4.htm) 
 
1.6.5 Autotransporters secretion mechanism (Type V secretion) 
    The autotransporter (AT) pathway is apparently the simplest process of secretion 
amongst the diverse pathways by which extracellular proteins can cross the outer membrane 
in Gram-negative bacteria. As their name implies, autotransporters do not require specific 
accessory molecules for secretion, and the information required for export is encoded inside 
the polypeptide itself. This family of secreted proteins includes those secreted via the 
autotransporter system (type Va or AT-1), the two-partner secretion pathway (type Vb), and 
the recently described type Vc system (also termed AT-2) (Desvaux et al., 2004). The 
primary structures and modes of biogenesis of proteins secreted by these pathways are 
similar (Desvaux et al., 2003) (Fig. 1.17). Various proteins including proteases, toxins, 
adhesins, invasins, S-layers and lipases, are exported to the cell surface via the 
autotransporter secretion system (Henderson et al., 1998; Henderson and Nataro, 2001). 
These are typically virulence factors with different roles in pathogenesis (Kostakioti and 
Stathopoulos, 2004).  
It has been shown that the genomes of the three bordetellae encode 22 autotransporters 
(Table 1.1). B. bronchiseptica encodes more autotransporters (20) than the other two 
bordetellae in terms of several of the genes encoding putative autotransporters are 
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pseudogenes or have been deleted from the genome of B. pertussis (13 autotransporters) or 
B. parapertussis (16 autotransporters) (Preston et al., 2004). 
   
Figure 1.17 Schematic overview of the type V secretion systems. The signal 
sequence, the passenger (α) domain, the linker region, and the β-domain are the four functional 
domains of the proteins. The autotransporter polyproteins are synthesized and generally exported via 
the inner membrane using the Sec machinery. The signal sequence is then cleaved and the β-domain 
inserted into the outer membrane to form a β-barrel pore structure. The passenger α-domain is 
finally inserted into the pore and translocated to the bacterial cell surface, where it may or may not 
experience further processing (Henderson et al., 2004). 
 
1.6.5.1 Type Va (AT-1)  
    This secretion system was initially described for the immunoglobulin A1 (IgA1) protease 
of Neisseria gonorrhoeae, although many Gram-negative bacteria are now known to use 
this pathway to secrete a diversity of cell-surface and extra cellular enzymes and adhesins 
(Fig 1.18).   
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Figure 1.18 Type Va autotransporters. Neisseria extracellular IgA protease is 
synthesized as a pre-proenzyme. After Sec-mediated translocation across the inner-membrane, the 
C-terminal domain of the proenzyme inserts into the outer-membrane, which provides a pore to 
allow the N-terminal domain to translocate through its lumen. Protease activity can cleave the N-
terminal domain from the C-terminal domain (arrowhead) and it is then released into the 
extracellular milieu. [Drawing adapted from Pohlner et al., 1987]. SecYEG are components of the 
inner membrane-embedded translocation machinery. 
 
Autotransporters are basically composed of three domains: a signal peptide (also called the 
signal sequence or leader sequence), the extracellular domain (also called the α-domain, N-
passenger domain, or N-domain) and a translocation unit (also called the β-domain, helper 
domain, C-domain, transporter domain, or autotransporter domain) with characteristics 
comparable to those found in most outer membrane proteins. Translocation is performed in 
two steps including: (i) insertion of the C-terminal translocation unit into the outer 
membrane; and (ii) translocation of the passenger (Klauser et al., 1992).     
The passenger domain or α-domain confers the different effector functions of the various 
autotransporters. The C-terminus of these proteins (250 to 300 amino acid residues), the β-
domain, is conserved and is necessary for the secretion of passenger proteins across the 
outer membrane (Yanagida et al., 1986; Fischer et al., 2001) by acquiring a tertiary 
structure once implanted into the outer membrane. In a model of autotransporter secretion 
(Henderson et al., 1998), an N-terminal signal sequence facilitates translocation of the 
preproprotein across the inner membrane, via the Sec pathway. At the N-terminus of the 
protein, a Sec-dependent signal sequence allows targeting of the protein to the cytoplasmic 
membrane for its translocation into the periplasmic space. The signal sequence consists of 
(i) an n-domain containing positively charged amino acid residues, (ii) an h-domain 
  Signal sequence 
          N-terminus 
     C-terminus 
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including hydrophobic amino acid residues, and (iii) a c-domain containing a consensus 
signal peptidase recognition site, which frequently has helix-breaking proline and glycine 
amino acid residues along with uncharged and short lateral-chain residues that define the 
site of signal sequence cleavage site (Martoglio and Dobberstein, 1998). Some proteins 
larger than 100 kDa possess extended signal sequences. It has been suggested that the 
unusually long signal sequence might serve to recruit accessory proteins (Henderson et al., 
1998). At least two pathways are employed in E. coli to translocate their proteins by the use 
of the Sec translocon: (i) molecular chaperone SecB, maintains the preprotein in a 
translocation-competent state and targets it to SecA (Randall and Hardy, 2002), and (ii) 
direct co-translational translocation of the preprotein by targeting the ribosome-SRP 
complex to the translocon (SRP pathway) (Herskovits et al., 2000). 
The autotransporters are produced in a pre-pro-protein structure in the bacterial cytoplasm 
and then released into the periplasm in a pro-protein form. The secretion of the 
autotransporters from the cytoplasm to the extracellular milieu is completed by the 
translocation through the outer membrane. The pro-protein, depending on the 
autotransporter, may then be cleaved from the β-barrel domain or remain coupled with the 
domain (Desvaux et al., 2003). Protein (antifolding) chaperones either prevent the folding 
of the passenger domain to allow its translocation through the narrow channel of the β-
translocator (upper panel of Fig 1.19) or translocate globular proteins with considerable 
tertiary structure, as in IgA protease β-barrel (lower panel of Fig 1.19). It was recently 
suggested that the IgA protease β-domain is capable of forming channels with an inner 
diameter of 2 nm (Veiga et al., 2002). The channel possesses a 2.5–5 times smaller size than 
the other well-characterized type II and type III secretion system secretins that translocate 
folded proteins (Thanassi, 2002). However, this size of channel is sufficient for secreting 
small folded proteins or protein domains (Veiga et al., 1999), although a channel of this size 
would be incapable of secreting larger folded passenger domains. These molecules must 
therefore be upheld in a translocation-competent unfolded state in the periplasm. It is not 
clear how such large proteins can retain an unfolded or partially folded state and not be 
degraded by periplasmic proteases. In this context, the formation of disulphide bonds in the 
passenger domain in the presence of DsbA (disulphide bond isomerase, chaperone) reduces 
the efficiency of secretion of the passenger domain which indicates the accessibility of the 
proprotein to periplasmic proteins (Brandon and Goldberg, 2001). 
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Figure 1.19 Model for outer-membrane translocation of passenger domains. 
The passenger proteins are exported through a channel formed by a single β-barrel (upper panel) or 
multimers (lower panel). Folding of passenger proteins is either circumvented (upper panel) by 
periplasmic chaperones or supported (lower panel) before translocating across the outer membrane 
(Adapted from Pugsley et al., 2004).  
 
The crucial features necessary for passenger secretion are the β-core and a short preceding 
linker region (Miyazaki et al., 1989; Oliver et al., 2003a), together referred to as the 
translocation unit.  Secondary structural analysis of autotransporter proteins (Klauser et al., 
1993; Maurer et al., 1999; St Geme and Cutter, 2000) consistently predicts that the β–core 
forms an amphipathic β-barrel structure and the linker region forms α-structure (Henderson 
et al., 1998; Oliver et al., 2003b). This linker is an α-helical secondary structure in the N-
terminus of the translocator domain placed on the periplasmic side of the outer membrane, 
folds into the aqueous pore, forming a hairpin structure that conducts the translocation of 
passengers through the channel (Oomen et al., 2004). The passenger domain may finally be 
cleaved from the translocation unit and remain non-covalently connected to the bacterial 
surface, or released into the extracellular milieu. The cleavage of the passenger domain may 
happen by means of an autoproteolytic mechanism (if the passenger domain is a protease) 
or an endogenous outer membrane protease may mediate it (Oomen et al., 2004). 
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Recently, the assembly and secretion of some outer membrane proteins has been shown to 
involve Omp85 (Fig. 1.20), which has homologues with highly conserved structure in all 
the complete genome sequences of Gram-negative bacteria. The Omp85 family has also 
been characterized in the outer membrane of mitochondria in eukaryotes from plants to 
humans and is an important element of the protein insertion machinery. However, the 
Omp85 was first shown to be involved in lipid export from the inner to the outer membrane. 
The Omp85 model hypothesizes that translocation of an AT involves Omp85, a protein that 
promotes the insertion of integral outer membrane proteins (Voulhoux et al., 2003). It has 
been reported that, following Omp85 depletion in bacteria, unassembled forms of different 
outer membrane proteins including autotransporters were accumulated (Henderson et al., 
2004). Members of the Omp85 family of proteins are identified by the existence of two 
domains: (i) an N-terminal periplasmic domain, which is rich in POTRA (Polypeptide-
Transport-Associated) repeats, and (ii) a C-terminal β-barrel domain inserted in the outer 
membrane. It has also been suggested that it has a chaperone-like function and interacts 
with the protein substrates prior to translocation by POTRA repeats (Gentle et al., 2005).  
It has been mentioned that lack of Omp85, a highly conserved protein, resulted in defective 
membrane insertion, folding and/or oligomerisation of many outer-membrane proteins 
(Robert et al., 2006). It has also been shown that the secretion level of the proteolytically 
processed amino-terminal domains of BrkA expressed in an E. coli depletion background 
for Omp85 was reduced compared with the wild-type, suggesting that the Bordetella sp. are 
also dependent on Omp85 for proper outer membrane assembly (Jain and Goldberg, 2007). 
Moreover, the sequence similarity of Omp85 in Gram-negative bacteria with Toc75, which 
is involved in protein import into the chloroplast (Voulhoux and Tommassen, 2004), and 
the relationship with the two-partner secretion system of FhaC in B. pertussis (next section), 
suggests a common evolutionary origin (Gentle et al., 2005). 
Although the “Omp85 model” seems to be the most favoured (Oomen et al., 2004) model 
for the insertion into and translocation across the outer membrane of passenger domains, 
several issues need to be addressed in future studies such as the role of Omp85 in the 
translocation of passenger domains if the passenger domain employs the translocation unit, 
and whether the translocation of passenger domain and the insertion of the translocation 
unit are two distinct steps or one single step (Rutherford and Mourez, 2006).     
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Figure 1.20 The translocator domain, because of its outer membrane 
protein characteristics, targets the Omp85 complex. The passenger is secreted via the 
Omp85 complex during insertion of the translocator domain into the outer membrane (Oomen et al., 
2004). 
 
1.6.5.2 Two-Partner Secretion (TPS) Pathway (Type Vb): 
TPS systems are distinct pathways, which share several similarities with the AT (type Va), 
and are composed of two separate proteins; TpsA the secreted protein (exoprotein) and 
TpsB the specific outer membrane transporter. The secreted proteins (passenger domain) 
(TpsA), like the autotransporter (AT) secretion pathway (Va), possess an N-terminal 
cleavable signal sequence, which directs translocation across the inner membrane in a Sec-
dependent manner (Jacob-Dubuisson et al., 2004). Some of the TpsA proteins have 
extended signal sequences of 40-70 residues, similar to some of the ATs, although the 
precise function of these extended signal peptides is unknown; their deletion did not inhibit 
secretion across the inner membrane (Lambert et al., 1998). The TpsA is characterized by 
repeated amphipathic motifs predicted to adopt a β-helical structure (Kajava et al., 2001). 
The TpsB proteins are large (approx. 60kDa), pore-forming outer-membrane transporters 
that are predicted to form β-barrels with 20-22 β-strands (Surana et al., 2004). TpsB 
proteins are also synthesized with an N-terminal signal sequence for translocation across the 
inner membrane via the Sec system (Fig. 1.21). A family of very large proteins of over 1000 
amino acid residues is secreted by using the two-step secretion mechanism. However, the 
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TPS systems are considered as autotransporters, but the passenger domain and the 
translocator domain are uncoupled and there is no sequence similarity between the TpsB 
transporter and the translocator domain of conventional autotransporters (Voulhoux et al., 
2003). The TpsB shows sequence similarity to Omp85 (see previous section).  
 
Figure 1.21 Comparison of the AT and TPS pathways. (A) The AT pathway. SP = 
signal peptide, P = passenger domain β = transporter domain. After export across the inner 
membrane via the Sec machinery, the translocation of the N-terminal passenger domain across the 
outer membrane is mediated by the β-domain, which embeds into the outer membrane. (B) The TPS 
pathway. TPS represents the TPS domain of the TpsA protein. After Sec-dependent translocation of 
both proteins, TpsB inserts into the outer membrane and then the TPS domain of the TpsA protein 
recognizes the TpsB transporter, which mediates the translocation of the TpsA across the outer 
membrane. The curved arrow symbolizes the specific interactions between the two partners, which 
seemingly occur in the periplasm (Jacob-Dubuisson, 2004). TpsA may then stay coupled with the 
cell surface or be released into the extra cellular milieu (Thanassi et al., 2005).  
 
Usually, the genes encoding the secreted protein (TpsA) and its cognate transporter (TpsB) 
are located in the same operon (Thanassi et al., 2005). It is suggested that a TPS domain 
(Fig. 1.21), the hallmark of the TPS pathway with a 110-residue conserved region 
presumably interacts specifically with its cognate transporter to start translocation, which is 
essential for TpsA secretion or release into the extra cellular milieu (Fig. 1.21). It has also 
been suggested that the TPS domain may provide a recognition site for TpsB. B. pertussis 
FHA adhesin is one of the best-studied TPS systems (Jacob-Dubuisson et al., 2004). 
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Figure 1.22 Model for secretion by the TPS pathway. Only secretion across the 
outer membrane is shown. (A) The N-terminal TPS domain (green) of TpsA binds to TpsB, 
possibly gating open the channel. TpsA secretion initiates from the N- to the C- terminus. 
(B) The TPS domain folds initially on the cell surface and then the TPS domain induces 
secretion and folding of the rest of TpsA into a repetitive β-sheet structure at the cell surface 
(C) (adapted from Thanassi et al., 2005).  
 
1.6.5.3 Type Vc (AT-2) 
The AT-2 family has only been identified recently as a subfamily of surface-attached 
oligomeric autotransporters and consists of Hia of H. influenzae, the oligomeric coiled-coil 
adhesins (Oca) such as YadA of Y. enterocolitica, and some other proteins of α, β, and γ-
Proteobacteria. However, the translocation unit of these proteins is much shorter than that of 
AT-1 proteins. The AT-2 family possesses all the aspects of ATs such as N-terminal signal 
sequence, a surface-exposed passenger domain, a linker region and a C-terminal domain 
predicted to form β-strands. It has been reported that the translocation unit of AT-2 appears 
to be a trimer consisted of 12 transmembrane β-strands (Oomen et al., 2004) and is an 
alternative model for autotransporter secretion system (Cotter et al., 2005) (Fig. 1.17).  
1.6.6 Type VI and VII secretion systems 
A novel system recently discovered in several Gram-negative pathogenic bacteria was 
named type VI (T6SS). T6SS gene clusters, which have been implicated in virulence-related 
processes by directly secreting virulence factors into host cells (Mougous et al., 2006), are 
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highly conserved and are present in one or more copies in many pathogenic Gram-negative 
bacterial species such as E. coli, P. aeruginosa, Y. pestis, V. cholerae (Pukatzki et al., 
2007). The proteins secreted by this system lack a Sec signal peptide, but information on the 
identity, location and functions of most of the T6SS components remains unknown 
(Economou et al., 2006). More recent evidence also showed a novel type VII secretion 
system, which mycobacteria employed to transport extracellular proteins across their 
hydrophobic and highly impermeable cell wall (Abdallah et al., 2007).    
1.7 Aims and Objectives 
    The main objective of the project was to characterize the BapC protein of B. pertussis. A 
suggested role in conferring serum resistance would be investigated, as well as the role of 
this protein in other virulence functions such as colonization of the mouse respiratory tract. 
As both BrkA and BapC are thought to contribute to serum resistance and mouse virulence, 
it was proposed to compare the role of BapC and BrkA in the same B. pertussis genetic 
background. The previous study (Bokhari, 2002) compared only mutants in different B. 
pertussis strains that may not have been otherwise isogenic. Also, by creating a bapC, brkA 
double mutant, it should be possible to determine whether it is fully serum sensitive or 
whether there are additional factors in B. pertussis that confer some degree of serum 
resistance. The authenticity of the mutants should be confirmed by PCR, Western blotting, 
Southern blotting, gene sequence analysis and slide agglutination tests.  
The serum sensitivity and other properties of recombinant E. coli strains, which over-
express the BapC, could be investigated and compared with the host strain. It was envisaged 
that the functions of BapC might be more easily studied in this strain than in B. pertussis, 
which expresses other autotransporter proteins with possibly similar or overlapping 
functions. 
During the course of this investigation, it became apparent that not all B. pertussis strains or 
Bordetella species might express a functional BapC protein. Thus, some characterization of 
the bapC gene in different strains and species was undertaken.   
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2. Materials and Methods 
2.1 General bacteriological procedures 
2.1.1. Bacterial strains, storage and growth media 
    The details of E. coli strains used in this study are given in Table 2.1. Bordetella strains 
used in the study are given in the Table 2.2. Unless otherwise stated, all strains were 
available from culture collections within the Division of Infection and Immunity, University 
of Glasgow. The compositions of the following media used in the study are given in 
Appendix I.1. Luria Bertani (LB) broth; Luria Bertani agar; Bordet-Gengou (BG) agar; 
Casamino acids (CAA) solution; Cyclodextrin liquid (CL) medium; SOC medium; Stainer-
Scholte (SS) and modified Stainer-Scholte media. All media were sterilised by autoclaving 
at 15 p.s.i (121°C) for 15 min unless stated. Heat-labile ingredients such as antibiotics 
(Table 2.3) and vitamin supplements were sterilised by filtration through a sterile 0.22 µm 
membrane filter (Gelman Sciences, USA) and were added to the growth media at 
appropriate concentrations. Glassware was sterilised by heating to 160°C for 2h. 
For long term storage, the E. coli strains were kept at -70°C in LB broth supplemented with 
50% (v/v) glycerol. Bordetella strains were resuspended in 1% CAA containing 20% (v/v) 
glycerol and stored at -70°C. Long term storage was performed by freeze drying to increase 
shelf life of Bordetella strains. 
2.1.2. Growth of B. pertussis strains 
    B. pertussis was grown routinely on Bordet-Gengou (BG) agar containing 15% (v/v) 
defibrinated horse blood and 1% (v/v) glycerol. Plates were placed in a humidified 
environment (e.g. sandwich box containing a beaker of water) at 37°C for up to 3 days. The 
B. pertussis colonies can be maintained for a period of 7-10 days on BG agar plates stored 
inverted at room temperature or at 4°C in humidified conditions.  
For liquid culture, B. pertussis was inoculated from BG plates into Stainer-Scholte (SS) 
liquid medium or Cyclodextrin Liquid (CL) medium and grown for 3 days at 37°C with 
shaking at 150-200 rpm. A loopful of bacteria was inoculated into 5 ml of liquid medium in 
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a universal or approximately 1.5 ml of bacterial culture was inoculated into 250 ml of liquid 
medium in a 500 ml flask.  
To check the identity and purity of B. pertussis strains, Gram staining, plating onto nutrient 
agar and BG sandwich agar, for β-haemolysis, and slide agglutination tests with anti-B. 
pertussis serum were carried out. For preparation of the BG sandwich plates, a layer of BG 
agar without blood was poured onto a plate. Once set, a thin layer of BG agar with blood 
was added on top.  
2.1.3. Growth of other Bordetella species 
    B. parapertussis, B. bronchiseptica, B. avium, B. hinzii, B. holmesii, and B. trematum 
were grown routinely at 37°C on BG agar plates for 48-72h. Where necessary, 500 ml of 
CL or SS medium in 2L dimpled flasks were inoculated from such BG plates and incubated 
for 48-72 h at 37°C with shaking at 150-200 rpm. 
2.1.4. Growth of E. coli  
    E. coli strains were grown overnight on Luria-Bertani (LB) agar at 37°C. Where 
necessary, 500 ml of LB broth in a 2 L dimpled flask was inoculated from such plates or 
with 5 ml of liquid culture grown overnight in LB medium in a universal bottle. Then, the 
flasks were incubated overnight at 37°C with shaking at 150-200 rpm. Stocks of E. coli 
were prepared by adding 420 µl of 70% (v/v) sterile glycerol to 580 µl of an E. coli 
overnight culture in LB broth and stored at -80°C 
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Table 2.1 E. coli strains used in this study 
Strains Genotype/Phenotypes Sources/Remarks 
E. coli M15p (REP4) NalS, StrS, RifS, Thi-, Ara+, Gal+, 
Mtl-, RecA+, Uvr+, Lon+ 
Qiagen; Recombinant 
protein expression 
strain  
E. coli M15pQE60 
(ATG1) 
E. coli M15p (REP4) above, also 
containing pQE60 (ATG1) 
Blackburn PhD 
thesis,2000 
E. coli TOP10 F’{lacIq, Tn10(Tetr)}, mcrA, D(mrr-
hsdRMS-mcrBC) f80lacZDM15 
DlacX74, deoR, recA1, araD139 
D(ara-leu)7697, galU, galK, rpsL 
(StrR), endA1, nupG 
Invitrogen; General 
transformation strain 
E. coli DH5α F'/endA1 hsdR17(rK-mK+) supE44 
thi-1 recA1 gyrA (Nalr) relA1 
∆(laclZYA-argF)U169 deoR 
(F80dlacD(lacZ)M15) 
Invitrogen; General 
transformation strain 
E. coli JM109 recA1, supE44, endA1, hsdR17, 
gyrA96, relA1, thi ∆(lac-proAB) 
Promega; General 
transformation strain 
E. coli SM10.λpir recA::RP4-2-Tc::Mu, λpir, R6K, thi, 
thr, leu, tonA, lacY, supE,  
Division of Infection 
and Immunity, 
University of Glasgow; 
DNA mobilising strain 
E. coli XL1 Blue recA1, endA1, gyrA96, thi-1, 
hsdR17, supE44, relA1, lac [F´ 
proABlacIqZ∆M15 Tn10 (Tetr)] 
Stratagene; Host strain 
for routine cloning 
applications 
E. coli BL21/DE3* F– ompT gal dcm lon hsdSB(rB- mB-) 
λ(DE3 [lacI lacUV5-T7 gene 1 ind1 
sam7 nin5])  
Invitrogen; 
Recombinant protein 
expression strain 
E.coli 
BL21(DE3)pLysS** 
F- ompT gal dcm lon hsdSB(rB- mB-) 
λ(DE3) pLysS(cmR) 
Invitrogen; 
Recombinant protein 
expression strain 
 
*E. coli BL21(DE3) is ideal for use with bacteriophage T7 promoter-based expression 
systems (e.g. pET). BL21(DE3) carries the lambda DE3 lysogen. Recombinant proteins 
that are non-toxic to E. coli are generally expressed at higher levels in strain BL21(DE3) 
than in BL21(DE3)pLysS (see below). The basal expression levels of heterologous 
genes are significantly higher in BL21(DE3) than in BL21(DE3)pLysS. 
**E. coli BL21(DE3)pLysS is also used with T7 promoter-based expression systems 
(e.g. pET). This strain carries both the DE3 lysogen and the plasmid pLysS. pLysS 
constitutively expresses low levels of T7 lysozyme, which reduces basal expression of 
recombinant genes by inhibiting basal levels of T7 RNA polymerase. 
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Table 2.2 Bordetella strains used in this study 
Species/Strains Genotype/ Phenotype Source 
B. pertussis Taberman Wild-type Isolated from a child post-mortem. 
Ruchill Hospital, Glasgow (1979) 
B. pertussis Taberman I Smr and Nalr derivative of 
BP Taberman parent 
Division of Infection & Immunity, 
University of Glasgow (Bokhari, 
2002, PhD Thesis) 
B. pertussis Taberman 
II 
BP Taberman I bapC::Kan; 
Nalr, Smr, Kanr 
Division of Infection & Immunity, 
University of Glasgow (Bokhari, 
2002, PhD Thesis) 
B. pertussis Tohama Wild-type Division of Infection & Immunity, 
University of Glasgow 
B. pertussis Tohama I Smr and Nalr derivative of 
BP Tohama wild-type 
Division of Infection & Immunity, 
University of Glasgow (Bokhari, 
2002, PhD Thesis) 
B. pertussis Tohama II BP Tohama I bapC::Kan; 
Nalr, Smr, Kanr 
Division of Infection & Immunity, 
University of Glasgow (Bokhari, 
2002, PhD Thesis) 
B. pertussis BP338 Derivative of BP Tohama 
(Nalr). Parent of BP2041 and 
BP347 
Weiss, A. Dept. of Molecular 
Genetics, University of Cincinnati 
B. pertussis BP2041 
[BP338 (BrkA-)] 
BP338 brkA1::Tn5  
Nalr, Kanr 
Weiss, A. Dept. of Molecular 
Genetics, University of Cincinnati 
B. pertussis BP347 
[BP347 (Bvg-)] 
BP338 bvgS1::Tn5  
Nalr, Kanr 
Weiss, A. Dept. of Molecular 
Genetics, University of Cincinnati 
B. pertussis 18323 Wild-type, standard mouse-
virulent strain 
Division of Infection & Immunity, 
University of Glasgow 
B. pertussis PICU  Originaly from HPA, Colindale 
B. parapertussis 
NCTC5952 
Wild-type Division of Infection & Immunity, 
University of Glasgow 
B. bronchiseptica 214 Wild-type Division of Infection & Immunity, 
University of Glasgow 
B. avium 4480 Wild-type Division of Infection & Immunity, 
University of Glasgow 
B. hinzii Wild-type Division of Infection & Immunity, 
University of Glasgow 
B. holmesii Wild-type Division of Infection & Immunity, 
University of Glasgow 
B. trematum 
 
 
Wild-type Division of Infection & Immunity, 
University of Glasgow 
 
B. pertussis BP338S Smr derivative of BP338 This study 
B. pertussis BP2041S  Smr derivative of BP2041  This study 
B. pertussis BP338 
(BapC-) 
BP338S bapC::Tet  
Nalr, Smr, Tetr 
This study 
B. pertussis BP338 
(BrkA-, BapC-) 
 
BPM2041S bapC::Tet 
Nalr, Kanr, Smr, Tetr 
This study 
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 Table 2.3 Antibiotics used in this study 
 
Antibiotic Final concentration (µg/ml) 
Ampicillin (Ap) 100 
Cephalexin 100 
Chloramphenicol (Cm) 20 and 34  
Gentamicin sulphate 40 
Kanamycin (Km) 40 
Nalidixic acid (mono-sodium salt) (Nal) 40 
Streptomycin (Sm) 100 
Tetracycline (Tet) 2-40 
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2.1.5. Spontaneous antibiotic-resistant strains of B. pertussis 
    It is often desirable, in the genetic manipulation of bacteria, to utilise strains that are 
easily selectable, for example on antibiotic-containing plates. Streptomycin and nalidixic 
acid are the most commonly used antibiotics for generating spontaneous antibiotic-resistant 
strains of B. pertussis. In order to select such strains, a 10 ml volume of a mid-log phase 
culture was centrifuged and resuspended in 0.1-0.2 ml of fresh Stainer-Scholte medium. 
Aliquots (100 µl or 50µl) of bacterial suspension were then spread on BG agar plates 
containing 100 µg/ml of streptomycin or 40µg/ml of nalidixic acid and incubated at 37°for 
4-5 days in humidified conditions to allow the growth of spontaneous resistant strains.  
2.2 DNA extraction 
2.2.1 Isolation of genomic DNA    
    For routine isolation of genomic DNA from B. pertussis, Promega`s Wizard genomic 
DNA purification kit was used. Bacteria from 1ml volume of an overnight culture grown, in 
appropriate medium, to OD600nm ~ 0.6-0.7 were harvested by centrifugation at 13000 rpm 
using a tabletop micro centrifuge (Biofuge, Heraeus, Germany) for 2 min in a 1.5 ml micro 
centrifuge tube, and the supernate was discarded. 600 µl of Nuclei Lysis Solution 
(Promega) was added to the pellet, and the mixture was pipetted gently until the cells were 
resuspended. The mixture was then incubated at 80°C for 5 min to lyse the cells, and then 
cooled at room temperature. 3 µl of RNase solution (Promega) was added to the cell lysate 
and, after thorough mixing, the sample was incubated at 37°C for 45 min, and then cooled 
to room temperature. 200 µl of Protein Precipitation Solution (Promega) was added to the 
RNase-treated cell lysate, then the mixture was vortexed vigorously at high speed for 20 sec 
to mix the protein precipitation solution with the cell lysate. Next, the sample was incubated 
on ice for 5 min, and again centrifuged at 13000 rpm for 3 min. The supernate containing 
the DNA was carefully transferred to an eppendorf tube (1.5 ml) containing 600 µl of 
isopropanol at room temperature and mixed gently by inversion until the thread-like strands 
of DNA formed a visible mass. The sample was centrifuged at 13000 rpm for 2 min, and the 
supernate was poured off and the tube drained on clean absorbent paper. To the pellet was 
added 600 µl of 70% v/v ethanol at room temperature and the mixture gently inverted 
several times to wash the DNA pellet. Then, the sample was centrifuged for 2 min at 13000 
rpm. The supernate was carefully aspirated, and the pellet allowed to air-dry for 10-15 min. 
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The DNA pellet was rehydrated by adding 100µl of DNA Rehydration Solution (Promega) 
for 1 h at 65°C and periodically mixed by gently tapping the tube.  Alternatively, the DNA 
was rehydrated by incubating the solution overnight at room temperature or at 4°C. Finally, 
the DNA was aliquoted and stored at 2-8°C or –20°C for longer storage.   
2.2.2 Isolation of plasmid DNA  
 
    Plasmids used in this study are listed in Table 2.4. The QIA prep Mini prep Purification 
System (Qiagen) was used for plasmid DNA isolation according to the manufacturer’s 
protocol. A 5 ml volume of an overnight E. coli culture in LB (Luria-Bertani) broth was 
centrifuged at 10000 ×g for 10 min. The bacterial pellet was resuspended in 250 µl of buffer 
P1 and transferred to a micro centrifuge tube. No cell clumps should be visible after re-
suspension of the pellet. Then, 250 µl of buffer P2 (alkali-detergent solution) was added, 
and the tube gently inverted 4-6 times at room temperature to mix. It should not be 
vortexed, as this will result in shearing of genomic DNA. The tube was inverted until the 
solution became viscous and slightly clear, but the lysis reaction was not allowed to proceed 
for more than 5 min. The macromolecules were then precipitated using 350 µl of buffer N3 
(Chaotropic solution) and centrifuged at 13000 rpm for 10 min in a tabletop micro 
centrifuge. To avoid localised precipitation, the solution was mixed gently, but thoroughly, 
immediately after addition of buffer N3, and the solution became cloudy. After 
centrifugation, a compact white pellet was formed. The supernate from the last step was 
added to the QIA prep Spin Column by decanting or pipetting, and centrifuged for 30-60 
seconds, then the flow-through was discarded. The QIA prep Spin Column was washed by 
adding 0.5 ml of buffer PB (trace nuclease removal) and centrifuged for 30-60 seconds, and 
the flow-through was discarded. This wash step was performed only for endA+ strains, 
including the JM series such as E. coli JM109 as used in this study, or any wild-type strains, 
which had high levels of nuclease activity or high carbohydrate content. This additional 
wash step was not used for host strains such as XL-1 blue and DH5α. Then, the QIA prep 
Spin Column was washed by adding 0.75 ml of buffer PE containing ethanol and 
centrifuged for 30-60 seconds. The flow-through was discarded and a final centrifuge step 
was performed for an additional 1 min to remove residual wash buffer. The residual wash 
buffer was completely removed since the residual ethanol from buffer PE might inhibit 
subsequent enzymatic reactions. To elute the DNA, 50 µl of buffer EB (10 mM Tris-HCl, 
pH 8.5) was added to the centre of the QIA prep Spin Column, and let stand for 1 min, then 
centrifuged for 1 min.  
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Table 2.4 Plasmids used in this study 
 
Plasmid name Description     Source 
pQE60 (ATG1) 
 
Vector (Qiagen) for expression of 
recombinant protein with His-tag, 
containing most of full length of bapC 
gene 
Blackburn PhD thesis, 
2000 
pSS1129 Suicide vector for gene replacement in 
B. pertussis  
Stibitz et al., 1986 
pbap5-Kana [P-B-5] Suicide vector pSS1129 containing 
most of bapC gene, disrupted by 
insertion of kanamycin resistance 
cassette 
Bokhari PhD thesis, 2002 
pCR-Script (Bap-5;Kmr) 
 
[pCR-Script bapC::Km] 
Cloning vector pCR-Script containing 
most of bapC gene disrupted with 
kanamycin resistance cassette 
Blackburn PhD thesis, 
2000 
pQE60 (NTS) Recombinant protein expression 
vector pQE60 containing gene for part 
of BapC N-terminus   
Blackburn PhD thesis, 
2000 
pGEMT-Bap5 
 
cloning vector pGEMT containing 
most of bapC gene 
Blackburn PhD thesis, 
2000 
pSS1129 (bapC::Tet) 
[pBapC-Tet(bapC::Tet)] 
 
Suicide vector pSS1129 containing 
most of bapC gene, disrupted with 
tetracycline resistance cassette   
This study 
pET33b [pET-33b(+)] Expression vector based on the T7 
promoter-driven system (Appendix II) 
Novagen 
pET33b (BapC + SS) pET33b expression vector containing 
full length of bapC gene with 
predicted signal sequence 
 
This study 
pET33b (BapC – SS) pET33b expression vector containing 
full length of bapC gene without 
predicted signal sequence 
This study 
pBR322 Cloning vector (Appendix II); source 
of tetracycline resistance cassette 
Division of Infection & 
Immunity, University of 
Glasgow 
pGEMT-Tet cloning vector pGEMT containing 
tetracycline resistance cassette  
This study 
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2.3 Agarose gel electrophoresis  
2.3.1 Sample preparation 
    The sample DNA (5-30 µl) was mixed with 6×DNA loading buffer in a 5:1 (vol:vol) ratio 
prior to loading into the wells. Molecular weight markers (1 kb ladder, Promega) were used. 
2.3.2 Gel preparation and electrophoresis 
    Pre-weighed agarose (TypeII-A medium EEO, Sigma), was suspended in 0.5 × Tris-
Borate-EDTA (TBE) buffer (Appendix AI.2.1) and heated until the agarose solution 
became clear (completely dissolved). The solution was allowed to cool to the extent that it 
was still warm and ethidium bromide (Bio-Rad, UK) was added to a final concentration of 
0.5 µg/ml. A gel tray was prepared by taping the edges with adhesive tape and the gel was 
cast to the desired thickness. Upon setting, the gel was immersed in 0.5×TBE buffer 
containing ethidium bromide (0.5 µg/ml) in a horizontal submarine electrophoresis tank. A 
power pack was used to provide a constant voltage corresponding to 1-5∗ volts/cm 
(measured as the distance between the electrodes). Electrophoresis was carried out until the 
marker dye in the loading buffer had migrated an appropriate distance through the gel.  
∗During electrophoresis the ethidium bromide migrates toward the cathode (in the direction 
opposite to that of the DNA). Extended electrophoresis can remove much of the ethidium 
bromide from the gel, making detection of small fragments difficult. Since sometimes this 
occurred, the gel was re-stained by soaking it for 30-45 minutes in a solution of ethidium 
bromide (0.5 µg/ml). 
2.3.3 Visualisation of DNA 
    The ethidium bromide-stained DNA was visualised using a UV transilluminator (model 
TM-40, UVP Inc., California, USA). Images were stored electronically as appropriate using 
the Gel Documentation System-Image Store 5000, version 7.2 (UltraViolet Products, 
Cambridge, UK) as well as printed using a video graphic printer. Electronic images were 
edited using Adobe PhotoShop 3.0 and images labelled with Microsoft PowerPoint 4.0 
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2.3.4 Gel extraction procedure 
    A QIAquick Gel Extraction kit (Qiagen) was used according to the manufacturer’s 
instructions. The DNA fragment of interest was excised from the agarose gel with a clean, 
sharp scalpel. The size of the gel slice was minimised by removing extra agarose around a 
band. The gel slice was weighed in a colourless tube and 3 volumes of buffer QG were 
added to 1 volume of gel (100 mg ≈  100 µl). For >2% agarose gels, 6 volumes of buffer 
QG were added. The tubes were incubated at 50°C for 10 min or until the gel slice was 
completely dissolved. The tubes were mixed by vortexing every 2-3 min during the 
incubation to help the gel to dissolve. The colour of the mixture should be yellow (similar to 
the buffer QG without dissolved agarose) after the gel slice was completely dissolved. If the 
colour of the mixture was violet, 10µl of 3M-sodium acetate, pH 5.0 was added and then the 
colour turned to yellow. The yellow colour indicates the pH ≤ 7.5 where the absorption of 
DNA to the QIAquick membrane in a later step is most efficient.  
One gel volume of isopropanol was added to the sample and mixed. This step increases the 
yield of DNA fragments <500 bp and >4 kb. For DNA fragments between 500 bp and 4 kb, 
addition of isopropanol had no effect on yield. The maximum volumes of 800 µl samples 
were applied to the QIAquick column to bind DNA and then centrifuged at 13000 rpm 
using a tabletop micro centrifuge (Biofuge, Heraeus, Germany) for 1 min. Sample volumes 
of more than 800 µl were simply loaded and spun again. The flow-through was discarded 
and the QIAquick column placed back in the same collection tube. To remove all traces of 
agarose, 0.5 ml of buffer QG was added to QIAquick column and centrifuged at 13000 rpm 
for 1 min. To wash the column, 0.75 ml of buffer PE was added to QIAquick column and 
left for 2-5 min and then centrifuged at 13000 rpm for 1 min. 2-5 min incubation time was 
used for salt-sensitive applications, such as blunt-ended ligation and direct sequencing.  
The flow-through was discarded and, to remove completely the residual ethanol from buffer 
PE, the QIAquick column was centrifuged for an additional 1 min at 13000 rpm. The 
QIAquick column was placed into a clean 1.5 ml centrifuge tube and 50 µl buffer EB added 
to the centre of the QIAquick membrane and the column was then centrifuged at 13000 rpm 
for 1 min to elute DNA. The average eluate volume was 48 µl from 50 µl elution buffer 
volume, and the maximum elution efficiency was achieved between pH 7.0 and 8.5.  
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2.4 Restriction enzyme reactions 
    Restriction enzymes or endonucleases cleave double-stranded DNA (dsDNA) at specific 
sites within or adjacent to their recognition sequences. All reaction were performed based 
on the manufacturer’s instructions (Promega). Total reaction was performed in a volume of 
20 µl on 0.2-1.5 µg of substrate DNA, using usually 5-fold excess of enzyme over DNA. In 
a sterile tube, reagents were added in order as follows: sterile deionized water 16.3 µl, 
restriction enzyme 10× buffer 2 µl, acetylated BSA (to enhance the enzyme activity) 0.2 µl 
of 10 µg/µl, DNA 1 µl of 1 µg/µl, and mixed by pipetting, then the restriction enzyme 0.5 
µl of 10u/µl was added. It was then mixed gently by pipetting and centrifuged for a few 
second and finally incubated at the optimum temperature for 1-4h. 4 µl of 6× loading buffer 
was added prior to gel analysis. Where appropriate, the enzymes were heat-inactivated at 
65°C or 80°C for 15 min according to manufacturer’s instructions.  
2.5 Cloning protocol           
2.5.1 DNA preparation 
    Vector and insert DNA were subjected to restriction endonuclease digestion to obtain 
complimentary cohesive overhangs and the resultant fragments were gel purified. DNA 
concentrations were estimated and ratios determined according to the equation (1) and (2), 
respectively.  
Equation 1: 
Concentration of DNA (ng/µl) = A260nm × 50 × dilution factor 
For quantitating the amount of DNA, readings were taken at wavelengths of 260 nm and 
280 nm. The reading at 260 nm allows calculation of nucleic acid in the sample. An OD of 
1 corresponds to approximately 50 µg/ml for double-stranded DNA, 40 µg/ml for single-
stranded DNA, and ∼20 µg/ml for single-stranded oligonucleotides. The ratio between the 
readings at 260 nm and 280 nm (OD260/OD280) provides an estimate of the purity of the 
nucleic acid. Pure preparations of DNA have OD260/OD280 values of 1.8. If there is 
contamination with protein or phenol, the OD260/OD280 will be significantly less than the 
values given above, and accurate quantitation of the amount of nucleic acid will not be 
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possible. Alternatively, band intensity of a sample of DNA was compared with those of 
molecular weight standards of known concentration after agarose gel electrophoresis. 
Equation 2: 
   ng of vector × kb size of insert  
    
Insert: Vector ratios of 1:1 and 3:1 were commonly utilised. 
2.5.2 Ligation strategies 
    Ligation reactions were performed in a total volume of 10 µl using 3 units of T4 DNA 
ligase and ligase 10×buffer (Promega, USA). After incubation at 16°C for 18h for a blunt-
end ligation, or at room temperature (22°C) for 3h or 4-8°C overnight for a sticky-end 
ligation, the ligation was terminated by heating the reaction mix at 70°C for 10 min, and 
then the products were stored at −20°C until use. The correct and complete ligation was 
analysed by gel electrophoresis using unligated material as a suitable control. 
2.6 Transformation 
2.6.1 Preparation of electroporation-competent cells 
    A 2-L dimpled flask containing 500 ml of fresh LB broth was inoculated with 5 ml of an 
overnight culture of E. coli strain. The flask was incubated at 37°C on a shaker until an 
OD600nm of 0.5-0.7 was obtained. The flask was then chilled on ice for 30 min and thereafter 
harvested at 2500 ×g (10000 rpm) for 15 min in a Sorvall superspeed (rotor GS-3). The 
resultant bacterial pellet was resuspended in 500 ml of cold sterile distilled water and then 
centrifuged for 15 min as mentioned previously. The cell pellet was resuspended in 250 ml 
of cold sterile distilled water and then centrifuged for 15 min as previously described. The 
cell pellet was suspended in 10 ml of cold sterile glycerol 10% (v/v) in distilled water and 
then the final centrifugation performed for 15 min, as before. The cell pellet was 
resuspended in 1.5 ml of sterile 10% (v/v) glycerol and 40-100 µl aliquots were snap frozen 
in liquid nitrogen or on dry ice. Finally, the aliquots were stored at -70°C. Cells are usable 
       kb size of vector 
×  Molar ratio of  Insert  
Vector  
= ng of insert 
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for approximately 6 months. For use, cells were kept cold (on ice) at all times during the 
procedure to be as close to 0°C as possible.  
2.6.2 Electroporation procedure     
    Electroporation cuvettes (0.1 cm or 0.2 cm) (Bio-RAD, UK) and the safety chamber were 
previously chilled at –20°C. To chilled eppendorf tubes, 1-5 µl of DNA (ligation mix or 
plasmid preparation) and 40 µl of thawed competent cells on ice were added.   The mixture 
was gently swirled (to avoid multiple pipetting) and incubated on ice for 10-20 min, then 
transferred to pre-chilled cuvettes on ice. The cuvettes were gently tapped to deposit the 
liquid at the botton of the tube, and placed in a Bio-Rad Gene Pulser (model 1652098, Bio-
Rad laboratories, UK) set at 1.5 KV, 25 µFD, and 200 Ω for 0.1 cm or 2.5 KV, 25 µFD, and 
200Ω for 0.2 cm. The cells were pulsed once for 4-5 msec. At no time were the cells 
exposed to room temperature except for a few seconds.  Immediately following 
electroporation, 1 ml of pre-warmed (37°C) SOC medium (Appendix AI.1) was added to 
the cells and incubated for 1-2 h at 37°C with shaking at 225-250 rpm. This growth step 
before spreading the transformation mixture onto plates is usually necessary for efficient 
transformation when non-lactamase selection markers are used. Finally, various volumes of 
the mixture (e.g. 10 µl, 100 µl) were plated on selective LB agar containing the appropriate 
antibiotics, and incubated overnight at 37°C. 
2.6.3 Preparation of competent cells for heat shock transformation 
    A 1ml overnight culture was inoculated into LB broth and grown for about 3h at 37°C in 
a shaking incubator until the OD600 was approximately 0.5-0.7. The culture was then cooled 
on ice and cells pelleted by centrifugation at 2500 ×g for 10 min at 4°C in a Sorvall RT 
6000B refrigerated centrifuge. The cells were resuspended in 50 ml of cold 50 mM CaCl2 in 
distilled water and left on ice for 30 min. Cells were then pelleted as before and 
resuspended in 10 ml of cold 50mM CaCl2 , 15% (v/v) glycerol. 200 µl aliquots were snap 
frozen and stored at -70°C. 
2.6.4 Heat shock transformation   
Competent cells from -80°C prepared for heat shock transformation were thawed on ice for 
10 min. 5 µl of each ligation reaction was added to 100 µl competent cells and incubated on 
  Materials & Methods  
 
78 
ice for a further 30 min. The cells were then heat shocked by transferring to a water bath at 
42°C for 45 sec, then returned to ice for 2 min before addition of 950 µl of SOC medium. 
The cultures were incubated at 37°C with shaking for 1 h and then 100 µl of each was 
plated on LB agar containing appropriate antibiotics. Plates were incubated at 37°C 
overnight and next day were checked for the appearance of colonies.  
2.7 Bacterial conjugation and gene replacement  
2.7.1 Construction of BapC mutant of BP338 
    The replacement of a chromosomal gene with its in vitro-altered counterpart by 
homologous recombination is a standard method for use with B. pertussis. The most widely-
used suicide vector, pSS1129, is a derivative of pRTP1, and was constructed by Stibitz et 
al. (1986) (Table 2.4). 
Bacterial conjugation was carried out by plate mating on BG agar plates between E. coli 
SM10.λpir (donor strain)(a DNA mobilising strain) carrying, on pSS1129, the mutated 
bapC gene, disrupted with the tetracycline cassette (Table 2.4), and B. pertussis BP338S 
(Table 2.2) (see Fig. 2.1).  
B. pertussis BP338S and E. coli SM10.λpir with pSS1129 (bapC::Tet)(donor strain) were 
grown on BG agar containing 15% v/v horse blood and streptomycin (100 µg/ml), and LB 
agar containing tetracycline (20 µg/ml), respectively. Colonies of B. pertussis were 
inoculated into 10 ml of CL medium (Appendix I.1) and grown at 37°C for 14-18 h. 
Colonies of E. coli were inoculated into 10 ml of LB broth and incubated at 37°C for 3-4 h. 
The resulting OD600nm for E. coli SM10.λpir in two different experiments was 0.4 (1×108 
CFU/ml) and  1.0, and for B. pertussis was 0.5 (~early logarithmic phase) and 0.8, 
respectively. The concentration of B. pertussis was adjusted by comparison with an opacity 
rod (5th International Reference of Opacity, Perkins et al. 1973) to 10 opacity units i.e.~ 109 
CFU/ml. 1 ml volumes of E. coli and B. pertussis cultures were then separately centrifuged 
in a tabletop micro centrifuge (Biofuge, Heraeus, Germany) at 13000 rpm for 1 min.  
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Figure 2.1 Construction of bapC mutant of B. pertussis by conjugation of 
BP338 strain with E. coli carrying  suicide vector pSS1129 containing 
bapC::Tetr 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*To select for the suicide 
plasmid (pBapC::Tetr) 
incorporated into the 
recipient chromosome 
**To select for loss of the 
plasmid and a second 
recombination event (due to 
sensitivity to Sm) 
♣To facilitate conjugation 
Grow in CL medium (OD600 = 0.4 - 0.5) & 
wash and resuspend in SS medium  
Grow in LB broth (OD600 =0.4 – 0.5) 
& wash and resuspend in SS 
medium 
Mix in SS medium at different donor-recipient 
ratios 
E. coli SM10. λpir (Donor strain) 
with suicide vector pSS1129 
(Sms/Ampr/Gmr/Kms) carrying 
bapC::Tetr 
Resuspend in SS medium 
Plate on:  Cephalexin + Nal + Tet 
                                (40 µg/ml)     (40 µg/ml)     (20 µg/ml) 
* Single (first) crossover [incubate for 4-5 days] at 37°C 
Select individual colonies and plate on: Sm + Tet + Nal 
**Double (second) crossover [Incubate for 3-4 days] at 37°C 
 
∗∗∗∗Check growth on BG agar 
containing ampicillin (100µg/ml) 
B. pertussis BP338  
(Nalr) 
Incubation 14h on BG agar+MgCl2 10mM (37˚ C ) ♣ 
[In the form of 10µl drops at various spots] 
 
∗∗∗∗To confirm the loss of 
integrated plasmids. These 
strains are not able to grow 
on BG agar containing Amp 
(a marker in the suicide 
plasmid) 
Select spontaneous Smr derivative of B. pertussis 
BP338 (Nalr/Smr) 
Stock Smr/Tetr/Nalr clones 
Amps clones should be bapC mutants 
Check by PCR & 
Southern blotting 
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The supernates were aspirated and pellets resuspended and washed twice in 1 ml of 
respective media (at the same speed as above for 5 min). The pellets of both donor and 
recipient were resuspended in 100 µl of CL medium and mixed together in a 1.5 ml 
eppendorf tube at different donor: recipient ratios such as 1:1, 1:2, 1:3, 1:4, 1:10 and 1:100. 
Aliquots of 10 µl of mixture were plated on freshly-made and dried BG agar containing 10 
mM MgCl2, which facilitates conjugation, in the form of drops, and were incubated at 37ºC 
for 3-14 h (Stibitz, 1994). 
The bacterial cells were then collected from the agar surface with a loop and resuspended in 
SS-X medium, and then washed and resuspended in 100 µl fresh SS-X medium. To select 
for the first (single) crossover, where the suicide plasmid is incorporated into the B. 
pertussis chromosome, bacterial suspensions were then plated onto BG agar plates 
containing cephalexin (40 µg/ml), nalidixic acid (40 µg/ml) and different tetracycline 
concentrations (2, 3, 5 µg/ml). The plates were incubated at 37ºC for 5-6 days to select the 
exconjugants. The cephalexin was included to select against growth of the E. coli donor as 
B. pertussis is naturally resistant to cephalexin (40 µg/ml).  
The second crossover was obtained by selecting for the loss of the integrated plasmid. The 
exconjugants were plated on BG agar plates supplemented with streptomycin (100 µg/ml), 
nalidixic acid (40 µg/ml), and tetracycline (2, 3, 5 µg/ml), and were incubated at 37ºC for 5-
6 days: The suicide vector pSS1129 has the rspL gene which encodes streptomycin 
sensitivity and only those bacteria that have lost the plasmid will be able to grow.  
To confirm the loss of integrated plasmid, the survivors of the above selection were grown 
on BG agar containing ampicillin (100 µg/ml), a marker on the suicide plasmid (pSS1129). 
Survivors of streptomycin selection that are ampicillin sensitive show that they have lost the 
vector (Fig. 2.1). Colonies of B. pertussis that are TetR, SmS should have the bapC allele 
replaced with the bapC::TetR allele.   
2.7.2 Construction of BrkA-, BapC- double mutant 
    Construction of BrkA-, BapC- double mutant was performed under the same conditions 
for making BP338 (BapC-) except in some steps. Bacterial conjugation was carried out by 
plate mating the E. coli SM10.λpir (donor strain) carrying on pSS1129 the mutated bapC 
gene disrupted with the tetracycline cassette and B. pertussis BP2041S (brkA mutant). B. 
pertussis BP2041S was grown on BG agar containing 15% v/v horse blood and kanamycin 
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(40 µg/ml). For the first (single) crossover, where the suicide plasmid is incorporated into 
the B. pertussis chromosome, bacterial suspensions were plated onto BG agar plates 
containing kanamycin (40µg/ml), cephalexin (40 µg/ml), nalidixic acid (40 µg/ml) and 
different tetracycline concentrations (2, 3, 5 µg/ml).  
The second crossover was performed by selecting for the loss of the integrated plasmid via 
plating the exconjugants on BG agar plates supplemented with streptomycin (100 µg/ml), 
kanamycin (40 µg/ml), nalidixic acid (40 µg/ml), and tetracycline (2, 3, 5 µg/ml), and 
incubation at 37ºC was continued for 5-6 days:  
2.8 Polymerase chain reaction 
   The PCR conditions were optimised, where necessary, according to the orthogonal array 
method described by Cobb et al. (1994). The annealing and elongation thermal parameters 
were then adjusted to obtain optimal conditions. A Hybaid thermal cycler was used for all 
reactions. The products of the PCR were stored at –20°C or used immediately.  
2.8.1 Primers   
During primer design, care was taken to avoid potential internal secondary structure, and 
where possible, a GC clamp was engineered at the 3`end of the primer. Additionally, 
primers were checked to avoid overlapping regions and possible dimerisation, potential for 
secondary structure formation and for compatible Tm values. Tm values were calculated 
according to the equation:  
                          Tm°C = 4 (G+C) + 2 (A+T) - 5°C 
Primers were obtained from Invitrogen and resuspended in filter sterilized distilled water to 
give a final concentration of 100 pmol/µl or 25 pmol/µl for PCR (Details of primers used in 
this study are given in Table 2.5). 
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Table 2.5 Primers used in this study 
 
Primer designation Primer sequence                 Comments 
bapC  forward 5’ to 3’ 
(BAP5F)  
 
ATGGCACCTCGCCTTCGATTCGCGTCCAAG 
 
Amplifies bapC gene from nucleotide 728 (see Appendix II) 
bapC reverse 3’ to 5’ 
 (BAP5R)  
 
AGGTGGAACGTCCAAGGCAAGGTCAGCTTG 
 
Amplifies bapC gene from nucleotide 2960 
Forward (5’ to 3’) primer 
of  tetracycline-resistance 
gene (TCF1) 
 
AATC/CATGGTTCTCATGTTTGACAGCTTATCATCG 
 
Amplifies Tet  cassette from pBR322 with a designed NcoI 
recognition sequence  
Reverse (3’ to 5’) primer 
of tetracycline-resistance 
gene (TCR1) 
 
ACGC/CATGGTTTGCGCATTCACAGTTCTCCGC 
 
Amplifies Tet cassette from pBR322 with a designed NcoI 
recognition sequence 
Forward (5’ to 3’) primer 
of bapC gene with signal 
sequence (BAPCF14) 
 
TAATAATCATATGAATGACAGAAAATCCAATAGC 
                                         
                                        NdeI recognition sequence 
 
Amplifies full length bapC gene from first codon of the signal 
sequence and with a designed NdeI recognition sequence  
Forward (5’ to 3’) primer 
of bapC gene without 
signal sequence 
(BAPCF24) 
 
TAATAATCATATGCAGGCCGCGCCGGCCGCCGCC                                 
                             
                                       NdeI recognition sequence 
 
Amplifies bapC gene after signal sequence  with a designed 
NdeI recognition sequence 
NcoI recognition sequence 
NcoI recognition sequence 
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Reverse (3’ to 5’) primer 
of bapC gene 
(BAPCR12) 
 
ACGGATCCGACTACCAGGTGTAGCGATAGCCC 
                              
                                   BamHI recognition sequence                                   
 
Amplifies bapC gene from nucleotide 2982 with a designed 
BamHI recognition sequence 
 
Forward (5’ to 3’) primer 
of bapC gene without 
signal sequence 
(BAPCF25) 
 
AATAATGCTAGCATGCAGGCCGCGCCGGCCGCCGCC 
                                     
                                      NheI recognition sequence 
 
Amplifies bapC gene from first codon after signal sequence 
and with a designed NheI recognition sequence 
 
Forward (5’ to 3’) primer 
of bapC gene with signal 
sequence (BAPCF15) 
 
AATAATGCTAGCATGAATGACAGAAAATCCAATAGC 
                                        
                                     NheI recognition sequence 
 
Amplifies full length bapC gene from first nucleotide of the 
signal sequence and a designed NheI recognition sequence 
Forward (5’ to 3’) primer 
of bapC gene (MNF1) 
 
ATGAATGACAGAAAATCCAATAGC 
 
Amplifies bapC gene from first codon of the signal sequence 
to determine the region encompassing poly(C) tract 
Reverse (3’ to 5’) primer 
of bapC gene (MNR1) 
 
GCTGTCACGCACGGTGAGCGAACG 
 
Amplifies bapC gene from nucleotide 408 
Forward (5’ to 3’) primer 
of bapC gene (MNF2) 
 
CGTGTATGTCGACTCGGAGCACCG 
 
Amplifies bapC gene from nucleotide 363 to determine the 
region encompassing poly(G) tract 
Reverse (3’ to 5’) primer 
of bapC gene (MNR2) 
 
CCAGACCCTGTTGCCACCACAGCG 
 
Amplifies bapC gene from nucleotide 818  
 
Forward (5’ to 3’) primer 
of brkA gene (BRKF) 
               
CGGTTGACCGACGGCGCCACGGCGC 
 
Amplifies brkA gene from nucleotide 2701 (see Appendix II.4)  
   
  Materials & Methods                                
 
84 
Reverse (3’ to 5’) primer, 
in Tn5 (TN5R1) 
 
ATGCGCCCACTGCGCAGGCTCAAGC Amplifies Tn5 gene from nucleotide 4919  
 
Reverse (3’ to 5’) primer, 
in Tn5 (TN5R2) 
 
 
CACCACGAAGCGCTCGTTATGCGCC 
 
Amplifies Tn5 gene from nucleotide 5101  
 
Reverse (3’ to 5’) primer, 
in Tn5 (TN5R3) 
 
 
GTGGTGCTTCGCGAGCAATACGCG 
 
Amplifies Tn5 gene from nucleotide 718  
 
Forward (5’ to 3’) primer 
of brkA gene (BRKAF2) 
 
 
AACTGCCGGGTGAAGACGGCGCCG 
 
Amplifies brkA gene from nucleotide 61 
 
Reverse (3’ to 5’) primer 
of brkA gene (BRKR2) 
 
 
 
AAGCTGTAGCGGTAGCCGGCGTGG 
 
Amplifies brkA gene from nucleotide 4238 
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2.8.2 HotStar Taq PCR Method      
   Hot-start PCR was performed according to the HotStar Taq PCR kit manufacturer’s 
instructions (Invitrogen). The following mixture was prepared in a thin-walled 0.5 ml tube 
immediately before use. 
Mixture per reaction (µl) 
     10×PCR buffer (containing 15 mM MgCl2 )∗                                        5     
     5× Q solution∗∗                                                                                      10 
     10 mM dNTPs                                                                                         1 
      Primer 1 (Forward) [25 pmol/µl]                                                           2 
      Primer 2 (Reverse) [25 pmol/µl]                                                            2 
      Hot Star Taq DNA polymerase [5 units/µl]                                          0.2 
 
      dH2O (filter sterilized)[for negative control = 29.8 µl]                     28.8                                                
 
      Template DNA                                                                                       1 
 
     Total volume in each PCR tube                                                                                  50 
∗ Final concentration of MgCl2 is 1.5 mM. 
∗∗ Q solution facilitates amplification of difficult templates by modifying the melting 
behaviour of DNA. This reagent will often enable or improve a suboptimal PCR caused by 
templates that have high degree of secondary structure or that are GC-rich. 
The following thermo-cycling parameters were used:   
                                                                                     Time             Temperature 
                           Initial activation step:                          10 min                95°C                                                                        
                           30 cycles of: 
                             
  Materials & Methods  
 
86 
                                       Denaturation:                              1 min                 94°C 
 
 Annealing:                                1 min                 56°C 
 
                                        Extension:                                   4 min                 72°C  
 
 
             Final extension time:                             10 min               72°C 
 
 
2.8.3 Touchdown PCR 
    Touchdown PCR is a simple method to optimize yields of amplified DNA when the 
melting temperature of hybrids between the oligonucleotide primers and their target 
sequences is not known with certainty, and spurious smaller bands appear in the product 
spectrum.  
The earliest steps of a touchdown PCR cycle have high annealing temperatures (least-
permissive of non-specific binding) and, every subsequent cycle, the annealing temperature 
is decreased by 1 or 2 degrees Celsius. In this study, after initial denaturation at 95°C for 5 
min, the reaction mix in the earliest steps of a touchdown PCR cycle had a high annealing 
temperature of 64°C for 1 min. For every subsequent 5 cycles, the annealing temperature 
was decreased by 2°C. The final 10 cycles were then performed at 54°C to make a total of 
35 cycles. The cycling conditions for denaturation at 95°C for 1 min, annealing for 1 min 
and elongation at 72°C for 3 min were used before a final elongation step at 72°C for 10 
min.   
2.8.4 Colony PCR 
    Colony PCR is the screening of bacterial (E. coli) clones for correct ligation or plasmid 
products. Selected colonies of bacteria were picked with a sterile toothpick or pipette tip 
from a growth plate (LB agar with appropriate antibiotic), and swirled into 25 µl of TE 
(Appendix AI.2.4) in an autoclaved microfuge tube. The area of picked bacteria was 
marked and (preferably) numbered on the bottom of the plate (and the microfuge tube). 
The mix tube was heated in a heating block at 90-100°C for 10 min, and then the samples 
were incubated at -20°C for 5 min and centrifuged for 10 min at 13000 rpm. 20 µl of the 
supernatant was then transferred into a new microfuge tube and 1-2 µl of the supernatant 
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was used as template in a 50 µl PCR standard reaction. PCR was conducted to determine if 
the colony contained the DNA fragment or plasmid of interest.  
2.8.5 Nested PCR  
    Nested PCR means that two pairs of PCR primers were used for a single locus. The first 
pair amplified the locus as in any PCR experiment. The second pair of primers (nested 
primers) bind within the first PCR product, and produce a second PCR product that will be 
shorter than the first one. The logic behind this strategy is that if the wrong locus was 
amplified by mistake, the probability is very low that a second pair of primers would also 
amplify it a second time. The thermo-cycling parameters for both external and internal 
PCR rounds were 1 cycle of 94°C for 5 min; 30 cycles of 94°C/1 min, 60°C/1 min and 
72°C/3 min and a final extension time at 72°C for 7 min.    
2.8.6 Multiplex PCR 
    In order to develop a multiplex PCR system for the simultaneous detection of different 
gene fragments in the target, the following mixture was prepared. Each of the 0.5 ml 
eppendorf tubes contained 2 µl of 10 mmol 1-1 dATP, dTTP, dGTP and dCTP, 5 µl of 
10×PCR buffer containing 15 mmol 1-1 MgCl2, 10 µl of 5×Q solution, 25 ρmol of each 
primer and 2 µl of target DNA. After adding 0.5 µl of DNA Taq polymerase, the final 
volume of the mixture was then adjusted to 50 µl by adding sterilised distilled water. The 
following thermo-cycling parameters were used; 94°C for 4 min followed by 35 cycles of 
PCR (94°C, 1 min; 60°C, 30s; and 72°C, 1 min for denaturation, annealing and extension 
in each cycle). Final extension was performed at 72°C for 10 min. 
2.8.7 Purification of PCR products 
    A QIAquick PCR purification kit was used according to the manufacturer’s instructions 
(Qiagen). This protocol is used to purify fragments ranging from 100 bp to 10 kb away 
from primers, nucleotides, polymerases, and salts.  
5 volumes of buffer PB were added to 1 volume of the PCR sample and mixed. The sample 
was then applied to the QIAquick column to bind DNA, and this was centrifuged by 
tabletop micro centrifuge (Biofuge, Heraeus, Germany) for 1 min at 13000 rpm. The flow-
through was discarded and the QIAquick column returned to the same tube. To the 
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QIAquick column was added 0.75 ml buffer PE to wash the column and this was 
centrifuged for 1 min at 13000 rpm. The flow-through was discarded and the column was 
again centrifuged for an additional 1 min to completely remove residual ethanol from the 
column. The column was placed in a clean 1.5 ml microcentrifuge tube and 30-50 µl buffer 
EB was added to the centre of membrane to elute DNA. The column was left for 1 min and 
then centrifuged by table top micro centrifuge (Biofuge, Heraeus, Germany) for 1 min at 
13000 rpm.   
2.9 DNA sequencing 
    Plasmid from E. coli M15pQE60 and pET-33b (+) expression vectors carrying a part or 
the whole of bapC gene, respectively, were purified using the QIA prep Mini prep 
purification kit. Appropriate concentrations of primers (bapC forward and bapC reverse) 
(Table 2.5) and plasmids were sent to the Molecular Biology Support Unit (MBSU) at the 
University of Glasgow to perform DNA sequencing. A MegaBACE1000 (96 capillary) 
sequencer, which used Big Dye (Applied Biosystems) and ET-Dye Terminator (Amersham 
Bioscience) chemistries, was employed. The reaction chemistry was based on the dideoxy 
method developed by Sanger et al. (1977). Each dideoxy nucleotide contained a specific 
fluorescent dye that could be excited by a laser. The signals were then collected and 
analysed by specific software. A coloured electropherogram was produced. The data were 
downloaded and saved on to a CD. For data analysis, Chromas (versions 2.3 & 1.15) and 
DNAstar softwares were utilised. Preparations of clean template DNA produced a read of 
around 600 bases, including 400-600 bases of accurate sequence. The length of accurate 
sequence is primarily determined by the quality of the template DNA and the efficiency of 
primer annealing.    
2.10 Southern blotting  
    The term ‘Southern blotting’ is commonly used to encompass DNA transfer from any 
type of gel to any type of filter matrix. The DNA samples were separated by 
electrophoresis through an agarose gel and stained with ethidium bromide and then the gel 
photographed. The DNA was depurinated and denatured within the gel prior to transfer. 
The depurination was accomplished by treating the gel in 0.25M hydrochloric acid for 10 
min in an orbital shaker at room temperature, and then rinsing the gel thoroughly twice in 
dH2O.  
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Depurination of the DNA in acid makes the DNA more flexible and is critical for complete 
transfer of fragments of > 4kb which would otherwise diffuse poorly through the gel. 
However, it has been noted that the depurination is apparently unnecessary for the transfer 
of small (<10-kb) fragments (Boehringer Mannheim). Moreover, excessive depurination is 
very damaging to the DNA in the gel. The gel was allowed to float in denaturing solution 
for 2×15 min with gentle shaking followed by rinsing it twice with dH2O. It was then 
submerged for 2×15 min in neutralising solution 20×SSC (Appendix AI.4).  
For transfer, a typical blotting apparatus was set up using a clean reservoir filled with at 
least 500 ml of 20×SSC. A flat platform was set up and covered with three wet sheets of 
Whatman 3MM in 20×SSC. The ends of the 3MM paper dipped into the 20×SSC reservoir 
and served as a wick. Air bubbles were removed by rolling a clean pipette over it. The 
neutralised gel was placed on the saturated 3MM paper on the level platform and any air 
bubbles that might be trapped between the paper and the gel were removed.  
The exact size of nylon membrane (Hybond-N, Amersham) was cut and soaked by laying 
it on the surface of distilled water and then submerging. The water was poured off and the 
filter soaked in 20×SSC, and then placed on the top of the gel. Any air bubbles were 
removed and Saran wrap or parafilm was placed around the edges of the gel so that no part 
of the membrane could directly contact the 3MM paper wick. Five sheets of dry 3MM 
paper were placed on the top of the filter and stacked paper towels to a thickness of 4cm on 
top of the 3MM paper. A glass plate was put on top of the paper towels and a small weight 
(approx. 500-750g) added to the top. This was left overnight to blot by capillary action.  
After disassembling the blotting set up, the position of wells on the filter were marked and 
one corner was cut to allow orientation of the gel. The nylon membrane was carefully 
peeled off and gently submerged in a solution of 2×SSC for 3 min to remove any agarose 
particles and excess salt and then it was wrapped in cling film. The filter should still be a 
clear white at this stage since patches of yellow on the filter that have appeared during the 
blot indicate that the gel was incompletely neutralised before transfer. The gel was then re-
stained with ethidium bromide to check that most of the DNA had been transferred. DNA 
was then crosslinked to the wet membrane without prior washing, after exposure to a UV 
cross linker (Spectrolinker XL-1000, Spectroline, New York, USA) for about 1 min.  
After the UV cross-linking, the membrane was briefly rinsed in dH2O and allowed to air-
dry. The membrane was either utilised immediately for prehybridisation or stored at +4°C 
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for future use. The prehybridisation was performed for 4-6 h in a rolling hybridisation oven 
(model HB-1D, Techne, Cambridge, UK) with at least 20 ml of prehybridising solution 
(Appendix AI.4). The temperature of the oven was set at 65°C for prehybridisation. This 
temperature was maintained for the subsequent hybridisation and washing steps. 
2.10.1 Preparation of digoxigenin-labelled probes 
    The digoxigenin (Dig)-labelled probes were synthesised using a PCR Dig Probe 
Synthesis Kit (Roche). The PCR Dig-labelling kit is provided with the reagents required 
for the direct digoxigenin (Dig)-labelling of DNA fragments generated by the polymerase 
chain reaction (PCR) process.  
The kit enables the synthesis of highly sensitive probes by incorporation of DIG-dUTP into 
a PCR product. However the purity of template DNA is less critical with this method 
compared to other methods and, in this study, genomic DNA was used and extracted by the 
genomic DNA purification kit (Promega). The nucleotide mixture contains dATP, dCTP, 
dGTP, dTTP, DIG-11-dUTP. Due to multiple incorporation of DIG-dUTP during the PCR 
process, the molecular weight of the PCR product is increased significantly compared to 
the unlabelled PCR product. A 1:6 ratio of DIG-dUTP:dTTP was used to amplify the 
fragments larger than 1kb since these fragments were poorly amplified when high 
concentrations of DIG-dUTP were utilised as the polymerase is slowed by the presence of 
the DIG hapten.  
According to the manufacturer’s instructions, the components were mixed in 
microcentrifuge tubes on ice and run in a thermal cycler with the following parameters: 
initial denaturation at 95°C for 2 min, 30 cycles of; denaturation at 95°C for 30 sec, 
annealing at 60°C for 30 sec and elongation at 72°C for 2 min, and then one cycle final 
elongation step at 72°C for 7 min.  
The primer sequences brkA Forward and brkA Reverse (Table 2.5), which cover a 1500 bp 
in the middle of the brkA gene were utilised. However the PCR-generated probes are very 
pure and can be used directly in the hybridisation reaction, the PCR product was purified 
using the PCR product purification kit as previously described (section 2.8.7). The contents 
of the labelling tube were then stored at –20°C for future use or denaturation of the probe 
was performed for 10 min in a boiling water bath followed by immediate snap-cooling on 
ice just before use.  
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The probe was then diluted in prehybridization solution for optimal probe concentrations 
(5-25 ng/ml). The standard probe concentration is 2 µl of probe per ml of hybridisation 
buffer. In the case of a faint labelled PCR product band on the evaluation gel, up to 4 µl of 
probe per ml of hybridization buffer was used, and if the labelled band was very strong 
only 1 µl or even as little as 0.5 µl of probe per ml of hybridization buffer was used. 
2.10.2 Probe hybridisation 
    The prehybridization of the membrane was performed at 65°C-68°C for 4-6 h in 1 ml of 
pre-warmed prehybridization buffer (Appendix AI.4) per 10 cm2 of filter. The filter should 
be able to move freely in the roller tube or sealed bag and the solution should sweep gently 
over the surface of the filter. The prehybridising solution was then discarded and the 
denatured Dig-labelled probe in hybridisation buffer immediately added to the roller tube 
carrying the DNA samples cross-linked to the nylon membrane.  
Hybridization was performed overnight (12-14 h) at 65°C-68°C. The probe was decanted 
into a universal tube and stored at -20°C. The hybridization solution contains unannealed 
Dig-labelled probe and can be reused in future hybridization experiments. The membrane 
was washed twice, 5-15 min per wash, in 50 ml of 2×SSC / 0.1% (w/v) SDS solution at 
room temperature (low stringency washing). It was followed by 2×15 min washes in 50 ml 
of 0.1×SSC / 0.1% (w/v) SDS at 65°C-68°C [according to the manufacturer’s instructions, 
for long probes (>100 bp) the membrane was washed at 68°C]. These washes (low and 
high washes) remove unbound probe, which will lead to high backgrounds if not removed. 
For most applications, washing in 0.5 × washing solution (Appendix AI.4) is stringent 
enough. It was determined empirically whether it was necessary to wash with 0.1× wash 
solution. 
2.10.3 Colourimetric detection with BCIP/NBT  
    Detection was performed according to the protocol described in the Dig system User’s 
Guide for Filter Hybridization (Boehringer Mannheim). After hybridization and post-
hybridization washes, the membrane was equilibrated in washing buffer (Appendix AI.4) 
for 1-2 min. The membrane was then incubated in blocking buffer (Appendix AI.4) for 30-
60 min. The anti-digoxigenin-AP (Fab fragments from an anti-digoxigenin antibody from 
sheep, conjugated with alkaline phosphatase) was centrifuged by tabletop micro centrifuge 
(Biofuge, Heraeus, Germany) for 5 min at 13000 rpm in the original vial prior to each use, 
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to remove any aggregates and then the necessary amount was pipetted carefully from the 
surface of the vial.  
The anti-digoxigenin-AP was diluted to 1:5000 (after centrifugation) in blocking buffer for 
a working concentration of 150 mU/ml (2 µl per 10 ml) and mixed gently by inversion. 
The blocking buffer was poured off, and the membrane incubated for 30 min in at least 20 
ml of the prepared antibody solution at room temperature. The antibody solution was 
discarded and the membrane washed twice, 15 min per wash, in 100 ml of washing buffer. 
The membrane was then equilibrated in 20 ml of detection buffer (Appendix AI.4) for 2 
min. The detection buffer was poured off, and approximately 10 ml ready mixed 
BCIP/NBT (5-bromo-4-chloro-3-indolyl phosphate / nitro blue tetrazolium) (Sigma) (a 
solution for detection of alkaline phosphatase-coupled immune complexes) added to the 
membrane in a plastic bag sealed without bubbles, and then incubated in the dark for 15-45 
min at room temperature. The container was not shaken while the colour was developing. 
Once the desired bands were detected, the membrane was washed with distilled water to 
prevent over-development.  
2.10.4 Stripping membrane for reprobing 
    Stripping of blots where DNA fragments have been detected colourimetrically was only 
possible when nylon membranes were used for blotting, since using DMF 
(dimethylformamide) to remove the colour precipitate will dissolve nitrocellulose under 
such conditions. A large glass beaker of dimethylformamide was heated to 50-60°C in a 
water bath. The membrane was incubated in the heated DMF until the colour was removed. 
Changing the DMF solution frequently will increase the speed of decolourization. The 
membrane was thoroughly rinsed and washed in dH2O for 1 min, and not allowed to dry 
prior to probe removal. The membrane was then incubated twice for 10 min in alkaline 
probe-stripping solution (Appendix I) at 37°C. This incubation removes the alkali-labile 
Dig-labelled probe. The membrane was thoroughly rinsed in 2×SSC solution, and 
reprobing with the prehybridization step of the desired hybridization procedure was 
performed.                              
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2.11 Protein analysis 
2.11.1 Fractionation of bacterial cells 
    Bordetella strains were cultured on BG agar plates containing 15% (v/v) horse blood 
and incubated for 48-72 h at 37°C. Ten ml volumes of CL medium were inoculated and 
incubated for 48 h on a shaker (120 rpm) at 37°C. Two litre dimpled flasks containing 
1000 ml of CL medium were pre-warmed overnight at 37°C. Ten ml volumes of the 48 h 
culture were added to the 1000 ml volumes of pre-warmed CL medium and incubated until 
mid-log phase (approx. 48 h) on an orbital shaker (120 rpm) at 37°C.     
Bacterial cells were harvested in 500-ml Nalgene centrifuge bottles by centrifugation at 
5000 × g for 20 min at 4°C in a Sorval superspeed centrifuge (rotor GS-3). Cells were 
resuspended in envelope buffer (10 mM sodium phosphate, pH 7.2) with a total volume not 
exceeding 50 ml. The resuspended cells were transferred to 50 ml Nalgene tubes and kept 
on ice overnight. The cells were then washed by centrifuging at 5000 × g in a Sorval 
superspeed centrifuge (rotor GS-3) for 30 min at 4°C and resuspended in approximately 8 
ml of ice-cold 10 mM sodium phosphate (pH 7.2). The final volume must not exceed 10 ml 
and cells must be kept on ice. The cells were disrupted on ice using a cell sonicator (probe 
SM 05: 12 microns amplitude) in 10 sec intervals for 5 min. The sonicated samples were 
poured into clear 10 ml Nalgene tubes which were placed in iced water for 10 min and then 
on ice until ready. The samples were then centrifuged at 5000 × g, in the same centrifuge 
and rotor as above, for 30 min at 4°C to pellet large debris, unbroken cells and insoluble 
materials.  
The supernate was carefully removed using long-form Pasteur pipettes and transferred to 
10-ml ultracentrifuge tubes. The samples were then centrifuged at 100,000 × g at 4°C for 1 
h in a Sorvall ultracentrifuge to pellet the cell envelopes. The resulting supernate contained 
the soluble content of the cytoplasm and periplasm.  
The supernate was collected and the gelatinous pellet thoroughly resuspended in 
approximately 7 ml of envelope buffer containing sodium N-lauroylsarcosine (Sarkosyl) 
0.5% (w/v) at room temperature. The mixture was vortexed every 5 min for 10 sec to 
differentially solubilise the cytoplasmic membrane proteins.  
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The samples were again centrifuged to pellet the outer-membrane proteins at 42000 rpm 
(100,000 × g) for 1 h. The supernate contained the sarkosyl-soluble inner-membrane 
proteins and the gelatinous pellet contained the sarkosyl-insoluble outer-membrane 
proteins. The pellet was then resuspended in envelope buffer and further centrifugation 
performed as previously described at 42000 rpm for 1 h. The outer membrane-enriched 
fractions were resuspended in approximately 1 ml (final volume depends on size of pellet) 
of 10 mM sodium phosphate (pH 7.2). The final solutions were stored at -70°C for further 
use, and 50 µl volumes of outer membrane transferred to eppendorf tubes used for protein 
assay. 
2.11.2 Expression of recombinant proteins   
    Overnight cultures (5 ml) of E. coli strains (Table 2.1) containing expression constructs 
were used to inoculate 2 L dimpled flasks containing 500 ml volumes of LB broth with 
appropriate antibiotics. The cultures were then incubated at 37°C with shaking until an 
OD600nm of 0.7-0.9 was obtained. IPTG (1mM final concentration) was added to the culture 
and incubated at 37°C on the shaker for a further 3h. The cells were harvested at 4000 rpm 
(5000 x g) for 20 min in a Sorvall superspeed centrifuge (rotor GS-3). For further 
processing, the supernate was discarded and the pellet resuspended in 5-10 ml of PBS and 
then sonicated (next section).   
2.11.3 Preparation of bacterial sonicated extract 
    Sonicated extracts of different bacteria were prepared from 24-72 h broth cultures for E. 
coli or B. pertussis, respectively. A purity test was done using Gram-staining of a smear 
preparation and direct checking by light microscopy. Cells were collected by centrifugation 
at 5,000 × g for 20 min at 4°C and washed three times with PBS. A thick suspension of 
bacteria in PBS was lysed by sonication using a Vibra Cell ultrasonic processor (Jencons-
PLS, Leighton Buzzard, United Kingdom) for three 60-s bursts with intermittent cooling 
on ice. The broken-cell suspension was centrifuged at 3,000 × g for 30 min at 4°C, and the 
supernate was filtered through a 0.2 µm pore size membrane (Sartorius). The protein 
concentration was determined by modified Lowry procedure (section 2.11.4.1) and 
adjusted to a desired concentration by adding sterile PBS. 
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2.11.4 Protein estimation 
    All of the cell-free extracts, OMP and other bacterial preparations were subjected to 
protein quantification to measure the protein content and to set the desired concentrations. 
The most common methods for the colourimetric detection and quantitation of total protein 
can be divided into two groups based upon the chemistry involved. Protein assay reagents 
involve either protein-dye binding (coomassie) chemistry or protein-copper chelation 
chemistry.             
2.11.4.1 Lowry (modified) procedure for membrane proteins (Folin-
Ciocalteau) 
    In Lowry protein assay, or Lowry Method, copper (II) ion in alkaline solution reacts 
with protein to form complexes, which react with the Folin-phenol reagent, a mixture of 
phosphotungstic acid and phosphomolybdic acid in phenol. Bound reagent is slowly 
reduced and changes color from yellow to blue and can be detected colourimetrically by 
absorbance at 650 nm. 
To make the working solution, 100 parts of solution A [2% (w/v) Na2CO3, 0.4% (w/v) 
NaOH, 0.16% (w/v) sodium tartarate, 1% (w/v) SDS and distilled water] were mixed with 
1 part of reagent B [4% (w/v) CuSO4 and distilled water] to form reagent C, the alkaline 
copper reagent. Sample volumes of 1 ml (50 µl sample + 950 µl dH2O) containing 10-100 
µg of protein, along with the protein standard BSA (Bovine Serum Albumin) ranging from 
20-500 µg/ml were added to 3 ml of reagent C and incubated at room temperature for 60 
min.  
The samples were then vigorously mixed with 0.3 ml of diluted Folin-Ciocalteau reagent 
(1vol:1vol) with distilled water and incubated for 45 min at room temperature. The 
absorbance was determined at 630 nm on a spectrometer using blanks made up as above 
except that the protein was replaced by water. 
2.11.4.2 Standard procedure for soluble proteins (Bio-Rad) 
    The Bradford protein assay is a simple procedure for determination of protein 
concentrations in solutions that depends upon the change in absorbance of Coomassie Blue 
G-250 upon binding of protein (Bradford, 1976). This method is not susceptible to 
interference by a wide variety of chemicals present in samples except at high 
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concentrations of detergents. Concentrated dye reagent was diluted using 1 part with 4 
parts of double distilled water according to the manufacturer’s instructions. Dilutions of 
standard protein (BSA) and unknown samples were prepared in 96-well microtiter plates.  
The standard was dissolved in the same buffer as the unknowns. Protein solutions were 
normally assayed in duplicate or triplicate. 20 µl of each sample solution or standard, 
containing different protein concentrations, was added into microtiter plate wells. Then, the 
diluted dye reagent (200µl) was added to each well. The sample and reagent were 
thoroughly mixed using a multichannel pipette and incubated at room temperature for 15 
min (maximum 1h) and absorbance measured at 595nm. Finally, the protein concentration 
in the test was estimated from the standard curve.        
2.11.5 Sample preparation for electrophoresis 
    10 µl of 6× protein loading dye (Appendix AI.3) was mixed with 50 µl of sample. 
Samples were stored at -20°C until loading. Samples, except marker, were heated in a 
boiling water bath for 5 min just before loading into the polyacrylamide gel to denature the 
proteins. A protein marker (SeeBlue Plus2, Invitrogen) which consisted of 10 pre-stained 
protein bands (8 blue and 2 contrasting colours) in the range of 4-250 kDa was used 
according to the manufacturer’s instructions.  
2.11.6 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
    Gel cassette preparation and Mini-PROTEAN 3 Electrophoresis Module assembly was 
carried out according to the manufacturer’s instructions (Bio-Rad). The resolving gel 
(Appendix AI.3) containing 10% acrylamide was poured into the gap between two glass 
plates and 100% ethanol was used as an overlay. The gel was allowed to set for 
approximately 1 hour in a vertical position at room temperature. The overlay prevents 
oxygen from diffusing into the gel and inhibiting polymerization. Once the polymerization 
was completed (30 min), the overlay was poured off and the top of the gel washed several 
times with deionized water to remove any unpolymerized acrylamide. From the top of the 
gel, as much fluid as possible was drained and any remaining water removed with the edge 
of a paper towel. Stacking gel (Appendix AI.3) containing 4% acrylamide in a 1 ml 
volume was poured on top of the resolving gel and a comb was immediately placed within 
the stacking gel, which was then allowed to set at room temperature. The comb was 
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removed and samples were run for 45 min at 200V in 1× electrophoresis buffer (Appendix 
AI.3.2.1) or until the bromophenol blue reached the bottom of the resolving gel. The gel 
was removed and stained with Coomassie blue (AI.3.1.4) overnight on a slowly rotating 
platform for protein visualisation. The stain was replaced with destain solution (Appendix 
AI.3) until the background was decolourised.   
2.11.7 Western blotting protocol and development of blots 
    The proteins of the sample were separated according to size using SDS-PAGE (section 
2.7). Then, the proteins in the gel were transferred to immobilising nitrocellulose 
membrane (Hybond-C, Amersham) according to the method described by Towbin et al. 
(1979). Briefly, the stacking gel was cropped and the separating gel soaked in 
electroblotting buffer (Appendix AI.3) for 5 min. The blot was then assembled and placed 
in the electroblotting apparatus containing electroblotting buffer that was stirred 
magnetically. The protein was transferred from the gel to the membrane using a constant 
100 volts for 1 h or, occasionally, at 20 volts overnight. To prevent overheating, and the 
consequent formation of air bubbles in the sandwich, transfer was carried out using an ice-
pack in the tank.   
To visually determine whether the proteins were transferred effectively, and to locate 
molecular-weight markers, the proteins on the membrane were visualised by staining in 
Ponceau S solution (Sigma, 0.1% w/v Ponceau S in 5% (v/v) acetic acid) for 1-2 min. 
Background was removed by destaining in water for 2 min and the positions of the 
molecular weight markers were marked with indelible ink. The membrane was then 
destained in PBS for 10 min and placed in a heat-sealable plastic bag to which was added 
0.1 ml of blocking buffer (Appendix AI.3) per square centimetre of filter. The membrane 
was kept for 1 h at room temperature with gentle agitation on a platform shaker in order to 
prevent non-specific protein interaction between the membrane and the antibody. The 
plastic bag was then opened and the blocking solution discarded. The primary polyclonal 
antibody was then diluted appropriately in blocking buffer (1:250-1000) and incubated 
with the membrane for 1 h at room temperature with gentle agitation. The membrane was 
then washed for 15 min in two changes of PBS at room temperature. Horseradish 
peroxidase-conjugated secondary monoclonal antibody (anti-rabbit or anti-mouse IgG 
peroxidise conjugate as appropriate (cat. No. A 0168, Sigma) was diluted appropriately 
(1:10000) in blocking buffer, added to the membrane and incubated for 1 h at room 
temperature. Then, the membrane was washed twice in two changes of fresh PBS for 15 
min at room temperature. The membrane was then immersed in freshly prepared 3, 3` 
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diaminobenzidine (DAB) (Sigma) (Appendix I) solution (0.05% w/v in PBS) for 
approximately 1-2 min and the staining reaction was stopped by washing the membrane in 
distilled water.   
The primary antibody used for these blots was a rabbit polyclonal anti-BapC serum, which 
had been prepared (Bokhari, PhD thesis 2002) against the purified, His-tagged 
recombinant truncated BapC expressed in E. coli expression strain M15 from the construct 
pQE60 (Blackburn, 2000). The BapC fragment had been further purified by SDS-PAGE 
and transferred by blotting onto a nitrocellulose membrane. Then, the BapC band was 
excised from the membrane and an extract sent to Dr. D. Xing, NIBSC, London to raise a 
rabbit antiserum. 
To minimize the effect of cross-reacting antibodies in immunoblotting of recombinant 
BapC protein expressed by E. coli (section 3.10), an absorbed BapC serum was utilised. B. 
pertussis BP Taberman (BapC-) and E. coli M15 (pREP4) strains were grown overnight in 
appropriate liquid media and antibiotics. The cultures were then centrifuged and washed 3 
times with saline and the resultant suspensions were adjusted to OD600nm of 0.8-1.0. Cells 
were sonicated for a few min and the resultant sonicates used to absorb the anti-BapC 
serum. The anti-BapC serum was mixed twice, with an equal volume of sonicates for 30 
min followed by centrifugation steps.  
2.11.8 Protein identification by mass spectrometry  
 
    Selected bands were manually excised from an SDS-PAGE gel and placed in a 1.5 ml 
eppendorf tube for transfer to the Sir Henry Wellcome Functional Genomics Laboratory at 
the University of Glasgow. Mass spectrometry analysis was performed by Dr. R. 
Burchmore following standard protocols for LC-MS/MS (Mutapi et al., 2005). The peptide 
mass fingerprint obtained by MS was subjected to a database search by pasting the peptide 
masses into a protein database (MASCOT®, Matrix Science), which uses a probability-
based scoring system to define a significant match with known protein sequences.  
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2.12 In vitro tests 
2.12.1 Effect of antimicrobial peptides  
2.12.1.1 Radial diffusion assay 
    This method of radial diffusion (Lehrer et al., 1991) was used to determine the effect of 
antimicrobial peptides on B. pertussis strains. B. pertussis strains were grown on Bordet-
Gengou agar medium supplemented with 12% (v/v) horse blood as described previously. 
The bacteria were harvested in modified Stainer Scholte (Appendix AI.1) broth to an 
optical density at 600 nm of approximately 0.2, and 0.2 ml of this suspension was added to 
10 ml of molten (52°C) 1% agarose (type I; low electroendosmosis; catalogue no. A 6013, 
Sigma) in modified SS broth containing supplements and 0.15% bovine serum albumin 
(Sigma). 
The agarose was dispersed into petri dishes and was allowed to harden. Holes (3 mm in 
diameter) were made with an aspirator punch and 5 µl of peptide (Sigma) serially diluted 
in sterile, filtered distilled water was placed therein. After a 4-h incubation at room 
temperature to allow for diffusion, a 10-ml overlay of SS-agarose without bacteria was 
added. The resultant zones of inhibition were read and measured 24 to 48-h later with a 
metric scale under a stereomicroscope. The Student t test was employed to analyse the 
data. 
2.12.1.2 Microtiter plate assay 
    The C-50%, that is the concentration of peptide according to the method of Fernandez 
and Weiss (1996) for killing or inhibiting the growth of 50% of the organisms, was 
determined as follows. Serial dilutions of the different antimicrobial peptides were 
prepared in 100 µl of RPMI medium in a microtiter plate. 10 µl of B. pertussis in modified 
SS-broth (see above) was added to each well to a final concentration of approximately 
2×106 CFU/ml. Then, after a 2-h incubation at 37°C, 100 µl from each well was diluted in 
900 µl of SS-broth and the number of survivors were ascertained by plating out 10-fold 
serial dilutions on Bordet-Gengou agar. As a control, bacteria were similarly added to 
wells containing RPMI medium but no peptides. The C-50% was determined and adjusted 
according to the purity of the peptide stated by the manufacturer. 
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2.12.2 Agglutination test 
    This test was carried out to detect surface-exposed BapC in B. pertussis and E. coli 
strains using the rabbit anti-BapC serum used previously (section 2.11.7). The BapC 
mutant was used as a negative control in the agglutination tests. An antibody raised against 
whole B. pertussis cells, available from departmental stocks, was also used in the study. B. 
pertussis strains were collected from BG plates that had been incubated for 48-72 h at 
37°C. E. coli strains were collected from LB plates that had been incubated for 18-24 h at 
37°C. One ml of a thick bacterial suspension was obtained by centrifuging ∼7 ml volume 
of culture containing ∼2×109 CFU/ml of the various B. pertussis strains and the pellets 
were re-suspended in 1 ml of PBS. A 100 µl volume from the thick suspension was added 
to individual wells in a 96-well U-shaped plate (Greiner, UK) in triplicate. 50 µl volumes 
of 10-fold dilution of antisera were thereafter added to each well. The samples were then 
mixed thoroughly in each well with a multichannel pipette and plates placed on a rotating 
shaker at room temperature for 1h. Plates were then incubated at 37°C for 3-4 h and finally 
left at 4°C for 24-48 h. Agglutination or button formation at the bottom of each well, and 
also the type of agglutination, was recorded. 
2.12.3 Serum killing assay 
2.12.3.1 Collection of normal human serum 
    Serum was obtained from the blood samples of 8-10 volunteers from the Division of 
Infection and Immunity who were not actively engaged in working with B. pertussis. After 
collection, the blood samples were allowed to clot for 1 h at 37˚C. They were then placed 
on ice for 1-2 h to retract and the clear serum was collected after centrifugation at 10000×g 
for 5 min without disturbing the clot. The serum was centrifuged again to remove any 
remaining particles and the supernate was collected. The individual sera were pooled, 
distributed into 2 ml aliquots and stored frozen at -70°C.  
2.12.3.2 Bactericidal assays with normal human serum 
    B. pertussis cells were harvested from BG agar plates incubated at 37°C for 24-48 h and 
suspended at ~ 2×109 CFU/ml by comparison with the opacity rod (5th International 
Reference of Opacity, Perkins et al., 1973), in pre-warmed (37°C) Stainer and Scholte (SS-
X) medium. A volume of 100 µl of bacterial suspension was transferred to an eppendorf 
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tube containing 350 µl of SS-X medium and 50 µl of normal or heat-inactivated (30 min at 
56°C) control serum and the contents mixed.  
The tubes were incubated at 37°C in a water bath for 45 min. The tubes were then shifted 
to ice for 5 min to stop the complement reaction. A 20-µl aliquot of the mixture was added 
to 180 µl of phosphate-buffered saline (PBS) (pH 7.4) with 10 mM EDTA (inactivates 
complement activity). Ten-fold serial dilutions were performed in SS-X medium. The 
dilutions were then plated in duplicate on BG agar, and incubated at 37°C.  
Bacterial colony forming units were counted after 3-4 days. Survival in normal human 
serum was calculated as a percentage of the number obtained from the SS medium control 
(non-killing control without serum). Heat-inactivated (56˚C for 30 min) serum also acted 
as a control in case of an apparent reduction in viable count due to presence of 
agglutinating antibodies. Percentage killing was calculated by comparison with 100% 
survival of the SS medium control. Statistical analysis was performed using Student’s t-
test.   
2.13 In vivo test 
2.13.1 Competition assay for mouse virulence of B. pertussis 
strains 
    In competition assays, the animal is infected with a mixture of mutant and wild type 
bacteria. After giving the bacteria time to establish themselves, samples can be taken from 
various parts of the animal, and the ratio of mutant to wild type is determined. If the ratio 
of the mutant to wild type is the same as in the infecting dose, the mutation had no 
detectable effect on virulence but, if the wild type outcompetes the mutant, the mutation 
clearly had a negative effect. In other words, disappearance of the mutant after a certain 
period of time indicates that, in the animal, the mutant was not able to compete 
successfully with the wild type.  
In this study, the in vivo competition assay was done by growing the strains of B. pertussis 
to be compared on BG plates containing appropriate antibiotics for 3 days in humidified 
conditions at 37°C. Lawn cultures were then made under the same conditions, with 
antibiotics, for a further 24h. The resultant growth was suspended in 1% (w/v) casamino 
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acids solution (CAA) (Appendix I) and adjusted to 10 opacity units using the 5th 
International Reference of Opacity (Perkins et al., 1973) i.e. approx. 2×109 CFU/ml.  
After serial dilution in 1% (w/v) CAA, 100 µl volumes of 1×103 CFU/ml of two strains to 
be compared were mixed and individual cultures or the mixture were plated in duplicate on 
BG agar plates with and without appropriate antibiotics. From plates without antibiotics, 
the total number of colonies was estimated. By appropriate choice of antibiotics, it was 
possible to estimate the numbers of just one strain in the mixture. By simple subtraction, 
the number of the other member of the mixture could be determined and then the ratio of 
strain 1 : strain 2 calculated. This was done as a preliminary test to investigate the growth 
effect of one strain on another strain. Colonies were counted after 3-4 days and data 
analysed with Student’s t-test.   
For the animal experiments, B. pertussis suspensions were prepared containing 4 × 106 
CFU/ml of each strain, either alone or as a two-strain mixture. Thus, a sublethal dose of 
50-µl volume would contain 1 × 105 CFU of each strain. Randomised groups of five 
female CD1 mice (Harlan Olac, Bicester, Oxfordshire, UK) aged 3 weeks were allowed to 
acclimatise for 3-4 days. They were divided into different test groups, which were 
categorised according to experiment number. Each group comprised five mice and, after 
light halothane anaesthesia, each mouse was instilled intranasally with 50-µl volumes of 
prepared suspensions of B. pertussis strains.  
Two experiments were set up. In experiment I, mice were intranasally instilled with B. 
pertussis strains BP338 (W/T), BP338 (BapC-) mixture; BP338, BP338 (BrkA-, BapC-) 
mixture. In experiment II, mice were intranasally instilled with B. pertussis strains BP338, 
BP338 (BrkA-) mixture; BP338 (BapC-), BP338 (BrkA-, BapC-) mixture; BP338 (BapC-), 
BP347 (Bvg-) mixture; BP338 (BapC-), BP338 (BrkA-) mixture. The mouse virulent strain 
18-323 was used as a positive control, in a separate group. 
The weight of each group of mice was recorded prior to challenge as well as at regular 
intervals afterwards. The mice were sacrificed after 7 days and the lungs were removed 
aseptically into sterile universal bottles. Lungs were homogenised in 10 ml of CAA with a 
sterile homogeniser (Silverson machines, UK). 100 µl volumes from undiluted samples 
and 1:10, 1:100, 1:1000 and 1:10000 dilutions in 1% (w/v) CAA were cultured on 
duplicated BG agar plates with and without appropriate antibiotics and incubated at 37°C 
in a humidified box. Colonies were counted after 3-4 days, and the number of colony 
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forming units per lung was calculated. Nominal values of 100 and 107 were given to counts 
outside the detection limits <100 and >3×106 per organ, respectively.  
The log10 counts were calculated and the means, standard deviation and standard error 
values of each group were calculated in Excel. The data were analysed by applying the 
Student’s t-test and one way of analysis of variance (ANOVA).   
2.14 Sequence analysis tools (bioinformatics) 
    Three primary sequence databases; GenBank which is maintained by the National 
Center for Biotechnology Information (NCBI), the Nucleotide Sequence Database 
maintained by the European Molecular Biology Laboratory (EMBL) and the DNA 
Databank of Japan (DDBJ) were used to annotate and highlight the important properties of 
the raw sequence data. Entrez, a WWW-based data retrieval tool (NCBI), was employed to 
search multiple biological databases and retrieve relevant information including nucleotide, 
protein sequences and whole genomes. Entrez can be accessed via the NCBI web site at the 
following URL: http://www.ncbi.nlm.nih.gov/Entrez/. Sequence similarity searches of 
databases were performed to extract the similarities using Basic Local (Linear) Alignment 
Search Tool (BLAST) and FASTA programs. Information about these extracted sequences 
can be used to predict the structure or function of the query sequence. BLAST utilizes 
statistical theory to produce a bit score and expect value (E-value) for each alignment pair 
(query to hit). The bit score indicates how good the alignment is; the higher the score, the 
better the alignment. The E-value indicates the statistical significance of a used pairwise 
alignment and reveals the size of the database and the scoring system. The lower the E-
value, the more significant the hit. A sequence alignment that has an E-value of 0.05 means 
that this similarity has a 5 in 100 (1 in 20) chance of occurring by chance alone. The p 
value of a similarity score is the high probability of obtaining the score in a chance 
similarity between two unrelated sequences of similar composition. Low p value 
corresponds to significant matches that are likely to have real biological significance. In 
general, the score is calculated by an equation which considers identical or similar residues 
and any gaps in the aligned sequences using BLOSUM62 to assign a score for aligning any 
possible pair of residues. 
Many proteins are composed of domains in a modular architecture. Pfam and SMART 
(Simple Modular Architecture Research Tool; http://smart.embl-heidelberg.de) were 
employed to analyze protein domain families. The domain within the query sequence in the 
SMART program was selected and the BLAST run based on BLOSUM62 matrix, filter 
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default and E-value 10 by the Bork group’s advanced BLAST2 Search Service at EMB. 
The Pfam database (http://www.sanger.ac.uk/Software/Pfam) is a collection of many 
common protein domains and families, and HMMs (Hidden Markov models).    
ProtParam is a tool which allows the computation of various physical and chemical 
parameters for a given protein stored in Swiss-Prot or TrEMBL or for a user-entered 
sequence. The computed parameters include the molecular weight, theoretical pI, amino 
acid composition, atomic composition, extinction coefficient, estimated half-life, instability 
index, aliphatic index and grand average of hydropathicity.                  
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3. Results 
3.1 Characterisation of B. pertussis strains  
 
    A number of strains, which were available from previous studies (Blackburn, 2000; 
Bokhari, 2002), were investigated for their phenotypes and genotypes by growth in the 
presence of different antibiotics in appropriate concentrations (Table 2.3) by Gram-
staining, and by slide agglutination test; respectively. Results are shown in Table 3.1.  
All strains listed in Table 3.1 had the expected antibiotic sensitivities / resistances and the 
properties expected of B. pertussis i.e. inability to growth on nutrient agar, Gram-negative, 
agglutination by anti-whole B. pertussis or anti-BapC sera (where appropriate) and 
production of β-haemolysin on BG sandwich agar, as well as the expected colonial 
morphology. Some other strains from the departmental culture collection either did not 
grow or did not have the expected properties and so were not used in the present study. 
Antibiotic sensitivity showed that BP Tohama W/T and BP Taberman W/T did not grow, 
as expected, in the presence of Amp, Km, Nal or Sm. Slide agglutination tests 
demonstrated strong agglutination reactions with both anti-whole pertussis and anti-BapC 
sera, suggesting the presence of expressed BapC protein on the surface of these organisms. 
However, with B. pertussis Tohama II, a very weak agglutination was observed with anti-
BapC sera, and no agglutination was detected with B. pertussis Taberman II, suggesting 
lack of BapC expression in these mutants. The weak reaction with BP Tohama (BapC-), 
could possibly have been due to a cross-reaction with other surface components or due to a 
large amount of bacteria loaded on the agglutination test. Strains BP Tohama I and BP 
Taberman I, parents of the BapC mutants, which had been used to construct the original 
BapC mutant strains, appeared to be authentic in antibiotic sensitivities since they were 
spontaneous streptomycin-resistant derivatives of the original wild-type strains which 
possessed nalidixic acid resistance. BP Tohama II (BapC-) and BP Taberman II (BapC-) 
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strains were found to have the same antibiotic resistances (SmR, NalR) as their parents but 
also showed kanamycin resistance, since a kanamycin resistance cassette had been inserted 
into the bapC gene using homologous recombinant technology to make BapC mutant 
strains. BP338 and BP338 (BrkA-) (2041 Weiss) strains showed the expected phenotype 
with regard to antibiotic sensitivities, reaction to anti-BapC and anti-whole pertussis sera 
and other aspects such as the size of the amplified bapC fragment in PCR reaction. These 
strains were used, in this study, to make single (BapC-) and double (BrkA-, BapC-) 
mutants, respectively). The presence of bapC gene of the expected size in BP338 and 
BP338 (BrkA-) was confirmed, making them suitable for bapC mutant construction in the 
same genetic background (see next section).  
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Table 3.1 Antibiotic sensitivities and other features of B. pertussis strains 
available at the start of this study 
 
Antibiotic sensitivity / other properties 
 
Strain  Amp Km Nal Sm N.A. Gram 
reaction 
S.A.T. 
1       2 
β-h. 
PCR 
product* 
1 BP Tohama (W/T)  S S S S _  
-ve 
+       +    + 2.2 kbp 
2 BP Tohama parent of 
BapC mutant  
(Tohama I) 
SmR/NalR 
S S R R _  
-ve 
+       +    + 2.2 kbp 
3 BP Tohama (BapC-) 
(Tohama II) 
SmR/NalR/KmR 
S R R R _  
-ve 
+       ± + 3.5 kbp 
4 BP338 (Weiss) 
NalR   
S S R S _  
-ve 
+       + + 2.2 kbp 
5 BP338 (BrkA-) (2041 
Weiss) 
NalR/KmR 
S R R S  _  
-ve 
+       + + 2.2 kbp 
6 BP Taberman (L1) 
(W/T) 
S S S S _  
-ve 
+       + + 2.2 kbp 
7 BP Taberman parent of 
BapC mutant  
 (Taberman I) 
SmR/NalR 
S S R R _  
-ve 
+       + + 2.2 kbp 
8 BP Taberman (BapC-) 
(Taberman II) 
SmR/NalR/KmR 
S R R R _  
-ve 
+        -      + 3.5 kbp 
 
 
 
 
 
 
Amp: Ampicillin 
Km: Kanamycin      
Nal: Nalidixic Acid  
Sm: Streptomycin     
R: Resistance 
S: Sensitive  
N.A: Growth on Nutrient Agar                                                                                                                                                                          
β-h: β-haemolysis on BG sandwich agar                                                                                                  
S.A.T1: Slide Agglutination Test with rabbit polyclonal anti-whole B. pertussis serum 
S.A.T2: Slide Agglutination Test with rabbit polyclonal anti-BapC serum 
W/T: Wild Type  
* With primers BAP5F and BAP5R (Table 2.5) 
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3.2 Confirmation of the bapC genotype of the B. pertussis 
strains 
PCR reactions with genomic DNA from the wild-type and bapC mutant strains of B. 
pertussis, described in Table 3.1, showed the expected sizes of bapC (2.2 kbp) and the 
bapC gene with the inserted Km resistance cassette (3.5 kbp), respectively (Fig. 3.1 and 
Table 3.1). PCR was carried out using the bapC specific primers (Table 2.5), bapC forward 
(BAP5F) and bapC reverse (BAP5R), which amplify most of the full length bapC gene 
from nucleotide position 728 to 2960 (starting just downstream from the first previously 
predicted start codon site) (Appendix II.). The PCR results using genomic DNA extracted 
from B. pertussis Taberman I strain and its bapC defective mutant (Taberman II), as well 
as B. pertussis Tohama I and its bapC defective mutant (Tohama II), indicated that 
bapC::Kmr is present in the chromosome of the mutant strains. This is clear evidence that 
bapC gene has been replaced by the mutated allele, bapC::Kmr. The difference between 
the parent strains and the bapC mutant strains is expected from the insertion of the 1.3 kbp 
kanamycin resistance cassette. The PCR reaction with the BP338 (BrkA-) genomic DNA 
also confirmed bapC of the expected size, 2.2 kbp, indicating the presence of the unaltered 
bapC gene in this strain.   
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Figure 3.1 Agarose (0.8%) gel showing the PCR amplimers derived from the 
bapC gene in B. pertussis strains 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
            
   
 
 
PCR was performed on chromosomal DNA (extracted as described in section 2.2.1) using 
primers BAP5F and BAP5R (Table 2.5) which amplify most of the bapC gene. 
M = DNA marker                  
-Ve = Negative                     
1 = BP338 (Weiss)                  
2 = BP338 (BrkA-) (2041 Weiss)                                           
3 = BP Tohama (W/T) 
4 = BP Tohama I (parent of BapC mutant) 
5 = BP Tohama II (BapC-)  
6 = BP Tohama II (BapC-) 
7 = BP Taberman (parent of BapC mutant) 
8 = BP Taberman II (BapC-) 
9 = BP Taberman II (BapC-) 
 
  1000 bp 
  1500 bp 
  2000 bp 
  4000 bp 
  3000 bp 
  M  -Ve  1   2   3   4   5   6         7   8   9 
3.58 kbp 
2.28 kbp
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3.3 Characterization of BapC protein in B. pertussis 
strains by immunoblotting 
    Immunoblotting experiments with a rabbit anti-BapC serum were done with B. pertussis 
strains that were expected to be expressing the BapC protein {BP Taberman and BP 
Tohama wild-type strains, BP338 and BP338 (BrkA-)} or not expressing the protein (i.e., 
when grown in modulating conditions with MgSO4; in BP Taberman II and BP Tohama II 
BapC- mutants) or BP347 (Bvg- strain). The results are shown in Figures 3.2 and 3.3.  
As can be seen from Figures 3.2 and 3.3, a band of approximately 70 kDa appeared to be 
expressed in all strains, whether grown under modulating or non-modulating conditions 
and this presumably represents a non-Bvg-regulated protein that may be antigenicaly 
related to BapC and other autotransporter proteins. It would have been interesting to have 
identified this protein by N-terminal sequencing or mass spectrometry. The 73-kDa protein 
(which is the expected size of the mature form of BrkA) in Figures 3.2 & 3.3 is presumably 
the processed form of BrkA protein that also appears to cross-react with the anti-BapC 
serum and this was not present in modulating conditions nor in the brkA mutant (BP2041). 
There was an interesting and potentially important difference between Taberman and 
Tohama wild-type and BapC mutants, where the 73-kDa protein seemed to be fainter in 
both Tohama II (BapC-) and Taberman II (BapC-) mutant strains compared to their wild-
type strains, suggesting that a lack of BapC influenced the amount of BrkA made by the 
cells. A band at ~90 kDa is presumed to represent some form of BapC since it was present 
in the wild-type B. pertussis strains; BP Taberman (W/T) (lane 1, Fig. 3.2), BP Tohama 
(W/T) and BP338 (lanes 1 and 3, respectively, Fig. 3.3); and also in BP338 (BrkA-) 
(BP2041) (lane 5, Fig. 3.3) but absent in the bapC mutants: BP Taberman II (lanes 3 and 4, 
Fig. 3.2), and BP Tohama II (BapC-) (lane 7, Fig. 3.3). The absence of this 90 kDa band in 
BP338 (Bvg-) (BP347) and in all strains grown under modulating conditions again 
indicated that the BapC protein is a bvg-regulated protein.   
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Figure 3.2 Immunoblotting with anti-BapC serum of whole cells of B. 
pertussis Taberman strains grown in modulating and non-modulating 
conditions. 
 
Equal amounts of the protein were subjected to SDS-PAGE (10%), and then blotted to 
Hybond-C membrane and probed with anti-BapC serum. 
 
 
            
            
            
            
            
            
            
            
            
            
            
        
 
 
 
 
M= Marker                                                  
1= BP Taberman (W/T)                            
2= BP Taberman (W/T) + MgSO4             
3= BP Taberman II (BapC-) 
4= BP Taberman II (BapC-) 
5= BP338 (Bvg-) (BP347)  
 
M             1          2           3           4         M          5 
  98 kDa 
     64 kDa 
90 kDa 
73 kDa 
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Figure 3.3 Immunoblotting with anti-BapC serum of B. pertussis Tohama 
strains grown in modulating and non-modulating conditions 
 
 
 
Equal amounts of the protein were subjected to SDS-PAGE (10%), and then blotted to 
Hybond-C membrane and probed with anti-BapC serum. 
 
 
 
 
            
            
            
            
            
            
            
            
            
            
            
            
            
            
             
 
 
 
 
 
 
 
 
 
 
 
 
 
M= Marker                                             5= BP338 (BrkA-) (BP2041)   
1= BP Tohama (W/T)                            6= BP338 (BrkA-) + MgSO4 
2= BP Tohama (W/T) + MgSO4                7= BP Tohama II (BapC-) 
3= BP338  
4= BP338 + MgSO4 
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3.4 Localisation of BapC protein in outer-membrane 
preparations of B. pertussis strains 
This experiment was intended to give information on the nature and localisation of the 
BapC protein in the outer membrane fraction of B. pertussis cells. Figures 3.4 and 3.5 
show the protein profiles and immunoblots with rabbit anti-BapC serum, respectively, of 
B. pertussis strains grown in modulating (nicotinic acid, 16mM) and non-modulating 
conditions. Major differences in Fig. 3.4 are in the 30-32 kDa and ∼90 kDa regions. These 
bands were not found in the modulated or Bvg- strain, BP347. The 30-32 kDa bands 
correspond in size to the β-domains (see Introduction, section 1.6.5) of the various 
autotransporters of B. pertussis and presumably, therefore, could represent these fragments 
of the autotransporters left in the outer membrane after cleavage and release of the 
passenger domains. They are still present in the BP Taberman (BapC-) and BP338 (BrkA-) 
strains that, although each lacking one autotransporter, will produce the other 
autotransporter proteins.  
The immunoblots of the outer-membrane preparations gave somewhat different patterns to 
those obtained with whole cells (Figs 3.2, 3.3). In Fig. 3.5, prominent differences were 
observed in the ∼98 kDa and ~70 kDa regions. The band at ∼98 kDa in Fig. 3.5 is possibly 
the BapC protein as it was present in BP Taberman (W/T), BP338 and faintly in BP338 
(BrkA-) (although the amount of protein in this sample appears to be low, see Fig. 3.4), but 
not found in BP Tohama II or in the strains grown in modulated conditions (nicotinic acid, 
16mM) or in the Bvg- strain, BP347, which again confirmed the regulation of BapC via 
bvg-regulation system. This band runs at a higher molecular weight than the predicted size 
of the processed form of BapC i.e. 71 kDa, and it may be the apparent size of the 
unprocessed form of BapC after the cleavage of a signal sequence which, calculated using 
the ProtParam tool, is about 100 kDa. Alternatively, the protein runs anomalously on SDS-
PAGE. Such behaviour has been previously described for other autotransporter proteins 
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such as mature pertactin, which has calculated molecular weight of 61 kDa but runs at 69 
kDa on SDS-PAGE. The inner-membrane fractions of BP Taberman showed a similar 
protein profiles to the bapC derivative (not shown). The band at ∼64 kDa in Fig. 3.5 
possibly corresponds to the processed form of BrkA protein (73 kDa) since it was not 
present in BP338 (BrkA-), the Bvg- strain, BP347 or in the strains grown in modulated 
conditions. These observations also confirm the regulation of BrkA protein by the BvgAS 
two-component regulatory system. This pattern was found to be similar to that in the whole 
cells immunoblots (Figs. 3.2 and 3.3) in that 73 kDa was present in the B. pertussis wild-
type and their BapC mutant strains, whereas it was missing in the BrkA- strain. However, 
the apparent size differences are difficult to explain. The identity of the other two 
prominent bands in lanes 1, 3, 4, and 6 in the 64-98 kDa region is unknown. However, they 
appear to be Bvg-regulated, are abundant in the outer-membrane preparations and cross-
react with the anti-BapC serum. It may be that these represent other antigenically-related 
autotransporter proteins that are more abundant than BapC and BrkA. For example, the 
lower band could represent the mature form of pertactin (69 kDa) and the upper band could 
represent mature Vag-8 (95 kDa) or unprocessed form of TcfA (90 kDa) but further work, 
e.g. by N-terminal sequencing or peptide finger printing, would be required to confirm 
their identities. It was also curious that the anti-BapC serum did not react with the 30-32 
kDa bands even though it was raised against a recombinant protein fragment of BapC that 
contained the β-domain.  
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Figure 3.4 Outer-membrane protein profiles of B. pertussis strains grown in 
modulating and non-modulating conditions 
 
Protein profiles were obtained by SDS-PAGE in gel containing 10% acrylamide using 
equal amounts of the protein. 
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1 = BP Taberman Wild Type (W/T) 
2 = BP Taberman Wild Type (W/T) + Nicotinic acid 
3 = BP Taberman II (BapC-) 
4 = BP338  
5 = BP338 + Nicotinic acid 
6 = BP338 (BrkA-)(BP2041)  
7 = BP338 (Bvg-)(BP347)  
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Figure 3.5 Immunoblotting with anti-BapC serum of outer-membrane 
preparations of B. pertussis strains grown in modulating and non-
modulating conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
Equal amounts of the protein were subjected to SDS-PAGE (10%), and then blotted to 
Hybond-C membrane and probed with anti-BapC serum. 
 
M = marker 
1 = BP Taberman (W/T) 
2 = BP Taberman (W/T) + Nicotinic acid 
3 = BP Taberman II (BapC-) 
4 = BP338  
5 = BP338 + Nicotinic acid 
6 = BP338 (BrkA-)(BP2041)  
7 = BP338 (Bvg-)(BP347)  
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3.5 Localisation of BapC in B. pertussis strains 
In an attempt to investigate the expression of BapC protein in B. pertussis strains, an 
agglutination procedure was carried out using the rabbit polyclonal anti-BapC serum 
absorbed with a B. pertussis BapC mutant strain (section 2.12.2) to reduce the cross-
reaction with other B. pertussis antigens that was evident from the immunoblots. The 
agglutination test was performed in 96-well u-shaped microplates using bacterial cells 
scraped from BG plates and suspended in PBS and the suspension standardized at OD600 ∼ 
0.8. The polyclonal anti-BapC serum strongly agglutinated the B. pertussis strains 
expressing BapC protein.  
Table 3.2 shows the agglutination reaction of the different B. pertussis strains with the 
rabbit polyclonal anti-whole cell and the (absorbed) anti-BapC sera and these results 
largely agree with those shown for the unabsorbed anti-BapC serum in Table 3.1. These 
strains were strongly agglutinated by the anti-whole cell pertussis serum, confirming the 
reliability of strains used in the study. The absorbed polyclonal anti-BapC serum strongly 
agglutinated B. pertussis strains which should have been expressing BapC such as; BP 
Taberman (W/T), BP338 and BP338 (BrkA-). However, there was only a weak 
agglutination with the B. pertussis BP Tohama wild-type strain. Much less agglutination 
was seen with strains which should not express BapC [(BP Tohama (BapC-) or Bvg- 
(BP347)], and not at all with BP Taberman (BapC-) or any of the strains grown in the 
presence of a high concentration of MgSO4 (Bvg- phase). These results also confirmed that 
expression of the BapC protein is controlled by the BvgAS two-component regulatory 
system since it was not detected by anti-BapC serum under modulating conditions. 
Another important finding was that the B. pertussis BP338 (BrkA-) strain expressed the 
BapC protein because it was strongly agglutinated by the anti-BapC serum.    
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Table 3.2 Agglutination of B. pertussis strains grown in modulating 
(+MgSO4) and non-modulating conditions 
 
Strains Agglutination with  
anti whole-cell B. 
pertussis serum 
 
Agglutination with 
anti-BapC serum ∗ 
 
 Bacteria alone 
(Self-agglutination 
control) 
 
B. pertussis Taberman 
W/T 
 
++++ 
 
 
++++ 
 
_ 
B. pertussis Taberman 
W/T (+ MgSO4) 
 
 
+++ 
 
_ 
 
_ 
B. pertussis Taberman II 
(BapC-)  
+++ _ _ 
B. pertussis Tohama 
W/T 
 
 
+++ 
 
±? 
 
_ 
B. pertussis Tohama 
W/T (+ MgSO4) 
 
 
+++ 
 
_ 
 
_ 
B. pertussis 338 Weiss ++++ ++++ 
 
_ 
B. pertussis 338 Weiss (+ 
MgSO4) 
 
 
+++ 
 
_ 
 
_ 
B. pertussis 338 (BrkA-) 
(2041 Weiss) 
 
 
++++ 
 
++++ 
 
_ 
B. pertussis 338 (BrkA-) 
(2041 Weiss)  
(+ MgSO4) 
 
+++ 
 
_ 
 
_ 
B. pertussis Tohama II 
(BapC-) 
 
 
+++ 
 
+ 
 
_ 
B. pertussis 338 
(Bvg-) (BP347) 
 
+++ 
 
+ 
 
_ 
 
 
 
- = No agglutination 
+ = Weak agglutination 
++ = Moderate agglutination 
+++ = Strong agglutination 
++++ = Very strong agglutination  
 
 (+ MgSO4) = denotes growth in modulating (Bvg-) conditions  
∗ The serum was absorbed with whole cells of B. pertussis BP Taberman II strain to 
remove antibodies to any other surface proteins.  
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3.6 Serum killing assays of B. pertussis strains 
The serum killing assays were carried out to investigate whether BapC due to its structural 
homology with the autotransporter protein BrkA, could confer a serum resistance 
phenotype on B. pertussis. Previous work by Bokhari (PhD thesis, 2002) had suggested 
that the BapC protein of B. pertussis, like BrkA, could confer resistance to killing by 
normal human serum. The main objective of the present work was to confirm and extend 
these findings and to determine the relative contribution of the two proteins to serum 
resistance. The first step was to characterize the serum sensitivity of the B. pertussis and 
recombinant E. coli strains that were available at the start of the present study.  
All of the serum killing assays in the present investigation were performed using pooled 
normal human serum (section 2.12.3.1) obtained from volunteers with no recent history of 
pertussis. The survival was calculated from the number of survivors from the normal 
human serum as a percentage of the number of survivors from heat-inactivated serum. The 
heat treatment (56°C for 30 min) destroys the inherent complement activity of the serum. 
A preliminary comparison of the number of survivors in PBS controls (i.e. no added 
serum) and in heat-inactivated serum did not show any significant difference over the 
incubation period. These observations suggested that any decrease in bacterial counts due 
to agglutination by any antibodies present in the normal human serum, rather than by 
killing, was negligible. Different normal human serum dilutions (10%, 20%, 30%, 50% 
and neat) in a time-course study (exposure for 30, 45, 90 and 120 min) were performed to 
determine the optimal time of exposure to normal human serum. The time-course of 
killimg different B. pertussis strains by 10% normal human serum is shown in Fig. 3.6a. 
From these time-course results, an incubation time of 45 min was selected for further 
serum killing assays as there was little change thereafter in the number of CFU of B. 
pertussis recovered from the normal serum. In these experiments, BP338 and its BrkA- 
mutant (BP2041) were used as controls.  
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Figure 3.6b shows a comparison of the serum sensitivity of some of the various B. 
pertussis strains available at the start of this study, when exposed to normal human serum 
(NHS) for 45 min. B. pertussis BP338 and B. pertussis Taberman (wild type) were the 
most resistant to killing, showing some survival even in neat serum after 45 min. 
Moreover, B. pertussis Tohama derivative, BP338, seemed to be inherently more resistant 
compared to the B. pertussis Tohama wild type. The Tohama wild type strain was 
somewhat more sensitive but still showed some (i.e. 5%) survival in neat serum. B. 
pertussis BP2041, the BrkA mutant, was much more sensitive than its parent strain BP338, 
with 10% survival in 1/3 dilution of serum and no detectable survival in neat serum. The 
difference in serum sensitivity between the brkA mutant and its parent strain BP338 was 
found to be similar, but not as great, as that reported by Fernandez and Weiss (1994). The 
BapC mutant strains, BP Tohama II and BP Taberman II, constructed by Bokhari (2002) 
were more sensitive than their parents and showed a similarly sensitivity to B. pertussis 
BP2041. 
 Although in all experiments pooled human serum was utilised, the activity of the 
complement proteins which are the key players in killing of B. pertussis, could be affected 
by the preparation steps involved and during storage of the serum. An experiment was 
designed to assess serum killing using de-complemented serum, by heating it to 56°C for 
30 min, and adding a prepared source of complement (guinea pig serum, Sigma). The 
guinea pig serum was expected to be free of antibodies against B. pertussis, whereas the 
heat-inactivated human serum could possibly act as a source of cross-reacting antibodies. 
5% v/v guinea pig serum, as a source of complement, was added to the 10% v/v heat-
inactivated human serum. As expected, B. pertussis BP338 was found to be more resistant 
compared to its brkA mutant strain, BP2041 (data not shown). Therefore, the data obtained 
from the use of an external source of complement added to the de-complemented human 
serum supported the previous findings. It was also concluded that the activity of the 
complement proteins of the human serum preparation was preserved.  
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Figure 3.6a. Time course of killing of B. pertussis strains by 10% normal 
human serum (NHS) 
 
The results are the means of three separate experiments and bars indicate the standard 
deviations. 
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Figure 3.6b Comparison of serum sensitivity of B. pertussis strains  
 
Strains were exposed for 45 min to neat or 1/3 dilution of normal human serum (NHS) or 
NHS that had been heated to 56°C for 30 min. The results are the means of three separate 
experiments and bars indicate the standard deviations. 
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F = BP Taberman II (BapC-) 
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3.7 Expression and characterisation of recombinant 
BapC protein from E. coli M15 pQE60 (ATG1) 
E. coli M15 (pQE60) is a high-level expression strain used for expression of recombinant 
proteins. For stable propagation of expression constructs encoding potentially toxic 
proteins, a higher level of lac repressor is required which is obtained in trans with 
repressor plasmid pREP4 to express the lac repressor at high levels. The E. coli M15 
(pREP4) strain in induced and non-induced conditions was used as controls.         
Fig. 3.7 shows the SDS-PAGE protein profile of whole cells of E. coli M15 pQE60 
(ATG1) expressing BapC (from the previously predicted first ATG1) in non-induced and 
induced conditions with IPTG. On this SDS-PAGE 10% polyacrylamide gel, a band at 
approximately 90 kDa was present in the induced cultured of E. coli M15 pQE60 (ATG1) 
(lane 1) but was absent in the uninduced culture and in the corresponding control 
preparation from E. coli M15 pREP4, without the bapC insert. Thus, the band is presumed 
to be the expected BapC fragment. Previous work had suggested a molecular weight of 
about 90 kDa for this product (Bokhari, 2002). The predicted molecular weight of this 
fragment of BapC is 79.5 kDa (see section 3.8) using ProtParam (ExPASy ProtParam) and 
Biopeptide, which are peptide molecular weight calculator tools. However, the apparent 
molecular weight of the BapC band according to the calibration of Promega markers (Fig. 
3.8) was around 90 kDa. In all cases, protein expression was tightly regulated and was not 
detectable from uninduced cultures in either Coomassie-blue stained gels or, where 
performed, immunoblots with anti-His6 antibodies (section 3.9).  
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Figure 3.7 Protein profile of E. coli strains grown in non-induced and 
induced conditions with IPTG 
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Figure 3.8 Calibration of Promega protein molecular weight markers 
(SeeBlue Plus2 Pre-Stained Standard) 
The Rf values for the molecular mass standards were determined by drawing reference 
lines at the top and bottom of the gel and dividing the distance from the upper reference 
line to the middle of the protein band (d1) by the distance from the upper reference line to 
the lower reference line (d2). Rf = d1/d2                                                       
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3.8 Identification of bapC gene and BapC protein in 
recombinant E. coli  
To confirm the identification of the cloned bapC gene and expression of BapC in E.coli, 
DNA sequencing of the insert and peptide fingerprints of  the 90 kDa protein expressed in 
E. coli M15 pQE60 (ATG1) were performed. However, as noted earlier, this plasmid did 
not contain the full-length bapC gene.  
The sequence of the cloned bapC gene from the purified plasmid of E. coli M15 pQE60 
(ATG1) carrying the bapC gene was obtained using Chromas (versions 2.3 & 1.15) and 
DNAstar softwares. Then, BLAST analysis of this sequence, using the BLAST2 sequence 
alignment tools (results not shown), showed the exact nucleotide identity to the bapC gene 
sequence which was in GenBank with accession numbers of AF081494 (Blackburn, 1998) 
and CAC14167 (Henderson, 2000).   
A BLAST search of the peptide sequences obtained by peptide fingerprinting and mass 
spectrometry of the BapC protein cut from a SDS-PAGE gel (see section 2.11.8) showed a 
strong homology between the expressed protein and BapC protein (Henderson et. al., 
2000) and Bap5 protein (Blackburn, 1998), and strong homology with other 
autotransporters, such as pertactin and BrkA of B. pertussis, putative autotransporters of B. 
bronchiseptica and B. parapertussis (Parkhill et. al., 2003) and an autotransporter 
(pseudogene) of B. pertussis Tohama I (Parkhill et. al., 2003). Also, there was an 
interesting homology (55% identity) between BapC protein and chaperone Hsp70; an auto-
regulated heat shock protein of E. coli.  
Amino acid sequence of BapC by mass spectrometry:  
The sequence below is from NCBI BLAST search. Peptides from the expressed BapC 
protein that matched with this sequence (55% coverage) are shown in bold red, thus 
confirming the identity of the expressed protein. 
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Nominal mass (Mr): 79551 
 
MCDTCRDDDG TSPSIRVQGG VVQGGMGANN VAVVATGSGK VAIENAELLG ASGMYATFGA 
QVDMKGGRIL AHNTNILGSQ GYADGPYGGV VVTEDGQVNL EGAKVSATGL 
GAAGLWLLGD KDTSPRASLR NTDVHGEVAA IALGFNGEAN ISGGSLSVED GAVLTTLTPD 
AVEYYYDYAL SMEHLPADAP LTPVRVTLSD GARASGETLI AHGGLLPMTL RLSSGVDARG 
DIVTLPPSAP PDSAEQPDAE PEPDAELEPD AAAQSDAKAN ARVMAQVDGG EPVAVPIPAP 
SHPDAPIDVF IDSGAQWRGM TKTVNALRIE DGTWTVTGSS TVNSLHLQAG KVAYATPAES 
DGEFKHLRVK TLSGSGLFEM NASADLSDGD LLVVSDEASG QHKVLVRGAG TEPTGVESLT 
LVELPEGSQT KFTLANRGGV VDAGAFRYRL TPDNGVWGLE RTSQLSAVAN AALNTGGVGA 
ASSIWYAEGN ALSKRLGELR LDPGAGGFWG RTFAQKQQLD NKAGRRFDQK VYGFELGADH 
AIAGQQGRWH VGGLLGYTRA RRSFIDDGAG HTDSAHIGAY AAYVADNGFY FDSTLRASRF 
ENDFTVTATD AVSVRGKYRA NGVGATLEAG KRFTLHDGWF VEPQSEVSLF HASGGTYRAA 
NNLSVKDEGG TSAVLRLGLA AGRRIDLGKD RVIQPYATLS WLQEFKGVTT VRTNGYGLRT 
DLSGGRAELA LGLAAALGRG HQLYTSYEYA KGNKLTLPWT       FHLGYRYTW  
 
Yellow highlighted segment is the putative cleavage site of BapC protein.   
 
 
Protein information regarding BapC fragment expressed by E. coli M15 pQE60 
(ATG1), as obtained from Mascot: 
        
        Molecular Weight 79484.46 Daltons 
        759 Amino Acids 
        64 Strongly Basic (+) Amino Acids (K, R) 
        87 Strongly Acidic (-) Amino Acids (D, E) 
        274 Hydrophobic Amino Acids (A, I, L, F, W, V) 
        179 Polar Amino Acids (N, C, Q, S, T, Y) 
        5.132 Isoelectric Point   
        -20.408 Charge at pH 7.0 
 
 
3.9 Characterization of recombinant BapC protein using 
anti-His-tagged antibody 
 To detect the BapC protein in E. coli M15 pQE60 (ATG1), which is expressing most of 
the bapC gene, anti-His tagged monoclonal antibody was utilised in immunoblotting. It 
was not certain that the recombinant BapC protein would in fact be His-tagged. In the 
original reverse primer (Bap-5 CTERM3`) used by Blackburn (2000) to produce pQE60 
(ATG1) (pQE60 BAPM1, designation of Blackburn) there appears to be a stop codon 
before the His-tag. Blackburn (2000) was unable to purify the BapC protein by Ni-agarose 
affinity chromatographs, although Bokhari (2002) did appear to be able to do this. This 
was further investigated in the present study. Lane 1 (Fig. 3.9) shows the reaction between 
anti-His-tagged antibody and the recombinant BapC protein fragment, which is expressed 
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only after induction with IPTG. It appears that the molecular weight of the His-tagged 
BapC fragment is approximately 90 kDa, as in Fig. 3.7. 
 
Figure 3.9 Immunoblotting with anti-His-tagged antibody of E. coli strains 
grown in induced and non-induced conditions 
 
 
 
 
 
 
                                                                                                                   
 
                            
3.10 Characterization of recombinant BapC protein by 
immunoblotting  
In the immunoblot of the E. coli strains grown in induced and non-induced conditions (Fig. 
3.10), the unabsorbed anti-BapC serum was clearly reacting strongly with many different 
components of E. coli as well as with the putative BapC fragment (labelled as 79.5 kDa 
band). To minimize the effect of cross-reacting antibodies in immunoblotting of this 
recombinant BapC protein expressed by E. coli, the BapC serum was absorbed with both 
B. pertussis BP Taberman (BapC-) and E. coli M15 (pREP4) strains before use.  
M = Marker  
1 = E. coli M15 pQE60 (ATG1)(IPTG+) 
2 = E. coli M15 pQE60 (ATG1)(IPTG-) 
3 = E. coli M15 pREP4 (ATG1)(IPTG+) 
4 = E. coli M15 pREP4 (ATG1)(IPTG-) 
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Figure 3.10 Immunoblotting with unabsorbed anti-BapC serum of E. coli 
strains grown in induced and non-induced conditions 
 
 
 
 
 
 
                                                                                                  M = Marker 
                                                          1 = M15 pREP4 (IPTG+) 
                                                          2 = M15 pREP4 (IPTG-) 
                                                          3 = M15 pQE60 (ATG1)(IPTG-) 
                                                          4 = M15 pQE60 (ATG1)(IPTG+) 
     
Figure 3.11 Immunoblotting with absorbed anti-BapC serum of E. coli 
strains grown in induced and non-induced conditions. 
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Figures 3.10 and 3.11 show the immunoblotting of E. coli M15 pQE60 (ATG1) strain with 
unabsorbed and absorbed sera, respectively, after growth in induced and non-induced 
conditions with IPTG. Figure 3.10 shows strong cross-reaction of anti-BapC serum with E. 
coli bands, particularly in lane 4, with the induced E. coli M15 pQE60 (ATG1) strain. The 
arrow shows the most likely band corresponding to BapC fragment. Given that the 
strongest cross-reactions are with pQE60 (ATG1) induced by IPTG, the lower molecular 
weight bold bands that cross-reacted with anti-BapC serum were presumably breakdown 
products of the BapC fragment. Figure 3.11 shows the immunoblotting with the absorbed 
serum, which demonstrates a clear band at approximately 79.5-90 kDa presumed to be 
BapC fragment and fewer, lower molecular weight cross-reacting bands. This band 
appeared to be run at somewhere in the region between 79.5 kDa (the predicted size of 
BapC fragment) and 90 kDa (estimated previously). The estimated size, using the 
calibrated markers, may not be accurate since any small changes in logarithmic 
calculations make a huge change in the estimated size of the protein. When compared with 
figure 3.10, the intensity of the immunoblotting reaction with the main band and lower 
molecular weight bands has been reduced.     
3.11 Localisation of BapC in E. coli strains 
In previous studies by Blackburn (PhD thesis, 2000) and Bokhari (PhD thesis, 2002) 
different parts of the bapC gene had been cloned into different expression vectors in E. 
coli. When these studies were done, before the publication of the B. pertussis genome 
sequence (Parkhill et al., 2003), the bapC gene was assumed to start at position 703 and 
the corresponding gene fragment was thus named ATG1 (Blackburn, PhD thesis, 2000). A 
shorter fragment corresponding to the N-terminus of BapC, from positions 778 to 1234 on 
the bapC gene (Appendix II), and cloned into the expression vector, was designated NTS. 
In the present study, these E. coli strains were grown in LB broth and induced with IPTG 
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(section 2.11.2) and the resulting cell suspensions were tested by slide agglutination with 
anti-whole pertussis and (unabsorbed) anti-BapC sera.  
Table 3.3 shows the agglutination reaction of these different E. coli strains expressing most 
of the bapC gene or part of 5´ terminus of the gene, with a rabbit polyclonal anti-BapC 
serum. The polyclonal anti-BapC serum strongly agglutinated the E. coli strain expressing 
BapC [M15 pQE60 (ATG1)] when induced with IPTG and also very weak agglutination 
when not induced. However, it also cross-reacted to some extent with E. coli M15 pREP4 
induced or not induced (Table 3.3), which is a parent strain control, and with E. coli 
expressing a part of the N-terminal sequence (NTS) of the bapC gene [M15 pQE60 
(NTS)], induced or not induced. In fact, none of these strains should express any part of the 
BapC protein on their surface since the expressed fragment should not be carrying the 
signal peptide that targets the nascent protein to the inner membrane. However, 
overexpression of the BapC fragment by E. coli M15 pQE60 (ATG1) after induction could 
perhaps allow some of the protein to reach the cell surface by some unknown means. 
Moreover, the NTS fragment does not have the β-domain for transport through the outer 
membrane. Thus, the low level of agglutination of some of these E. coli strains could be 
due to the antigenic cross-reactions already noted and the specificity of the polyclonal anti-
BapC serum should be improved for further studies.  
In an attempt to further clarify the level of BapC protein expression in E. coli, the 
agglutination procedure was repeated using the rabbit polyclonal anti-BapC serum that had 
absorbed both with a B. pertussis BapC mutant strain and with E. coli pRep4 strain. This 
time, a fine type of agglutination reaction was observed with the E. coli strains carrying 
pQE60 (ATG1) and pRep4 although at lower titres than in Table 3.3. Thus, it seems that 
the polyclonal anti-BapC antibody was not suitable for detecting the BapC protein 
specifically in E. coli, although it clearly reacts with the protein as shown by 
immunoblotting experiments (Figs. 3.10 & 3.11). However, when used in agglutination 
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tests with the various B. pertussis strains grown under normal or modulating (Bvg-) 
conditions, the expected results were obtained in most cases (Table 3.2).  
 
Table 3.3  Slide agglutination test with different E. coli expression strains 
in induced and non-induced conditions with IPTG 
 
The agglutination test was performed in 96-well u-shaped microplates using bacterial cells 
scraped from LB plates and suspended in PBS and the suspension standardized using 
OD600 ∼ 0.6. 
 
 
 
E. coli strains 
Agglutination 
with polyclonal 
anti-BapC 
 
Self-agglutination 
control* 
               
      Comment 
 
M15 pQE60 (ATG1) 
(IPTG+) 
 
 
++++ 
 
_ 
Small clumps of 
aggregation with clear 
background 
M15 pQE60 (ATG1) 
(IPTG-) 
 
 
± 
 
_ 
 
 
M15 pQE60 (NTS) 
(IPTG+) 
 
 
++ 
 
_ 
Fine clumps of 
aggregation with 
cloudy background 
 
M15 pQE60 (NTS) 
(IPTG-) 
 
 
± 
 
_ 
 
 
 
M15 pREP4 (IPTG+) 
 
 
+ 
 
_ 
Small clumps of 
aggregation with 
cloudy background 
 
M15 pREP4 (IPTG-) 
 
 
± 
 
_ 
 
         
                   * Bacteria alone 
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3.12 Characterisation of BapC as a serum-resistance 
factor in E. coli 
This experiment was designed to generate information on the sensitivity to killing by 
normal human serum of E. coli strains containing most of bapC gene or part of the bapC 
gene in an expression vector, grown in induced and non-induced conditions. As explained 
in the previous section, in the light of current knowledge of the bapC gene and BapC 
protein, the E. coli strain M15 pQE60 (ATG1) should not have expressed BapC on its 
surface although the agglutination tests with anti-BapC serum suggested that it did. 
Expression in E. coli M15 pQE60 of most of the whole bapC gene (from the previously 
predicted first ATG1) induced by IPTG did in fact confer significant (P value <0.05) 
serum resistance to the host strain when compared to the uninduced strain (Fig. 3.12). This 
difference was especially clear when the strains were exposed to the 1/5 dilution of the 
normal human serum (NHS), which is approximately the same concentration as in human 
lungs (Persson, 1991). Thus, even the incomplete BapC protein missing the signal 
sequence and part of the N-terminal domain, appeared to be reaching the E. coli cell 
surface and conferring serum resistance. However, expression of only part of the N-
terminal sequence (NTS) of the BapC protein without the β-domain conferred no 
significant resistance in the serum killing assay (Fig. 3.13), at either 1/5 dilution of serum 
or at 1/10 dilution. These figures also show that NHS heated to 56˚C for 30 min had no 
killing effect on the E. coli strains or cause any apparent reduction in viable numbers 
compared to untreated controls.  
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Figure 3.12 Serum sensitivity of E. coli M15 pQE60 (ATG1) with or without 
IPTG induction 
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         NHS = Normal human serum 
         IPTG = Isopropylthio-beta-D galactoside  
The results are the means and standard deviations of 3 separate experiments. Student’s t-
test was used to compare the strains. 
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Figure 3.13 Serum sensitivity of E. coli M15 pQE60 (NTS) with or without 
IPTG induction 
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NHS = Normal human serum 
IPTG = Isopropylthio-beta-D galactoside  
The results are the means and standard deviations of 3 separate experiments. Student’s t-
test was used to compare the strains. 
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3.13 Identification of cloning and expression vectors 
PCR was performed on the different purified plasmids of E. coli cloning and expression 
strains available from previous studies (Table 2.4) to confirm their identities and to show 
which plasmids were carrying the bapC gene disrupted by the Km resistance cassette. It 
was carried out using the bapC specific primers, bapC forward (BAP5F) and bapC reverse 
(BAP5R) (Table 2.5), which cover most of the full length of bapC gene from the ATG at 
position 728. To make a new bapC mutant and also a BrkA, BapC double mutant, it was 
necessary to confirm the identity of these constructs, which would be useful in the next 
steps. As figure 3.14 shows, PCR results showed the expected size of 3.5 kbp for the bapC 
gene disrupted by the kanamycin resistance cassette in P-B-5 (Bokhari, 2002) and pCR-
Script bapC::km (Blackburn, 2000), as suicide and cloning vectors, respectively. These 
plasmids were used to create a new bapC fragment containing Tetr in place of Kmr. Lanes 
3-6 show no band amplified by BAP5F and BAP5R with other (control) plasmid DNAs. 
Lanes 7-12 show preparations of different plasmids extracted from E. coli strains.    
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Figure 3.14 Agarose (0.8%) gel showing the PCR products and extracted 
plasmids of some E. coli strains with bapC specific primers 
 
PCR was performed on plasmid DNA extracted as described in section 2.2.2, using primers 
bapC forward (BAP5F) and bapC reverse (BAP5R) which amplify the bapC fragment. 
 
                       
 
  M = Marker                                                           7 = pCR-Script (bapC::km)(plasmid)      
-Ve = Negative                                                         8 = E. coli JM109 (plasmid) 
  1 = P-B-5 (PCR product)                                      9 = pSS1129 (plasmid) 
  2 = pCR-Script bapC::km (PCR product)          10 = pQE60 (ATG1) (plasmid)   
  3 = E. coli JM109  (PCR product)                       11 = pREP4 (plasmid) 
  4 = pSS1129 (PCR product)                                12 = pQE60 (NTS) (plasmid) 
  5 = E.coli M15 pQE60 (NTS) (PCR product) 
  6 = E. coli M15 pREP4 (PCR product)   
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3.14 Generation of bapC single and brkA, bapC double 
mutants 
The suicide vector pSS1129 was utilised to promote allelic exchange of the wild-type 
bapC gene on the chromosome with its in vitro-mutated counterpart on the plasmid, by 
homologous recombination. The construction of pRTP1 has been previously described 
(Stibitz et al., 1986). This plasmid allows one to introduce a cloned gene into a bacterial 
recipient by conjugation with an E. coli donor and then to select for two successive 
crossovers between the cloned gene and the recipient chromosome. A 2.4-kb BamHI-PvuII 
fragment had been added to pRTP1 to make pSS1129 (Fig. 3.15) (Stibitz, 1994). This 
fragment had been derived from pSK6 (S. Kagan, Ph.D. Thesis, Univ. of Wisconsin, 
Madison (1981), and the PvuII site and SmaI site involved in the cloning were both 
destroyed. 
The important features of this construct are that the transfer to the recipient bacterium can 
be accomplished because the plasmid contains the origin of transfer from RP4, a 
promiscuous, IncP plasmid. OriT allows pRTP1 containing cloned B. pertussis sequences 
to be complemented for the ability to transfer via conjugation from E. coli into recipient B. 
pertussis strains. When Tra functions are provided in trans, pRTP1 will be transferred into 
the recipient bacterium via conjugation. The pRTP1 also contains a vegetative origin of 
replication derived from ColE1; an ApR gene; the gene for E. coli ribosomal protein S12 
(rspL) which codes RspL protein that is responsible for the streptomycin-sensitive (SmS) 
phenotype in bacterial strains (due to a gene-dosage effect) normally resistant to 
streptomycin (SmR) due to mutation in the chromosomal rspl homologue; and the cos site 
of bacteriophage λ.  
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Figure 3.15 Restriction map of pRTP1 and pSS1129 (Stibitz, 1994) 
 
The 2.4 kbp BamH1-PvuII fragment, which was derived from pSK6, was added to pRTP1 
to make pSS1129. Note that the PuvII site and SmaI site involved in the cloning were both 
destroyed. 
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Once the plasmid DNA has been transferred the vector, it is unable to be maintained in B. 
pertussis due to the ColE1 origin of replication. First crossover will select for those 
bacteria in which the plasmid has integrated into the chromosome. 
If the cloned segment homologous to the chromosome is contained within this plasmid, 
integration will most likely occur by homologous recombination. If selection for Amp 
resistance is imposed, only those bacteria in which the incoming plasmid has been 
integrated into the chromosome will survive. 
The second crossover is obtained by selecting for the loss of the integrated plasmid. This is 
accomplished by expression of the wild type E. coli rspL gene in pRTP1 which confers a 
streptomycin-sensitive phenotype on strains otherwise resistant due to a mutation in the 
chromosomal rpsL homologue. Thus streptomycin-resistant survivors will be those which 
will have lost the plasmid copy of rpsL. The mechanism by which this loss occurs is via 
homologous recombination between the direct repeats which flank the vector as a result of 
its integration. Loss of Amp resistance is indicative of plasmid loss.  
 
3.14.1 Construction of E. coli carrying the suicide vector 
containing bapC::Tet 
To create a brkA, bapC double mutant, appropriate antibiotic resistances were required for 
clonal selection as BP2041 brkA mutant was kanamycin and nalidixic acid resistant and 
also the available bapC mutants (BP Taberman II or Tohama II) were kanamycin resistant. 
A tetracycline resistance cassette was therefore used to replace the kanamycin resistance 
cassette used previously to disrupt the bapC gene at position 1244 (Fig. 3.16). Suicide 
plasmid pSS1129 and its derivative pBap-5 Kana (P-B-5) (Bokhari, 2002), were extracted 
by the QIA prep Mini prep purification system (Qiagen), subjected to restriction digestion 
with BglII, which cuts either side of the bapC fragment inserted (with kanamycin cassette)  
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Figure 3.16 Map of suicide construct pBapC-Tet [pSS1129 (bapC::tet)] 
 
The suicide vector pSS1129 was used to create pBapC-Tet (bapC::tet). The bapC gene 
was disrupted by insertion of a tetracycline resistance gene at an NcoI site 1244 bp from 
the predicted translational start site. The vector has a ColE1 origin of replication that is 
incapable of replication in B. pertussis and many other bacterial species. There is an origin 
of transfer (oriT) from the RP4 plasmid. The vector contains the E. coli rspL gene, which 
encodes streptomycin sensitivity, and an ampicillin resistance gene. The mutated bapC 
gene was cloned into pSS1129 at a BglII site to make the pBapC-Tet (bapC::tet) construct.   
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into the suicide vector. The suicide vector had been employed to create pBap-5 Kana (P-B-
5), which is the bapC gene disrupted with kanamycin cassette at NcoI site, and cloned into 
pSS1129 at a BglII site (13380 bp) (Kanamycin cassette; 1.3 kbp, bapC gene; 2.28 kbp, 
Suicide vector; 9.8 kbp). Fig. 3.16 shows the map of the suicide construct pBapC-Tet 
which kanamycin cassette replaced by tetracycline cassette.  
Lane 1 in figure 3.17A shows the size of the suicide vector pSS1129 as 9.8 kbp. Lane 2 
shows two bands, the bapC gene disrupted with kanamycin resistance cassette (3.5 kbp) 
and suicide vector (9.8 kbp) after digestion of pBap-5 kana (P-B-5) with BglII. 
The extracted plasmids were also subjected to restriction digestion with NcoI, which cuts 
either side of the kanamycin resistance cassette inserted into the bapC gene (Fig. 3.17B). 
Lanes 2 shows two bands, the kanamycin resistance cassette (1.3 kbp) and the suicide 
vector with bapC gene (9.8 kbp + 2.28 kbp).  
Since the restriction map of the suicide vector was not available, many more restriction 
digestions were performed to distinguish those enzymes which could cut the suicide vector 
only in one site without any restriction site in bapC (Figures not shown).  
To create a new bapC mutant and a double mutant of bapC and brkA; the first step was the 
construction of the bapC gene with a tetracycline resistant cassette. The TetR resistance 
cassette (TetR) (Fig. 3.19) was initially amplified from pBR322 (Appendix II) using 
primers TCF1 and TCR1 (Table 2.5) each of which contained an NcoI site (Fig. 3.18A) 
and the final product was cloned into pGEMT (3 kbp) to create 4.3 Kb pGEMT (Tet). The 
1.3 kbp bands in Fig. 3.18A show the amplified tetracycline cassette of plasmid pBR322. 
The cloned tetracycline cassette in pGEMT vector was sequenced by the Molecular 
Biology Sequencing Unit of Glasgow University, and BLAST search showed 100% 
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identity of the insert with the Tet resistance cassette. The 1.3 and 3 kbp in Fig. 3.18B 
represent the tetracycline resistance cassette and pGEMT plasmid, respectively, after 
restriction digestion with NcoI.    
Figure 3.17 Agarose (0.7%) gel showing plasmid pSS1129 and P-B-5 
digested with BglII (A) and NcoI (B) 
 
 
 
 
 
 
 
  
Figure 3.18 Agarose gel (0.7%) showing the PCR product of amplified 
tetracycline gene of pBR322 (A) and pGEMT(Tet) digested with NcoI (B) 
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Figure 3.19 Sequence of the tetracycline resistance gene of pBR322 
(adapted from www.fermentas.com/techinfo/nucleicacids/mappbr322.htm) 
 
 
*ttctcatgtttgacagcttatcatcgataagctttaatgcggtagttta tca cag tta aat tgc taa cgc agt cag gca ccg tgt atg aaa tct  
                                                                               S     Q     L    N    C     •     R      S     Q      A     P     C    M    K     S 
 
 
aac aat gcg ctc atc gtc atc ctc ggc acc gtc acc ctg gat gct gta ggc ata ggc ttg gtt atg ccg gta ctg ccg ggc  
  N     N    A      L    I      V    I      L     G      T      V    T     L     D    A     V     G     I      G     L    V    M     P     V    L      P      G     
ctc ttg cgg gat atc gtc cat tcc gac agc atc gcc agt cac tat ggc gtg ctg cta gcg cta tat gcg ttg atg caa ttt cta  
  L    L     R      D    I      V    H     S     D     S      I     A      S     H    Y     G     V     L    L     A      L   Y     A     L    M    Q    F    L 
tgc gca ccc gtt ctc gga gca ctg tcc gac cgc ttt ggc cgc cgc cca gtc ctg ctc gct tcg cta ctt gga gcc act atc  
 C     A      P     V    L     G      A     L    S      D     R     F    G      R     R     P      V    L     L     A    S     L     L    G      A     T    I 
gac tac gcg atc atg gcg acc aca ccc gtc ctg tgg atc ctc tac gcc gga cgc atc gtg gcc ggc atc acc ggc gcc  
  D     Y     A     I     M     A      T     T      P     V    L     W    I      L    Y     A     G      R     I      V     A     G      I      T      G     A        
aca ggt gcg gtt gct ggc gcc tat atc gcc gac atc acc gat ggg gaa gat cgg gct cgc cac ttc ggg ctc atg agc gct  
  T     G     A    V     A     G     A    Y     I      A     D     I      T      D    G      E      D     R     A     R     H     F     G     L    M    S       A 
tgt ttc ggc gtg ggt atg gtg gca ggc ccc gtg gcc ggg gga ctg ttg ggc gcc atc tcc ttg cat gca cca ttc ctt gcg  
 C    F     G     V     G     M    V    A      G      P      V    A     G      G     L     L     G      A    I       S    L    H     A     P     F    L    A 
gcg gcg gtg ctc aac ggc ctc aac cta cta ctg ggc tgc ttc cta atg cag gag tcg cat aag gga gag cgt cga ccg atg  
  A      A     V    L      N     G     L     N     L    L     L     G      C    F    L     M    Q     E      S     H     K      G     E     R      R     P     M 
ccc ttg aga gcc ttc aac cca gtc agc tcc ttc cgg tgg gcg cgg ggc atg act atc gtc gcc gca ctt atg act gtc ttc ttt  
  P     L     R     A     F    N      P     V     S     S     F     R     W    A      R      G     M    T     I      V    A      A    L    M    T     V    F    F 
atc atg caa ctc gta gga cag gtg ccg gca gcg ctc tgg gtc att ttc ggc gag gac cgc ttt cgc tgg agc gcg acg atg  
  I     M     Q    L     V     G     Q     V     P      A      A     L     W    V    I     F    G      E      D     R     F    R     W     S     A      T     M 
atc ggc ctg tcg ctt gcg gta ttc gga atc ttg cac gcc ctc gct caa gcc ttc gtc act ggt ccc gcc acc aaa cgt ttc  
  I      G     L     S     L    A      V    F    G      I     L     H     A     L     A    Q     A     F     V    T     G    P       A     T     K     R     F 
ggc gag aag cag gcc att atc gcc ggc atg gcg gcc gac gcg ctg ggc tac gtc ttg ctg gcg ttc gcg acg cga ggc  
  G      E      K     Q     A     I     I      A      G    M     A     A      D     A     L      G     Y    V    L     L     A     F     A     T      R      G 
tgg atg gcc ttc ccc att atg att ctt ctc gct tcc ggc ggc atc ggg atg ccc gcg ttg cag gcc atg ctg tcc agg cag  
 W    M    A     F     P     I     M    I     L    L     A    S     G      G     I      G     M     P     A     L     Q      A    M    L     S     R      Q 
gta gat gac gac cat cag gga cag ctt caa gga tcg ctc gcg gct ctt acc agc cta act tcg atc act gga ccg ctg atc  
  V    D     D     D     H    Q      G     Q     L     Q     G     S     L      A     A    L    T     S      L     T     S    I       T     G     P     L      I 
gtc acg gcg att tat gcc gcc tcg gcg agc aca tgg aac ggg ttg gca tgg att gta ggc gcc gcc cta tac ctt gtc tgc  
  V    T      A     I     Y    A      A    S      A     S      T      W    N     G     L     A     W    I     V     G     A      A    L     Y    L    V    C 
ctc ccc gcg ttg cgt cgc ggt gca tgg agc cgg gcc acc tcg acc tga atg gaa gcc ggc ggc acc tcg cta acg gat  
  L     P     A     L     R     R     G     A    W     S      R      A     T      S     T      •    M     E      A     G     G      T     S     L     T      D   
 
                                                                                     
 
tca cca ctc caa gaa ttg gag cca atc aat tct tgc gga gaa ctg tga atg cgc aaa cca acc ctt ggc aga aca tat cca  
 S      P     L     Q     E     L     E      P      I     N    S    C     G      E      L     •     M    R      K      P 
 
 
 
 
*F. primer: aat c/ca tgg ttc tca tgt ttg aca gct tat cat cg 
 
 
*R. primer: acg c/ca tgg ttt gcg cat tca cag ttc tcc gc 
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During a ligation reaction with PCR-amplified DNA and a plasmid which carries identical 
termini (e.g. NcoI sites), the capacity to circularize and to form tandem oligomers can be 
avoided by removing the 5’-phosphate groups of the plasmid with alkaline phosphatase 
and by adjusting the concentrations of the two types of DNA in the ligation reaction to 
optimize the number of correct ligation products. The 1.3 kbp band (Fig. 3.20) in lane 1 
shows the purified PCR product of pBR322 using tetracycline primers (TCF1 and TCR1) 
then subjected to NcoI restriction enzyme digestion. Two bands of 1.3 and 12 Kbp in lanes 
2 and 3 are the kanamycin resistance cassette and suicide plasmid, pSS1129, disrupted 
with bapC fragment after digestion of plasmid P-B-5 with NcoI restriction enzyme and 
treatment with alkaline phosphatase, respectively.        
 
Figure 3.20 Agarose gel (0.7%) showing amplified TetR gene and products 
of plasmid P-B-5 after digestion with NcoI ± alkaline phosphatase. 
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The TetR cassette was purified from pGEMT(Tet) after cutting the plasmid with NcoI and 
inserted at the NcoI restriction site of bapC (Appendix II.3) already cloned into the suicide 
vector, leaving enough bapC flanking regions for homologous recombination to take place 
for the construction of the B. pertussis bapC mutant strains. The ligation of the tetracycline 
cassette flanking NcoI restriction sites into the suicide vector carrying disrupted bapC was 
achieved after many attempts (Fig. 3.21), and the plasmid construct was then transferred by 
electroporation or heat shock into an E. coli host strain, JM109, and into an E. coli 
mobilising strain SM10.λPIR.. Fig. 3.21 shows a 1.3 kbp band by colony PCR using 
tetracycline primers (TCF1 and TCR1) of a selected colony, from many colonies screened, 
after successful ligation, electroporation and transformation.  
The constructed plasmid was then isolated from the E. coli host (JM109) and mobilising 
(SM10.λPIR) strains. When the plasmid pBapC-Tet (bapC::tet), carrying the bapC gene 
disrupted by the tetracycline resistance cassette, was isolated from E. coli JM109 and 
SM10.λPIR and digested with NcoI, the expected two bands of 12 kbp (pSS1129 + bapC 
fragment) and 1.3 kbp (tetracycline resistance cassette) were obtained (Fig. 3.22 and 
3.24A). When the plasmid pBapC-Tet (bapC::tet) obtained from these E. coli strains was 
subjected to BglII restriction enzyme, the expected two bands of 9.8 kbp, the linearised 
suicide plasmid pSS1129, and 3.5 kbp, the bapC fragment disrupted with tetracycline 
resistance cassette were released (Results not shown).  
To further confirm the successful ligation of the mutated bapC in the suicide vector, the 
isolated plasmids were then targeted by PCR reactions using bapC primers and Tet 
primers. Bands of 3.5 kbp (bapC fragment + tetracycline resistance cassette) and 1.3 kbp 
were obtained from the plasmid pBapC-Tet (bapC::tet) of E. coli strains, JM109 and 
SM10λ.PIR, using BapC primers (BAP5F, BAP5R) and Tet primers (TCF1, TCR1), 
respectively (Figs, 3.23A & B and 3.24B).  
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Figure 3.21 Agarose gel (0.7%) showing PCR product, using primers TCF1 
and TCR1, of a selected colony of E. coli containing plasmid with the bapC 
gene disrupted by TetR cassette 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 Agarose gel (0.7%) showing plasmid pBapC-Tet (bapC::tet) 
from E. coli strain JM109 digested with NcoI 
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Figure 3.23 Agarose gel (0.7%) showing the amplified bapC gene of pBapC-
Tet plasmid from E. coli strain JM109 (Fig. A), and Nested PCR of amplified 
bapC gene using tetracycline primers (Fig. B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.24 Agarose gel (0.7%) showing plasmid pBapC-Tet (bapC::tetr) 
from E. coli strain SM10λ.pir digested with NcoI (A) and PCR product of 
amplified bapC gene disrupted by tetracycline resistance cassette (B). 
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3.14.2 Creation of spontaneous SmR derivative of B. pertussis 
BP338 and brkA mutant 
Spontaneous streptomycin resistant derivatives of BP338 and BP338 (BrkA-) (BP2041) 
were constructed for use in allelic exchange experiments with the suicide vector pSS1129 
carrying bapC disrupted with tetracycline cassette (pBapC-Tet) by the procedure described 
in section 2.7. 10 ml volumes of mid-log phase cultures of BP338 and BP2041 were 
centrifuged and resuspended in 0.1-0.2 ml of fresh SS medium. SmR derivatives of BP338 
and BP2041 strains were selected by plating 100-µl aliquots onto BG agar plates 
containing 100 µg of streptomycin per ml. SmR colonies of each strain were selected for 
further studies and were named BP338S and BP2041S. With the exception of SmR, 
BP338S and BP2041S exhibited the same antibiotic susceptibility profiles as BP338 and 
BP2041, respectively, which strongly suggested that SmR was due to an rpsL mutation.  
The outer-membrane protein profile of BP2041S (Fig. 3.26) was to some extent different 
from BP2041, but a band (at ~73-kDa) in the wild-type strain BP338, which presumably 
represents the BrkA protein was absent in both BP2041 and BP2041S. PCR reaction (Fig. 
3.25) for the presence of the bapC gene using bapC primers (BAP5F, BAP5R), showed a 
2.2 kbp band, as expected. 
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Figure 3.25 Agarose gel (0.7%) showing PCR product of streptomycin 
resistant derivative of B. pertussis brkA mutant (BP2041S) using bapC 
primers. 
 
 
 
 
 
 
 
 
Figure 3.26 Outer-membrane protein profiles of B. pertussis strains 
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3.14.3 Conjugation to introduce the constructed plasmid into B. 
pertussis strains 
Conjugation between the E. coli mobilising strain SM10.λPIR carrying plasmid pBapC-Tet 
(bapC::tetr) and B. pertussis strains (BP338S and BP2041S) was performed according to 
the procedure given in section 2.7. The exconjugants of BP338S and SM10.λPIR carrying 
plasmid pBapC-Tet (bapC::tet) were selected by plating onto BG agar containing Nal (40 
µg/ml), Tet (2-10 µg/ml) and cephalexin (40 µg/ml) (Fig. 2.1), whereas the exconjugants 
of BP2041S and SM10.λPIR carrying plasmid pBapC-Tet (bapC::tet) were selected by 
plating onto Km (40 µg/ml), Nal (40 µg/ml), Tet (2-10 µg/ml) and cephalexin (40 µg/ml). 
As B. pertussis strains are inherently resistant to cephalexin, it was added to the plates to 
further improve the selection against the E. coli donor strain. The survivors of the first 
selections (single cross-over) were assumed to be B. pertussis that contained the plasmid 
incorporated into the chromosome. The survivors of this step were then restreaked onto BG 
plates containing Sm (100 µg/ml) to select for loss of the plasmid. The survivors obtained 
were assumed to be the bacteria that had lost the incorporated plasmid encoding sensitivity 
to streptomycin due to the second recombination or a double cross-over event, due to 
homologous recombination between the region of bapC present in the plasmid and in the 
host chromosome.  
The loss of the integrated plasmid was then confirmed by growing the survivors on BG 
agar containing ampicillin, a marker in the suicide vector. Those colonies that were 
sensitive to ampicillin were assumed to be the designed bapC mutant and brkA, bapC 
double mutant. At the end of these manipulations, two crossovers had occurred between 
the plasmid-encoded and chromosomal copies of the gene in question. The molecular 
mechanism of gene replacement in this procedure is summarised in Fig. 3.27. 
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Figure 3.27 Strategy adopted for replacement of bapC gene with bapC with 
inserted tetracycline resistance cassette 
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PCR was carried out on DNA extracted from selected colonies from the final selection to 
confirm that the wild-type bapC gene in the B. pertussis strains had been successfully 
replaced by the mutated bapC gene in the plasmid.  PCR was performed using the bapC 
specific primers, bapC forward and bapC reverse (BAP5F, BAP5R) (Table 2.5), which 
covers most of the length of the bapC gene. The PCR results (Fig. 3.28 & 3.29) using 
genomic DNA extracted (section 2.2.1) from B. pertussis 338S and its bapC defective 
mutant, as well as B. pertussis BP2041S and its bapC mutant, clearly showed that 
bapC::tet of expected size was present in the chromosome of the B. pertussis mutant 
strains. Lanes 1 and 2 in Fig. 3.29 show the PCR products (2.2 kbp) from the parent B. 
pertussis strains BP338S and BP2041S and lanes 1 and 2 in Fig. 3.28A show the PCR 
products (3.5 kbp) from the B. pertussis strains with the mutated bapC gene, BP338 
(BapC-) and BP338 (BrkA-, BapC-). In the selected clones, there was no evidence of a 2.2 
kbp band, representing the native bapC gene, from the PCR reactions of the mutated 
chromosomal DNA. Thus, it was concluded that cross-overs had occurred on each side of 
the site of TetR cassette insertion and the wild type bapC allele in the B. pertussis 
chromosome had been completely replaced. If such a double cross-over had not occurred, 
as shown by the example in Fig. 3.30, there would have been two PCR products obtained 
from the B. pertussis strain in terms of both the wild type allele bapC (2.2 kbp) and the 
mutated allele bapC::tet (3.5 kbp). 
Further confirmation of the successful constructs was performed using the amplified bapC 
fragment product, after gel extraction, as a template for nested PCR to amplify the 
tetracycline resistance cassette using Tet primers (TCF1, TCR1). A band of 1.3 kbp, 
corresponding to the TetR cassette, was observed in the bapC gene of the BP338 (BapC-) 
and BP338 (BrkA-, BapC-) (Fig. 3.28B), further confirming the presence of tetracycline 
resistance cassette in bapC.  
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Figure 3.28 Amplified bapC gene of BP338 (BapC-) and BP338 (BrkA-, 
BapC-) mutant strains disrupted by tetracycline cassette (Fig. A) and 
tetracycline gene inserted in bapC gene amplified by nested PCR (Fig. B). 
 
     
 
 
 
Figure 3.29 Amplified bapC gene of BP338S and BP2041S strains using 
bapC primers 
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Figure 3.30 Amplified bapC gene in a selected colony showing a non-
double chromosomal cross-over 
              
 
 
                                                        
 
 
 
 
Figure 3.31 5’-terminus (B) and 3’-terminus (A) amplification of the mutated 
bapC gene in constructed mutants using bapC forward and Tet reverse 
primers (B); and Tet forward and bapC reverse primers (A), respectively. 
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Another attempt to confirm the successful constructions was performed by PCR to amplify 
the 5’-terminus of the mutated bapC gene using bapC forward primer (BAP5F) and Tet 
reverse (TCR1) (Fig. 3.31B) and 3’-terminus of mutated bapC gene using Tet forward 
(TCF1) and bapC reverse (BAP5R) (Fig. 3.31A), respectively. Amplimers of the expected 
sizes were obtained. 
Further confirmation of the successful construction of the bapC mutants was achieved 
using the Southern blotting procedure. Genomic DNA from the parent and bapC mutant 
strains was digested with restriction enzyme XhoI (Fig. 3.32). This enzyme has no 
restriction sites in bapC or in the TetR locus. The rational for performing this southern 
blotting was to probe the digested DNA with a Dig-labelled bapC-specific probe, which 
would confirm the different size of XhoI fragments between the parent and mutant strains. 
Southern blot analysis showed that the specific Dig-labelled bapC probe hybridised to an 
approximately 7.7 kbp fragment in both parent DNA preparations, BP338S and BP2041S, 
whereas it hybridised to an approximately 9 kbp fragment in both mutant strains, BP338 
(BapC-) and BP338 (BrkA-, BapC-). Lanes 3 and 4 in Fig. 3.33 represent the XhoI digested 
genomic DNA from the B. pertussis 338S and BP2041S strains, respectively, probed with 
Dig-labelled bapC gene. Lanes 1 and 2 represent the bapC mutant strains, BP338 (BapC-) 
and BP338 (BrkA-, BapC-), respectively, containing the tetracycline resistance cassette 
insertion into bapC. The difference of 1.3 kbp between the parent strains and the bapC 
mutant strains was expected from the insertion of the ∼ 1.3 kbp tetR cassette. 
Further confirmation to show the presence of the intact brkA gene and the brkA gene 
disrupted by Tn5 transposon insertion, along with the intact bapC and mutated bapC genes 
was performed by multiplex PCR, with strains BP338 and BP338 (BrkA-, BapC-). Intact 
brkA and bapC genes were amplified in BP338 wild type using BrkA and BapC primers 
(Table 2.5), which amplified 1538 and 2233 bp fragments of the brkA and bapC genes, 
respectively (Fig. 3.34). Many unsuccessful attempts were performed using sets of brkA 
  Results 
 
156 
forward primers and Tn5 reverse primers or Tn5 forward primers with brkA reverse 
primers (Table 2.5) to show the mutated brkA gene. Only non-specific bands were 
amplified, even using different magnesium chloride concentrations and different PCR 
parameters as in gradient PCR. The use of BrkA primers to show Tn5 insertion was 
considered inappropriate as the size of Tn5 is 5.8 kbp.  
Further confirmation of the mutated BrkA with the Tn5 transposon inserted, into position 
3232, was therefore done using the Southern blotting procedure. Genomic DNA from the 
parent, BP2041S, and its bapC mutant strain, BP338 (BrkA-, BapC-), were digested with 
restriction enzymes ClaI, EcoRI and EcoRV (Fig. 3.35). These enzymes have unique 
restriction sites in brkA and no site in transposon Tn5. The rationale for performing this 
was that, on probing the digested DNA with a Dig-labelled brkA specific probe, a predicted 
different band size would be detected between the parent and mutant strains. Southern blot 
analysis showed that the Dig-labelled brkA probe hybridised similarly to BP2041S and its 
bapC mutant BP338 (BrkA-, BapC-), using ClaI, EcoRI and EcoRV restriction enzymes 
(Fig. 3.36). The size differences between the parent strains and the brkA mutant strains, 
BP2041S and BP338 (BrkA-, BapC-), were as expected from the insertion of the Tn5 
transposon. No differences were seen between BP2041S and BP338 (BrkA-, BapC-), as 
expected.    
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Figure 3.32 Digestion of genomic DNA of B. pertussis strains with XhoI 
enzyme 
 
Chromosomal DNA was extracted by the procedure described in section 2.2.1, then 
subjected to restriction digestion with XhoI, which does not cut either the bapC gene or the 
tetracycline resistance cassette, and the fragments were separated on a 0.7% agarose gel. 
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Figure 3.33 Southern blotting of digested genomic DNA of B. pertussis 
strains with a bapC-specific probe 
 
Chromosomal DNA was digested and separated as in Fig. 3.32 and then transferred to a 
nylon membrane and probed with a Dig-labelled bapC gene fragment prepared as 
described in section 2.10.1. All four samples were run on the same gel and probed on the 
same membrane. The image is a composite to represent spatially disparate bands.  
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Figure 3.34 Agarose gel 0.7% showing amplified wild-type bapC and brkA 
genes by multiplex PCR using bapC and brkA primers. 
 
 
Chromosomal DNA was extracted by the procedure described in section 2.2.1, and then 
subjected to multiplex PCR with bapC and brkA primers, which amplify 2.2 kbp and 1.5 
kbp fragments, respectively.   
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Figure 3.35 DNA genomic digestion of B. pertussis strains with ClaI, EcoRI 
and EcoRV enzymes 
 
Chromosomal DNA was extracted by the procedure described in section 2.2.1, and then 
subjected to restriction digestion with ClaI, EcoRI and EcoRV enzymes which cut the brkA 
gene at unique sites but do not cut the Tn5 gene. Fragments were separated on a 0.7% 
agarose gel. 
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Figure 3.36 Southern blotting of digested genomic DNA of B. pertussis 
strains with a brkA-specific probe 
 
Chromosomal DNA was digested and separated as in Fig. 3.35 and then transferred to a 
nylon membrane and probed with a Dig-labelled brkA gene fragment prepared as described 
in section 2.10.1.                    
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3.15 Determining the serum sensitivity of the bapC and 
brkA, bapC mutants 
The rationale for creating the new mutants and for performing serum killing assays was to 
determine the relative contributions of the BapC and BrkA proteins to the serum resistance 
phenotype of B. pertussis. As in earlier serum killing assays (section 3.6) the assays were 
performed using human pooled sera (section 2.12.3.1) collected from adult volunteers who 
had no history of recent pertussis. Heat inactivation, when appropriate, was carried out at 
56°C for 30 min. To compare the number of survivors from a PBS control and the heat-
inactivated serum as a second control (non-killing control), a preliminary test was 
performed. There was no significant killing, and no significant difference (P > 0.05) 
between these two controls in a time-course study over 120 min (data not shown). This 
revealed that any agglutination by antibodies present in the human sera did not 
significantly affect the bacterial counts.  
The standard incubation time for the serum killing assays (usually 45’) had been suggested 
by time-course studies on killing of B. pertussis strains with the human serum by Barnes 
and Weiss (2001) and Bokhari (2002). The survival of the bacteria was calculated relative 
to a non-killing heat-inactivated serum or PBS (without added serum) control. The percent 
survival was reported as: {the number of bacteria exposed to normal serum}/{the number 
of bacteria in heat-inactivated serum (or media lacking serum such as PBS)}×100. At least 
three separate experiments were performed for each comparison of wild-type and mutants, 
and data were analysed by Student’s t-test. P values <0.05 were assumed to be significant.  
Time-course experiments indicated that, after exposure to 1/40 (Fig. 3.37) and 1/80 (Fig. 
3.38) dilutions of the pooled human serum (more potent batch than used previously) for 15, 
30 and 45 min, B. pertussis BP338 strain survived much better compared with its BapC 
and BrkA mutants or BP Taberman (BapC-) mutant. Even after longer exposure to normal 
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human serum, up to 120 min, in 1/40 and 1/80 human serum dilutions, BP338 was still a 
better survivor compared to its BrkA or BapC mutants (data not shown). As shown in Figs 
3.37 and 3.38 the double mutant was more serum sensitive than either the BrkA or BapC 
single mutants, but it was not as sensitive as the Bvg- strain (BP347). This finding suggests 
that other bvg-regulated factors might confer or be involved in serum resistance.  
The serum killing assays of B. pertussis strains in modulating (40 mM magnesium 
sulphate) and non-modulating conditions (Figs 3.39 & 3.40) also showed that B. pertussis 
BP338 strain appeared to be more resistant to serum killing compared to all other strains at 
1/40 serum dilution, as other strains were killed within 15’ so there was no discrimination 
between the serum sensitivity of these strains. Survival of B. pertussis BP338 and its BrkA 
and BapC mutants, grown under modulating conditions, was significantly reduced when 
exposed to normal human serum compared to that of its counterpart grown under non-
modulating conditions. 
With 1/80 dilution of normal human serum (NHS), there was greater discrimination 
between the strains and a clearer picture. BP338 was much more serum resistant than the 
double mutant, as shown previously (Fig. 3.40), but BP338 and BP338 (BrkA-, BapC-) 
strains had similar sensitivities when grown in modulating conditions. Moreover, BP347 
(Bvg-) showed similar sensitivity whether grown in modulating or non-modulating 
conditions and was greater than the other strains, even in modulating conditions (Fig. 
3.40).      
Overall, these data indicated that, in addition to the known role of BrkA in serum 
resistance, BapC also seems to play a role in conferring resistance on B. pertussis against 
complement killing. A comparison of the double mutant and strains grown in modulating 
conditions, and with BP347, strongly suggested that other bvg- regulated factors may be 
involved in serum resistance.  
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Figure 3.37 Comparison of serum killing of B. pertussis strains (1/40 
human serum) 
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Figure 3.38 Comparison of serum killing of B. pertussis strains (1/80 
human serum) 
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Figure 3.39 Comparison of serum killing of B. pertussis strains grown in 
modulating and non-modulating conditions (1/40 human serum) 
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 Figure 3.40 Comparison of serum killing of B. pertussis strains grown in 
modulating and non-modulating conditions (1/80 human serum) 
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3.16 Susceptibility of B. pertussis strains to antimicrobial 
peptides 
Antimicrobial peptides are used as effector molecules of the innate immune system. 
Different groups of antimicrobial peptides are defined, based on structural characteristics. 
Small cationic peptides with broad-spectrum antimicrobial activity are produced by a wide 
variety of plants and animals and represent a non-specific arm of the immune systems of 
these organisms. Antimicrobial peptides are believed to kill bacteria by damaging the 
cytoplasmic membrane by a mechanism that does not appear to involve interaction of the 
peptide with discrete protein targets. 
In general, antimicrobial peptides are about 12-50 amino acids in size and are 
predominantly cationic in terms of their net charge. These peptides include two or more 
positively charged residues provided by arginine, lysine or, in acidic environments, 
histidine, and a large proportion (generally > 50%) of hydrophobic residues. They exist in 
four secondary structures, including i) alpha helices (e.g. cecropins) ii) antiparallel beta 
sheets (e.g. defensins) due to the presence of 2 or more disulphide bonds iii) beta hairpin or 
loop due to the presence of a single disulphide bond/or cyclization of the peptide chain, 
and iv) extended. In Gram-negative bacteria, the interaction of these cationic peptides with 
the negatively-charged lipopolysaccharide-lipid A perturbs the outer membrane. However, 
the cytoplasmic membrane is the lethal target for antimicrobial peptides, where they can 
make channels which subsequently results in the disruption of the membrane, which leads 
to cell death.  
It has been shown that the lysis of Gram-negative bacteria by complement is due to the 
insertion of the C9 component of the membrane attack complex into the cytoplasmic 
membrane, which is analogous to the mechanism of killing by antimicrobial peptides in 
that lysis is also dependent on insertion of the peptide into the cytoplasmic membrane. 
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Fernandez and Weiss (1996) had shown the BrkA, in addition to conferring resistance to 
serum killing, also conferred resistance to certain antimicrobial peptides such as cecropin 
P1. Thus, it was decided to examine and compare the susceptibility of the BapC and BrkA 
mutants to killing by antimicrobial peptides. 
The susceptibility of B. pertussis strains to various commercially-available antimicrobial 
peptides was assessed by a modification of the radial diffusion assay described by Lehrer 
et al. (1991). In addition, the concentration of peptide required to kill or inhibit the growth 
of 50% of the organisms (C-50%) was determined for each peptide in a microtiter plate 
method and adjusted according to the purity of the peptide stated by the manufacturer. 
Initially the susceptibility of B. pertussis BP338 strain to the different antimicrobial 
peptides was investigated and varied with the type of peptide. In order of decreasing 
potency, the C-50% of the peptides was ranked as follow: cecropin P1 > mastoparan > 
protamine. The susceptibility of the different B. pertussis strains, wild type and mutants, to 
inhibition by antimicrobial peptides was next determined by the radial diffusion assay to 
find out whether there were any differences in susceptibility. 
Exposure of B. pertussis strains to the three different antimicrobial peptides resulted in 
three types of responses. Compared with the wild type strains, the BrkA- strain and the two 
BapC- strains were more susceptible to inhibition by cecropin P1 and the BP338 (BrkA-, 
BapC-) double mutant was even more sensitive (Fig. 3.41). The susceptibility of avirulent 
strain BP347 (Bvg-) was marginally more than that of the BP338 (BrkA-, BapC-) double 
mutant, but it was not statistically significant (p>0.05). These findings may suggest that 
bvg-activated factors in addition to BrkA and BapC can mediate some resistance to killing 
by this peptide. Thus, the sensitivity of B. pertussis strains to antimicrobial peptide 
cecropin P1 was in the order:  
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Figure 3.41 Susceptibility of B. pertussis strains to the antimicrobial 
peptide Cecropin P1 (0.25 µM) 
 
The susceptibility of B. pertussis strains was compared by using a radial diffusion assay. 
Each bar represents the mean and standard deviation of five separate experiments.  
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Figure 3.42 Susceptibility of B. pertussis strains to the antimicrobial 
peptide Protamine (2.4 µM) 
 
The susceptibility of B. pertussis strains was compared by using a radial diffusion assay. 
Each bar represents the mean and standard deviation of five separate experiments.  
 
 
 
 
 
 
 
0
5
10
15
20
25
30
BP338 (BrkA-,
BapC-)  
BP338 (BapC-) BP338 (BrkA-) BP338 (W/T) BP Taberman
(W/T)
BP Taberman
(BapC-)
BP347 (Bvg-)
B. pertussis  strains
Zo
n
e 
Si
ze
 
(m
m
)
  Results 
 
170 
Figure 3.43 Susceptibility of B. pertussis strains to the antimicrobial 
peptide Mastoparan (0.48 µM) 
 
The susceptibility of B. pertussis strains was compared by using a radial diffusion assay. 
Each bar represents the mean and standard deviation of five separate experiments.  
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BP347 (Bvg-) > BP338 (BrkA-, BapC-) > BP338 (BapC-) = BP338 (BrkA-) > BP338 = BP 
Taberman 
In contrast, the bvg mutant strain BP347 was most resistant to inhibition by protamine and 
the two wild-type strains were most sensitive (Fig. 3.42). The sensitivity of the different B. 
pertussis strains to protamine was in the order:  
BP Taberman > BP338 > BP338 (BapC-) = BP338 (BrkA-) > BP338 (BrkA-, BapC-) = BP 
Taberman (BapC-) > BP347 (Bvg-)  
Finally, both BP338 and BP347 were equally susceptible to inhibition by mastoparan (Fig. 
3.43). However, the susceptibility of BP338 (BapC-) and BP338 (BrkA-, BapC-) was 
marginally more than wild-type strains to this antimicrobial peptide, but it was not 
statistically significant (p<0.05). Overall, the sensitivity of B. pertussis strains to the 
antimicrobial peptide mastoparan was in the order:  
BP338 (BrkA-, BapC-) = BP338 (BapC-) > BP338 (BrkA-) = BP Taberman (BapC-) > BP 
Taberman = BP347 (Bvg-)  
It can be concluded that BrkA and BapC can both mediate resistance to inhibition by the 
antimicrobial peptide cecropin P1 as well as resistance to killing by complement. It is also 
evident from Fig. 3.41 that, in addition to brkA and bapC, there could be other bvg-
activated genes in the wild-type strain that participate in the resistance to killing by 
cecropin P1, since BP347 is more susceptible than the brkA, bapC single or double mutants 
to cecropin P1.  
In summary, B. pertussis strains exhibited a broad range of susceptibility to different kinds 
of antimicrobial peptides. For one of these peptides, cecropin P1, expression of BrkA and 
BapC appeared to confer resistance to inhibition, whereas for protamine, expression of 
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these factors appeared to confer greater susceptibility. However, it would be of greater 
interest to examine the susceptibility of the B. pertussis to those peptides that are naturally 
present in the human lungs or trachea, which is the colonisation site by B. pertussis, but 
commercial products were not available at the time of experiment.                                  
3.17 Effect of BapC protein on virulence of B. pertussis  
    There are several autotransporter proteins in B. pertussis which are thaught to play 
important roles in the pathogenesis of pertussis. The interaction of B. pertussis with 
ciliated epithelial cells in the respiratory tract is thought to be mediated in part by adhesion 
proteins such as, pertactin, BrkA and tracheal colonisation factor. It was, therefore, of 
interest to determine the potential role of BapC autotransporter protein in virulence of B. 
pertussis in a mouse model of infection since BapC revealed some structural homology to 
the other, better-characterised autotransporters. 
To investigate and quantify the degree of virulence attenuation of individual strains, 
competition assays were performed. In brief, pairs of strains to be compared e.g. wild-type 
and mutant strains were mixed at a ratio of 1:1, and then inoculated intranasally into 
randomised groups of five mice. After 7 days, lung counts were done and the output of 
strain 1 (e.g. mutant strain) CFU compared to the strain 2 (e.g. wild-type strain) CFU was 
determined by selection on appropriate antibiotics plates. If the ratio of mutant to wild type 
was the same as in the infecting dose, the mutation had no detectable effect on virulence, 
but if the wild type out-competed the mutant, the mutation obviously had a negative effect. 
Comparison of two strains in the same individual mouse helps reduce inter-mouse 
variation, which may mask small differences in virulence between the two strains.  
In preliminary tests, these 1:1 mixtures were simply plated onto BG agar containing 12% 
horse blood with appropriate antibiotics to show that the selective media could allow 
selection and enumeration of each strain and that one organism did not affect the growth of 
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the other in vitro. Results are shown in Fig. 3.44 and confirmed that the selection was 
suitable e.g. that BP338 (BapC-) grew equally well on BG agar containing streptomycin as 
on BG agar and that the count (of BP338 (BapC-)) from the 1:1 mixture with the parent 
strain when plated on BG agar with streptomycin was exactly half that on BG agar. When 
grown competitively in vitro (BG agar with appropriate antibiotics) no defect was observed 
for the mutant strains during 3 days of culture, showing that the brkA and bapC mutant 
strains do not have an inherent growth defect, at least in these growth media (Fig. 3.44). 
The randomised groups of 5 mice were inoculated intranasally with approximately 1×105 
colony forming units/mouse of each strain to be compared, i.e. 2×105 CFU/mouse in total 
(section 2.13.1). The standard mouse virulent strain B. pertussis 18-323 was used as a 
positive control in all experiments. The mice were weighed at regular intervals and 
sacrificed on day 7. The lungs were then removed aseptically into sterile universal bottles, 
weighed and then homogenised in CAA solution and plated onto appropriate selective 
agar, as above. The number of colony forming units (CFU) of each B. pertussis strain 
recovered from the lungs of each mouse were tabulated and competitive indices (CI) 
calculated. Data were analyzed for statistical significance by using the Student t-test or the 
nonparametric Mann-Whitney test. Statistical significance was defined as P < 0.05. 
Mouse virulence tests were performed in two separate experiments. In the first experiment, 
three groups of mice were used and intranasally instilled with either: B. pertussis strains 
BP338 and BP338 (BapC-); BP338 and BP338 (BrkA-, BapC-) and a control group with B. 
pertussis 18-323, a standard mouse virulent strain, alone. In the second experiment, five 
groups of mice were used and intranasally instilled with either: B. pertussis strains BP338 
and BP338 (BrkA-); BP338 (BapC-) and BP338 (BrkA-, BapC-); BP338 (BapC-) and 
BP347 (Bvg-); BP338 (BapC-) and BP338 (BrkA-) and control group with strain 18-323. 
  Results 
 
174 
When bacterial counts in the lungs were assessed at 7 days post-infection, there were 
significant differences between the numbers of bacteria recovered, depending on the 
mixtures used (Fig. 3.45). The ratio of two strains recovered after infection (corrected for 
the input ratio) was used to determine whether one strain was out-competed by the other 
and was therefore attenuated for survival in the host.  
The in vivo competitive index (CI) was calculated as the reciprocal of (the ratio of strain 1 
to strain 2 recovered from the lungs divided by the ratio of strain 1 to strain 2 inoculated 
into each animal). CI = 1 / (ratio of strain 1 to strain 2 output CFU / ratio of strain 1 to 
strain 2 input CFU) 
Results in Fig. 3.45 show that for example, when BP338 (BapC-) strain was compared with 
BP347 (Bvg-) strain, competitive indices of ~0.2 were obtained from all five mice, 
indicating that far fewer colonies of BP347 were recovered, ∼1/5 the number of those of 
BP338 (BapC-). Thus BP347 is much less able to persist in the mouse lung than the BapC 
mutant (P<0.05). In brief, the in vivo analysis revealed that the Bvg- strain (BP347) was 
the least virulent of the strains. The data also indicated that BP338 was far better in 
colonising the mouse lung than its bapC, brkA single and brkA, bapC double mutants 
(P<0.05). The data also showed however that the double mutant BP338 (BrkA-, BapC-) 
was less virulent than either BapC or BrkA single mutants alone, as revealed by a lower 
survival rate of the double mutant strain from infected mice compared to the single mutants 
(P<0.05), although it was not so low in virulence as BP347 (Bvg-). The recovered lung 
count for B. pertussis 18-323, the standard mouse-virulent B. pertussis strain used for 
vaccine tests, was significantly (P<0.05) higher than for BP338 (data not shown). Overall, 
the mouse virulence of the test strains was in the order as follows: 
BP338 (W/T) > BP338 (BrkA-) > BP338 (BapC-) > BP338 (BrkA-, BapC-) double mutant 
> BP347 (Bvg-)  
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Figure 3.44 Effect of growth of two strains input mixture on BG agar  
B. pertussis strains were grown on BG agar containing appropriate antibiotics for 3 days and then 
lawn culture made for further 24h. The resultant was suspended and adjusted by serial dilution to 
1×103 CFU/ml in 1% CAA, and 0.1 ml of two strains to be compared, were plated in duplicated on 
BG agar plates. Colonies were counted after 3-4 days. The data presented are the means and 
standard deviations.      
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        Fig. 3.44 Continued.  
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For competition experiments, different strains of B. pertussis were mixed in a 1:1 ratio and 3 week old mice were infected 
intranasally. At 7 days, lung counts were used to determine the output of strain 1 CFU compared to the strain 2 CFU by 
selection on appropriate antibiotic plates. In vivo competitive indices (CI) for each mouse were calculated as: 
CI = 1 / (ratio of strain 1 to strain 2 output CFU / ratio of strain 1 to strain 2 input CFU). 
 Figure 3.45 Competition assays of virulence for mice 
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3.18 Identification of the bapC locus in other Bordetella 
species 
To identify the presence of the bapC locus in other Bordetella species, PCR reactions with 
bapC primers were performed initially. Forward and reverse primers (BAP5F, BAP5R), 
which amplify most of the bapC gene in B. pertussis Tohama I, were utilised and PCR was 
performed on chromosomal DNA extracted as described in section 2.2.1. Many attempts 
were carried out to amplify the bapC fragment in other bordetellae using different PCR 
parameters and CaCl2 or Q-solution concentrations. Fig. 3.46 shows that the bapC gene (2.2 
kbp) was amplified in B. pertussis, B. parapertussis and B. bronchiseptica strains only, and 
no evidence was obtained of any bands in B. avium, B. hinzii, B. holmesii or B. trematum 
species.      
Figure 3.46 Agarose gel (0.7%) showing the PCR products of Bordetella 
genomic DNAs using forward and reverse bapC primers 
 
 
          
             
 
 
 
 
 M           -Ve        1               2             3              4            5             6             7 
M = marker                                         4 = B. avium 
-Ve = negative                                      5 = B. hinzii 
1 = B. pertussis BP338                         6 = B. holmesii 
2 = B. parapertussis                             7 = B. trematum 
3 = B. bronchiseptica  
 
PCR was performed on chromosomal DNA extracted as described in section 2.2.1, using 
primers bapC forward and reverse (BAP5F, BAP5R) which amplify most of the bapC gene.  
 2000 bp 
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Another attempt, using the Southern blot method, was performed to detect the bapC locus or 
homologous sequences in other Bordetella species. An amplified digoxigenin-labelled probe 
of the bapC gene (section 2.10.1) was used. Southern blots containing NdeI, BglII or XhoI-
digested chromosomal DNA from B. pertussis (BP338), B. parapertussis, B. bronchiseptica, 
B. avium, B. hinzii, B. holmesii and B. trematum were probed with a labelled fragment of 
bapC gene. To overcome the low yield of Dig-labeled PCR product and hybridization 
smearing, PCR parameters were optimized after many attempts by adding Q-solution and 
reducing the concentration of DIG-dUTP and template. DIG-dUTP nucleotides in the 
template slow the polymerase and eventually reduce the ability of the polymerase to 
synthesize full length products that consist of primer sequences required for the next 
amplification round.  The optimal amount of template used was 10 ng genomic DNA and for 
the probe 0.5 µl of labelled PCR product was used per ml hybridization buffer. High 
background was the other problem that was overcome, to some extent, by preheating the 
wash buffers, reducing the probe concentration and using high stringency buffer.  
Bordetella genomic DNAs were digested with NdeI, BglII or XhoI and analysed by agarose 
gel electrophoresis (Figs. 3.47A, B and C). Figures 3.48A, B and C show the result of 
Southern blotting analysis of the DNA with the bapC probe. Strong bands were observed in 
lanes 1, 2 and 3 which imply hybridisation to the genomes of B. pertussis, B. pertussis and 
B. parapertussis. No evidence of the bapC locus or true orthologues was found in any of the 
other Bordetella species.  
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Figure 3.47 Bordetella genomic DNAs digested with XhoI (a), BglII (b) and 
NdeI (c) enzymes and analysed by gel electrophoresis (0.7% agarose) 
 
                     
                                                                                  
 
    7     6     5      4    3     2     1    M   M    1    2     3     4     5     6     7 
  B:   A: 
C: 
   M     1       2      3      4     5       6      7 
M = marker 
1 = B. pertussis BP338 
2 = B. parapertussis 
3 = B. bronchiseptica 
4 = B. avium 
5 = B. hinzii  
6 = B. holmesii 
7 = B. trematum  
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Figure 3.48 Southern blot analysis of Bordetella genomic DNAs, digested 
with XhoI (A), BglII (B), and NdeI (C), with bapC probe 
 
Chromosomal DNAs were isolated, digested with NdeI, BglII and XhoI and separated on a 
0.7% agarose gel. A blot was probed with labelled DNA from the bapC locus. DNA markers 
(in base pairs) are indicated on the gel. All samples were run on the same gel and probed on 
the same membrane. The image is a composite to represent spatially disparate bands. 
                   
                   
 
                                                                                          
       
                           
                 
 
 
     M             1             2             3             4            5              6          7 
     M             1           2             3             4            5             6             7 
   M               1             2               3              4            5             6            7 
6557 bp 
A: 
B: 
M = Marker                                                 4 = B. avium 
1 = B. pertussis                                             5 = B. hinzii 
2 = B. parapertussis                                      6 = B. holmesii 
3 = B. bronchiseptica                                   7 = B. trematum 
C: 
6557 bp 
  6557 bp 
4361 bp 
4361 bp 
  4361 bp 
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3.19 Prediction of a signal sequence in the BapC protein 
of Bordetella species 
 
    Bioinformatics is concerned with the computational prediction of structural and functional 
properties of genes and the proteins they encode, based on their nucleotide and amino acid 
sequences. Since one of the crucial properties of a protein is its subcellular location, 
prediction of protein sorting is an important question in bioinformatics. A fundamental 
distinction in protein sorting is that between secretory and non-secretory proteins, 
determined by a cleavable N-terminal sorting signal, the secretory signal peptide.  
SignalP is the most popular software for prediction of classically-secreted proteins. In 
version 3, correctness of the cleavage site predictions have increased notably for all three 
organism groups, eukaryotes, Gram-negative and Gram-positive bacteria. SignalP consists 
of two different predictors based on neural network and hidden Markov model algorithms. 
The signal prediction server has been developed a similar procedure based on pair-wise 
alignments for sequences with functional sites. 
3.19. 1 Description of the scores 
    The graphical output from SignalP (neural network) comprises three different scores, C, S 
and Y. Two additional scores are reported in the SignalP3-NN output, namely the S-mean 
and the D-score.  
For each organism class in SignalP; Eukaryote, Gram-negative and Gram-positive, two 
different neural networks are used, one for predicting the actual signal peptide and one for 
predicting the position of the signal peptidase I (SPase I) cleavage site. The S-score for the 
signal peptide prediction is reported for every single amino acid position in the submitted 
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sequence, with high scores indicating that the corresponding amino acid is part of a signal 
peptide, and low scores indicating that the amino acid is part of a mature protein.  
The C-score is the “cleavage site” score. For each position in the submitted sequence, a C-
score is reported, which should only be significantly high at the cleavage site. Confusion is 
often seen with the position numbering of the cleavage site. When a cleavage site position is 
referred to by a single number, the number indicates the first residue in the mature protein, 
meaning that a reported cleavage site between amino acid 26-27 means that the mature 
protein starts at position 27. Y-max is a derivative of the C-score combined with the S-score 
resulting in a better cleavage site prediction than the raw C-score alone. This is due to the 
fact that multiple high-peaking C-scores can be found in one sequence, where only one is 
the true cleavage site.  
The cleavage site is assigned from the Y-score where the slope of the S-score is steep and a 
significant C-score is found. The S-mean is the average of the S-score, ranging from the N-
terminal amino acid to the amino acid assigned with the highest Y-max score, thus the S-
mean score is calculated for the length of the predicted signal peptide. The S-mean score 
was used in SignalP version 2.0 as the criterion for discrimination of secretory and non-
secretory proteins. The D-score is introduced in SignalP version 3.0 and is a simple average 
of the S-mean and Y-max score. The score shows superior discrimination performance of 
secretory and non-secretory proteins to that of the S-mean score which was used in SignalP 
version 1 and 2. For non-secretory proteins all the scores represented in the SignalP3-NN 
output should ideally be very low. The hidden Markov model calculates the probability of 
whether the submitted sequence contains a signal peptide or not. Furthermore, the cleavage 
site is assigned by a probability score together with scores for the n-region, h-region, and c-
region of the signal peptide, if such one is found. 
  Results               
 
183 
At the start of this project, no signal sequence had been identified for BapC from B. 
pertussis Taberman W/T strain. Available genome sequences and BapC protein sequences 
of B. pertussis Tohama I (locus_tag BP2738), B. parapertussis (locus_tag BPP2591) and B. 
bronchiseptica (locus_tag BB2033) allowed prediction of signal sequences. Analysis of 
BapC protein in B. pertussis (Fig. 3.49), B. parapertussis (Fig. 3.50) and B. bronchiseptica 
(Fig. 3.51) with signalP 3.0 server showed a signal peptide of 24 amino acids by the Neural 
Network prediction method (A) and a maximum cleavage site probability at 38 amino acids 
by the Hidden Markov Model method (B) for B. pertussis (Fig. 3.49), and a signal peptide of 
29 amino acids by the neural Network prediction method and a maximum cleavage site 
probability at 38 amino acids by the hidden Markov Model for both B. parapertussis (Fig. 
3.50) and B. bronchiseptica (Fig. 3.51). 
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Figure 3.49 SignalP-NN result of BapC in Bordetella pertussis 
A: 
 
 
B:  
 
 
 
 
 
 
Measure  Position  Value  Cutoff  signal peptide? 
  max. C    25       0.090   0.52   NO 
  max. Y    25       0.185   0.33   NO 
  max. S    22       0.959   0.92   YES 
  mean S     1-24    0.772   0.49   YES 
       D     1-24    0.478   0.44   YES 
Most likely cleavage site between pos. 24 and 25: AVA-GV 
Prediction: Signal peptide; Signal peptide probability: 0.917 
Max cleavage site probability: 0.844 between pos. 38 and 39 
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Figure 3.50 SignalP-NN result of BapC in Bordetella parapertussis 
A: 
 
 
B:  
 
 
 
 
 
 
 
Measure  Position  Value  Cutoff  signal peptide? 
  max. C    25       0.059   0.52   NO 
  max. Y    30       0.174   0.33   NO 
  max. S    21       0.973   0.92   YES 
  mean S     1-29    0.775   0.49   YES 
       D     1-29    0.475   0.44   YES 
Most likely cleavage site between pos. 29 and 30: AAG-AL 
Prediction: Signal peptide 
Signal peptide probability: 0.897 
Max cleavage site probability: 0.825 between pos. 38 and 39 
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 Figure 3.51 SignalP-NN result of BapC in Bordetella bronchiseptica 
A:  
 
 
B:  
 
 
            
            
            
            
            
    
Measure  Position  Value  Cutoff  signal peptide? 
  max. C    25       0.059   0.52   NO 
 max. Y    30      0.180   0.33   NO 
  max. S    21       0.975   0.92   YES 
  mean S     1-29    0.779   0.49   YES 
       D     1-29    0.479   0.44   YES 
Most likely cleavage site between pos. 29 and 30: AAG-AL 
Prediction: Signal peptide 
Signal peptide probability: 0.833 
Max cleavage site probability: 0.735 between pos. 38 and 39 
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3.20 Cloning and expression of BapC with and without a 
signal sequence  
    It was of interest to investigate the role of the BapC protein, for example in serum 
sensitivity, away from the other autotransporter proteins of B. pertussis by directionally 
ligating the whole bapC gene with and without signal sequence (amino acids 1-38) into an 
expression vector pET33b (+) (Novagen) (Appendix II.2) for high level expression in E. coli 
BL21 (DE3) and BL21 (DE3) pLysS (Table 2.1). The latter was used to reduce basal (leaky) 
expression of their recombinant gene. This would make purified recombinant protein 
available for further study.   
The vector was separately digested with NdeI/BamHI or NheI/BamHI and bands of the 
expected size, 5383 bp, were obtained, shown in Fig. 3.52. For vector preparation, the 
restriction enzyme manufacturer’s recommended buffer and incubation conditions were 
used. In accordance with the manufacturer’s instruction, when using compatible buffers and 
those whose sites are more than 10 bp apart the two enzymes could be used together in the 
same reaction. Unfortunately, after many attempts, these enzymes displayed “star activity” 
or poor cutting. Digestion was therefore performed sequentially; with the first digestion 
using the enzyme that was the poorest cutter and then the second enzyme added after the 
digestion had been verified, by running a sample of the reaction on an agarose gel and gel 
extraction (section 2.3.4). To decrease the non-recombinant background caused by religation 
of the digested vector, which was undetectable by gel analysis, the cut vector was 
dephosphorylated with calf intestinal alkaline phosphatase. Following digestion, the vector 
was gel-purified (section 2.3.4) before insert ligation to remove residual supercoiled 
plasmids in order to reduce the effort required to screen for the correct constructs. 
For amplification of DNA encoding the bapC gene without the signal sequence, an ATG 
start codon was engineered into the 5’ end of the artificial open reading frame, once the NheI 
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restriction had been incorporated into primers, to permit translation (BAPCF25) (Table 2.5). 
Primers were designed according to the bapC sequence of the B. pertussis Tohama genome 
sequence (locus_tag BP2738) and a B. pertussis BP338 genomic DNA was used as template. 
Restriction sites such as NdeI (BAPCF14 and BAPCF24) or BamHI (BAPCR12) were 
incorporated into the primers (Table 2.5) to allow directional cloning into the expression 
vector. High fidelity Pfu DNA polymerase enzyme, a limited number of PCR cycles and 
high concentrations of primers and target DNA were utilised to minimize the potential for 
mutation due to errors generated by the PCR reaction.  
The amplified DNAs encoding the bapC gene with or without signal sequence were 
subjected to restriction digestion with either NdeI/BamHI or NheI/BamHI as appropriate and 
then gel-purified. Figs 3.53a and b show bands of the expected size, 2981 bp and 2870 bp 
for bapC gene with and without signal sequence, respectively. Ligations were performed 
according to section 2.5.2 and products transformed by electroporation into either E. coli 
BL21 (DE3) or BL21 (DE3) pLysS (Table 2.1) competent cells, as appropriate. The 
resultant colonies were screened for the presence of insert of the correct size, either directly 
with colony PCR (Fig. 3.54) (section 2.8.4) or after plasmid extraction and digestion with 
the enzymes used to generate the cohesive ends prior to ligation (Fig. 3.55). Fig. 3.54 shows 
the results obtained from the clones that were selected because they showed the inserts of 
the appropriate size. Lanes 1 and 2 show the expected band of 2981 bp after amplification of 
the bapC gene with signal sequence, and lanes 3 and 4 show the expected size of 2870 bp 
after amplification of the bapC gene without signal sequence. Those containing an insert of 
correct size were subjected to sequencing (section 2.9) and then aligned with the genome 
sequence (data not shown).  
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Figure 3.52 Agarose gel (0.7%) showing purified digested pET33b vector.  
 
 
        
                                                           
  
Figure 3.53 Agarose gel (0.7%) showing digested and purified PCR products 
of bapC gene with signal sequence (a) and digested purified nested gradient 
PCR products of bapC gene without signal sequence (b). 
 
 
 
 
 
                                                              
 
 
 
5383 bp 
  10000 bp 
    8000 bp 
    4000 bp 
  3000 bp 
10000 bp 
  8000 bp 
  1500 bp 
       1            M           2 
  
 2981 bp 
a: b: 
M = marker 
 1 = pET33b vector cut with NheI/BamHI 
 2 = pET33b vector cut with NdeI/BamHI 
 
2870 bp 
4000 bp 
   2500 bp 
   M        1          2     2         1          M 
Restriction digestion of pET33b vector was performed using two sets of enzymes (NheI/BamHI 
or NdeI/BamHI) and then purified. 
M = marker 
 
1 = PCR product digested   with 
NdeI/BamHI 
2 = PCR product digested with 
NheI/BamHI 
 
M = marker 
 
1 = PCR product digested   
with NdeI/BamHI 
2 = PCR product digested 
with NheI/BamHI 
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Figure 3.54 Agarose gel (0.7%) showing PCR products of selected clones 
using bapC primers after plasmid purification 
 
                                
 
 
Figure 3.55 Agarose gel (0.7%) showing purified plasmid from selected 
clones digested with NheI/BamHI and NdeI/BamHI enzymes  
 
                                   
 
 
 
     4             3            M           1             2 
2981 bp 2870 bp 
M = marker 
1 = PCR product using primers BAPCF14, BAPCR12  
2 = PCR product using primers BAPCF15, BAPCR12 
3 = PCR product using primers BAPCF24, BAPCR12 
4 = PCR product using primers BAPCF25, BAPCR12 
        1                   2                     3                   4     
5383 bp 
2870 bp 
2981 bp 
1 = pET33b (BapC - SS) digested with NdeI/BamHI 
2 = pET33b (BapC - SS) digested with NheI/BamHI 
3 = pET33b (BapC + SS) digested with NdeI/BamHI 
4 = pET33b (BapC + SS) digested with NheI/BamHI 
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3.20.1 Sequencing of cloned bapC and aligning with the bapC in 
database 
Automated sequencing (section 2.9) was performed on pET33b (BapC - SS) and pET33b 
(BapC + SS) vectors by the Molecular Biology Support Unit (MBSU). As the accurate 
average read length was around 400-600, the plasmids were sequenced in both directions to 
allow more sequences to be obtained for analyses. The resultant sequences derived from 
electropherograms were analyzed and edited manually using Chromas (version 1.45) and 
BioEdit version 5.0.6 and then aligned with the bapC gene of B. pertussis Tohama in the 
database using BLAST2 Sequences. The sequence alignments for both constructs showed no 
difference in both forward and reverse directions compared to the bapC gene in the database 
(data not shown).     
3.20.2 Overexpression of BapC protein in E. coli 
    After the pET33b plasmids were established in E. coli BL21 (DE3) and BL21 (DE3) 
pLysS strains, expression of the bapC DNA was induced by the addition of IPTG to cultures 
growing in LB. Similar results were obtained with both strains and only the results for BL21 
(DE3) pLysS will be described. In brief, a single colony was picked off from a freshly 
streaked plate and inoculated into 5 ml of LB containing appropriate antibiotics (34 µg/ml of 
chloramphenicol for BL21 (DE3) pLysS) and grown overnight at 25°C-30°C. One ml of this 
culture was then transferred into 100 ml of LB (section 2.11.2). Once the OD600nm had 
reached 0.5-0.6, a range of IPTG concentrations from 0.1 to 1 mM were added to establish 
the optimal IPTG concentration at 25°C-30°C to maximise the yield of the recombinant 
protein. The induced cultures were examined for target protein expression using SDS-PAGE 
and Western blotting. Just prior to induction, the 100 ml culture was split into 2×50 ml 
cultures, and 1 mM final concentration of IPTG added to one of the 50 ml cultures and the 
other used as an un-induced control. In all cases, BapC protein expression was tightly 
regulated and was not detectable from uninduced cultures in either a Coomassie-blue stained  
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Figure 3.56 Protein profile showing the whole-cell fractions of E. coli BL21 
(DE3) pLysS containing pET33b (+) vector expressing BapC protein with or 
without the signal sequence 
  
       
                    
 
 
 
 
The figure shows the whole-cell protein profiles by SDS-PAGE (10%) of the E. coli strains 
grown in LB medium, with and without induction with 1 mM IPTG.  
 
 
 M               1              2              3              4              5              6 
M = marker                                                         
1 = E. coli pET33b (BapC + SS) + IPTG          4 = E. coli pET33b (BapC - SS) - IPTG 
2 = E. coli pET33b (BapC + SS) - IPTG           5 = E. coli pET33b + IPTG         
3 = E. coli pET33b (BapC - SS) + IPTG           6 = E. coli pET33b - IPTG                                            
 
   98 kDa 
       64 kDa 
 50 kDa 
22 kDa 
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gel (Fig. 3.56) or, where performed, immunoblots with anti-His6 antibodies (data not 
shown).  
Figure 3.56 shows the protein profiles of the whole-cell fractions of E. coli BL21 (DE3) 
pLysS expressing the full length BapC protein with signal sequence in induced (lane 1) and 
uninduced (lane 2) and without signal sequence in induced (lane 3) and uninduced (lane 4) 
conditions. Lanes 5 and 6 show protein profiles of E. coli control strains with the pET33b 
vector alone with no insert, in induced (lane 5) and uninduced (lane 6) conditions. The top 
arrowed band in lane 1 at ∼90 kDa is presumed to represent either the unprocessed (104 
kDa) or the processed (71 kDa) form of BapC. The second arrowed band in lane 1 that is 
slightly more prominent than in other lanes could possibly be the N-terminus or α-domain of 
BapC after cleavage since it is nearer to ∼71 kDa, the molecular weight of the α-domain. 
The predicted molecular weight of the whole BapC (from the first ATG in signal sequence) 
and the N-terminal or passenger domain are about 104 and 71 kDa, respectively, using 
ProtParam tool (http://www.expasy.org/tools/protparam.html).  
3.20.3 Identification of BapC protein expressed in E. coli  
    The identification of the BapC protein in E. coli expression strains was performed by 
manually excising the bands of interest (red arrows) from an SDS-PAGE gel and subjecting 
them to mass spectrometry (section 2.11.8). The peptide mass fingerprints obtained by MS 
were subjected to a database search by pasting the peptides into a protein database (Mascot) 
search tool which defines significant matches with known protein sequences (Appendix 
II.7a). The results showed that the ∼90 kDa band in lane 1 in Fig. 3.56 corresponded to the 
unprocessed form of BapC protein published in the database (locus_tag BP2738) with 46% 
known-peptide coverage (Appendix II.7b), suggesting that the BapC in B. pertussis strain 
BP338 would indeed be expressed in this strain. However, the lower molecular weight band 
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in lane 1 showed only slight identity to the α-domain of BapC with 14% known-peptide 
coverage. 
3.21 Sequence determination of bapC gene  
The gene in the genome sequence of B. pertussis strain Tohama encoding BapC protein was 
reported by Sebaihia in 2006 (GenBank) to be a pseudogene (Accession No. NP_881344) 
with frameshifts in two homopolymeric tracts (HPT), one of 13 cytosine residues and less 
likely one of 11 guanine residues towards the 5’ end of bapC (Appendix II.3). The 
consequences of these mutations alter the amino acid sequences and result in premature 
termination of the protein. In the present study with strain Tohama (section 3.3) and in the 
previous studies of Bokhari (2002) and Blackburn (2000), with strains BP Taberman and BP 
Tohama, evidence was presented that the BapC protein was in fact expressed. To address 
this anomaly, the bapC gene of different B. pertussis strains was sequenced using bapC 
forward and reverse primers (Table 2.5) amplifying two overlapping fragments of the 5’-end 
sequence of the bapC gene carrying either the poly(C) or poly(G) sequences to determine 
any variations in different B. pertussis strains and to compare them with the published 
Tohama I genome sequence.  
B. pertussis strains were grown in CL medium (Appendix I) and genomic DNAs were 
isolated using standard procedures (section 2.2.1). PCR reactions were performed (section 
2.8) using primer pairs MNF1/MNR1 and MNF2/MNR2 (Table 2.5) to amplify the regions 
containing the poly(C) or poly(G) sequences, respectively (Appendix II.3). Approximately 
50 bp of overlapping sequence was generated between individual sequence reads to allow 
contigs to be assembled using Seqman II and BioEdit tools. DNA sequence determinations 
were performed by sending the excised and purified bands of the amplified PCR products 
from agarose gel electrophoresis to MBSU (Molecular Biology Support Unit) at Glasgow 
University for sequencing using the dideoxy method (section 2.9). The data were finally 
analysed via BioEdit tool, version 5.0.6.  
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Figure 3.57 Agarose gel (0.7%) showing the amplified fragment of bapC 
gene encompassing the poly(C) region, using primers MNF1, MNR1 
 
 
 
  
 
 
 
 
 
 
Figure 3.58 Agarose gel (0.7%) showing amplified fragment of bapC gene 
encompassing the poly(G) region, using primers MNF2, MNR2 
 
       
  
                                      
 
 
 
 
                              M = marker                                   4 = BP PICU 
                              1 = BP338                                       5 = BP18323 
                              2 = BP Tohama I                           6 = BP338 (BrkA-) 
                              3 = BP Taberman                          7 = BP Taberman (L1) 
 
 
 
 
 
 
 
 
 
M     1     2     3     4      5     6     7 
M = marker                                   4 = BP PICU 
1 = BP338                                       5 = BP18323 
2 = BP Tohama I                           6 = BP338 (BrkA-) 
3 = BP Taberman                          7 = BP Taberman (L1) 
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456 bp 500 bp 
   250 bp 
         7      6      5      4     3      2       1     
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The PCR results (Fig. 3.57) using genomic DNA extracted from B. pertussis strains BP338 
(a Tohama derivative), BP338 (BrkA-), BP Tohama I, BP Taberman, BP Taberman (L1) 
(mouse lung passaged strain), BP18323, BP PICU (Table 2.2), lanes 1-7 showed an 
expected approx. 408 bp of amplified fragment of the bapC gene downstream from the first 
ATG codon of the putative signal sequence, encompassing the poly(C) region.        
An approximately 456 bp fragment that encompasses the poly(G) region of the bapC gene 
was also amplified from these six B. pertussis strains (Fig. 3.58) (lanes 1-7), using primers 
(MNF2/MNR2) which overlapped by 50 bp with the poly(C)-containing region to allow the 
two segments to be assembled as a continuous sequence.     
 
3.21.1 Nucleotide sequence analysis of bapC gene region 
spanning the poly(C) and poly(G) tracts of different B. pertussis 
strains 
Sequence analyses of amplicons were performed using software packages BioEdit and 
Seqman II. From dideoxynucleotide analyses, sequence data from forward and reverse 
primers were combined and aligned using CLUSTALW [http://www.ebi.ac.uk/clustalw] and 
MUSCLE (Multiple Sequence Comparison by Log-Expectation) 
[http://www.ebi.ac.uk/muscle] tools.  
Analysis of the region spanning the poly(C) sequence in B. pertussis strains exhibited a 
polymorphism varying from 13-15 C nucleotides (Fig. 3.59). B. pertussis strains BP 
Taberman (I), BP338 (BrkA-), BP338, BP PICU and BP Tohama I (Glasgow strain) showed 
no difference in the number of C nucleotides compared to the BP Tohama genome sequence 
published in the database (without the frameshifts). B. pertussis strains BP Taberman (L1) 
and BP18323 exhibited 14 and 15 C nucleotides in poly(C) variable segment, respectively.  
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Figure 3.59 CLUSTAL W (1.83) multiple sequence alignment of 5’-end of 
bapC gene encompassing poly(C) sites 
 
 
BP18323           ---------------------GCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 39 
BP TabermanI      ---------------------GCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 39 
BP338BrkA-        AAATCCAATAGCATGTCGCCAGCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 60 
BP338             ---------------TCGCCAGCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 45 
BP TabermanL1     ---------------------GCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 39 
BPPICU            ------------------CCAGCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 42 
BP TohamaI        ---------------------GCGGCGAGATACTTGCGTTTCGGCGTTGTCGCGGTAGCG 39 
                                       *************************************** 
 
BP18323           GGTGTAGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 99 
BP TabermanI      GGTGTAGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 99 
BP338BrkA-        GGTGTGGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 120 
BP338             GGTGTGGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 105 
BP TabermanL1     GGTGTGGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 99 
BPPICU            GGTGTGGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 102 
BP TohamaI        GGGTGTGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCCGCGCCGGCCGCC 99 
                  **    ****************************************************** 
 
BP18323           GCCGAGGTAGCCAAGATCGAGGCTCTGTCGGATGCGGACATTTACAGCGACTACGAGCAC 159 
BP TabermanI      GCCGAGGTAGCCAAGATCGAGGCTCTGTCGGATGCGGACATTTACAGCGACTACGAGCAC 159 
BP338BrkA-        GCCGAGGTAGCCAAGATCGAGGCTCTGTCGGATGCGGACATTTACAGCGACTACGAGCAC 180 
BP338             GCCGAGGTAGCCAAGATCGAGGCTCTGTCGGATGCGGACATTTACAGCGACTACGAGCAC 165 
BP TabermanL1     GCCGAG-TACC--AAATC-AG-CTCT-TCG-ATC--GACATACAC---GACTAC--ACAC 145 
BPPICU            GCCGAG-TACC--AAATCGAG-CTCTGTCG-ATGCGGACATTTACAGCGACTAC--ACAC 155 
BP TohamaI        GCCGAG-TACC--AAATCGAG-CTCTGTCG-ATC--GACATACAC---GACTAC--ACAC 147 
                  ****** ** *  * *** ** **** *** **   *****  **   ******   *** 
 
BP18323           GAGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 219 
BP TabermanI      GAGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 219 
BP338BrkA-        GAGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 240 
BP338             GAGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 225 
BP TabermanL1     -AGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 204 
BPPICU            -A-CATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 213 
BP TohamaI        GAGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGTTACAGGTCCGCC 207 
                   * ********************************************************* 
 
BP18323           GAGAGCGGTCGTCCGAAGCCCCCCCCCCCCCCCTTTTCAAACTTCAAACCATTGGGTAAT 279 
BP TabermanI      GAGAGCGGTCGTCCGAAGCCCCCCCCCCCCC---TTTCAAACTTCAAACCATTGGGTAAT 276 
BP338BrkA-        GAGAGCGGTCGTCCGAAGCCCCCCCCCCCCC---TTTCAAACTTCAAACCATTGGGTAAT 297 
BP338             GAGAGCGGTCGTCCGAAGCCCCCCCCCCCCC---TTTCAAACTTCAAACCATTGGGTAAT 282 
BP TabermanL1     GAGAGCGGTCGTCCGAAGGCCCCCCCCCCCCCCTTTTCAAACTTCAAACCATTGGGTAAT 264 
BPPICU            GAGAGCGGTCGTCCGAAG--CCCCCCCCCCCCCTTTTCAA-CTTCAAACCATTGGGTAAT 270 
BP TohamaI        GAGAGCGGTCGTCCGAAG---CCCCCCCCCCCCCTTTCAAACTTCAAACCATTGGGTAAT 264 
                  ******************   **********   ****** ******************* 
 
BP18323           GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTAT 339 
BP TabermanI      GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACTGAACCCTCGGCGTGTAT 336 
BP338BrkA-        GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTAT 357 
BP338             GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTAT 342 
BP TabermanL1     GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTAT 324 
BPPICU            GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTAT 330 
BP TohamaI        GACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTCGGCGTGTAT 324 
                  ******************************************  **************** 
 
BP18323           GTC------------------- 342 
BP TabermanI      GTCGACTCGGAGCACCGTT--- 355 
BP338BrkA-        GTCGACTCGGAGCACCGTTCGC 379 
BP338             GTCGACTCGGAGCACCGTTCGC 364 
BP TabermanL1     GTCGACTCGGAGCACCGTTCGC 346 
BPPICU            GTCGACTCGGAGCACCGTTCC- 351 
BP TohamaI        GTCGACTCGGAGCACCG----- 341 
                  ***                    
 
 
 
 
 
Grey fragments highlighted are asumed to be in-frame shifts, and yellow highlighted regions 
are poly(C) tracts [HPT]. TGA, red-bold type, is a stop codon.  
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Figure 3.60 CLUSTAL W (1.83) multiple sequence alignment of 5’-end of 
bapC gene encompassing poly(G) sites 
 
 
BP18323           ---GTGCGTGACAGCACGATAGATGCATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 57 
BP338BrkA-        ------CGTGACAGCACGATAGATGCATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 54 
BPPICU            ACGGTGCGTGACAGCACGATAGATGCATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 60 
BP TabermanI      ACCGTGCGTGACAGCACGATAGATGTATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 60 
BP TohamaI        ------------------------GCATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 36 
BP TabermanL1     ACGGTGCGTGACAGCACGATAGATGCATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 60 
BP338             ---GTGCGTGACAGCACGATAGATGCATACGGCAAGCCGCCTTCCGTCGACTCTCCCGAT 57 
                                          * ********************************** 
 
BP18323           TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 117 
BP338BrkA-        TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 114 
BPPICU            TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 120 
BP TabermanI      TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 120 
BP TohamaI        TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 96 
BP TabermanL1     TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 120 
BP338             TATTACGGTGCCGCGGCTGTCTACGCCGGTACGCTGAATATCGAGAATTCCACGGTTCAC 117 
                  ************************************************************ 
 
BP18323           CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 177 
BP338BrkA-        CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 174 
BPPICU            CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 180 
BP TabermanI      CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 180 
BP TohamaI        CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 156 
BP TabermanL1     CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 180 
BP338             CATAACTATGCGGCCCAGCCGTTCGAAGACGCGGTAGGAGTCGGGGTAACCTCGCTCGGG 177 
                  ************************************************************ 
 
BP18323           GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 237 
BP338BrkA-        GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 234 
BPPICU            GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 240 
BP TabermanI      GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 240 
BP TohamaI        GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 216 
BP TabermanL1     GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 240 
BP338             GATAAGGCCATACTCAACGTTACCGACAGCGAGGTATCGGGTGCGAGGGGCGCGGTCATC 237 
                  ************************************************************ 
 
BP18323           GGTTGGGGGGGGG------AAGCGACATTT-ACCGATTCGGTCCTGCGT-GGTTCGGCCT 289 
BP338BrkA-        GGTTGGGGGGGGGGGG---AAGCGACATTT-ACCGATTCGGTCCTGCGT-GGTTCGGCCT 289 
BPPICU            GGTTGGGGGGGGGGGC--GAAGCGACATTTTACCGATTCGGTCCTGCGTTGGTTCGGCCT 298 
BP TabermanI      GGTTGGGGGGGGGGGC--GAA-CGACATTT-ACCGATTCGGTCCTGCGT-GGTTCGGCCT 295 
BP TohamaI        GGTTGGGGGGGGGGGCAAGAAGCGACATTT-ACCGATTCGGTCCTGCGT-GGTTCGGCCT 274 
BP TabermanL1     GGTTGGGGGGGGGGG---GAAGCGACATTT-ACCGATTCGGTCCTGCGT-GGTTCGGCCT 295 
BP338             GGTTGGGGGGGGGGG---GAAGCGACATTT-ACCGATTCGGTCCTGCGT-GGTTCGGCCT 292 
                  *************      ** ******** ****************** ********** 
 
BP18323           TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 349 
BP338BrkA-        TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 349 
BPPICU            TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 358 
BP TabermanI      TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 355 
BP TohamaI        TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 334 
BP TabermanL1     TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 355 
BP338             TCGGGCTGTACGCCGAAATGTGCGACACCTGCAGAGATGATGATGGCACCTCGCCTTCGA 352 
                  ************************************************************ 
 
BP18323           TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGCCGAAATGTGCG 409 
BP338BrkA-        TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGTCT--------- 400 
BPPICU            TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACG------------ 406 
BP TabermanI      TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGTC---------- 405 
BP TohamaI        TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAAT---------------- 378 
BP TabermanL1     TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGTC---------- 405 
BP338             TTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATGGGTGCAAATAACGTCCT-------- 404 
                  ********************************************                 
 
 
 
Yellow highlighted regions are poly(G) tracts [HPT]. 
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Table 3.4 Number of C and G residues in the bapC poly(C) and poly(G) tracts 
in B. pertussis strains 
 
DNA source 
 
Type of DNA sequenced 
 
No. of C residues in 
poly(C) tract 
 
No. of G residues in 
poly(G) tract 
BP18323 Amplicon 15 9 
BP PICU Amplicon 13 11 
BP Taberman (L1) Amplicon 14 12 
BP Taberman (I) Amplicon 13 11 
BP338 Amplicon 13 12 
BP338 (BrkA-) Amplicon 13 12 
BP Tohama I (Glasgow 
strain) 
Amplicon 13 11 
BP Tohama  (Actual 
genome sequence, with 
frame shift) 
Chromosomal library 
clone 
14 11 
BP Tohama published 
sequence without frameshift 
Chromosomal library 
clone 
13 9 
 
 
  Results               
 
200 
Downstream of the poly(C) tract in B. pertussis BP Taberman I there was, surprisingly, a 
stop codon (TGA, red-bold type), which could be a true or false termination as a 
consequence of PCR reaction.  
Interestingly, the region 5’-upstream of the poly(C) fragment in BP TohamaI strain, BP 
Taberman (L1) and BP PICU showed an in-frame shift of a fragment containing 40-47 
nucleotides (Fig. 3.59, grey highlighted fragments).  
Analysis of the segment encompassing the homopolymeric tract of 9 guanine residues in B. 
pertussis strains exhibited a polymorphism of 9-12 (G) nucleotides (Fig. 3.60). B. pertussis 
strains such as BP Taberman (I), BP PICU and BP Tohama (Glasgow strain) showed no 
difference in the number of (G) nucleotides compared to the BP Tohama genome sequence, 
published in the database. However, B. pertussis strains BP Taberman (L1), BP338 and 
BP338 (BrkA-) had a G (12) tract with an extra (G) nucleotide compared to those described 
above. Table 3.4 shows the number of C and G nucleotides in the HPT variable segments of 
bapC gene.  
3.21.2 Amino acid sequence analysis of bapC gene region 
spanning the poly(C) and poly(G) tracts of different B. pertussis 
strains 
In view of the above variations in the homopolymeric tracts and flanking regions of the 
bapC gene in different B. pertussis strains, it was important to determine whether such 
changes would allow expression of the full-length BapC protein. As explained above, the 
frameshifts in the actual sequence of the B. pertussis Tohama genome strain would not allow 
this. 
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Figure 3.61 CLUSTAL W (1.83) multiple sequence alignment of amino acids 
at N-terminus of BapC, corresponding to region containing the poly(C) 
sequences 
 
 
BP18323           -------AARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEVAKIEALSDADIYSDYEH 53 
BP338BrkA-        KSNSMSPAARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEVAKIEALSDADIYSDYEH 60 
BP TabermanI      -------AARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEVAKIEALSDADIYSDYEH 53 
BP338             -----SPAARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEVAKIEALSDADIYSDYEH 55 
BP TohamaI        -------AARYLRFGVVAVAGCAAGALPSSDVDAQAAPAAAEY-QIELCRS-TYTTT--H 49 
BPPICU            ------PAARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEY-QIELCRCGHLQRL--H 51 
BP TabermanL1     -------AARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEY-QIS--SSIDIHDY--T 48 
                         ************** ********************  :*.              
 
BP18323           EHGIVMTPDGKDDYISYRSAESGRPKPPPPPFSNFKPLGNDVVAERIRVEVHGDETLGVY 113 
BP338BrkA-        EHGIVMTPDGKDDYISYRSAESGRPKPPPP-LSNFKPLGNDVVAERIRVEVHGDETLGVY 119 
BP TabermanI      EHGIVMTPDGKDDYISYRSAESGRPKPPPP-LSNFKPLGNDVVAERIRVEVHGD-TLGVY 111 
BP338             EHGIVMTPDGKDDYISYRSAESGRPKPPPP-LSNFKPLGNDVVAERIRVEVHGDETLGVY 114 
BP TohamaI        EHGIVMTPDGKDDYISYRSAESGRPK-PPPPLSNFKPLGNDVVAERIRVEVHGDETLGVY 108 
BPPICU            THGIVMTPDGKDDYISYRSAESGRPK-PPPPLFNFKPLGNDVVAERIRVEVHGDETLGVY 110 
BP TabermanL1     QHGIVMTPDGKDDYISYRSAESGRPKAPPPPFSNFKPLGNDVVAERIRVEVHGDETLGVY 108 
                   ************************* *** : ********************* ***** 
 
BP18323           V------ 114 
BP338BrkA-        VDSEHRS 126 
BP TabermanI      VDSEHR- 117 
BP338             VDSEHRS 121 
BP TohamaI        VDSEH-- 113 
BPPICU            VDSEHRS 117 
BP TabermanL1     VDSEHRS 115 
                  *       
 
 
The yellow highlighted fragments are in-frame shifts upstream to poly amino acid proline, 
grey regions.  
Figure 3.62 CLUSTAL W (1.83) multiple sequence alignment of amino acids 
at N-terminus of BapC, corresponding to region containing the poly(G) 
sequences 
 
 
BP TohamaI        --------AYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 52 
BP18323           -VRDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 59 
BP338BrkA-        --RDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 58 
BP338             -VRDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 59 
BP TabermanL1     TVRDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 60 
BP TabermanI      TVRDSTIDVYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 60 
BPPICU            TVRDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFEDAVGVGVTSLG 60 
                          .*************************************************** 
 
BP TohamaI        DKAILNVTDSEVSGARGAVIGWGGGQEATFTDSVLRGSAFGLYAEMCDTCRDDDGTSPSI 112 
BP18323           DKAILNVTDSEVSGARGAVIGWGG--EATFTDSVLRGSAFGLYAEMCDTCRDDDGTSPSI 117 
BP338BrkA-        DKAILNVTDSEVSGARGAVIGWGGG-EATFTDSVLRGSAFGLYAEMCDTCRDDDGTSPSI 117 
BP338             DKAILNVTDSEVSGARGAVIGWGGG-EATFTDSVLRGSAFGLYAEMCDTCRDDDGTSPSI 118 
BP TabermanL1     DKAILNVTDSEVSGARGAVIGWGGG-EATFTDSVLRGSAFGLYAEMCDTCRDDDGTSPSI 119 
BP TabermanI      DKAILNVTDSEVSGARGAVIGWGGG-RTTFTDSVLRGSAFGLYAEMCDTCRDDDGTSPSI 119 
BPPICU            DKAILNVTDSEVSGARGAVIGWGGGRSDILPIRSCVGSAFGLYAEMCDTCRDDDGTSPSI 120 
                  ************************     :.     ************************ 
 
BP TohamaI        RVQGGVVQGGMGAN--------------------------------- 126 
BP18323           RVQGGVVQGGMGANNAEMCDTCRDDDGTSPSIRVQGGVVQGGMGANN 164 
BP338BrkA-        RVQGGVVQGGMGANNV------------------------------- 133 
BP338             RVQGGVVQGGMGANNV------------------------------- 134 
BP TabermanL1     RVQGGVVQGGMGANNV------------------------------- 135 
BP TabermanI      RVQGGVVQGGMGANNV------------------------------- 135 
BPPICU            RVQGGVVQGGMGANN-------------------------------- 135 
                  **************                                  
 
The yellow highlighted fragment is an in-frame shift downstream to poly amino acid 
glycine, grey regions.   
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Translated and deduced amino acid sequences (Figs 3.61 and 3.62) using ExPASy translate 
tool (http://www.expasy.org/tools/dna.html) were analyzed for the different B. pertussis 
strains and multiple alignments of the amino acid sequences were created with the 
CLUSTALW program.  
The translated region spanning the poly(C) tract in B. pertussis strains (Fig. 3.61, grey 
highlighted fragments) showed no difference in the number of proline residues (4), except 
for BP18323 (5), compared to the BP Tohama (genome) amino acid sequence published in 
the database. An extra in-frame amino acid proline and leucine replacement by 
phenylalanine were observed in BP18323 strain due to insertion of extra two (C) 
nucleotides. In addition, the region 5’-upstream of the poly(C) fragment in BP TohamaI 
strain, BP Taberman (L1) and BP PICU showed an in-frame shift of 12-15 amino acids (Fig. 
3.61, yellow highlighted regions). No hit was found using ScanProsite 
(http://www.expasy.org/tools/scanprosite) release 20.11 tool to retrieve any identical or 
similar pattern, profile or motif stored in the database, in comparison with this variable 15 
amino acids segment. Nevertheless, a possible function was obtained for the conserved 
fragment (VAKIEALSDADIYSD) when compared with motifs stored in the Protein Blast 
database (www.ncbi.nlm.nih.gov/blast) (BLASTP 2.2.16 release). This motif was a part of 
periplasmic binding protein (PBP) using for transporting a wide variety of substrates, such 
as amino acids, peptidases, sugars, vitamins and inorganic ions via bacterial periplasmic 
transport systems and may indicate an evolutionary or environmental compatibility at this 
region. Taking account of Cs and flanking regions, the sequences of the most of strains were 
in-frame and would not prevent them expressing BapC.   
Analysis of translated and deduced amino acid sequences using ExPASy tool and multiple 
alignment of the amino acid sequences of the poly(G) tracts showed an extra in-frame 
glycine codon in all of the B. pertussis strains, except for BP18323, when compared with the 
Tohama genome sequence in the database (Fig. 3.62). Moreover, the region 3’-downstream 
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of the poly(G) tract in BP PICU strain showed an in-frame shift of 11 amino acids (Fig. 
3.62, yellow highlighted fragment). However, no hit was again found using ScanProsite 
(http://www.expasy.org/tools/scanprosite) release 20.11 tool to retrieve the occurrence of 
any identical or similar pattern, profile or motif stored in the database in comparison with 
this variable 11-amino acid segment (RSDILPIRSCV), although it showed a resemblance to 
a periplasmic binding protein using for transporting a wide variety of substrates by bacterial 
periplasmic transport systems, using Protein BLAST search (www.ncbi.nlm.nih.gov/blast) 
(BLASTP 2.2.16 release). Moreover, an additional search using BLASTp for the 11-amino 
acid conserved fragment (GEATFTDSVLR) in the other B. pertussis strains compared in 
this study showed an 88% identity with a hypothetical protein of Collinsella aerofaciens.  
It can therefore be concluded from the above observations that, although the entire bapC 
gene was not sequenced in these different B. pertussis strains, there are some minor 
nucleotide and amino acid changes in some strains but it is likely that all would be able to 
produce some form of BapC, unlike the B. pertussis Tohama genome strain. Thus, the data 
supported the findings by Blackburn (2000) and Bokhari (2002) that B. pertussis Tohama 
(Glasgow strain) and Taberman produce BapC protein.  
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4. Discussion 
4.1 Overview 
The autotransporters are a family of extracellular proteins found in many Gram-negative 
bacteria. Several of these proteins are known to play essential roles in the pathogenesis of 
bacterial infections and have been characterised in detail. However, most of the 
autotransporter proteins remain to be characterised. The main three characteristics of these 
proteins are that most of the mature proteins are processed into a large N-terminal domain 
and an approximately 30-kDa C-terminal domain, the C-terminal domain is predicted to 
produce an amphipatic β-barrel in the outer membrane, creating an integral outer-
membrane pore and, finally, export of these proteins through the outer membrane does not 
necessitate accessory proteins, as their names imply.  
The bordetellae have the capacity to encode 22 of these proteins (Table 1.1), of which a 
few (BrkA, pertactin, SphB1, TcfA and Vag8) have been assigned functions in host 
interaction and virulence (Parkhill et al., 2003). However, B. pertussis (13) and B. 
parapertussis (16) each have fewer autotransporter ORFs and more autotransporter 
pseudogenes compared with B. bronchiseptica (20), although it should be noted that bapC 
was not shown as a pseudogene by Parkhill et al. (2003). The number of autotransporter 
pseudogenes is reflected in the overall genome structure, where B. bronchiseptica has only 
18 (0.4% of the total number of genes) pseudogenes, whereas B. pertussis and B. 
parapertussis have 358 (9.4%) and 220 (5%), respectively (Preston et al., 2004). The 
greater number of autotransporters and surface-protein coding capacity of B. 
bronchiseptica could be a reflection of its abilities to bind to tissues in, and infect, a wider 
range of hosts.    
One of the Bordetella autotransporter genes (initially named bap-5; Appendix II.3) was 
first identified due to a misprimed PCR reaction designed to amplify the prn gene from the 
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B. pertussis genome (Blackburn, 1998). An identical gene/protein was later identified and 
named BapC, the product of bapC gene, by Henderson et al. (2000), and this terminology 
has been adopted in the present study. A database search showed that homologous genes 
were also present in B. parapertussis and B. bronchiseptica (Blackburn, 2000). The 
structural similarities between BapC (the product of bapC) and other, already well-
characterised B. pertussis autotransporter proteins i.e. PRN, TCF and BrkA (Fig. 1.11) 
suggested that the BapC protein might have similar functions, perhaps as an adhesin or a 
serum resistance factor. Similarities such as the integrin-binding motif (RGD), 
glycosaminoglycan-binding site (SGXG), proteolytic processing site (ALSKRLGEL) and 
outer membrane localisation signal, which ends at a cyclic amino acid like other 
autotransporters in Gram-negative bacteria (FHLGYRTW), are common outstanding 
features of autotransporters.  
Further work by Bokhari (2002) had provided preliminary evidence that BapC was a 
putative virulence factor of B. pertussis, providing resistance to serum killing, by 
interfering with the classical pathway of complement activity (like BrkA), and possibly 
adherence to certain mammalian cell types. The aim of the present project was to further 
characterize this potentially important component. However, during the course of this 
thesis, further interesting, and apparently conflicting data on BapC were reported. With the 
publication of the genome sequences of three Bordetella strains (Parkhill et al., 2003), it 
became evident that the sequences reported by Blackburn (1998) and Henderson (2000) 
did not reflect the complete gene or protein. Although the three Bordetella species were 
reported as containing a number of autotransporter pseudogenes, bapC was not shown as a 
pseudogene in any of the species (Parkhill et al., 2003). The subsequent literature on BapC 
has also been confusing. For example, in the table of Henderson et al., (2004) (Table 1.1) 
BapC is shown as protein of 998 amino acids in B. bronchiseptica but in B. pertussis 
Tohama and B. parapertussis as 102 and 100 amino acids, truncated due to frameshift or 
insertion of a stop codon. GenBank data by Sebaihia in 2006 reported BapC as putative 
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autotransporter with 993 amino acids ORF in B. bronchiseptica (Accession No. 
NP_888576) but as a pseudogene in B. pertussis (Accession No. NP_881344) and B. 
parapertussis (Accession No. NP_884815). To add to the confusion, the amino acid 
sequence of BapC in B. pertussis and B. parapertussis in GenBank and the corresponding 
nucleotide sequences of B. pertussis and B. parapertussis in GenBank show full-length 
proteins and the unmutated genes, respectively.        
In previous studies from our laboratory, by RT-PCR and the immunoblotting with a rabbit 
anti-BapC serum (as used in the present study), it appeared that the bapC gene was 
expressed in B. pertussis strains Tohama and Taberman (Bokhari, 2002). The RT-PCR 
results also suggested that bapC expression was regulated by the Bvg two-component 
regulatory system. Moreover, disruption of the bapC gene in these two strains of B. 
pertussis gave mutants with altered properties such as increased serum sensitivity, reduced 
adhesion to the non-respiratory HeLa cells and to human respiratory epithelial laryngeal 
(Hep-2) cells and reduced virulence for mice by the intranasal route (Bokhari, 2002). In 
view of these apparent discrepancies, further genetic and functional characterisation of 
BapC was undertaken in the present study.   
4.2 Construction of bapC-defective mutants 
Although, bapC mutants were available from previous work, the rational for creating 
BP338 (BapC-) and BP338 (BrkA-, BapC-) mutants was to determine the exact role of 
BapC in the same genetic background. 
The bapC-defective mutants of B. pertussis were created using the suicide vector pSS1129 
(Stibitz, 1986) for gene replacement. This vector had been used previously for creating 
mutants in B. pertussis e.g. fhaB-defective and bvgA-defective mutants. The potential 
usefulness of this specific vector in different bacterial species other than E. coli depends on 
the proper function of two basic aspects, its capacity for transfer to, but inability to 
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replicate in these species. The construct has an origin of transfer from plasmid RP4 and, 
provided that tra functions are supplied in trans, the vector will be transferred into the 
recipient bacterium by conjugation. The ligation of the mutated (with inserted tetracycline 
resistance cassette) bapC gene into the pSS1129 vector proved to be a difficult task, 
probably due to the high GC-content of the bapC gene. The derived streptomycin resistant 
strain of B. pertussis provided a valuable selection marker for selecting the exconjugant 
strains of B. pertussis and also for inhibiting the growth of the undesired DNA-mobilising 
E. coli strain SM10.λpir.   
The rationale behind the two-step selection used is that the first cross-over is accomplished 
by selecting for the vector or a marker within the cloned sequence, since the vector is a 
member of ColE1 family and is not able to replicate in B. pertussis and many other 
bacteria. The first step was therefore to select for those bacteria in which the plasmid had 
integrated into the chromosome. If the cloned segment within the plasmid was homologous 
to the chromosome, integration would very likely occur via homologous recombination. 
The second step was used to select for the loss of the integrated plasmid. This was 
accomplished because of the wild-type E. coli rspL gene in pRTP1 (pSS1129) that confers 
a streptomycin-sensitive phenotype on strains. Streptomycin-resistant survivors would 
therefore be those which had lost the plasmid copy of rpsL. This loss occurs by the 
mechanism of homologous recombination between the direct repeats, which flank the 
vector as a result of its integration. As a result of this manipulation, two crossovers would 
have occurred between the plasmid with the encoded gene and chromosomal copies of the 
gene in question. If these crossovers occured on opposite sides of the site of alteration in 
the cloned gene, the net result is that the desired alteration would be obtained. If the 
crossovers occur at the same side, the original allele would remain (Fig. 3.30). PCR and 
Southern blotting results showed the successful incorporation of the mutated bapC into the 
chromosome of B. pertussis strain 338 wild type and its brkA mutant (BPM2041).   
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Some unwanted background reactions were found at each recombination step. For 
example, at the first crossover when there is no cloned homologous segment present in the 
vector, one can still isolate at a low frequency, insertions of the vector into the 
chromosome. These illegitimate insertions do not occur via homologous recombination as 
a result of sequence similarity between plasmid and chromosomal homology of genes as 
they can occur at random sites. Another background reaction may appear at the second 
crossover. If survivors are selected for the second plasmid marker such as ampicillin 
resistance, some of them contain this marker and some do not. It has been suggested that 
they may have been obtained via some undefined or less defined mechanisms involving 
spontaneous deletion. These exceptions occur when attempting to do allelic exchange 
under non- or less optimal conditions. If there is a sufficient flanking homology, for 
example 500 bp on each side of the mutation, and if a reasonable screen exists for 
incorporation of the mutation, this background will happen with only a low frequency. 
Two more points have to be borne in mind when using mutant strains. As the mutagenesis 
is performed by inserting a cassette downstream of the predicted translational start site, 
there could be the possibility of getting truncated peptides and that could cause difficulties 
in defining the role of the gene. Another possiblity is the effect of the mutagenesis on 
neighbouring genes (polar effect). In the case of the bapC gene, a database search of the 
bapC flanking regions using the B. pertussis Tohama I genome sequence (BLAST search 
at http://www.Sanger.ac.uk/projects/B_pertussis) contig BX640419 indicated the presence 
of a probable ammonium transporter gene (amtB, locus_tag BP2737) 5’-upstream of bapC 
and a hypothetical gene encoding a putative TetR-family transcriptional regulator 
(locus_tag BP2741) located 3’-downstream of the bapC gene. These two loci do not 
therefore appear to form a part of an operon with bapC and mutagenesis of bapC would be 
unlikely to have any effect on these neighbouring genes. In fact, by immunoblotting, the 
amount of BrkA in BapC mutants (Figs 3.2 and 3.3) appeared to be somewhat reduced, as 
if bapC mutation had some effect on BrkA expression. However, the brkA gene (locus_tag 
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3494) is far away from bapC gene (locus_tag 2738) on the B. pertussis genome and it is 
unlikely that mutation in that bapC gene could have any effect on brkA gene and also there 
is no evidence that brkA and bapC genes are regulated in an operon, where any effect on 
one transcript may affect the following transcripts. One possible line of future work would 
be to restore BapC expression to the BapC-deficient mutants by returning the bapC gene 
on a plasmid, to investigate the effect of BapC on BrkA expression.     
4.3 Role of BapC in serum resistance  
A range of surface-associated or released virulence factors is employed by B. pertussis to 
survive in its host, and to delay or evade the immune effector mechanisms deployed 
against it. B. pertussis is a mucosal pathogen; nevertheless it can be exposed to levels of 
complement about 20% of that of normal human serum due to extravasation or plasma 
exudation via valve-like openings between epithelial cells (Persson, 1991). However, the 
mucosal exudation of plasma characteristically occurs in health and disease; levels may be 
further increased during inflammation (Persson, 1991; Barnes and Weiss, 2001). This 
organism, like other mucosal pathogens appears to possess mechanisms in place to resist 
complement (Weiss et al., 1999).  
However, B. pertussis does show some sensitivity to complement killing and this is 
attributed in part to the absence of O-side chain on its LOS. B. bronchiseptica and B. 
parapertussis strains with the longer LPS and expressing of O antigens are completely 
resistant to naïve serum complement whereas O-chain defective mutants are very sensitive 
to complement (Burns et al., 2003). In the absence of O antigens, B. pertussis does 
therefore require other mechanisms to resist complement.  
It had been suggested earlier that BapC has a role in B. pertussis Taberman and Tohama in 
conferring some resistance to complement-mediated killing. BapC was shown to confer a 
resistance on B. pertussis Taberman and Tohama to killing by normal human serum 
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compared to their BapC-deficient mutants (Bokhari, 2002). Moreover, it was observed that 
BapC protects B. pertussis mainly from the classical (antibody-dependent) pathway of 
complement activation (Bokhari, 2002). The present study has also confirmed that BapC 
may play a role in protecting B. pertussis from killing by normal human serum since the 
BapC mutant strains: BP Taberman (BapC-), BP Tohama (BapC-) (section 3.6), BP338 
(BapC-) and BP338 (BrkA-, BapC-) (section 3.15) were more sensitive than their parents to 
killing by normal human serum. BapC was shown to confer a considerable resistance on B. 
pertussis BP338 to killing by normal human serum compared to its BapC-deficient mutant 
(P<0.05). Moreover, it was demonstrated that the BP338 (BrkA-, BapC-) double mutant 
was significantly (P<0.05) more sensitive to killing by complement than the single BrkA- 
or BapC- mutants in the same genetic background (BP338). It was also shown that the 
killing of B. pertussis BP338 and its BrkA- and BapC- single and BrkA-, BapC- double 
mutants, grown under modulating conditions, was significantly (P<0.05) greater when 
exposed to normal human serum compared to those grown under non-modulating 
conditions. Moreover, although the double mutant was more serum sensitive than either the 
BrkA- or BapC- single mutants, it was not as sensitive as the Bvg- derivative of BP338 
strain (BP347). These data suggest that although BapC, in addition to BrkA, seems to play 
a role in conferring resistance on B. pertussis to killing by complement, other as yet 
unidentified bvg-regulated factors may also be involved in serum resistance.   
The complement system is part of the innate immune defences, and provides a first line of 
defence against pathogens that the host has not encountered previously. The complement 
system can be activated in several ways. The classical pathway is usually activated by 
deposition of antibody on the bacterial surface via binding of C1 protein to the Fc regions 
of two antibodies in close proximity, which changes the C1 conformation so that it 
becomes proteolytically active. However, in the absence of antibody, C1 can directly 
activate the classical pathway by binding to bacterial targets such as porins (Alberti et al., 
1995; Barnes and Weiss, 2003). Complement is also activated by binding of mannose-
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binding-lectin (MBL) to mannose residues on the bacterial surface which activates C4 and 
C2 of the classical pathway in a manner similar to the antibody/C1 activation process. This 
lectin pathway is an antibody-independent route of the classical pathway. MBL has 
structurally similar to C1q and is able to activate complement via associated serine 
proteases (MASP-1 and MASP-2) (Matsushita and Fujita, 1992). Killing is mediated by 
the terminal lytic complement pathway or possibly by increasing phagocytosis. However, a 
role for the MBL pathway has been ruled out in killing of B. pertussis with intact LPS 
(LOS) since mannose is not a component of the B. pertussis LPS (LOS) (Barnes and 
Weiss, 2003).  
The alternative pathway, the second complement pathway, is activated by carbohydrates 
on the surface of bacteria (such as LPS). However, the surface of B. pertussis appears not 
to be able to activate the alternative pathway of complement (Fernandez and Weiss, 1994; 
Barnes and Weiss, 2003) and B. pertussis is killed in the absence of the alternative 
pathway suggesting that only the classical pathway of complement mediates killing of B. 
pertussis (Barnes and Weiss, 2003). Furthermore, it has been suggested that resistance to 
the alternative pathway in some bacterial pathogens is achieved due to modification of 
their LPS by addition of sialic acid in particular (Parsons et al., 1989). There is no report 
that B. pertussis can modify its LPS (LOS) in this way. 
It has been shown that naïve serum resistance is acquired by both BrkA and Bvg mutants 
of B. pertussis in vivo (Pishko et al., 2003). A BrkA mutant of BP338 (RFBP 2152) 
acquired a significant amount of resistance in vivo, but the level of resistance acquisition 
was not as high as in wild-type strains which suggested that the BrkA protein is not 
involved in the acquisition of resistance to complement (alternative pathway) killing in 
vivo (Pishko et al., 2003). This in vivo acquisition of complement resistance suggested that 
there could be a novel O antigen-independent method by which B. pertussis evades 
complement-mediated killing (Pishko et al., 2003). It is therefore possible that B. pertussis 
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has more than one mechanism for complement evasion (Berggard et al., 2001) and the 
BrkA-dependent mechanism may be more effective against the antibody-mediated 
classical pathway killing during the adaptive immune response. However, it has been 
shown that the BrkA is involved in resisting both antibody-independent and –dependent 
pathways of complement killing in vitro (Elder and Harwill, 2004) and increased 
sensitivity of all brkA mutants in B. pertussis isolates to both naïve and immune serum 
suggested a noncritical or redundant function for BrkA in complement resistance to killing 
(Elder and Harvill, 2004). It was also found that the critical function of BrkA in vivo was 
independent from its effects in resisting to lysis mediated by complement, and there was no 
correlation between in vitro sensitivity to complement and in vivo infection ability (Elder 
and Harvill, 2004). This phenomenon might be justified by the fact that B. pertussis strains 
can even acquire resistance to complement-mediated killing during the first 24 h of 
infection, in the absence of BrkA or other regulated genes by BvgAS system (Pishko et al., 
2003). In addition, the high level of acquired complement resistance is specific to B. 
pertussis since wild-type B. bronchiseptica and B. parapertussis are normally resistant to 
the alternative complement pathway and it is doubtful whether they acquire resistance to 
the same extent as B. pertussis (Pishko et al., 2003). 
It has been shown that the BrkA protein of B. pertussis inhibits killing by the antibody-
dependent classical pathway of complement via the inhibition of deposition of C4, C3 and 
C9 and production of soluble membrane attack complex (Barnes and Weiss, 2001). In 
contrast, BrkA does not affect the deposition of C1, suggesting that BrkA possibly acts 
before C4 (the second component of the classical pathway to be activated) deposition.  
Recently, it has also been reported that bacterial concentrations greater than approximately 
107 CFU/ml deplete complement, resulting in decreased bacterial killing (Burns et al., 
2003) and the limited amount of complement in 10% serum has little effect on bacterial  
concentrations greater than approximately 109 CFU/ml, even with the most sensitive 
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strains (Burns et al., 2003). In addition to substantial variation in sensitivity between 
strains, it is possible that various growth conditions contribute to differences in the 
sensitivities of B. pertussis strains to complement (Pishko et al., 2003). Pishko et al. (2003) 
showed that growth on BG plates with blood, in contrast to growth in SS broth or on plates 
without blood, significantly increased the serum resistance of B. pertussis although the 
mechanism for this is unknown. In the present study, all B. pertussis strains were grown 
under the same conditions, on BG agar then suspended in SS-medium and exposed to 
normal human serum, at dilutions up to 1/80 at a concentration of 4×108 CFU/ml. Up to 
>99% killing of the most sensitive strains occurred with 45 min and there were clear 
differences between the sensitive and more resistant (wild-type) strains. 
It has also been shown that complement susceptibility of B. pertussis is growth stage 
specific but was not due to differential expression of BrkA, suggesting that factors in 
addition to BrkA play a role in conferring resistance to complement (Barnes and Weiss, 
2002). In the present study, the effect of growth phase on serum sensitivity was not 
examined, but all B. pertussis strains were grown under the same conditions so differences 
in serum sensitivity would not be due to differences in growth phase.   
Since one of the first lines of defence in the innate immunity is typically the complement 
system, bacteria have developed different ways to circumvent the effects of complement, 
including coating themselves in complement inhibitors (such as C1q binding protein, factor 
H, C4BP and so on). Although B. pertussis FHA can bind to C4 binding protein (C4BP), it 
did not appear to have a role in serum resistance (Fernandez and Weiss, 1998; Berggard et 
al., 2001). Binding of complement inhibitor factor H (Amdahl et al., 2006) and C1 esterase 
inhibitor (Marr et al., 2007) have been reported recently but the surface components 
involved have not yet been characterised. The mechanism of BapC action in resistance to 
complement was not examined in this study and further investigation would be required to 
determine, for example, whether it can bind to or inhibit key components of the various 
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complement pathways. The availablity of recombinant BapC from E. coli pET33b (BapC) 
(section 3.20), constructed in this study, should greatly facilitate this investigation.  
Another line of investigation would be to restore the ability of the BapC-deficient mutants 
to resist killing by serum or complement by allowing the spontaneous deposition of 
purified recombinant BapC protein on their surface and then performing serum killing 
assays on these strains along with parent and untreated bapC mutant strains. A similar 
experiment was performed using a purified preparation of BrkA with a brkA mutant and 
the outcome of the experiment confirmed the role of BrkA in serum resistance (Oliver and 
Fernandez, 2002). Another investigation would be to restore resistance to serum killing by 
putting back a wild-type copy of the bapC gene on a plasmid into the bapC-mutant strains 
of B. pertussis, in order to confirm the phenotype conferred by bapC. 
4.4 Expression of recombinant BapC 
To determine the role of BapC protein in serum resistance, a large portion of the bapC 
gene that had been cloned in pQE60 plasmid by Blackburn (2000) was expressed in E. coli 
after IPTG induction. Although this part of BapC should not have been expressed on the 
surface of E. coli because of the lack of a signal peptide in its sequence, necessary to target 
the nascent protein to the inner-membrane, the recombinant strain showed a strong 
agglutination reaction with anti-BapC serum. This suggested the presence of BapC on the 
surface and, interestingly, it did confer significant (P value <0.05) serum resistance to the 
host strain when compared to the uninduced strain. This difference was apparent when the 
strains were exposed to the 1/5 dilution of the normal human serum (NHS), which is 
approximately the same concentration as in human lungs (Persson, 1991). Thus, the 
incomplete BapC protein, without the signal sequence, appeared to be reaching the E. coli 
cell surface and conferring serum resistance. However, expression of only part of the N-
terminal sequence (NTS) of the BapC protein without the β-domain conferred no 
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significant resistance in the serum killing assay, at either 1/5 serum dilution of serum or at 
1/10 dilution. It was therefore necessary, in the light of B. pertussis complete genome 
sequence published in database, to express the whole BapC protein, with and without the 
signal sequence, to investigate the role of BapC in serum resistance, or in other virulence 
functions, away from other factors in B. pertussis.  
The identification of the BapC protein in the E. coli expression strain and the resulting 
peptide fingerprinting, after manually excising the bands of interest from an SDS-PAGE 
gel and subjecting the information obtained from MS to the database search, showed that 
the ∼90 kDa band corresponded to the unprocessed form of BapC protein published in the 
database (locus_tag BP2738) with 46% known-peptide coverage. This clearly showed that 
the BapC in B. pertussis strain BP338, a Tohama derivative, would indeed be expressed in 
this strain.  
The properties of E. coli pET33b (BapC ± SS) strains were not investigated in the present 
study because of lack of time. However, it would clearly be of interest to compare the 
serum sensitivity of the parent E. coli pET33b without insert, and those strains expressing 
full-length BapC, with and without the signal sequence. It was surprising that E. coli 
pQE60 (ATG1) expressing the incomplete protein, without the signal sequence and part of 
the N-terminus appeared to express the protein on its surface, as judged by its strong 
agglutination by anti-BapC serum and increased resistance to complement. Similar studies 
could be done with E. coli pET33b (BapC) strains, without induction or induced perhaps to 
different levels with IPTG, so that the protein is not grossly over-expressed. It would be of 
great interest to determine if the recombinant BapC is exported and processed in the same 
way as in B. pertussis. The great advantage of expressing BapC in E. coli is that it would 
be away from other potential serum resistance factors of B. pertussis and its properties for 
example as an adhesin, as well as a serum resistance factor might be easier to characterize.   
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It would also be of interest to investigate the mouse protection ability of purified 
recombinant BapC. This might have implications towards the use of BapC as an additional 
protective antigen in enhancing the protective efficacy of the new generation of acellular 
pertussis vaccines.  
4.5 Role of BapC in susceptibility to antimicrobial 
peptides (AMPs) 
It should be mentioned that lysis of Gram-negative bacteria by complement is due to the 
insertion of the C9 component of the membrane attack complex into the cytoplasmic 
membrane, which is analogous to the mechanism of killing by antimicrobial peptides in  
that lysis is also dependent on insertion of the peptide into the cytoplasmic membrane. 
Since BapC and BrkA proteins confer resistance levels to killing by complement, it was 
decided to examine and compare the susceptibility of their mutants to killing by 
antimicrobial peptides (AMPs). 
In these experiments, the BP338 (BrkA-, BapC-) mutant was found to be more susceptible 
to killing by cecropin P1 than the single BrkA- or BapC- mutants (P<0.05), but less 
susceptible than BP338 (Bvg-). The order of susceptibility to cecropin P1 in B. pertussis 
strains was approximately in the same order as serum sensitivity, suggesting a possible role 
for BrkA and BapC proteins in resitance to killing by some antimicrobial peptides and the 
possibility that the same mechanisms may be involved. Since BP338 (BrkA-, BapC-) was 
not as sensitive as the Bvg- strain, this again suggests that B. pertussis factors other than 
BrkA and BapC can confer resistance to cecropin P1, just like resistance to complement. 
Modulated strains were not tested in these experiments, but testing these would help to 
support this hypothesis. Fernandez and Weiss (1996) found the same order of resistance to 
cecropin P1 with some of the same strains: BP338 > BP338 (BrkA-) > BP338 (Bvg-). They 
also reported that the sensitivity of the mutant strains to mastoparan was equal to that of 
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the B. pertussis wild-type strains, as found here. The susceptibility of BP338 (Bvg-) to the 
different antimicrobial peptides was consistent with the work of Fernandez and Weiss 
(1996), since it was markedly (P<0.05) less susceptible to protamine than other strains and 
had nearly equal susceptibility (P>0.05) to mastoparan compared to B. pertussis wild-type 
and BapC- or BrkA- derivative strains. In this study, the B. pertussis wild-type strains were 
more sensitive than their BrkA, BapC single or BrkA; BapC double mutant strains to 
killing by protamine. Overall, therefore, the evidence suggests that BapC, like BrkA, 
seems to confer resistance to at least one antimicrobial peptide, cecropin P1, but may 
possibly contribute to sensitivity to protamine.  
AMPs are natural antibiotics that constitute a major part of the innate immunity of a wide 
range of organisms including humans. To date, more than 130 different AMPs have been 
characterised biochemically and have been shown to exhibit considerable variation both in 
amino acid sequence as well as in their secondary and tertiary structures. AMPs are small, 
most range from 14 to 40 amino acids in length, and polycationic amphipathic compounds 
(Reddy et al., 2004). The most studied group of antimicrobial peptides includes linear, 
mostly helical, peptides (40 amino acids) that are toxic to bacteria only, such as cecropins 
isolated from the cecropia moth or magainins from the skin of frogs. Although linear 
peptides vary considerably in their chain length, hydrophobicity and distribution of 
charges, they share common motifs. Although the exact mechanism by which this family 
of antimicrobial peptides kills bacteria is not clearly understood, it has been shown that 
peptide-lipid interaction, rather than a receptor-mediated recognition process, plays a major 
role in their function. The essential role of AMPs is in the first line of defence against 
invading pathogens and their uncontrolled proliferation. It is believed that antimicrobial 
peptides, with very few exceptions, exert their activities to kill bacteria through interaction 
with the cytoplasmic membrane where they may cause leakage of cytoplasmic materials, 
and/or inhibiting membrane-associated functions like nutrient transport and energy 
transduction and/or cell lysis. It has been described that the membrane permeation by these 
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antimicrobial peptides occurs through one of the two general mechanisms: (A) 
transmembrane pore formation via a “barrel-stave” mechanism, or (B) membrane 
destruction/solubilisation via a “carpet-like” mechanism (Shai, 1999; Reddy et al., 2004) 
such as in cecropin P1 (Yeaman and Nannette, 2003). Most of these peptides exhibit 
broad-spectrum antimicrobial activity in that they kill both Gram-negative and Gram-
positive bacteria, and some are even effective at killing fungi or inactivating enveloped 
viruses (Reddy et al., 2004).  
There are some exceptions to this broad-spectrum activity: the animal-derived peptides 
such as magainin 2, are more effective at killing Gram-negative bacteria, whereas the 
insect-derived peptides such as mastoparan, tested against B. pertussis in the present study, 
are known to be more potent against Gram-positives. Although, there is agreement on the 
ability of these peptides to disrupt membranes, a specific target within the cytoplasmic 
membrane (or the cytoplasm) has not been demonstrated. However, in addition to the 
cytoplasmic membrane as the target of peptide activity, there has been reported that AMPs 
have a lethal effect solely through an interaction with the cell surface outside the 
cytoplasmic membrane, e.g., by disrupting the outer membrane of Gram-negative bacteria. 
Nevertheless, studies on the mode of action of magainin 2 and protamine have shown that 
disruption of the outer-membrane was not in itself sufficient to infer cell killing (Aspedon 
and Groisman, 1996). AMPs, with some exceptions carry a net positive charge although 
they may differ in their amino acid sequence and three-dimensional structure.  
Although Gram-negative and Gram-positive bacteria differ in their cell envelope 
architecture, they are alike in that their cell surfaces usually carry a net negative charge. 
Thus, the initial bacterium-peptide interaction is an electrostatic attraction between the 
positively charged peptide and a negatively charged cell surface. The acidic groups (e.g., 
phosphates) residing in the teichoic acids associated with the cell wall confer this net 
negative charge in Gram-positive bacteria. In Gram-negative bacteria, it is the 
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lipopolysaccharide (LPS) in the outer membrane that bears the negative charge. It is 
expected that a resistance mechanism employed by bacteria is a reduction in the net 
negative charge of the cell surface. This reduction, which is not the only way to resist to 
the peptides, is influenced by the substitution of negatively-charged groups in the cell 
envelope with neutral or positively-charged moieties (Yeaman and Nannette, 2003). 
Stabilisation of the LPS in the outer-membrane bilayer so that there is less exposure to 
displacement by the peptide is another mechanism to be employed by the cell to reduce the 
uptake of AMPs. Mg+ serves to stabilise the LPS, and ultimately outer membrane integrity, 
by bridging adjacent LPS molecules through ionic association with phosphate residues on 
the lipid A core. Disruption of outer membrane integrity by AMPs is achieved through 
displacing Mg+ from the LPS and placing themselves into the outer-membrane bilayer so 
that it becomes permeable to the peptides or other compounds such as detergents.   
Another type of intrinsic resistance to antimicrobial peptides can be achieved by peptide 
and potassium transporters, as described by the sap (sensitive to antimicrobial peptides) 
regulon in Salmonella spp. The Sap system is thought to mediate resistance to AMPs by 
transporting them into the cytoplasm (and away from their putative membrane targets) 
where they are either degraded by peptidases or can initiate a regulatory cascade resulting 
in the activation of the resistance determinants (Parra-Lopez et al., 1993). BrkA and BapC 
are not like the Sap proteins in terms of sequence comparisons (Appendix AII.4 and AII.5) 
and so presumably do not operate in the same way.  
BrkA and BapC, because of their predicted location on the surface of the bacterium and by 
the predicted negative charge (pI 5.89 for BrkA and pI 5.13 for BapC) of their processed 
forms, may be involved as barriers in the outer membrane to prevent puncture by the 
cationic cecropin P1 peptide. The resistance of the avirulent bvg mutant strain BP347 to 
killing by protamine compared to the susceptibility of the wild-type, brkA, bapC, or 
brkA;bapC mutants is interesting. The presence of a crystalline porin structure which is 
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unique to the avirulent form of B. pertussis (Kessel et al., 1988), or the product(s) of a bvg-
repressed gene might be possible explanations. In brief, B. pertussis strains appear to 
exhibit a broad range of susceptibility to different kinds of AMPs. For one of these 
peptides, cecropin P1, the wild-type B. pertussis strains were relatively more resistant to 
killing compared with the brkA, bapC or brkA;bapC mutants and bvg mutant strain, and 
this may reflect a possible role for BrkA and BapC in the pathogenesis of whooping cough 
via resistance to killing by some AMPs in the human respiratory tract. However, it would 
be of greater interest to examine those peptides such as tracheal or lung AMPs (the effector 
molecules of the innate respiratory immune systems, expressed constitutively in the human 
adult and newborn lungs and trachea, such as human beta-defensin, hBD-1) that are 
present in the human respiratory tract, which is the colonisation site by B. pertussis. 
However, commercial products were not available at the time of the experiments. A 
porcine beta-defensin 1 (pBD-1), which is the only well-studied beta-defensin with 
significant homology to human beta-defensins, was found to demonstrate resistance 
against infection of the upper respiratory tract with B. pertussis in older piglets. 
Furthermore, treatment with pBD-1 conferred complete protection of newborn piglets from 
intrapulmonary infection with B. pertussis (Elahi et al., 2006). Another way of 
characterizing the role of BapC in resistance to AMPs, as well as its role in serum 
resistance, would be to study the recombinant form expressed in E. coli pET33b (BapC), 
away from other B. pertussis factors.  
Although most studies of antimicrobial peptides have focused on their individual action on 
antimicrobial activity, it is apparent that AMPs function together with other components of 
the innate and adaptive immune systems. Recent data suggest that not only chemokines 
and other chemoattractants but also α-defensins, β-defensins display chemotactic activity 
for various cell types (Yang et al., 2001). Neutrophil α-defensins are also chemotactic for 
immature dendritic cells, for resting CD4+ T cells, and for CD8+ T cells (Yang et al., 
2001). α-defensins also regulate processes such as complement activation, fibrinolysis, 
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mast cell degranulation and regulation of endogenous cortisol production (van Wetering et 
al., 1999).      
4.6 Effect of BapC protein on virulence of B. pertussis for 
mice 
The development of pertussis infection is thought to begin with entry of B. pertussis into 
the respiratory tract of a susceptible host with the help of a variety of surface-exposed 
virulence-related proteins that allow its attachment to cilia in the respiratory mucosa. The 
colonisation of the ciliated epithelial cells in human respiratory tract is mediated by 
attachment proteins such as fimbriae, pertactin, tracheal colonisation factor, pertussis toxin 
and filamentous haemagglutinin. Evasion of host defence is a second requirement, which is 
presumed to be facilitated by adenylate cyclase toxin, pertussis toxin and serum resistance 
factor (BrkA) and finally local and systemic effects are mediated by tracheal cytotoxin and 
pertussis toxin, respectively. These B. pertussis virulence factors, except TCT, are co-
ordinately regulated by the bvg locus, a two component regulatory system (Smith et al., 
2001).  
Most of the autotransporter proteins in bacteria studied to date that have been characterized 
are associated with virulence (Lipski et al., 2007). The potential role of BapC 
autotransporter protein in virulence of B. pertussis in a mouse model of infection was of 
interest since the BapC amino acid sequence revealed similarity to protein sequences of 
other, better-characterised, autotransporter proteins namely pertactin and BrkA. Moreover, 
a previous study (Bokhari, 2002) had suggested that a bapC mutant of the Taberman I 
strain of B. pertussis was less able to persist and colonise the trachea and the lungs of mice 
compared to its parent strain, which suggested that BapC, like pertactin and BrkA, might 
have a role in colonisation of the respiratory tract of the mouse by B. pertussis. A B. 
pertussis PRN mutant was cleared more quickly from the lungs of intranasally-infected 
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mice than its wild-type strain (Khelef et al., 1994) and a B. pertussis brkA mutant was 
found to be 10-fold less virulent in colonising the respiratory tract (lungs) in intranasally 
challenged infant mice than the parent strain (Fernandez and Weiss, 1994).  
In the present study, isogenic mutant and wild-type strains were compared in competition 
assays to quantify the virulence of individual strains. Preliminary tests with simple 
mixtures of two strains, wild-type and mutant, in a ratio of 1:1, and viable counting on 
plates showed no differences from the expected counts, which indicated no in vitro effect 
of one strain on the other.  
When mice were infected intranasally with these mixtures, the bapC mutant of BP338 and 
the  BP338 (BrkA-) strain were less able to persist in the lungs of mice compared to the 
parent strain, BP338, a nalidixic resistant-derivative of Tohama. Previously the same B. 
pertussis brkA mutant had been found to be 10-fold less virulent in colonising the 
respiratory tract (lungs) than the parent strain (Fernandez and Weiss, 1994). Thus, in the 
present study, the BrkA mutant of BP338 was less able to persist in the lungs of mice but 
not by as much as 10-fold. This difference from the work of Fernandez and Weiss (1994) 
may be a reflection of the different age of mice used for the infection and possibly mouse 
strain differences.  
The data also showed that the BapC mutant of BP338 was less able to survive in the lungs 
compared to the wild-type and even compared to the BrkA mutant of BP338, suggesting 
that it was less virulent than either strain. The BrkA, BapC double mutant of BP338 
showed a significantly lower (P<0.05) survival compared to the wild-type and both single 
mutants of BrkA or BapC, but it was not as poorly virulent as BP347 (Bvg-), which is what 
might be expected as the Bvg- mutant is defective in many virulence-associated factors 
which would still be expressed in BapC and BrkA mutants. It is well-known that BP338 
(Bvg-) has greatly reduced virulence in the mouse model compared to parent strain (Elder 
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and Harvill, 2004). It would seem clear, however, that both BapC and BrkA contribute to 
mouse virulence of B. pertussis.    
The order of virulence determined by the competition assays was: BP338 (W/T) > BP338 
(BrkA-) > BP338 (BapC-) > BP338 (BrkA-, BapC-) > BP347 (Bvg-), which is 
approximately the same as the order of resistance to serum killing; BP338 (W/T) > BP338 
(BapC-) ≥ BP338 (BrkA-) > BP338 (BrkA-, BapC-) > BP347 (Bvg-) and to the 
antimicrobial peptide (cecropin P1); BP338 (W/T) = BP Taberman (W/T) > BP338 (BapC-
) = BP338 (BrkA-) > BP338 (BrkA-, BapC-) > BP347 (Bvg-). Taken together, these 
findings suggest that BapC, like BrkA is an important virulence determinant of B. pertussis 
and also that the resistance to complement and antimicrobial peptides may have important 
roles in virulence. It is also possible that BapC may function as an adhesin, as indicated by 
the preliminary work of Bokhari (2002) but this needs further investigation. 
However, these findings should be treated with caution since they may not reflect the 
natural behaviour of B. pertussis in man and also the initiation of infectious in mice 
requires relatively large challenge doses, which may alter the course of infection since 
smaller doses may colonize the respiratory tract of man in a different way.  
4.7 Sequence of bapC gene in different B. pertussis 
strains and other Bordetella species 
Recently, the gene encoding BapC protein was reported as a pseudogene by Sebaihia in 
2006 with two frame shifts, one in the homopolymeric tract (HPT) of 13 cytosine (polyC) 
and another the in homopolymeric tract of 11 guanine residues at 5’-end of the α-domain 
of bapC of B. pertussis Tohama (locus_tag BP2738). A phase variable poly(C) was also 
reported in B. parapertussis 12822 and probably in B. bronchiseptica RB50, locus_tags 
BPP2591 and BB2033, respectively. B. bronchiseptica was predicted to express the full 
length BapC protein of 998 amino acids, whereas the products from B. pertussis Tohama 
  Discussion      
 
224 
and B. parapertussis strains were predicted to be truncated (Henderson et al., 2004). 
Previous work from this lab (Blackburn, 2000 and Bokhari, 2002) and this present study, 
however, suggested that BapC was produced by B. pertussis Taberman and the Glasgow 
University strain of Tohama. To address this apparent discrepancy, the 5’-end of the bapC 
gene was sequenced from chromosomal amplicons of a selection of B. pertussis strains and 
the nucleotide and deduced amino acid sequences were aligned. Sequencing was limited to 
the regions with the poly(C) and poly(G) tracts of bapC gene where variations had been 
observed in the Bordetella cluster (B. pertussis, B. parapertussis and B. bronchiseptica). 
Analysis of the regions spanning the poly(C) and poly(G) tracts at the 5’-end of the bapC 
gene in B. pertussis strains revealed polymorphisms varying from 13-15 (C) and 9-12 (G) 
nucleotides. However no difference was found between the numbers of (C) nucleotides in 
BP Taberman (I), BP Tohama (Glasgow University strain), BP PICU, BP338 and BP338 
(BrkA-) strains compared with the published sequence in the database without the frame 
shift (locus_tag BP2738). The 5’-region upstream to the homopolymeric (C) tract in BP 
PICU, BP Taberman (L1) and BP Tohama I strains exhibited 12-amino acid in-frame shift.  
A slightly higher degree of variability was observed in the second sequence repeat (polyG) 
of the bapC gene in B. pertussis strains. Analysis of the poly(G) homopolymeric tract 
showed a polymorphism which varied from 9(G) in BP Tohama (Glasgow University 
strain) to 12(G) in BP338 strain. The multiple alignment of deduced amino acid sequences 
was interesting as this revealed an additional in-frame amino acid glycine in the 
chromosomal amplicons of B. pertussis strains apart from BP18323, a standard B. pertussis 
strain. An in-frame 11-amino acid shift downstream to the poly(G) region in BP PICU 
strain was observed, a probable consequence of two additional (G) nucleotides compared 
with the database.  
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Gogol et al. (2007) examined a collection of 90-geographically separate-isolates of B. 
pertussis for phase variation at HPTs including those in bapC, and found (G) alleles 
varying from G8 to G12 using colony PCR/LDR (polymerase chain reaction / ligase 
detection reaction), an ideal method for detecting rare genotypes within a mixed sample. In 
most of these cases, mixed allelic content was verified by sequencing of individual strains 
(Gogol et al., 2007). The HPTs in BapC varied widely across the strain collection and 
allelic polymorphisms were detected even within a single round of culture (109 bacteria 
grown from a single colony). The predominant bapC HPT allele in 76/90 isolates was G11 
but even some of these isolates contained a detectable fraction of both G11 and G12 
alleles. Six strains carried primarily the G10 allele, two strains the G9 and four the G8 
allele. Gogol et al. (2007) noted that the G11 allele, as in the Tohama genome sequence, 
causes a shift in the reading frame, predicted to result in a truncated BapC protein whereas 
a single base contraction would restore the reading frame. Similar allelic contractions and 
expansions can occur in the poly(G) tract of the tcfA gene in B. pertussis and in 
recombinant E. coli strains, leading to polymorphisms and phase variation (Gogol et al., 
2007; van Gent et al., 2007).  
In a study performed by Packard et al. (2004), polymorphism was found in five genes 
examined, prnA, ptxA, ptxC, tcfA and fim2, in a large number of B. pertussis isolates from 
the UK collected between 1920 and 2002. No polymorphism or sequence variation was 
found in the brkA, bapC, cyaA, vag8 and ompQ genes; except a single nucleotide 
difference (a silent SNP) at position 2601 (2159 based on Henderson’s nucleotide sequence 
of bapC gene) in bapC of all nine isolates. However, the five primer sets used for bapC 
only covered nucleotides 661-2990 (position 219-2548 based on Henderson’s nucleotide 
sequence of bapC gene), starting downstream of the two potential phase variable 
homopolymeric C and G nucleotides tract.  
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A premature stop codon in bapC of B. pertussis Taberman (I) could be as a result of a 
frameshift in the homopolymeric (G) nucleotide tract upstream to this stop codon and 
consequently the disruption of the coupling of transcription and translation and eventually 
terminating the translation or could simply be result of a mismatch or error in PCR 
reaction. Expansion or contraction of the number of nucleotides in multiples of three, such 
as in B. pertussis BP 18323 (Table 3.4), could cause a size polymorphism of the protein or 
intriguingly change the function. AhpC protein of E. coli was described as having a simple 
reversible triplet expansion event in its coding sequence which altered function from a 
peroxiredoxin to a disulfide reductase in response to stress conditions (Ritz et al., 2001).  
It can therefore be concluded from the above observations that, although the entire bapC 
gene was not sequenced in these different B. pertussis strains, there are some minor 
nucleotide and amino acid changes in some strains but it is likely that all would be able to 
produce some form of BapC, unlike the B. pertussis Tohama genome strain. Thus, the data 
supported the findings by Blackburn (2000) and Bokhari (2002) that B. pertussis Tohama 
(Glasgow strain) and Taberman produce BapC protein.  
Repetitive DNAs are common in eukaryotic cells, and are frequently located in extragenic 
regions. They are also becoming increasingly recognised in prokaryote genomes. 
Repetitive DNAs consist of simple homopolymeric tracts of a single nucleotide type 
[poly(A), poly(C), poly(G) or poly(T)] or a group of large or small numbers of several 
multimeric classes of repeats. These simple sequence repeats are involved in various 
mechanisms of gene regulation. Multimeric repeats are composed of identical units 
(homogeneous repeats) such as (PQP)5 in pertactin, mixed units (heterogeneous repeats), 
or degenerate repeat sequence motifs. Monomeric sequences of variable length are tandem 
repeats, also called simple sequence repeats (SSRs). Their variability in repeat number is 
caused by slipped-strand mispairing, and is a mechanism for phase variation in e.g. 
fimbrial variation of B. pertussis. Mismatching of the neighbouring repeats in the tertiary 
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structure of DNA, results in insertion or deletion of nucleotides repeats during duplication 
mediated by DNA polymerase (Coenye and Vandamme, 2005). Those simple sequence 
repeats with longer monopolymeric nucleotides are more susceptible to slipped-strand 
mispairing and consequently show more mutability in their length than the shorter 
homopolymeric nucleotides. More presentation of A and T nucleotides in sequence repeats 
might possibly be explained by the fact that these nucleotides need less energy than C and 
G nucleotides for strand separation in slipped-strand mispairing (Coenye and Vandamme, 
2005). SSR loci have high mutation rates, ranging from 10-3 to 10-6 per generation (Xu et 
al., 2000). This high mutability is thought to play an important role in genome evolution 
via creating and maintaining genetic variation (Tautz et al., 1986).  
It has been shown that the number of mononucleotide repeats is correlated with genome 
size and GC content. Morgante et al. (2002) found that the overall SSR abundance was 
proportional to the genome size. In B. bronchiseptica, B. parapertussis and B. pertussis 
with 5.3, 4.7 and 4 million nucleotides, there are 7041, 6134 and 5684 mononucleotide 
repeats, respectively (Coenye and Vandamme, 2005). Intrinsic instability is one of the 
hypotheses for environmental selection to facilitate the process of evolutionary change by 
exploiting these “adjustable tuning knobs”. These repeats may reflect a strategy to cope 
with stresses (Rocha et al., 2002) and may have enormous potential as major sources of 
genomic and phenotypic diversity (Rocha, 2003). 
It is thought that the limitation of genetic diversity in many pathogens such as Bordetella 
species might be overcome by high frequency phase variation to adapt to the hostile and 
changing host environment. Reversible expansion or contraction of homopolymeric tracts 
(HPTs) are one of the most common mechanisms of phase variation (Gogol et al., 2007) to 
evade the immune system.               
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Variation in numbers of sequence repeats is also one possible mechanism of regulation of 
gene expression via altering the conserved spaces between important domains such as -35 
and -10 promoter regions and in the evolution of gene regulation (Huang et al., 2003). It 
has been discovered that a stretch of ∼15(C) nucleotides in the promoter region of the fim 
genes in B. pertussis is responsible for fimbrial phase transitions, by small insertions or 
deletions of 1-5 bp in this C-rich region (Willems et al., 1990). This affects the distance 
between the putative -10 box and the transcriptional start site. By this means, B. pertussis 
strains can switch on and off the expression of the fimbrial types 1, 2 and 3 independently, 
so that strains can vary between serotypes 1; 1, 2; 1, 3; 1, 2, 3. However, the activity of 
these promoters and consequent gene expression may be more subtly regulated by HPT 
expansions and contractions rather than a threshold of bases between the activator binding 
region and the -10 box (Gogol et al., 2007) as the HPT regions (such as C stretch regions) 
are hotspots for small insertions (duplications) or deletions due to transient misalignment 
during replication (Streisinger and Owen, 1985). Differences in DNA bending due to 
repeat sequences affecting DNA topography can also influence promoter strength and 
ultimately change gene expression (Perez-Martin et al., 1994). 
Another possible mechanism of regulation of gene expression by gaining or losing simple 
sequence repeats, a recA independent mechanism, is to change the integrity of ORFs (open 
reading frames) and result in phase variation via shifting in and out of frame (depending on 
the start of translation), which results in on-off switching of the gene product. This is more 
like the BapC situation, than fimbrial variation, since the Cs and Gs are not in the promoter 
region. The possibility of switching BapC on and off, according to the data of Gogol et al., 
(2007), could be a means of antigenic variation in B. pertussis (and possibly other 
Bordetellae) in order to stay one step ahead of the host immune system (like fimbrial 
variation-alteration of adhesins). Both BrkA and BapC appear to confer serum resistance, 
and B. pertussis appears to switch BapC off and on very readily. No such mechanism has 
been reported for BrkA so even the BapC mutants will have some residual serum 
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resistance, as shown in the present study. However, it has been shown by real-time RT-
PCR that the level of expression of the brkA gene and the relative amounts of brkA 
transcripts at different time points are strain dependent (Stefanelli et al., 2006).  
In future studies on BapC expression in different strains and species, in terms of observing 
frequent phase variation at the homopolymeric tract (HPT) in the coding region of the 
bapC gene, it would be advisable to check representative colonies of each strain or species, 
to determine whether BapC is expressed. Also, BapC expression could be quantified by 
real-time RT-PCR, then the sequence of the bapC gene in the individual clones analysed. 
Selection of phase variable poly(C) or (G) in B. pertussis strains could be evaluated by 
sequencing stored human isolates or studied in vivo by inoculating B. pertussis strains with 
variable poly(C) or poly(G) tracts in mouse and then direct sequencing of DNA from 
tracheal or lung samples taken 1-2 weeks after inoculation. The differences of these two 
repeated regions (C and G) could also be analyzed in B. parapertussis isolates of human 
and sheep origin and B. bronchiseptica isolates of animal and human origin, to examine 
any host specificity with respect to these Bordetella species.          
Evidence for the presence of the bapC locus or homologous sequences was detected in the 
genome of other Bordetella species using DNA hybridisation with a bapC probe. It showed 
and confirmed the presence of bapC in B. pertussis, B. parapertussis and B. bronchiseptica 
and this agrees with our knowledge of the genomes of these three species. However, no 
evidence of the bapC or any orthologous gene was found in the other Bordetella species 
examined, reflecting the known restricted genetic diversity between these three closely-
related organisms (Parkhill et al., 2003; Preston et al., 2004; Sebaihia et al., 2006).                                       
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4.8 Comparative analysis of BapC with BrkA and 
pertactin 
Bioinformatics is the combination of biology and information technology. Bioinformatics 
incorporates the development of databases to store and search data, and of statistical tools 
and algorithms to analyze and determine relationships between biological data. To 
represent nucleic acid or protein sequences, the conventional FASTA format is generally 
employed. Multiple sequence alignment can be performed to illustrate relationships 
between two or more sequences, and it can reveal many clues regarding protein structure 
and function.  
The theory underlying a sequence similarity search is that similar sequences are likely to 
be homologous and therefore to have similar functions. However, any pair of DNA 
sequences may show some degree of similarity; sequence alignment is the first step in 
quantifying this in order to distinguish between chance similarity and real biological 
relationships and can show the differences between sequences as changes (mutations), 
insertions or deletions. Protein sequence alignment can reveal more distant evolutionary 
relationships than comparison of nucleic acid sequences (Eddy, 1998). Multiple alignment 
is more informative than pair-wise sequence alignment concerning evolutionary 
conservation since, when a residue is conserved in a family of sequences, it indicates that 
the residue might play a key structural or functional role (Eddy, 1998). 
4.8.1 Protein comparison 
The databases were searched for the best homologies or similarities with BapC using 
BLAST and FASTA (SwissProt). The best match for BapC was the Bordetella outer 
membrane protein pertactin which had also been shown for BrkA (Fernandez and Weiss, 
1994). Although BrkA and BapC are 100 and 80 amino acids larger than pertactin, 
respectively, BrkA was found to be 29% identical and 40% similar to pertactin over a 
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common stretch of about 910 amino acids and BapC was 36.8% identical and 59.4% 
similar to pertactin over the same amino acid length, using Needle (global) pairwise 
alignment algorithms with Blosum62 matrix 
(http://www.ebi.ac.uk/emboss/align/index.html?). Moreover, BrkA and BapC exhibited 
30.8% identity and 56.2% similarity in their whole amino acid sequences using the same 
tool and parameters.  
BapC was previously predicted to be a protein of ∼79.5 kDa according to the sequence data 
of Blackburn (1998) and Henderson (2000). Available B. pertussis genome sequence 
published in 2003, allowed prediction of signal sequence and the consequent actual BapC 
protein. The predicted molecular weight of BapC using ExPASy ProtParam tool (section 
2.14) revealed a 104 kDa protein with an α-domain of 71 kDa after cleaving the signal 
sequence and C-terminus. However, the anti-BapC serum reacted with the whole cell 
fractions of B. pertussis strains at around ∼90 kDa in immunoblotting experiments. This 
anomaly can be compared with the anomalous mobility of PRN on SDS-PAGE, whose 
processed passenger domain is actually 61 kDa, but runs at 69 kDa on SDS-PAGE. 
However, the anti-BapC serum also cross-reacted to some extent with the BrkA protein 
(∼73 kDa) in the whole cell and outer membrane-enriched fractions of B. pertussis, which 
might be due to the existence of common epitopes.   
A comparison of the noticeable features of BapC with BrkA and pertactin determined 
using CLUSTALW [http://www.ebi.ac.uk/clustalw] and MUSCLE (Multiple Sequence 
Comparison by Log-Expectation) [http://www.ebi.ac.uk/muscle] tools (Fig. 4.1). Jalview 
version 2+, a multiple alignment editor, was used to edit alignments and for the analysis of 
sub-families, prediction of functional sites and analysis of the conservation patterns.           
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Figure 4.1 Alignment of protein sequences of BrkA, BapC and pertactin 
 
pertactin       ------MNMSLSRIVKAAP--LRRTTLAMALGALGAAPAAHADWNNQ------------- 39 
BapC            ------MNDRKSNSMSPAARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEVAKIEALS 54 
BrkA            MYLDRFRQCPSSLQIPRSAWRLHALAAALALAGMARLAPAAAQAPQPPVAGAPHAQDAGQ 60 
                       :   *  :  :.  *:  . *:*  . .  ..: .:                  
pertactin       --SIVKTGERQHGIHIQ--GSD------------------------PGGVRTASGTTIKV 71 
BapC            DADIYSDYEHEHGIVMTPDGKDDYISYRSAESGRPKPPPPLSNFKPLGNDVVAERIRVEV 114 
BrkA            EGEFDHRDNTLIAVFDDGVGINLDDDPDELGETAPPTLKDIHISVEHKNPMSKPAIGVRV 120 
                  .:    :   .:     * :                          .        :.* 
pertactin       SGRQAQGILLENPAAELQFRNGSVTSSGQLSDDGIRRFLGTVTVKAGKLVADHATLAN-- 129 
BapC            HGDETLGVYVDSEHRSLTVRDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNY 174 
BrkA            SGAGRALTLAGSTIDATEGGIPAVVRRGGTLELDGVTVAGGEGMEPMTVSDAGSRLSVR- 179 
                 *         .          ::   *   . .     *   : . .:    : :     
pertactin       VGDTWDDD-GIALYVAGEQAQASIADSTLQGAGG-VQIERGANVTVQR------------ 175 
BapC            AAQPFEDAVGVGVTSLGDKAILNVTDSEVSGARG-AVIGWGGEATFTD------------ 221 
BrkA            GGVLGGEAPGVGLVRAAQGGQASIIDATLQSILGPALIADGGSISVAGGSIDMDMGPGFP 239 
                 .    :  *:.:   .: .  .: *: :..  * . *  *.. :.               
pertactin       ---SAIVDGGLHIGALQSLQPEDLPPSRVVLRDTNVTAVPASGAP-AAVSVLGASELTLD 231 
BapC            ---SVLRGSAFGLYAEMCDTCRDDDGTSPSIRVQGGVVQGGMGANNVAVVATGSGKVAIE 278 
BrkA            PPPPPLPGAPLAAHPPLDRVAAVHAGQDGKVTLREVALRAHGPQATGVYAYMPGSEITLQ 299 
                   . : .. :   .               :     .          .     ..::::: 
pertactin       GGHITGGR-----AAGVAAMQGAVVHLQRATIRRGDAPAGGAVPGGAVP----GGAVPGG 282 
BapC            NAELLGASGMYATFGAQVDMKGGRILAHNTNILGSQGYADGPYGGVVVTE--DGQVNLEG 336 
BrkA            GGTVSVQGDDGAGVVAGAGLLDALPPGGTVRLDGTTVSTDGANTDAVLVRGDAARAEVVN 359 
                .. :           . . : ..      . :      :.*.  . .:     . .   . 
pertactin       FGPGGFGPVLDGWYGVDVSGSSVELAQSIVEAPELGAAIRVGRGARVTVSGGSLSAPHGN 342 
BapC            AKVSATGLGAAGLWLLGDKDTSPRASLRNTDVHGEVAAIALGFNGEANISGGSLSVEDGA 396 
BrkA            TVLRTAKSLAAGVSAQHGGRVTLRQTRIETAGAGAEGISVLGFEPQSGSGPASVDMQGGS 419 
                           *         : . :   .      .   :*   .   . .*:.   *  
pertactin       VIETGG------------ARRFAPQAAPLS---ITLQAGAHAQGKALLYRVLPEPVKLTL 387 
BapC            VLTTLTPDAVEYYYDYALSMEHLPADAPLTPVRVTLSDGARASGETLIAHGGLLPMTLRL 456 
BrkA            ITTTGN-----------RAAGIALTHGSARLEGVAVRAEGSGSSAAQLANGTLVVSAGSL 468 
                :  *              :       ..     :::   . ... : : .         * 
pertactin       TGGADAQGDIVATELPSIP----GTSIG-------------------------------- 411 
BapC            SSGVDARGDIVTLPPSAPP----DSAEQPDAEPEPDAELEPDAAAQSDAKANARVMAQVD 512 
BrkA            ASAQSGAISVTDTPLKLMPGALASSTVSVRLTDGATAQGGNGVFLQQHSTIPVAVALESG 528 
                :.. ..  .:.       *    .::                                   
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pertactin       -----------------PLDVALASQARWTGATRAVDSLSIDN-ATWVMTDNSNVGALRL 453 
BapC            GGEPVAVPIPAPSHPDAPIDVFIDSGAQWRGMTKTVNALRIED-GTWTVTGSSTVNSLHL 571 
BrkA            ALARGDIVADGNKPLDAGISLSVASGAAWHGATQVLQSATLGKGGTWVVNADSRVQDMSM 588 
                                  :.: : * * * * *:.:::  : . .**.:. .* *  : : 
pertactin       ASDGSVDFQQPAEA-GRFKVLTVNTLAGSGLFRMNVFADLGLSDKLVVMQDASGQHRLWV 512 
BapC            QA-GKVAYATPAESDGEFKHLRVKTLSGSGLFEMNASADLSDGDLLVVSDEASGQHKVLV 630 
BrkA            RG-GRVEFQAPAPE-ASYKTLTLQTLDGNGVFVLNTNVAAGQNDQLRVTGRADGQHRVLV 646 
                 . * * :  **   . :* * ::** *.*:* :*. .  . .* * *   *.***:: * 
pertactin       RNSGSEPAS-ANTLLLVQTPLGSAATFTLANKDGKVDIGTYRYRLAANG-NGQWSLVGAK 570 
BapC            RGAGTEPTG-VESLTLVELPEGSQTKFTLANRGGVVDAGAFRYRLTPD--NGVWGLERT- 686 
BrkA            RNAGGEADSRGARLGLVHTQGQGNATFRLANVGKAVDLGTWRYSLAEDPKTHVWSLQRAG 706 
                *.:* *. .    * **.    . :.* *** .  ** *::** *: :  .  *.*  :  
pertactin       APPAPKPAPQPGPQPPQPPQPQPEAPAPQPPAGRELSAAANAAVNTGGVGLASTLWYAES 630 
BapC            ---------------------------------SQLSAVANAALNTGGVGAASSIWYAEG 713 
BrkA            ---------------------------------QALSGAANAAVNAADL---SSIALAES 730 
                                                   **..****:*:..:   *::  **. 
pertactin       NALSKRLGELRLNPDAGGAWGRGFAQRQQLDNRAGRRFDQKVAGFELGADHAVAVAGGRW 690 
BapC            NALSKRLGELRLDPGAGGFWGRTFAQKQQLDNKAGRRFDQKVYGFELGADHAIAGQQGRW 773 
BrkA            NALDKRLGELRLRADAGGPWARTFSERQQISNRHARAYDQTVSGLEIGLDRGWSASGGRW 790 
                ***.******** ..*** *.* *:::**:.*: .* :**.* *:*:* *:. :   *** 
pertactin       HLGGLAGYTRGDRGFTGDGGGHTDSVHVGGYATYIADSGFYLDATLRASRLENDFKVAGS 750 
BapC            HVGGLLGYTRARRSFIDDGAGHTDSAHIGAYAAYVADNGFYFDSTLRASRFENDFTVTAT 833 
BrkA            YAGGLLGYTYADRTYPGDGGGKVKGLHVGGYAAYVGDGGYYLDTVLRLGRYDQQYNIAGT 850 
                : *** *** . * : .**.*:... *:*.**:*:.*.*:*:*:.** .* ::::.::.: 
pertactin       DGYAVKGKYRTHGVGASLEAGRRFTHADGWFLEPQAELAVFRAGGGAYRAANGLRVRDEG 810 
BapC            DAVSVRGKYRANGVGATLEAGKRFTLHDGWFVEPQSEVSLFHASGGTYRAANNLSVKDEG 893 
BrkA            DGGRVTADYRTSGAAWSLEGGRRFELPNDWFAEPQAEVMLWRTSGKRYRASNGLRVKVDA 910 
                *.  * ..**: *.. :**.*:**   :.** ***:*: ::::.*  ***:*.* *: :. 
pertactin       GSSVLGRLGLEVGKRIELAGGRQVQPYIKASVLQEFDGAGTVHTNGIAHRTELRGTRAEL 870 
BapC            GTSAVLRLGLAAGRRIDLGKDRVIQPYATLSWLQEFKGVTTVRTNGYGLRTDLSGGRAEL 953 
BrkA            NTATLGRLGLRFGRRIALAGGNIVQPYARLGWTQEFKSTGDVRTNGIGHAGAGRHGRVEL 970 
                .::.: ****  *:** *. .. :***   .  ***...  *:*** .        *.** 
pertactin       GLGMAAALGRGHSLYASYEYSKGPKLAMPWTFHAGYRYSW 910 
BapC            ALGLAAALGRGHQLYTSYEYAKGNKLTLPWTFHLGYRYTW 993 
BrkA            GAGVDAALGKGHNLYASYEYAAGDRINIPWSFHAGYRYSF 1010 
                . *: ****:**.**:****: * :: :**:** ****:: 
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Signal sequence (peptide): Pertactin: 34 aa (grey), BrkA: 42 aa (Oliver et al., 2003) 
(blue), BapC: 38 aa (this study, green) {45 aa predicted by Henderson et al., (2004)}.  
RGD motifs (green): Pertactin: 2, BrkA: 2, BapC: 1 
SGXG motif (grey): Pertactin: 0, BrkA: 2, BapC: 1 
Glu601–Ala692 (Blue-bold type): A conserved region within the Bordetella pertussis 
autotransporter BrkA, necessary for folding of its passenger domain (Oliver et al., 2003). 
Val472-Leu566 in pertactin: probably promotes folding of the passenger domain and is 
associated with protective immunity in a mouse aerosol model (Charles et al., 1991).  
Processing site: Asn731- Ala732 in BrkA (yellow), Asn631- Ala632 in pertactin (yellow), 
Asn714- Ala715 in BapC (with signal sequence) (blue). 
 
Arg260-Gly294 in pertactin: RGD motif is in the T1 loop of pertactin 
 
GGXXP5 : a heterogenic amino acid repeats in pertactin (region 1) 
 
Consensus symbols:  
An alignment displays by default the following symbols denoting the degree of 
conservation observed in each column: 
"*" means that the residues or nucleotides in that column are identical in all sequences in 
the alignment. 
":" means that conserved substitutions have been observed. 
"."means that semi-conserved substitutions are observed. 
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The most striking identities were found in the C-terminal ends (β-domain) of the three 
proteins. The BapC and BrkA proteins are 63% similar, BapC and pertactin are 79% 
similar, and BrkA and pertactin are 54.5% similar over their last 300 amino acids, as 
determined by BLASTp analysis (data not shown). They share a C-terminal outer 
membrane localisation motif (FHA/LGYRYS/TW/F), which consists preferentially of 
amino acid residues with hydrophobic side chains such as phenylalanine or tryptophan in 
the last nine C-terminal residues. The overall similarity of these β-domains is perhaps not 
surprising given that the function of these moieties is to form a β-barrel. Generally, the C-
terminus domains of autotransporters are composed of 250-300 amino acid residues, which 
all show some homology but vary in their sequences (Henderson et al., 2004). The amino 
acid sequence similarity of the passenger domains (α-domains) of BapC/BrkA and 
BapC/pertactin were 36.4% and 40.3%, respectively (data not shown).    
With regard to the signal sequence in these proteins, recent analysis of BrkA using the 
SignalP v.2.0 hidden Markov model method, and recent experiments, have shown a 
processing cleavage site between residues Ala42 and Gln43 (Oliver et al., 2003). Henderson 
et al. (2004) have reported a 34 amino acid signal sequence for pertactin and a predicted 45 
amino acid sequence for BapC. However, in this study, analysis of BapC in B. pertussis, B. 
parapertussis and B. bronchiseptica using SignalP v.3.0 (released 2004) revealed a signal 
peptide with a maximum cleavage site probability between amino acid residues Ala38 and 
Gln39 (Figs. 3.49, 3.50, 3.51).   
The transport mechanism of the passenger domain of the autotransporters across the outer 
membrane remains undefined, although four models of translocation such as hairpin, 
threading, multimeric and Omp85 (YaeT) have been proposed (see section 1.6.5). 
Kostakioti and Stathopoulos (2006) revealed that a strictly conserved 14-amino-acid motif 
(EVNNLNKRMGDLRD) within the predicted α-helical linker region, upstream of the β-
domain of SPATEs (serine protease subfamily of autotransporters) is important for 
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passenger secretion across the outer membrane and confers polarity on the helical 
structure. Mutation in this region showed a severe effect on the secretion process and seven 
of these amino acid residues are essential.  
The proteolytic processing site at amino acid 715 of BapC is located at the α-helical region 
of the N-terminus of the β-domain and sequence analysis of this region showed 
homologous or conserved sequences (EGNALSKRLGELRL) with the 14-amino-acid 
residues of the serine protease subfamily of autotransporters. It has been shown that this 
motif was also conserved with slight variations in other autotransporters such as B. 
pertussis BrkA and pertactin (Kostakioti and Stathopoulos, 2006). Sequential deletions or 
site directed mutagenesis of this region in BapC or other autotransporters could uncover 
the potential effect of this α-helical region in the efficiency of translocation.  
It has been shown that a conserved region within the C-terminus of the BrkA passenger 
domain, upstream of the predicted β-domain, from glutamic acid (E) at position 601 to 
alanine (A) at position 692 (Fig. 4.1, blue bold-type sequences) is necessary for correct 
passenger folding (Oliver et al., 2003) and functions as an intramolecular chaperone. The 
observation that this domain is conserved among other autotransporter proteins in Gram-
negative species such as E. coli, Shigella or Serratia, which possess diverse functions, 
suggests a possible general role for this region. It was noted that residues corresponding to 
the conserved region of BrkA (amino acids 606 to 702) in pertactin (amino acids 472 to 
566) were also located at the base of a β-helical structure (Oliver et al., 2003a).   
To identify regions of BapC homologous with the conserved domain in BrkA that might 
indicate a conserved function, a comparative analysis of this junction region in BrkA with 
BapC and pertactin using BLASTp (release 2.2.16) revealed 46% identity and 58% 
similarity between BrkA and pertactin; and 39% identity and 52% similarity between BrkA 
and BapC. Residues Phe588-Thr674 of the BapC passenger, which correspond to residues 
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Tyr604-Ala692 of BrkA, are predicted (by Proteus Structure Prediction Server (release 2.0), a 
secondary structure prediction tool) to be accommodated at the base of a β-strand structure.  
BapC, BrkA and pertactin proteins contain one, two and two arg-gly-asp (RGD) motifs 
respectively (Fig. 4.1) that may promote binding to integrins and are important in adhesion 
to mammalian cells (Wells et al., 2007). However the spacing of the RGDs is not 
conserved between these proteins and, interestingly, the second RGD motif of pertactin 
appears downstream of the processing site in the β-domain, quite far away from the first 
one, and is not a part of the mature protein. The first RGD motif of pertactin is located in 
the T1 loop (Arg260-Gly294) (Fig. 4.1), which is one of the three turns separating the three 
parallel β-strands of the β-helix of pertactin. This T1 loop contains proline-rich repeats, 
GGXXP5, named “region 1”, and is polymorphic in clinical isolates and vaccine strains 
(Mooi et al., 1998) and also associated with protection in an animal model (King et al., 
2001). The RGD motif in BapC is located halfway between the predicted signal sequence 
and processing site, similar to the position of the second RGD in BrkA, (positions 418 and 
490 in BapC and BrkA, respectively). 
In pertactin, there are two PRRs (proline rich regions) that are widely present in proteins 
with binding activity (Emsley et al., 1996). These protruding loop tandem repeat motifs 
interrupt the helical structure of the pertactin and provide a functionally important binding 
site. (GGXXP)5 (starting at position 266, Fig. 4.1) is one of the PRR that appears directly 
downstream of the first RGD motif that probably mediates interaction with epithelial cells, 
and the other is the (PQP)5 motif in the C-terminus of pertactin (starting at position 579, 
Fig. 4.1), which contains the immunodominant region of the protein and is a major 
immunoprotective epitope (Emsley et al., 1996). Unlike pertactin, BrkA and BapC do not 
possess the (GGXXP)5 and (PQP)5 tandem repeats. However, BrkA and BapC do have two 
and one potential glycosaminoglycan attachment sites (SGXG), respectively, which have 
been suggested may be involved in the mechanism for serum resistance in B. pertussis 
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possibly by inhibition of C9 polymerization (Fernandez and Weiss, 1994). This motif is 
absent in pertactin.  
These findings of conserved motifs within the α-helical region of autotransporters may 
provide a new tool(s) for the prevention and treatment of infectious disease as they could 
represent ideal antigens for vaccine development. Moreover, the critical requirement of 
certain residues within the 14-amino-acid passenger secretion motif of autotransporters 
makes them a potential target for novel antimicrobial peptides, as they could interfere with 
interactions necessary for the export or biogenesis of the secreted autotransporter virulence 
factors (Kostakioti and Stathopoulos, 2006). It has been demonstrated that the 
autotransporter proteins such as BrkA can be employed as surface display systems in 
vaccine strains for intranasal administration. Heterologous peptide (neutralizing peptide 
SP70 from enterovirus 71) was fused within the passenger domain of BrkA and expressed 
in the highly-attenuated vaccine strain BPZE1, and had potential ability to deliver 
heterologous vaccine antigens through the nasal route (Ho et al., 2007). 
4.8.2 Gene comparison 
Putative BvgA binding sites have been found in a region between brkA and brkB along 
with a single copy of the sequence TTTCCT upstream of the brkA and two copies 
upstream of brkB (Fernandez and Weiss, 1994). A database search of the upstream 
flanking region of bapC using the B. pertussis TohamaI genome sequence (BLAST search 
at http://www.Sanger.ac.uk/projects/B_pertussis) indicated two potential BvgA binding 
sites (TTTCATA and TTTCGTA) upstream of the bapC gene at positions -230 bp and -
144 bp, respectively (data not shown) from the start of the predicted signal peptide (contig 
BX640419) between a probable ammonium transporter gene (amtB, locus_tag BP2737) 
and the bapC gene. These two potential BvgA binding sites upstream of the predicted 
translational site of bapC are also similar to the characteristic heptameric sequence 
TTTC(C/T)TA identified by Kinnear et al. (1999) upstream of prnA. These sequences, 
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required for regulating the transcription of these genes through interaction with the RNA 
polymerase, are also located upstream of the Bvg-regulated ptx, cya, fha and bvg genes of 
B. pertussis. 
In order to identify the true bvg-dependent transcriptional start site of bapC or to 
characterize the cis-regulatory sequence upstream of and in the bapC promoter, a series of 
plasmid-borne bapC-lac transcriptional fusions should be introduced into B. pertussis 
BP338, a derivative of Tohama I, by conjugation to localize the region that determines the 
bvg-dependent transcriptional activity from the bapC promoter. Such investigations have 
been done for the pertactin gene (Kinnear et al., 1999). For further characterization of 
sequences necessary for bapC activation, the upstream region with lac fusions and with 
sequence alterations could be inserted into the chromosome of this strain. It will then be 
possible to determine the bapC promoter activity using β-galactosidase assays on the 
altered constructs. DNase I protection analysis could also demonstrate the BvgA binding 
site upstream of the putative bapC transcription site.  
No obvious -10 and -35 promoter sequences or Shine-Dalgarno sequences were detected 
either in brkA (Fernandez and Weiss, 1994) or in the bapC gene. Although a transcriptional 
start site was identified by primer extension analysis (Graeff-Wohlleben et al., 1995) in the 
prnA gene for pertactin, no σ70 consensus promoter was found upstream of this site. 
However, later genetic and biochemical analyses performed by Kinnear et al. (1999) 
showed the pertactin gene transcription start site as a cytosine residue located 125 bp 
upstream from the previously reported start site.  
The promoter region of bapC could also be analysed to determine which class of vag it 
belongs to (early or late vag) by determining at what stage it starts to be transcribed 
compared with the other vag genes. This could be performed by the RT-PCR method 
similar to that described earlier by preparing RNA samples at intervals after switching the 
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culture from Bvg- to Bvg+ phase. Alternatively, RNA preparations could be separated by 
electrophoresis in a formaldehyde agarose gel followed by transfer of the RNA to a nylon 
membrane and detecting the relevant RNA by hybridisation with a labelled probe. It could 
also be determined via fusion of the promoter region of bapC to the lac reporter function 
(or GFP or Lux reporters) to allow the time of promoter-activation to be determined.   
A search for similarities to the E. coli known promoter sequences revealed either no or 
only weak homologies. Another attempt to search in the 5’-upstream of bapC gene using 
the Neural Network Promoter Prediction (NNPP) tool (version 2.2) (1999) 
(http://www.fruitfly.org/seq_tools/promoter.html) demonstrated two potential promoters 
upstream of the putative signal peptide with a more than 0.90 cutoff score. One of the 
predicted promoters overlaps with the first potential start codon (0.98 cutoff score) of the 
signal sequence and the other is located 100 bp upstream of the signal sequence start codon 
(0.90 cutoff score) just a few nucleotides downstream of the second potential Bvg binding 
site. Nevertheless, primer extension analysis could identify the transcriptional start site of 
the bapC gene. These two promoters could be consistent with the previous study 
performed by Bokhari (2002) which revealed the existence of another smaller transcript by 
RT-PCR, in addition to one of the expected size, in Taberman I (wild-type) that could have 
been the product of another promoter in regulating the production of the smaller transcript.   
It should be taken into account that apart from the specific transcription factors, global 
mechanisms which change DNA topology or transcript stability via environmental stimuli 
such as different growth conditions can affect expression of virulence factors in B. 
pertussis (Graeff-Wohlleben et al., 1995). It would therefore be of interest to investigate 
whether additional parameters are involved in the expression of BapC, in response to 
differences in the DNA topology such as supercoiling, which may be influenced by 
changing the in vivo conditions and provide an additional or complementary mechanism 
for regulation, as shown for the effect of supercoiling on expression of pertussis toxin 
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(Scarlato et al., 1993) or, in the case of the pertactin gene, in response to a DNA gyrase 
inhibitor where the effect was different compared to that on other bvg-regulated genes 
(Graeff-Wohlleben et al., 1995).  
A rho-independent terminator sequence downstream of the translational stop codon of the 
bapC gene was found. This terminator adopts a hairpin or loop-shape secondary structure, 
consisting of a GC-rich stem-loop region followed by a run of U residues, which is 
considered responsible for RNA polymerase terminating mRNA synthesis. The 
downstream U-rich region destabilizes the RNA-DNA hybrid when RNA polymerase 
pauses at the terminator hairpin. A search upstream of the stop codon for a rut site (an 
acronym for rho utilization), a sequence within the transcript upstream of the site of 
termination for binding of the rho factor for rho-dependent termination which should be 
rich in C and poor in G that accounts for about half of E. coli terminators, showed only 
32% C nucleotide and 26% G nucleotide in this region, that could not function as a site for 
the binding of rho factor.           
In summary, the protein and gene comparative analysis between BapC, BrkA and pertactin 
clearly revealed the homology in their β-domains, as would be expected for autotransporter 
proteins but no clear homology in α-domains (passenger) to suggest common functions, 
despite BrkA and BapC apparantly having a role in serum resistance and all three proteins 
possibly being involved in adhesion.    
4.9 Modelling/prediction of BapC structure 
Homology or comparative modelling is a robust technique for predicting or generating 
detailed three-dimensional structures of proteins based on the coordinates of known 
homologues found in the Protein Data Bank (PDB). In homology modelling, the quality of 
the model strongly depends on the degree of similarity between the query sequence and the 
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matching database sequence, with proteins sharing the highest degree of similarity being 
modelled best. 
The Proteus structure prediction server 2.0, PROTEUS2 
(http://wks16338.biology.ualberta.ca/proteus2/index.jsp), a web server designed to support 
comprehensive protein structure prediction and structure-based annotation, found a file 
(1DABA) (i.e. P.69/pertactin) homologous to BapC with an overall confidence value of 
78.3%. The predicted helix content, beta sheet content and coil content were 4% (43 
residues), 53% (527 residues) and 43% (423 residues), respectively (Fig. 4.2). The 3D 
structure of the PDB homolog (1DABA) (Fig. 4.4) related to BapC protein with E-value of 
8.0 matches to residues 112-694 and can be seen with Webmol viewer in Java programme. 
Secondary structure prediction using PROTEUS2 also suggested a translocator domain in 
the C-terminus of BapC with 14 transmembrane anti-parallel β-strands and a 
transmembrane α-helix and forming a β-barrel with a central hydrophilic channel like 
other autotransporter proteins.  
SWISS-MODEL (version 3.5), an automated comparative modelling server of three-
dimensional (3D) protein structures, was used for the tertiary structure prediction of BapC 
via the web page (http://swissmodel.expasy.org) or directly as a link from SWISS-PROT 
entries on the ExPASy server. SWISS-PROT is primary database of confirmed protein 
sequences with annotations relating to structure, function and protein family assignment.    
Structural data are maintained as text files using the PDB format devised by the Protein   
Data Bank and contain atomic co-ordinates together with annotation, comments and 
experimental details derived from X-ray crystallography and NMR studies ( available at 
the following URL: http://www.pdb.org/).  
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Figure 4.2 Prediction of the secondary structure of BapC by Proteus tool 
Summary:  
• Sequence Name: BapC protein  
• Number of residues read in: 993  
• Number of useable PDB homologs found: 1  
o 1DABA, e-value = 8.0E-45 THE STRUCTURE OF BORDETELLA 
PERTUSSIS VIRULENCE FACTOR P.69  
• Overall confidence value: 78.3%  
• Predicted % Helix content: 4 % (43 residues)  
• Predicted % Beta sheet content: 53 % (527 residues) 
• Predicted % Coil content: 43 % (423 residues)   
 
Graphical Alignment of PDB Homologs:  
 
Legend: 
 
H = Helix 
E = Beta Strand 
C = Coil 
Line 1 = sequence (single letter IUPAC code, 60 characters per line)  
Line 2 = secondary structure (H, E or C)  
Line 3 = confidence score (0-9, 0 = low, 9 = high)  
 
A '*' character above the overall prediction indicates the homolog's 
structure was used at this residue. 
 
Predicted Secondary Structure:  
 
  1                                                               60 
      MNDRKSNSMSPAARYLRFGVVAVAGVAAGALPSSDVDAQAAPAAAEVAKIEALSDADIYS 
      CCCCCCCCCCCHHHHHHCEEEEEECCCCCCCCCCCCCCCCCCHHHHHHHHEECCCCCCCC 
      987787777646788744899875544567777887777655478887533367777777 
 
  61                                                     ********* 120 
      DYEHEHGIVMTPDGKDDYISYRSAESGRPKPPPPLSNFKPLGNDVVAERIRVEVHGDETL 
      CCCCCCEEEEECCCCCEEEEEECCCCCCCCCCCCCCCCCCCCCEEEEECCEEEEEECCEE 
      778876578867888757788667776667777667677777677876767899878877 
 
 121  ****************************************************  ****** 180 
      GVYVDSEHRSLTVRDSTIDAYGKPPSVDSPDYYGAAAVYAGTLNIENSTVHHNYAAQPFE 
      EEEEECCCEEEEEECCEEEECCCCCCCCCCCCCEEEEEEEEEEEEECCCCCCCCCCCCCC 
      999968876899877758876776667777765789988998898788656787777777 
 
 181  ** ********************************************  *********** 240 
      DAVGVGVTSLGDKAILNVTDSEVSGARGAVIGWGGEATFTDSVLRGSAFGLYAEMCDTCR 
      CCCCEEEEEECCCEEEEEEEEEEECCCCEEEECCCEEEEEEEEEEECCCCEEEEECCCCC 
      777768898588779998777898888989977877788899998589678898667777 
 
 241  ****************************** **************  ************* 300 
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      DDDGTSPSIRVQGGVVQGGMGANNVAVVATGSGKVAIENAELLGASGMYATFGAQVDMKG 
      CCCCEEEEEEECCCEEEECCCCCCEEEEEECCCEEEEECCEEEEEEEEEEECCEEEECCC 
      777758999976866885788887789997785789857578778788888898887688 
 
 301  ********           *********   ***********************   *** 360 
      GRILAHNTNILGSQGYADGPYGGVVVTEDGQVNLEGAKVSATGLGAAGLWLLGDKDTSPR 
      CEEEECCCEECCCCCEECCCCCCEEECCCCEEEECCCCCCCCCCCCCCEEEECCCCEEEE 
      589976765656775656788888877886799777777757778878888768856556 
 
 361  ******************  ****************************             420 
      ASLRNTDVHGEVAAIALGFNGEANISGGSLSVEDGAVLTTLTPDAVEYYYDYALSMEHLP 
      EEEEEECCCCCCEEEEEECCCEEEEECCEEEECCCEEEEECCCCCEECCCEEEEEEEECC 
      889998588886889998587578889999998887899767775656545676566567 
 
 421  **************   **********************************          480 
      ADAPLTPVRVTLSDGARASGETLIAHGGLLPMTLRLSSGVDARGDIVTLPPSAPPDSAEQ 
      CCCEEEEEEEEEECCEEEEEEEEEEEECCCCEEEEEECCEEEECCEEEEECCCCCCCEEE 
      899888578988999899888889997788778888889888775789966788775676 
 
 481                                           ********** ******** 540 
      PDAEPEPDAELEPDAAAQSDAKANARVMAQVDGGEPVAVPIPAPSHPDAPIDVFIDSGAQ 
      CCCCCCCEEEECCCEEEECCCCEEEEEEECCCCCEEEECCCCCCCCCCEEEEEEEECCEE 
      677766546656775777677667878867888788888877776777788898887889 
 
 541  ****************************************** *********** ***** 600 
      WRGMTKTVNALRIEDGTWTVTGSSTVNSLHLQAGKVAYATPAESDGEFKHLRVKTLSGSG 
      EEEEECCCEEEEEEEEEEEEECCCEEEEEEEEEEEEEEECCCCCCCCEEEEEEEEEEEEE 
      999888987899888889988898789988788779988888998989999999999999 
 
 601  ************************************************************ 660 
      LFEMNASADLSDGDLLVVSDEASGQHKVLVRGAGTEPTGVESLTLVELPEGSQTKFTLAN 
      EEEEEEECCCCEEEEEEEEEECCCEEEEEEEEEEEECCCCCEEEEEEECCCEEEEEEEEC 
      999999998898889999999999999999989988877877888999988889999999 
 
 661  *************************** ******                           720 
      RGGVVDAGAFRYRLTPDNGVWGLERTSQLSAVANAALNTGGVGAASSIWYAEGNALSKRL 
      CCCEEECCCEEEEEEECCCEEEEECCCCCCCCCHHHHHHHHHHHHHHHHHHHHHHHHHHH 
      999899899999998888899875677776664578899999999999999999998887 
 
 721                                                               780 
      GELRLDPGAGGFWGRTFAQKQQLDNKAGRRFDQKVYGFELGADHAIAGQQGRWHVGGLLG 
      HHCCCCCCCCEEEEEEECCCEECCCCCCCCEEEEEEEEEEEEEEEEECCCCCEEEEEEEE 
      645788877668999876765656776665555557888999999987998578999998 
 
 781                                                               840 
      YTRARRSFIDDGAGHTDSAHIGAYAAYVADNGFYFDSTLRASRFENDFTVTATDAVSVRG 
      EEEEEEEECCCCEEEEEEEEEEEEEEEECCCEEEEEEEEEEEEEEEEEEEEEECCCCCCC 
      876667756775777667777776676558756765656667777777778766777677 
 
 841                                                               900 
      KYRANGVGATLEAGKRFTLHDGWFVEPQSEVSLFHASGGTYRAANNLSVKDEGGTSAVLR 
      CCCCEEEEEEEEEEEEECCCCEEEEEEEEEEEEEEEECCCEEECCCEEEEECCCCEEEEE 
      666656899988777766787578765778899998577657567668997788678887 
 
 901                                                               960 
      LGLAAGRRIDLGKDRVIQPYATLSWLQEFKGVTTVRTNGYGLRTDLSGGRAELALGLAAA 
      EEEEEEEEEEECCCEEEEEEEEEEEEEEECCCCEEEECCEEEEECCCCEEEEEEEEEEEE 
      766555567747876888888889999977885788576689986888589998999999 
 
 961                                    993 
      LGRGHQLYTSYEYAKGNKLTLPWTFHLGYRYTW 
      ECCCEEEEEEEEEECCCCCCCCEEEEEEEEEEC 
      689779999988866777777667889999977 
 
  Discussion      
 
245 
Figure 4.3 Model of the tertiary structure of the passenger domain of the 
BapC protein obtained using the SWISS-MODEL programme 
          
Figure 4.4 Tertiary structure of pertactin (Dautin and Bernstein, 2007) 
                                                                    
  Discussion      
 
246 
The process for proteins of known sequence but unknown structure such as BapC, is first 
to retrieve homologous proteins via the ExPASy tool, (the most critical step in homology 
modelling) onto which one can subsequently align the sequence to build a preliminary 
three-dimensional model, and then the SWISS-MODEL server can build the final model 
based on the homology model. The pertactin PDB file based on the tertiary structure of 
PRN (Emsley et al., 1996) was automatically employed as a template for BapC modelling 
and alignment done with more than 30% homology during the model building process. The 
deduced automated homology modelling of a tertiary structure of BapC passenger domain 
can be seen in Fig. 4.3. The tertiary structure of pertactin is seen in Fig. 4.4. 
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6. 6. Appendices  
6.1 Appendix I 
AI.1 Media composition 
AI.1.1 Luria Bertani broth (LB) 
1 litre 
Tryptone (Duchefa Biochemie)                                                   10 g                                                         
Yeast extract (Duchefa Biochemie)                                               5 g                                                           
Sodium chloride                                                                           10 g                                                          
Add 1.2% microagar (Duchefa Biochemie) for making solid media and then autoclave at 
15 p.s.i. for 15 min. 
AI.1.2 Bordet Gengou agar (BG) 
1 litre 
Bordet Gengou agar base (Difco)                                                 30 g 
Glycerol                                                                                        10 ml 
Suspend 30 g of the powder in 1 L of distilled water containing 10 ml glycerol and mix 
throughly. Heat with frequent agitation and boil for 1 min to completely dissolve the 
powder, and then autoclave at 121°C for 15 min. Aseptically add 12% sterile, defibrinated 
blood to the medium at 45-50°C and mix well.    
AI.1.3 Cyclodextrin Liquid (CL) medium 
1 litre 
Sodium-L-glutamate                                                                    10.7 g 
L-proline                                                                                      0.24 g 
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Sodium chloride                                                                            2.5 g 
Potassium di-hydrogen orthophosphate                                        0.5 g 
Potassium chloride                                                                        0.2 g 
Magnesium chloride (6H2O)                                                         0.1 g 
Calcium chloride                                                                         0.02 g 
Tris                                                                                                6.1 g 
Casamino acids (DIFCO)                                                               10 g 
Methyl-β-cyclodextrin                                                                0.25 g 
Dissolve the above ingredients in distilled water and adjust pH to 7.6 with HCl, make up to 
vol., then autoclave at 15 p.s.i. for 15 min. Finally, add vitamin supplement solution to 
0.5% (5 ml/L). 
AI.1.4 Vitamin Supplement (Solution) 
L-cysteine                                                                                    0.04 g 
Ferrous sulphate (7H2O)                                                              0.01 g 
Nicotinic acid                                                                             0.004 g 
Glutathione                                                                                  0.15 g 
Ascorbic acid                                                                                 0.4 g 
Immediately before use, dissolve the ingredients above in 75 ml distilled water, sterilize by 
membrane filtration. 
AI.1.5 Stainer and Scholte (SS-X medium) 
1 litre 
L-glutamate (monosodium salt)                                                10.72 g 
L-proline                                                                                      0.24 g 
Sodium chloride                                                                             2.5 g 
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Potassium di-hydrogen orthophosphate                                         0.5 g 
Potassium chloride                                                                         0.2 g 
Magnesium chloride (6H2O)                                                          0.1 g 
Calcium chloride                                                                          0.02 g 
Tris                                                                                                 6.1 g 
Dissolve above ingredients in distilled water (approx. 800ml). Adjust the pH to 7.6 with 
HCl and make up the volume to 990ml with distilled water. Sterilize the medium by 
autoclaving at 15 p.s.i. for 15min. Immediately before use, dissolve the ingredients below 
in 10 ml distilled water, sterilize by membrane filtration and add to the above media.   
L-cysteine                                                                                       0.04 g 
Ferrous sulphate (7H2O)                                                                 0.01 g 
Ascorbic acid                                                                                  0.02 g 
Nicotinic acid                                                                                0.004 g 
Glutathione                                                                                       0.1 g 
* Cultures with Bvg- (C-mode) characteristics can be produced simply by omitting the 2.5g 
NaCl from the above medium and adding 5g MgSO4.7H2O to give SS-C medium.   
AI.1.6 Modified Stainer and Scholte (SS) medium 
1 litre 
 L-glutamate (monosodium salt)                                                      11.84 g 
L-proline                                                                                            0.24 g 
Sodium chloride                                                                                   2.5 g 
Potassium di-hydrogen orthophosphate                                               0.5 g 
Potassium chloride                                                                               0.2 g 
Magnesium chloride (6H2O)                                                                0.1 g 
Calcium chloride                                                                                0.02 g 
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Tris                                                                                                       1.5 g 
Casamino acids (Becton, Dickinson and Company)                            10 g                                                      
Methyl-β-cyclodextrin                                                                            1 g 
Adjust pH to 7.6 and autoclave it. Then, add 5ml of solution below made in 10ml distilled 
water (after filtration) into the above media. 
L-cysteine                                                                                           0.04 g 
Ferrous sulphate (7H2O)                                                                     0.01 g 
Ascorbic acid                                                                                        0.4 g 
Nicotinic acid                                                                                   0.004 g 
Glutathione                                                                                         0.15 g 
AI.1.7 Casamino acids (CAA) solution 
1 litre 
Casamino acids (DIFCO)                                                                   10 g 
Magnesium chloride (6H2O)                                                             0.1 g 
Sodium chloride                                                                                   5 g 
Calcium chloride                                                                           0.016 g 
pH to 7.1;  
Autoclave then supplement with 20% sterile (v/v) glycerol for use for storage of Bordetella 
strains at -80°C                
AI.1.8 SOC Medium 
1 litre 
Tryptone (Duchefa Biochemie)                                                           20 g 
Yeast extract (Duchefa Biochemie)                                                       5 g 
SaltI (250 mM KCl, 1M NaCl)                                                          10 ml 
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After autoclaving at 15 p.s.i, add 10 ml of 2M sterile glucose and 10 ml of SaltII (1M 
MgCl2.6H2O, 1M MgSO4.7H2O) 
AI.1.9 Phosphate-buffered saline (PBS) 
Sodium chloride                                                                         128 mM 
Potassium chloride                                                                      2.7 mM 
Potassium di-hydrogen orthophosphate                                      1.5 mM                              
di-potassium hydrogen phosphate                                               5.0 mM 
 
AI.2 Molecular biology solutions 
AI.2.1 Tris-Borate-EDTA (TBE) buffer. 5x stock solution 
1 litre 
Tris-base                                                                                        54 g 
Boric acid                                                                                    27.5 g 
EDTA (0.5 M stock) pH 8.0                                                         20 ml  
 
AI.2.2 DNA loading buffer. 6x stock solution 
Tris                                                                                            60 mM 
EDTA                                                                                          6 mM 
Sucrose                                                                                          40% 
Bromophenol blue                                                                      0.25% 
 
AI.2.3 Buffer EB 
Tris-HCl, pH 8.5                                                                        10 mM 
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AI.2.4 Buffer TE 
pH 8.0 
 
Tris-HCl                                                                                      10 mM 
EDTA                                                                                           1 mM 
 
AI.3 Protein analysis solutions 
AI.3.1 Solutions for SDS-PAGE (Sodium dodecyl sulphate polyacrylamide 
gel electrophoresis)  
AI.3.1.1 Protein sample buffer 
 
Glycerol                                                                                       5 ml 
20% SDS                                                                                  2.5 ml 
2-mercaptoethanol                                                                    0.5 ml 
Tris (0.5ml, pH 6.8)                                                                  2.5 ml 
Bromophenol blue                                                                   0.25 % 
 
 
AI.3.1.2 Separating gel 
 
 15 % 12.5 % 10 % 7.5 % 
Acrylamide/Bis 
30% 
5 ml 
 
4.16 ml 3.33 ml 2.5 ml 
Tris 1M pH: 8.8  3.75 ml 3.75 ml 3.75 ml 3.75 ml 
Distilled water 1.3 ml 2.13 ml 2.97 ml 3.8 ml 
SDS 10% 100 µl 100 µl 100 µl 100 µl 
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APS (Ammonium 
persulphate) 
100 µl 100 µl 100 µl 100 µl 
TEMED 10 µl 10 µl 10 µl 10 µl 
 
 
 
 
 
AI.3.1.3 Stacking gel 
 
 
30% Acrylamide/Bis (Bio-Rad)                                           9 ml 
Tris 1M  pH 6.8                                                                 7.5 ml 
Distilled water                                                                    42 ml 
SDS 10%                                                                             50 µl 
It should be kept at 4˚C for further use. Before use, add 
APS (Ammonium persulfate)                                                    60 µl 
TEMED                                                                                       5 µl 
to the 2 ml of above stacking gel preparation to make 2 gels.  
 
AI.3.1.4 Coomassie gel stain 
 
Coomassie blue                                                                           0.5 g 
Methanol                                                                                   400 ml 
Acetic acid                                                                                100 ml 
Distilled water                                                                           500 ml 
For destain preparation, coomassie blue was omitted from the coomassie gel stain recipe.          
 
AI.3.1.5 PAGE running buffer/Electrode buffer 10X 
 
1 litre 
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Tris                                                                                                 30 g 
Glycine                                                                                         144 g 
SDS                                                                                                10 g 
pH 8.3 
 
AI.3.1.6 Envelope buffer        
 
Sodium di-hydrogen orthophosphate (NaH2PO4)                                   20 mM 
di-sodium hydrogen orthophosphate (Na2HPO4)                                    20 mM 
  
AI.3.2 Western blotting solutions 
AI.3.2.1 Electroblotting buffer 
 
Tris base                                                                                            7.2 g 
Glycine                                                                                            33.4 g 
Dissolve the above in 2L distilled water, add 600 ml methanol and make up to 3L with 
distilled water. 
AI.3.2.2 Ponceau S solution 
 
Ponceau S                                                                                    0.5 g 
Glacial acetic acid                                                                        1 ml 
Make up to 100 ml with distilled water. 
  
AI.3.2.3 Blocking buffer 
 
Blotto (Marvel skimmed milk)                                                      6 g 
Tween-20                                                                                  400 µl 
PBS                                                                                          200 ml 
AI.3.2.4 Washing buffer 
 
Tween-20                                                                                  400 µl 
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PBS                                                                                          200 ml 
AI.3.2.5 DAB solution 
 
3,3’-Diaminobenzidine (DAB)                                                0.05 g 
PBS                                                                                           98 ml 
Filter through Whatman paper 1MM 
1% CoCl2                                                                                    2 ml 
30% H2O2                                                                                100 µl    
AI.4 Southern blot solutions and buffers 
AI.4.1 Hybridization solutions  
AI.4.1.2 Depurination solution 
 
Hydrochloric acid (HCl)                                                                      0.25 M 
AI.4.1.3 Denaturation solution 
 
Sodium hydroxide                                                                                 0.5 M 
Sodium chloride                                                                                    1.5 M 
AI.4.1.4 Neutralization solution 
 
Sodium chloride                                                                                      3 M 
Tris-HCl                                                                                   0.5 M, pH 7.5 
 
AI.4.1.5 N-lauroylsarcosine stock solution 
 
10% N-lauroylsarcosine (w/v) in sterile H2O 
Filtered through a 0.2-0.45 µm membrane 
AI.4.1.6 SDS stock solution 
 
10% SDS (w/v) in sterile H2O 
Filtered through a 0.2-0.45 µm membrane 
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AI.4.1.7 Standard prehybridization buffer 
 
5x SSC                                                                                                      88.8 ml 
N-lauroylsarcosine stock solution                                                                 1 ml  
SDS stock solution                                                                                     200 µl 
Blocking reagent stock solution                                                                  10 ml  
AI.4.2 Detection solutions and buffers 
AI.4.2.1 Maleic acid buffer 
 
Sodium chloride                                                                           0.15 M 
Maleic acid                                                                                     0.1 M   
Adjust pH to 7.5 at 20°C with concentrated or solid NaOH; autoclave. 
 
AI.4.2.2 Washing buffer / Equilibrating solution 
 
Maleic acid                                                                                   0.1 M 
Sodium chloride                                                                         0.15 M 
Tween-20                                                                                      0.3 % 
0.3% (v/v) Tween-20 was added to sterile Maleic acid buffer. (it should not be autoclaved 
while containing Tween-20).  
AI.4.2.3 Blocking reagent stock solution 
 
Blocking Reagent (Boehringer Mannheim) is dissolved in maleic acid buffer to a final 
concentration of 10% (w/v) with shaking and heating at 60°C for 1 h or until completely in 
solution. The solution was autoclaved using a regular program, such as that used for the 
sterilization of cell culture medium. Blocking reagent must be completely in solution 
before autoclaving. Autoclaved solution was stored at +4°C and checked before each use 
for contamination. 
AI.4.2.4 Blocking buffer / Antibody blocking solution 
 
Blocking reagent stock solution (10%)                                           20 ml 
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Maleic acid buffer                                                                          180 ml 
Diluted Blocking reagent stock solution 1:10 with Maleic acid buffer (1% final blocking 
reagent concentration). Dissolved with heating and shaking. The anti-Digoxigenin-AP 
antibody was added at 1:10000 dilution in blocking buffer. 
AI.4.2.5 Detection buffer 
 
Tris-HCl                                                                                           0.1 M, pH 9.5 (at 20°C) 
Sodium chloride                                                                               0.1 M 
AI.4.2.6 TE buffer 
 
Tris-HCl                                                                                          10 mM 
EDTA                                                                                                1 mM 
pH 8.0 (at 20°C) 
AI.4.2.7 Colour substrate solution 
 
(Freshly prepared) 
45 µl NBT (Nitro-Blue Tetrazolium Chloride) solution and 35 µl BCIP (5-Bromo-4-
Chloro-3'-Indolyphosphate p-Toluidine Salt) solution were added to 10 ml Detection 
buffer. 
AI.4.3 General solutions  
20 x SSC solution 
 
Sodium chloride                                                                         3 M 
Sodium citrate                                                                         0.3 M 
pH 7.0 (at 20°C), autoclaved at 15 psi for 15 min 
Washing solution 2x  
 
(for low stringency washing) 
2x SSC 
0.1 % SDS 
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Washing solution 0.5x 
 
(for high stringency washing) 
0.5 x SSC 
0.1% SDS 
Stripping solutions 
 
Dimethylformamide             100% ACS (American Chemical Society) grade N,N-                              
dimethylformamide (DMF) 
H2O                                                  Sterile, distilled water 
Alkaline probe-stripping solution    0.2 NaOH, 0.1% SDS 
2×SSC buffer                                   300 mM NaCl, 30 mM sodium citrate 
2×SSC / 0.1% SDS                          300 mM NaCl, 30mM sodium citrate, 0.1%(w/v) SDS  
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6.2 Appendix II 
AII.1 Map of the plasmid pBR322 
(http://www.fermentas.com/techinfo/nucleicacids/mappbr322.htm) 
 
 
 
The plasmid pBR322 is 4361 bp in length and contains:  
(1) the replicon rep responsible for the replication of plasmid (source - plasmid pMB1); (2) 
rop gene coding for the Rop protein, which promotes conversion of the unstable RNA I - 
RNA II complex to a stable complex and serves to decrease copy number (source - plasmid 
pMB1); (3) bla gene, coding for beta-lactamase that confers resistance to ampicillin 
(source - transposon Tn3); (4) tet gene, encoding tetracycline resistance protein (source - 
plasmid pSC101)( http://www.fermentas.com/techinfo/nucleicacids/mappbr322.htm). The 
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circular sequence is numbered such that 1 is the first T of the unique EcoRI site GAATTC 
and the count increases first through the tet gene, the pMB1 material, and finally through 
the Tn3 region. The map shows enzymes that cut pBR322 DNA once. The coordinates 
refer to the position of first nucleotide in each recognition sequence. 
  
AII.2  Map of pET-33b (+) expression vector 
(http://www.merckbiosciences.com/docs/docs/PROT/TB147.pdf) 
 
 
pET-33b(+) sequence landmarks 
 
T7 promoter                            384-400                             
T7 transcription start              383                                     His•Tag coding sequence      140-157 
His•Tag coding sequence       284-301                              T7 terminator                        26-72 
PKA site coding sequence      242-256                               lacI coding sequence            787-1866 
T7•Tag® coding sequence     206-238                               pBR322 origin                      3300 
Multiple cloning sites (BamH I - Xho I)    158-203            Kan coding sequence           4009-4821 
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The pET-33b(+) vector (Novagen, Cat. No. 69054-3) is derived from pET-28b(+) and 
carries a 15bp sequence encoding the protein kinase A (PKA) site RRASV, located 
between the thrombin cleavage and Nde I sites. Unique sites are shown on the above circle 
map. Note that the sequence is numbered by the pBR322 convention, so the T7 expression 
region is reversed on the circle map. 
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AII.3 Significant features of bapC gene and BapC protein   
 
                  Signal sequence 
          
                                      MNF1 
         M  N  D  R  K  S  N  S  M  S  P  A  A  R  Y  L  R  F  G  V   
      1 ATGAATGACAGAAAATCCAATAGCATGTCGCCAGCGGCGAGATACTTGCGTTTCGGCGTT 60 
                                                                    
         V  A  V  A  G  V  A  A  G  A  L  P  S  S  D  V  D  A  Q  A   
     61 GTCGCGGTAGCGGGTGTGGCGGCGGGCGCGCTGCCTTCGTCGGATGTCGATGCCCAGGCC 120 
       
         A  P  A  A  A  E  V  A  K  I  E  A  L  S  D  A  D  I  Y  S   
    121 GCGCCGGCCGCCGCCGAGGTAGCCAAGATCGAGGCTCTGTCGGATGCGGACATTTACAGC 180 
    
         D  Y  E  H  E  H  G  I  V  M  T  P  D  G  K  D  D  Y  I  S   
    181 GACTACGAGCACGAGCATGGCATCGTGATGACGCCCGATGGCAAGGACGACTACATCAGT 240 
                                      Poly(C) tract 
     
         Y  R  S  A  E  S  G  R  P  K  P  P  P  P  L  S  N  F  K  P   
    241 TACAGGTCCGCCGAGAGCGGTCGTCCGAAGCCCCCCCCCCCCCTTTCAAACTTCAAACCA 300 
     
         L  G  N  D  V  V  A  E  R  I  R  V  E  V  H  G  D  E  T  L   
    301 TTGGGTAATGACGTCGTAGCGGAGCGGATACGGGTAGAAGTGCACGGTGACGAAACCCTC 360 
                                  
     MNF2                                         MNR1 
                                              
         G  V  Y  V  D  S  E  H  R  S  L  T  V  R  D  S  T  I  D  A   
    361 GGCGTGTATGTCGACTCGGAGCACCGTTCGCTCACCGTGCGTGACAGCACGATAGATGCA 420 
     
         Y  G  K  P  P  S  V  D  S  P  D  Y  Y  G  A  A  A  V  Y  A   
    421 TACGGCAAGCCGCCTTCCGTCGACTCTCCCGATTATTACGGTGCCGCGGCTGTCTACGCC 480 
   
         G  T  L  N  I  E  N  S  T  V  H  H  N  Y  A  A  Q  P  F  E   
    481 GGTACGCTGAATATCGAGAATTCCACGGTTCACCATAACTATGCGGCCCAGCCGTTCGAA 540 
     
         D  A  V  G  V  G  V  T  S  L  G  D  K  A  I  L  N  V  T  D   
    541 GACGCGGTAGGAGTCGGGGTAACCTCGCTCGGGGATAAGGCCATACTCAACGTTACCGAC 600 
                                           Poly(G) tract 
     
         S  E  V  S  G  A  R  G  A  V  I  G  W  G  G  E  A  T  F  T   
    601 AGCGAGGTATCGGGTGCGAGGGGCGCGGTCATCGGTTGGGGGGGGGAAGCGACATTTACC 660 
Proposed start of bapC gene, according to Blackburn 
(1998) and Henderson et al., (2000) 
     
         D  S  V  L  R  G  S  A  F  G  L  Y  A  E  M  C  D  T  C  R   
    661 GATTCGGTCCTGCGTGGTTCGGCCTTCGGGCTGTACGCCGAAATGTGCGACACCTGCAGA 720 
     
                       BAPCF                         NTS-Forward            
         D  D  D  G  T  S  P  S  I  R  V  Q  G  G  V  V  Q  G  G  M   
    721 GATGATGATGGCACCTCGCCTTCGATTCGCGTCCAAGGCGGGGTTGTTCAGGGCGGCATG 780 
 
                                              MNR2 
         G  A  N  N  V  A  V  V  A  T  G  S  G  K  V  A  I  E  N  A   
    781 GGTGCAAATAACGTCGCTGTGGTGGCAACAGGGTCTGGAAAGGTCGCGATCGAGAATGCG 840 
     
         E  L  L  G  A  S  G  M  Y  A  T  F  G  A  Q  V  D  M  K  G   
    841 GAACTGCTCGGAGCCAGCGGCATGTACGCCACGTTCGGCGCGCAGGTCGATATGAAAGGC 900 
     
         G  R  I  L  A  H  N  T  N  I  L  G  S  Q  G  Y  A  D  G  P   
    901 GGGCGCATTCTGGCGCACAACACCAATATCCTGGGAAGCCAGGGTTACGCCGATGGTCCC 960 
     
         Y  G  G  V  V  V  T  E  D  G  Q  V  N  L  E  G  A  K  V  S   
    961 TATGGCGGCGTGGTCGTGACAGAGGACGGTCAAGTCAACCTGGAGGGCGCCAAGGTCAGT 1020 
  
         A  T  G  L  G  A  A  G  L  W  L  L  G  D  K  D  T  S  P  R   
   1021 GCAACTGGCCTGGGGGCCGCCGGCTTGTGGTTGCTGGGCGACAAGGACACCAGCCCGCGA 1080 
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         A  S  L  R  N  T  D  V  H  G  E  V  A  A  I  A  L  G  F  N   
   1081 GCCAGCCTGCGCAACACCGACGTCCACGGAGAGGTCGCCGCCATTGCGCTGGGGTTCAAT 1140 
    
         G  E  A  N  I  S  G  G  S  L  S  V  E  D  G  A  V  L  T  T   
   1141 GGCGAGGCGAACATCTCGGGCGGCAGCTTGAGCGTAGAGGATGGGGCCGTGCTCACCACC 1200 
    
                                                                                Tetracycline cassette insertion (NcoI                                                  
NTS-Reverse                                                 (1244) 
         L  T  P  D  A  V  E  Y  Y  Y  D  Y  A  L  S  M  E  H  L  P   
   1201 CTGACGCCCGATGCAGTCGAGTATTACTACGACTACGCCTTGTCCATGGAGCATCTGCCA 1260 
    
         A  D  A  P  L  T  P  V  R  V  T  L  S  D  G  A  R  A  S  G   
   1261 GCTGATGCGCCGTTGACGCCGGTCCGCGTCACGCTGTCCGATGGCGCGCGCGCCAGCGGA 1320 
    
         E  T  L  I  A  H  G  G  L  L  P  M  T  L  R  L  S  S  G  V   
   1321 GAAACGTTGATCGCGCATGGCGGGTTGTTGCCCATGACGCTGCGCTTGAGCAGCGGGGTC 1380 
 
              RGD motif 
         D  A  R  G  D  I  V  T  L  P  P  S  A  P  P  D  S  A  E  Q   
   1381 GACGCCCGCGGCGACATCGTCACGCTGCCGCCTTCCGCGCCGCCCGATTCCGCGGAGCAA 1440 
    
         P  D  A  E  P  E  P  D  A  E  L  E  P  D  A  A  A  Q  S  D   
   1441 CCGGATGCCGAGCCGGAACCGGATGCCGAGCTGGAACCGGACGCCGCGGCGCAGTCGGAC 1500 
 
         A  K  A  N  A  R  V  M  A  Q  V  D  G  G  E  P  V  A  V  P   
    1501  GCCAAGGCGAATGCGCGGGTCATGGCGCAGGTAGATGGCGGGGAACCTGTTGCCGTGCCG 1560 
    
         I  P  A  P  S  H  P  D  A  P  I  D  V  F  I  D  S  G  A  Q   
   1561 ATCCCGGCCCCTTCGCATCCCGATGCCCCGATCGACGTGTTCATCGACAGCGGTGCCCAA 1620 
    
         W  R  G  M  T  K  T  V  N  A  L  R  I  E  D  G  T  W  T  V   
   1621 TGGCGGGGCATGACCAAGACCGTCAATGCGTTGCGCATCGAGGACGGCACCTGGACCGTC 1680 
    
         T  G  S  S  T  V  N  S  L  H  L  Q  A  G  K  V  A  Y  A  T   
   1681 ACCGGGTCGTCCACGGTGAACAGCCTGCACCTGCAGGCAGGCAAGGTGGCGTACGCAACG 1740 
 
                                     Glycosaminoglycan-binding motif             
         P  A  E  S  D  G  E  F  K  H  L  R  V  K  T  L  S  G  S  G   
   1741 CCTGCCGAAAGCGACGGAGAATTCAAACACCTGCGGGTCAAGACCCTCTCGGGAAGCGGC 1800 
    
         L  F  E  M  N  A  S  A  D  L  S  D  G  D  L  L  V  V  S  D   
   1801 CTGTTCGAGATGAACGCCAGCGCCGACCTGAGCGATGGCGACCTGCTGGTCGTGTCCGAC 1860 
    
         E  A  S  G  Q  H  K  V  L  V  R  G  A  G  T  E  P  T  G  V   
   1861 GAGGCCAGCGGGCAGCACAAGGTGCTGGTGCGAGGAGCCGGCACGGAACCCACCGGTGTG 1920 
    
         E  S  L  T  L  V  E  L  P  E  G  S  Q  T  K  F  T  L  A  N   
   1921 GAAAGCCTGACGCTGGTCGAGCTGCCCGAGGGCAGCCAGACGAAGTTCACGCTTGCCAAC 1980 
    
         R  G  G  V  V  D  A  G  A  F  R  Y  R  L  T  P  D  N  G  V   
   1981 CGGGGCGGGGTGGTCGACGCCGGCGCGTTCCGCTATCGCCTGACGCCGGACAACGGTGTC 2040 
    
         W  G  L  E  R  T  S  Q  L  S  A  V  A  N  A  A  L  N  T  G   
   2041 TGGGGCCTGGAACGGACCAGCCAGCTTTCGGCCGTCGCCAACGCGGCCTTGAATACCGGG 2100 
 
 
 
                                                                                                   Putative cleavage site  
 
         G  V  G  A  A  S  S  I  W  Y  A  E  G  N  A  L  S  K  R  L   
   2101 GGCGTGGGCGCGGCCAGCAGCATCTGGTATGCGGAAGGCAATGCGCTCTCCAAGCGCCTG 2160 
 
         G  E  L  R  L  D  P  G  A  G  G  F  W  G  R  T  F  A  Q  K   
   2161 GGCGAGTTGCGGCTCGATCCCGGCGCGGGCGGCTTCTGGGGGCGCACGTTCGCCCAGAAG 2220 
    
         Q  Q  L  D  N  K  A  G  R  R  F  D  Q  K  V  Y  G  F  E  L   
   2221 CAGCAGCTCGACAACAAGGCTGGCCGACGCTTCGACCAGAAGGTGTACGGTTTCGAGCTG 2280 
    
         G  A  D  H  A  I  A  G  Q  Q  G  R  W  H  V  G  G  L  L  G   
   2281 GGGGCCGACCATGCCATCGCAGGACAGCAAGGGCGCTGGCACGTGGGCGGCCTGCTGGGC 2340 
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         Y  T  R  A  R  R  S  F  I  D  D  G  A  G  H  T  D  S  A  H   
   2341 TATACCCGCGCAAGGCGCAGCTTCATCGATGACGGCGCCGGGCATACCGACAGCGCGCAT 2400 
 
    
         I  G  A  Y  A  A  Y  V  A  D  N  G  F  Y  F  D  S  T  L  R   
   2401 ATCGGGGCCTACGCGGCGTACGTGGCGGACAACGGCTTCTATTTCGATTCGACCCTGCGC 2460 
    
         A  S  R  F  E  N  D  F  T  V  T  A  T  D  A  V  S  V  R  G   
   2461 GCCAGCCGCTTCGAGAACGACTTCACGGTAACGGCCACCGACGCCGTTTCCGTACGGGGC 2520 
    
         K  Y  R  A  N  G  V  G  A  T  L  E  A  G  K  R  F  T  L  H   
   2521 AAGTACCGGGCCAATGGGGTAGGCGCCACCTTGGAGGCCGGCAAACGTTTCACGTTGCAC 2580 
    
         D  G  W  F  V  E  P  Q  S  E  V  S  L  F  H  A  S  G  G  T   
   2581 GACGGCTGGTTCGTCGAACCTCAGTCCGAGGTGTCGCTGTTCCATGCCAGCGGCGGAACC 2640 
    
         Y  R  A  A  N  N  L  S  V  K  D  E  G  G  T  S  A  V  L  R   
   2641 TACCGTGCCGCGAACAACCTGTCGGTCAAGGACGAAGGCGGCACCTCCGCCGTGCTGCGC 2700 
    
         L  G  L  A  A  G  R  R  I  D  L  G  K  D  R  V  I  Q  P  Y   
   2701 CTGGGCTTGGCGGCCGGGCGACGCATCGACCTGGGCAAGGACCGCGTGATCCAGCCCTAT 2760 
    
         A  T  L  S  W  L  Q  E  F  K  G  V  T  T  V  R  T  N  G  Y   
   2761 GCCACCCTGAGCTGGCTGCAGGAATTCAAAGGCGTCACGACCGTTCGCACCAACGGGTAC 2820 
    
         G  L  R  T  D  L  S  G  G  R  A  E  L  A  L  G  L  A  A  A   
   2821 GGGCTGCGCACCGACCTGAGCGGTGGCCGGGCTGAATTGGCGCTGGGCCTGGCCGCCGCG 2880 
    
         L  G  R  G  H  Q  L  Y  T  S  Y  E  Y  A  K  G  N  K  L  T   
   2881 TTGGGGCGCGGCCACCAGCTCTACACTTCGTACGAGTACGCCAAGGGCAACAAGCTGACC 2940 
          
                            BAPCR 
         L  P  W  T  F  H  L  G  Y  R  Y  T  W  *   
   2941 TTGCCTTGGACGTTCCACCTGGGCTATCGCTACACCTGGTAG 2982 
 
    
                                     Outer-membrane localization signal      
 
 
 
 
 
 
The gene/protein sequence was obtained from the NCBI and shows the full length 
sequence without the frameshifts known to be present in the BP Tohama genome sequence. 
The first green highlighted segment is the signal sequence with 38 amino acids. The 
poly(C) and poly(G) tracts are highlighted in yellow with primer pairs, MNF1/MNR1 and 
MNF2/ MNR2, used to amplify these fragments, respectively. Other features of BapC such 
as RGD motif, glycosaminoglycan-binding site (SGXG), putative cleavage site and outer-
membrane localization signal are highlighted.  
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AII.4 brkA gene mutated by transposon 5 insertion and primers 
(Fernandez and Weiss, 1994)   
ATGTATCTCGATAGATTCCGTCAATGTCCGTCTTCCTTGCAGATCCCGCGTTCCGCGTGGCGCCTGCATG 
CGCTGGCCGCAGCTCTGGCGCTGGCCGGCATGGCCCGGCTGGCGCCCGCGGCGGCGCAGGCGCCGCAGCC 
GCCCGTGGCCGGCGCGCCGCATGCGCAGGACGCCGGGCAGGAAGGAGAGTTCGACCACCGGGACAACACG 
CTCATTGCAGTCTTTGACGACGGCGTCGGCATCAATCTCGACGACGATCCCGACGAGCTCGGCGAGACGG 
CGCCCCCCACGCTCAAGGACATCCACATCTCGGTGGAGCACAAGAACCCGATGAGCAAGCCGGCCATCGG 
GGTGCGTGTCAGCGGCGCCGGCCGCGCGCTGACGCTGGCCGGCTCGACCATCGATGCCACCGAGGGCGGC 
ATTCCCGCAGTGGTACGGCGCGGCGGCACGCTGGAGCTGGATGGCGTCACCGTGGCGGGCGGGGAAGGGA 
TGGAGCCGATGACGGTCTCTGACGCCGGCAGCCGCCTGAGCGTGCGCGGCGGCGTGCTGGGCGGCGAAGC 
GCCGGGCGTCGGCCTGGTCCGGGCCGCGCAAGGCGGCCAGGCGAGCATCATCGACGCGACGCTGCAGAGC 
ATCCTCGGGCCCGCGCTCATTGCCGACGGCGGCTCCATTTCCGTCGCCGGCGGTTCGATCGACATGGACA 
TGGGCCCGGGATTCCCGCCGCCGCCTCCACCGCTTCCCGGGGCGCCGCTGGCCGCGCATCCGCCGCTCGA 
TCGCGTTGCCGCGGTGCACGCCGGCCAGGACGGCAAGGTGACACTGCGGGAGGTGGCGCTGCGGGCTCAC 
GGGCCGCAGGCGACGGGCGTCTATGCGTATATGCCTGGCAGCGAAATCACCCTGCAGGGAGGCACAGTCA 
GCGTGCAGGGCGATGACGGGGCCGGCGTGGTCGCCGGCGCGGGCCTGCTCGACGCCTTGCCGCCCGGCGG 
CACGGTGCGGCTGGACGGAACCACGGTGTCGACCGATGGCGCCAACACCGATGCCGTGCTGGTTCGCGGC 
GACGCGGCGCGCGCCGAGGTCGTCAACACCGTGCTGCGCACCGCCAAGAGCCTGGCCGCCGGCGTATCGG 
CCCAGCATGGAGGCCGCGTCACGCTGCGGCAGACCCGCATCGAGACCGCGGGCGCGGGGGCCGAGGGCAT 
CTCCGTGCTGGGCTTCGAGCCGCAGTCCGGCTCCGGCCCGGCCAGCGTCGACATGCAGGGCGGCAGCATC 
ACCACGACCGGCAACCGCGCCGCCGGCATCGCGCTCACCCACGGCAGCGCCCGCCTGGAAGGCGTGGCGG 
TGCGCGCCGAGGGCAGCGGCTCGAGCGCCGCGCAGCTGGCCAACGGCACGCTGGTCGTCAGCGCAGGGTC 
GCTGGCCTCGGCCCAGTCCGGCGCGATCAGCGTGACCGACACGCCGCTGAAGCTGATGCCGGGCGCCCTG 
                BRKF       
GCCAGCAGCACGGTCTCGGTCCGGTTGACCGACGGCGCCACGGCGCAAGGCGGCAATGGCGTGTTCCTCC 
AGCAGCATTCCACCATTCCGGTGGCGGTTGCCCTCGAGAGCGGCGCCCTGGCTCGCGGCGATATCGTCGC 
CGACGGCAACAAGCCCCTCGATGCCGGGATCTCCCTCAGCGTGGCCAGCGGCGCCGCCTGGCACGGCGCC 
ACCCAGGTGCTCCAGTCGGCCACGCTGGGCAAGGGCGGAACCTGGGTCGTGAACGCCGACTCCCGGGTGC 
AGGACATGTCGATGCGCGGCGGGCGGGTCGAATTCCAGGCGCCCGCGCCCGAGGCCTCTTACAAGACCCT 
GACCCTGCAAACCCTGGACGGCAACGGCGTGTTCGTGCTGAACACCAACGTCGCCGCCGGGCAGAACGAC 
CAGTTGCGGGTCACCGGCCGCGCCGATGGCCAGCACCGCGTGCTGGTGCGCAATGCCGGAGGCGAGGCCG 
 
ACAGCCGGGGCGCCCGCCTGGGCCTGGTGCATACCCAGGGGCAGGGCAACGCCACCTTCCGGCTGGCCAA 
CGTCGGCAAGGCGGTTGACCTGGGCACGTGGCGCTACAGCCTGGCGGAGGATCCGAAGACGCATGTCTGG 
AGCTTGCAGCGCGCGGGCCAGGCCCTGTCGGGGGCGGCCAATGCCGCCGTGAACGCGGCGGATCTTTCCA 
GCATCGCCCTGGCCGAGTCCAACGCGCTGGACAAGCGCCTGGGCGAGCTGCGCCTGCGCGCCGACGCCGG 
CGGGCCATGGGCGCGTACGTTCAGCGAGCGCCAGCAGATCAGCAACCGCCACGCCCGCGCCTACGACCAG 
ACGGTCAGCGGGCTGGAGATCGGCCTGGACCGTGGCTGGAGCGCGTCGGGCGGGCGCTGGTACGCCGGCG 
GCCTGCTCGGCTACACCTATGCCGACCGCACCTATCCCGGCGACGGTGGCGGCAAGGTCAAGGGCCTGCA 
CGTCGGCGGCTACGCCGCCTATGTCGGCGATGGCGGCTACTATCTCGACACCGTGCTGCGGCTGGGCCGC 
TACGATCAGCAATACAACATTGCCGGCACCGATGGCGGCCGCGTCACCGCCGACTACCGCACAAGCGGCG 
CCGCATGGTCGCTCGAAGGCGGGCGCCGGTTCGAGCTGCCCAACGACTGGTTCGCCGAACCGCAGGCCGA 
GGTCATGCTGTGGCGCACGTCAGGCAAGCGCTATCGCGCCAGCAATGGCCTGCGCGTCAAGGTGGACGCC 
AACACCGCCACGCTGGGCCGCCTGGGCTTGCGCTTCGGCCGCCGCATCGCCCTGGCCGGCGGCAACATCG 
TGCAGCCCTACGCCAGGCTCGGCTGGACGCAGGAGTTCAAAAGCACGGGCGATGTGCGCACCAATGGCAT 
TGGCCATGCCGGCGCAGGCCGCCACGGCCGCGTGGAACTGGGCGCGGGCGTCGACGCCGCGTTGGGCAAG 
GGGCACAACCTCTATGCTTCGTACGAGTACGCGGCGGGCGACCGGATCAACATTCCGTGGTCGTTCCACG 
CCGGCTACCGCTACAGCTTCTGA 
                          BRKR2 
 
 
brkA gene forward primer (BRKF) nucleotide  
brkA gene reverse primer (BRKAR2) nucleotide  
   Tn5 transposon inserted in position 3232 in brkA gene 
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AII.5 BLAST2 sequence comparison of SapA protein of S. 
typhimurium with BapC of B. pertussis 
 
Blast 2 Sequences results 
PubMed Entrez BLAST OMIM Taxonomy Structure 
BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.15 [Oct-15-2006]  
Matrix BLOSUM62 gap open: 11 gap extension: 1  
x_dropoff: 50expect: 10.0 wordsize: 3 Filter View option 
Standard
    Masking character option 
X for protein, n for nucleotide
    Masking color option Black      
Show CDS translation Align  
Sequence 1: lcl|SapA Salmonella typhimurium 
Length = 549  
Sequence 2: lcl|BapC Bordetella pertussis 
Length = 993  
 
No significant similarity was found  
 
CPU time:     0.02 user secs.     0.00 sys. secs     0.02 
total secs. 
Lambda     K      H 
   0.319    0.133    0.402  
Gapped 
Lambda     K      H 
   0.267   0.0410    0.140  
Matrix: BLOSUM62 
Gap Penalties: Existence: 11, Extension: 1 
Number of Sequences: 1 
Number of Hits to DB: 3064 
Number of extensions: 2093 
Number of sequences better than 10.0: 0 
Number of HSP's gapped: 0 
Number of HSP's successfully gapped: 0 
Length of query: 549 
Length of database: 1,512,095,185 
Length adjustment: 140 
Effective length of query: 409 
Effective length of database: 1,512,095,045 
Effective search space: 618446873405 
Effective search space used: 618446873405 
Neighboring words threshold: 9 
X1: 16 (7.4 bits)  X2: 129 (49.7 bits)   X3: 129 (49.7 bits) 
S1: 41 (21.8 bits) S2: 82 (36.2 bits) 
 
 
 
 
  Appendices               
 
301 
AII.6 BLAST2 sequence comparison of SapA protein of S. 
typhimurium with BrkA of B. pertussis 
 
Blast 2 Sequences results 
PubMed Entrez BLAST OMIM Taxonomy Structure 
BLAST 2 SEQUENCES RESULTS VERSION BLASTP 2.2.15 [Oct-15-2006]  
Matrix BLOSUM62 gap open: 11 gap extension: 1  
x_dropoff: 50expect: 10.0 wordsize: 3 Filter View option 
Standard
    Masking character option 
X for protein, n for nucleotide
    Masking color option Black      
Show CDS translation Align  
Sequence 1: lcl|SapA Salmonella typhimurium 
Length = 549  
Sequence 2: lcl|BrkA Bordetella pertussis 
Length = 1010  
 
No significant similarity was found  
 
CPU time:     0.02 user secs.     0.00 sys. secs     0.02 
total secs. 
Lambda     K      H 
   0.319    0.133    0.402  
Gapped 
Lambda     K      H 
   0.267   0.0410    0.140  
Matrix: BLOSUM62 
Gap Penalties: Existence: 11, Extension: 1 
Number of Sequences: 1 
Number of Hits to DB: 3150 
Number of extensions: 2209 
Number of sequences better than 10.0: 0 
Number of HSP's gapped: 0 
Number of HSP's successfully gapped: 0 
Length of query: 549 
Length of database: 1,512,170,332 
Length adjustment: 140 
Effective length of query: 409 
Effective length of database: 1,512,170,192 
Effective search space: 618477608528 
Effective search space used: 618477608528 
Neighboring words threshold: 9 
X1: 16 (7.4 bits)   X2: 129 (49.7 bits)  X3: 129 (49.7 bits) 
S1: 41 (21.8 bits)  S2: 82 (36.2 bits) 
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AII.7a Mascot Search Results of full-length BapC protein expressed in E. coli 
 
User            : rb 
Search title    : Sample1 
MS data file    : C:\Documents and Settings\rjb12n\My Documents\Mojtaba.wiff 
Database        : NCBInr 20070524 (4970641 sequences; 1719627930 residues) 
Taxonomy        : Bacteria (Eubacteria) (2395850 sequences) 
 
Protein 
hits   :  gi|33593700  putative autotransporter (pseudogene)[Bordetella pertussis Tohama I] 
  
 gi|33597172 
 putative autotransporter [Bordetella parapertussis 12822] 
  
 gi|15803853 
 elongation factor EF-2 [Escherichia coli O157:H7 EDL933] 
  
 gi|15799798 
 pyruvate dehydrogenase (decarboxylase component) [Escherichia coli O157:H7 EDL933] 
  
 gi|24111558 
 pyruvate dehydrogenase (decarboxylase component) [Shigella flexneri 2a str. 301] 
  
 gi|147365 
 ATP-dependent protease binding subunit [Escherichia coli] 
  
 gi|56480150 
 heat shock protein [Shigella flexneri 2a str. 301] 
  
 gi|16759149  pyruvate dehydrogenase E1 component [Salmonella enterica subsp. enterica serovar Typhi str. 
CT18] 
  
 gi|15799694 
 molecular chaperone DnaK [Escherichia coli O157:H7 EDL933] 
  
 gi|16123568 
 pyruvate dehydrogenase E1 component [Yersinia pestis CO92] 
  
 gi|15799802 
 aconitate hydratase [Escherichia coli O157:H7 EDL933] 
  
 gi|16759005 
 molecular chaperone DnaK [Salmonella enterica subsp. enterica serovar Typhi str. CT18] 
  
 gi|43019 
 unnamed protein product [Escherichia coli] 
  
 gi|15800430 
 2-oxoglutarate dehydrogenase (decarboxylase component) [Escherichia coli O157:H7 EDL933] 
  
 gi|146312713 
 ATPase AAA-2 domain protein [Enterobacter sp. 638] 
  
 gi|37524440 
 translation elongation factor EF-G [Photorhabdus luminescens subsp. laumondii TTO1] 
  
 gi|21672436 
 DnaK protein [Buchnera aphidicola str. Sg (Schizaphis graminum)] 
  
 gi|114773099 
 ATP-binding subunit of Clp protease and DnaK/DnaJ chaperones [alpha proteobacterium HTCC2255] 
  
 gi|146642 
 protease La (lon) 
  
 gi|56460289 
 ATP-binding subunit of Clp protease and DnaK/DnaJ chaperones [Idiomarina loihiensis L2TR] 
  
 gi|123444103 
 elongation factor G [Yersinia enterocolitica subsp. enterocolitica 8081] 
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AII.7b Mascot Search Results of full-length BapC protein expressed in E. coli 
The protein was expressed by E. coli BL21 (DE3) pLysS containing plasmid pET33b (BapC + SS). 
 
Match to: gi|33593700 Score: 1576 
autotransporter (pseudogene) [Bordetella pertussis Tohama I] (locus_tag BP2738) 
Nominal mass (Mr): 104098; Calculated pI value: 4.98 
NCBI BLAST search of gi|33593700 against nr 
Sequence Coverage: 46% 
Matched peptides shown in Bold Red 
 
 
 
      1 MNDRKSNSMS PAARYLRFGV VAVAGVAAGA LPSSDVDAQA APAAAEVAKI  
    51 EALSDADIYS DYEHEHGIVM TPDGKDDYIS YRSAESGRPK PPPPLSNFKP  
   101 LGNDVVAERI RVEVHGDETL GVYVDSEHRS LTVRDSTIDA YGKPPSVDSP  
   151 DYYGAAAVYA GTLNIENSTV HHNYAAQPFE DAVGVGVTSL GDKAILNVTD  
   201 SEVSGARGAV IGWGGEATFT DSVLRGSAFG LYAEMCDTCR DDDGTSPSIR  
   251 VQGGVVQGGM GANNVAVVAT GSGKVAIENA ELLGASGMYA TFGAQVDMKG  
   301 GRILAHNTNI LGSQGYADGP YGGVVVTEDG QVNLEGAKVS ATGLGAAGLW  
   351 LLGDKDTSPR ASLRNTDVHG EVAAIALGFN GEANISGGSL SVEDGAVLTT  
   401 LTPDAVEYYY DYALSMEHLP ADAPLTPVRV TLSDGARASG ETLIAHGGLL  
   451 PMTLRLSSGV DARGDIVTLP PSAPPDSAEQ PDAEPEPDAE LEPDAAAQSD  
   501 AKANARVMAQ VDGGEPVAVP IPAPSHPDAP IDVFIDSGAQ WRGMTKTVNA  
   551 LRIEDGTWTV TGSSTVNSLH LQAGKVAYAT PAESDGEFKH LRVKTLSGSG  
   601 LFEMNASADL SDGDLLVVSD EASGQHKVLV RGAGTEPTGV ESLTLVELPE  
   651 GSQTKFTLAN RGGVVDAGAF RYRLTPDNGV WGLERTSQLS AVANAALNTG  
   701 GVGAASSIWY AEGNALSKRL GELRLDPGAG GFWGRTFAQK QQLDNKAGRR  
   751 FDQKVYGFEL GADHAIAGQQ GRWHVGGLLG YTRARRSFID DGAGHTDSAH  
   801 IGAYAAYVAD NGFYFDSTLR ASRFENDFTV TATDAVSVRG KYRANGVGAT  
   851 LEAGKRFTLH DGWFVEPQSE VSLFHASGGT YRAANNLSVK DEGGTSAVLR  
   901 LGLAAGRRID LGKDRVIQPY ATLSWLQEFK GVTTVRTNGY GLRTDLSGGR  
   951 AELALGLAAA LGRGHQLYTS YEYAKGNKLT LPWTFHLGYR YTW 
 
 
